PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| (51) International Patent Classification ⁶ : | | (11) International Publication Number: WO 99/66028 | | | |
|--|---|--|--|--|--|
| C12N 9/00 | A2 | (43) International Publication Date: 23 December 1999 (23.12.99) | | | |
| (21) International Application Number: PCT/EP | 71 [US/US]; 413 Vuncannon Drive, Fuquay-Varina, NC 27526 (US). | | | | |
| (22) International Filing Date: 16 June 1999 (| (74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Dept., CH-4002 Basel (CH). | | | | |
| (30) Priority Data: 09/099,504 18 June 1998 (18.06.98) 60/101,631 24 September 1998 (24.09.9 60/118,906 5 February 1999 (05.02.99) (71) Applicant (for all designated States except AT US): TIS AG [CH/CH]; Schwarzwaldallee 215, CH-40 (CH). (71) Applicant (for AT only): NOVARTIS-ERFINDUNG WALTUNGSGESELLSCHAFT MBH [AT/AT]; Strasse 59, A-1230 Vienna (AT). (72) Inventors; and (75) Inventors/Applicants (for US only): SCHUPP, [CH/CH]; Fröschmattweg 5, CH-4313 Möhl LIGON, James, Madison [US/US]; 3616 Sou Drive, Apex, NC 27502 (US). MOLNAR, Istvan 4004 Branchwood Drive, Durham, NC 277/ZIRKLE, Ross [US/US]; 6532 Wynbrook Way, NC 27612 (US). GÖRLACH, Jöm [DE/US]; 3 Charles Road, Durham, NC 27707 (US). CYI | (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published Without international search report and to be republished upon receipt of that report. | | | | |
| GA THE CONTROL FOR THE BYOCKNITHESIC OF EDOVERH OMES | | | | | |

(54) Title: GENES FOR THE BIOSYNTHESIS OF EPOTHILONES

(57) Abstract

Nucleic acid molecules are isolated from *Sorangium cellulosum* that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
|----|--------------------------|----|---------------------|----|-----------------------|----|--------------------------|
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Scnegal |
| ΛU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | | Republic of Macedonia | TR | Turkey |
| BG | Bulgaria | HU | Hungary | ML | Mali | TT | Trinidad and Tobago |
| BJ | Benin | Œ | Ireland | MN | Mongolia | UA | Ukraine |
| BR | Brazil | IL | Israel | MR | Mauritania | UG | Uganđa |
| BY | Belarus | IS | Iceland | MW | Malawi | US | United States of America |
| CA | Canada | IT | Italy | MX | Mexico | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NE | Niger | VN | Viet Nam |
| CG | Congo | KE | Kenya | NL | Netherlands | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NO | Norway | zw | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's | NZ | New Zealand | | |
| CM | Cameroon | | Republic of Korea | PL | Poland | | |
| CN | China | KR | Republic of Korea | PT | Portugal | | |
| CU | Cuba | KZ | Kazakstan | RO | Romania | | |
| CZ | Czech Republic | LC | Saint Lucia | RU | Russian Federation | | |
| DE | Germany | LI | Liechtenstein | SD | Sudan | | |
| DK | Denmark | LK | Sri Lanka | SE | Sweden | | |
| EE | Estonia | LR | Liberia | SG | Singapore | | |

GENES FOR THE BIOSYNTHESIS OF EPOTHILONES

FIELD OF THE INVENTION

The present invention relates generally to polyketides and genes for their synthesis. In particular, the present invention relates to the isolation and characterization of novel polyketide synthase and nonribosomal peptide synthetase genes from *Sorangium cellulosum* that are necessary for the biosynthesis of epothilones A and B.

BACKGROUND OF THE INVENTION

Polyketides are compounds synthesized from two-carbon building blocks, the β -carbon of which always carries a keto group, thus the name polyketide. These compounds include many important antibiotics, immunosuppressants, cancer chemotherapeutic agents, and other compounds possessing a broad range of biological properties. The tremendous structural diversity derives from the different lengths of the polyketide chain, the different side-chains introduced (either as part of the two-carbon building blocks or after the polyketide backbone is formed), and the stereochemistry of such groups. The keto groups may also be reduced to hydroxyls, enoyls, or removed altogether. Each round of two-carbon addition is carried out by a complex of enzymes called the polyketide synthase (PKS) in a manner similar to fatty acid biosynthesis.

The biosynthetic genes for an increasing number of polyketides have been isolated and sequenced. For example, see U.S. Patent Nos. 5,639,949, 5,693,774, and 5,716,849, all of which are incorporated herein by reference, which describe genes for the biosynthesis of soraphen. See also, Schupp et al., FEMS Microbiology Letters 159: 201-207 (1998) and WO 98/07868, which describe genes for the biosynthesis of rifamycin, and U.S. Patent No. 5,876,991, which describes genes for the biosynthesis of tylactone, all of which are incorporated herein by reference. The encoded proteins generally fall into two types: type I and type II. Type I proteins are polyfunctional, with several catalytic domains carrying out different enzymatic steps covalently linked together (e.g. PKS for erythromycin, soraphen, rifamycin, and avermectin (MacNeil et al., in Industrial Microorganisms: Basic and Applied Molecular Genetics, (ed.: Baltz et al.), American Society for Microbiology, Washington D. C.

pp. 245-256 (1993)); whereas type II proteins are monofunctional (Hutchinson *et al.*, in *Industrial Microorganisms: Basic and Applied Molecular Genetics*, (ed.: Baltz *et al.*), American Society for Microbiology, Washington D. C. pp. 203-216 (1993)).

For the simpler polyketides such as actinorhodin (produced by *Streptomyces coelicolor*), the several rounds of two-carbon additions are carried out iteratively on PKS enzymes encoded by one set of PKS genes. In contrast, synthesis of the more complicated compounds such as erythromycin and soraphen involves PKS enzymes that are organized into modules, whereby each module carries out one round of two-carbon addition (for review, see Hopwood *et al.*, in *Industrial Microorganisms: Basic and Applied Molecular Genetics*, (ed.: Baltz *et al.*), American Society for Microbiology, Washington D. C., pp. 267-275 (1993)).

Complex polyketides and secondary metabolites in general may contain substructures that are derived from amino acids instead of simple carboxylic acids. Incorporations of these building blocks are accomplished by non-ribosomal polypeptide synthetases (NRPSs). NRPSs are multienzymes that are organized in modules. Each module is responsible for the addition (and the additional processing, if required) of one amino acid building block. NRPSs activate amino acids by forming aminoacyl-adenylates, and capture the activated amino acids on thiol groups of phophopantheteinyl prosthetic groups on peptidyl carrier protein domains. Further, NRPSs modify the amino acids by epimerization, N-methylation, or cyclization if necessary, and catalyse the formation of peptide bonds between the enzyme-bound amino acids. NRPSs are responsible for the biosynthesis of peptide secondary metabolites like cyclosporin, could provide polyketide chain terminator units as in rapamycin, or form mixed systems with PKSs as in yersiniabactin biosynthesis.

Epothilones A and B are 16-membered macrocyclic polyketides with an acylcyste-ine-derived starter unit that are produced by the bacterium *Sorangium cellulosum* strain So ce90 (Gerth *et al.*, *J. Antibiotics* 49: 560-563 (1996), incorporated herein by reference). The structure of epothilone A and B wherein R signifies hydrogen (epothilone A) or methyl (epothilone B) is:

The epothilones have a narrow antifungal spectrum and especially show a high cytotoxicity in animal cell cultures (see, Höfle et al., Patent DE 4138042 (1993), incorporated herein by reference). Of significant importance, epothilones mimic the biological effects of taxol, both in vivo and in cultured cells (Bollag et al., Cancer Research 55: 2325-2333 (1995), incorporated herein by reference). Taxol and taxotere, which stabilize cellular microtubules, are cancer chemotherapeutic agents with significant activity against various human solid tumors (Rowinsky et al., J. Natl. Cancer Inst. 83: 1778-1781 (1991)). Competition studies have revealed that epothilones act as competitive inhibitors of taxol binding to microtubules, consistent with the interpretation that they share the same microtubule-binding site and possess a similar microtubule affinity as taxol. However, epothilones enjoy a significant advantage over taxol in that epothilones exhibit a much lower drop in potency compared to taxol against a multiple drug-resistant cell line (Bollag et al. (1995)). Furthermore, epothilones are considerably less efficiently exported from the cells by P-glycoprotein than is taxol (Gerth et al. (1996)). In addition, several epothilone analogs have been synthesized that have a superior cytotoxic activity as compared to epothilone A or epothilone B as demonstrated by their enhanced ability to induce the polymerization and stabilization of microtubules (WO 98/25929, incorporated herein by reference).

Despite the promise shown by the epothilones as anticancer agents, problems pertaining to the production of these compounds presently limit their commercial potential. The compounds are too complex for industrial-scale chemical synthesis and so must be produced by fermentation. Techniques for the genetic manipulation of myxobacteria such as *Sorangium cellulosum* are described in U.S. Patent No. 5,686,295, incorporated herein by reference. However, *Sorangium cellulosum* is notoriously difficult to ferment and production levels of epothilones are therefore low. Recombinant production of epothilones in heterologous hosts that are more amenable to fermentation could solve current production problems. However, the genes that encode the polypeptides responsible for epothilone bio-

PCT/EP99/04171

synthesis have heretofore not been isolated. Furthermore, the strain that produces epothilones, i.e. So ce90, also produces at least one additional polyketide, spirangien, which would be expected to greatly complicate the isolation of the genes particularly responsible for epothilone biosynthesis.

Therefore, in view of the foregoing, one object of the present invention is to isolate the genes that are involved in the synthesis of epothilones, particularly the genes that are involved in the synthesis of epothilones A and B in myxobacteria of the Sorangium/-Polyangium group, i.e., *Sorangium cellulosum* strain So ce90. A further object of the invention is to provide a method for the recombinant production of epothilones for application in anticancer formulations.

SUMMARY OF THE INVENTION

In furtherance of the aforementioned and other objects, the present invention unexpectedly overcomes the difficulties set forth above to provide for the first time a nucleic acid molecule comprising a nucleotide sequence that encodes at least one polypeptide involved in the biosynthesis of epothilone. In a preferred embodiment, the nucleotide sequence is isolated from a species belonging to *Myxobacteria*, most preferably *Sorangium cellulosum*.

In another preferred embodiment, the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes at least one polypeptide involved in the biosynthesis of an epothilone, wherein said polypeptide comprises an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: SEQ ID NO:2, amino acids 11-437 of SEQ ID NO:2, amino acids 543-864 of SEQ ID NO:2, amino acids 974-1273 of SEQ ID NO:2, amino acids 1314-1385 of SEQ ID NO:2, SEQ ID NO:3, amino acids 72-81 of SEQ ID NO:3, amino acids 118-125 of SEQ ID NO:3, amino acids 199-212 of SEQ ID NO:3, amino acids 353-363 of SEQ ID NO:3, amino acids 549-565 of SEQ ID NO:3, amino acids 588-603 of SEQ ID NO:3, amino acids 669-684 of SEQ ID NO:3, amino acids 815-821 of SEQ ID NO:3, amino acids 868-892 of SEQ ID NO:3, amino acids 903-912 of SEQ ID NO:3, amino acids 918-940 of SEQ ID NO:3, amino acids 1268-1274 of SEQ ID NO:3, amino acids 1285-1297 of SEQ ID NO:3, amino acids 973-1256 of SEQ ID NO:3, amino acids 1344-1351 of SEQ ID NO:3, SEQ ID NO:4, amino acids 669-1037 of SEQ ID NO:4, amino acids 1439-1684 of SEQ ID NO:4, amino acids 869-1037 of SEQ ID NO:4, amino acids 1439-1684 of SEQ ID NO:4, amino acids 1722-1792 of SEQ ID SEQ ID NO:4, amino acids 1500-1500 acids 1600-1600 acids 1600-1600 acids 1600-1600 acids 1722-1792 of SEQ ID NO:4, amino acids

NO:4, SEQ ID NO:5, amino acids 39-457 of SEQ ID NO:5, amino acids 563-884 of SEQ ID NO:5, amino acids 1147-1399 of SEQ ID NO:5, amino acids 1434-1506 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 3886-4048 of SEQ ID NO:5, amino acids 4433-4719 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, SEQ ID NO:6, amino acids 35-454 of SEQ ID NO:6, amino acids 561-881 of SEQ ID NO:6, amino acids 1143-1393 of SEQ ID NO:6, amino acids 1430-1503 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, amino acids 2053-2373 of SEQ ID NO:6, amino acids 2383-2551 of SEQ ID NO:6, amino acids 2671-3045 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, SEQ ID NO:7, amino acids 32-450 of SEQ ID NO:7, amino acids 556-877 of SEQ ID NO:7, amino acids 887-1051 of SEQ ID NO:7, amino acids 1478-1790 of SEQ ID NO:7, amino acids 1810-2055 of SEQ ID NO:7, amino acids 2093-2164 of SEQ ID NO:7, amino acids 2165-2439 of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:22.

In a more preferred embodiment, the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes at least one polypeptide involved in the biosynthesis of an epothilone, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:2, amino acids 11-437 of SEQ ID NO:2, amino acids 543-864 of SEQ ID NO:2, amino acids 974-1273 of SEQ ID NO:2, amino acids 1314-1385 of SEQ ID NO:3, SEQ ID NO:3, amino acids 72-81 of SEQ ID NO:3, amino acids 118-125 of SEQ ID NO:3, amino acids 199-212 of SEQ ID NO:3, amino acids 353-363 of SEQ ID NO:3, amino acids 549-565 of SEQ ID NO:3, amino acids 588-603 of SEQ ID NO:3, amino acids 669-684 of SEQ ID NO:3, amino acids 815-821 of SEQ ID NO:3, amino acids 868-892 of SEQ ID NO:3, amino acids 903-912 of SEQ ID NO:3, amino acids 918-940 of SEQ ID NO:3, amino acids 1268-1274 of SEQ ID NO:3, amino acids 1285-1297 of SEQ ID NO:3, amino acids 973-1256 of SEQ ID NO:3, amino acids 1344-1351 of SEQ ID NO:3, SEQ ID NO:4, amino acids 7-432 of SEQ ID NO:4, amino acids 139-859 of SEQ ID NO:4, amino acids 869-1037 of SEQ ID NO:4, amino acids 1439-1684

of SEQ ID NO:4, amino acids 1722-1792 of SEQ ID NO:4, SEQ ID NO:5, amino acids 39-457 of SEQ ID NO:5, amino acids 563-884 of SEQ ID NO:5, amino acids 1147-1399 of SEQ ID NO:5, amino acids 1434-1506 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 3886-4048 of SEQ ID NO:5, amino acids 4433-4719 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, SEQ ID NO:6, amino acids 35-454 of SEQ ID NO:6, amino acids 561-881 of SEQ ID NO:6, amino acids 1143-1393 of SEQ ID NO:6, amino acids 1430-1503 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, amino acids 2053-2373 of SEQ ID NO:6, amino acids 2383-2551 of SEQ ID NO:6, amino acids 2671-3045 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, SEQ ID NO:7, amino acids 32-450 of SEQ ID NO:7, amino acids 556-877 of SEQ ID NO:7, amino acids 887-1051 of SEQ ID NO:7, amino acids 1478-1790 of SEQ ID NO:7, amino acids 1810-2055 of SEQ ID NO:7, amino acids 2093-2164 of SEQ ID NO:7, amino acids 2165-2439 of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:22.

In yet another preferred embodiment, the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes at least one polypeptide involved in the biosynthesis of an epothilone, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: the complement of nucleotides 1900-3171 of SEQ ID NO:1, nucleotides 3415-5556 of SEQ ID NO:1, nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1,

nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1. nucleotides 15901-15924 of SEQ ID NO:1, nucleotides 16251-21749 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 21746-43519 of SEQ ID NO:1. nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1. nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1. nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 43524-54920 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, nucleotides 51534-52657 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, nucleotides 54935-62254 of SEQ ID NO:1, nucleotides 55028-56284 of SEQ ID NO:1, nucleotides 56600-57565 of SEQ ID NO:1, nucleotides 57593-58087 of SEQ ID NO:1, nucleotides 59366-60304 of SEQ ID NO:1, nucleotides 60362-61099 of SEQ ID NO:1, nucleotides 61211-61426 of SEQ ID NO:1, nucleotides 61427-62254 of SEQ ID NO:1, nucleotides 62369-63628 of SEQ ID NO:1, nucleotides 67334-68251 of SEQ ID NO:1, and nucleotides 1-68750 SEQ ID NO:1.

In an especially preferred embodiment, the present invention provides a nucleic acid molecule comprising a nucleotide sequence that encodes at least one polypeptide involved in the biosynthesis of an epothilone, wherein said nucleotide sequence is selected from the group consisting of: the complement of nucleotides 1900-3171 of SEQ ID NO:1, nucleotides 3415-5556 of SEQ ID NO:1, nucleotides 7610-11875 of SEQ ID NO:1, nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 11872-16104 of

SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1. nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, nucleotides 15901-15924 of SEQ ID NO:1, nucleotides 16251-21749 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 21746-43519 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 43524-54920 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, nucleotides 51534-52657 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, nucleotides 54935-62254 of SEQ ID NO:1, nucleotides 55028-56284 of SEQ ID NO:1, nucleotides 56600-57565 of SEQ ID NO:1, nucleotides 57593-58087 of SEQ ID NO:1, nucleotides 59366-60304 of SEQ ID NO:1, nucleotides 60362-61099 of SEQ ID NO:1, nucleotides 61211-61426 of SEQ ID NO:1, nucleotides 61427-62254 of SEQ ID NO:1, nucleotides 62369-63628 of SEQ ID NO:1, nucleotides 67334-68251 of SEQ ID NO:1, and nucleotides 1-68750 SEQ ID NO:1.

In yet another preferred embodiment, the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes at least one polypeptide involved in the biosynthesis of an epothilone, wherein said nucleotide sequence comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of a nucleotide sequence selected from the group consisting of: the complement of nucleotides 1900-3171 of SEQ ID NO:1, nucleotides 3415-5556 of SEQ ID NO:1, nucleotides 7610-11875 of SEQ ID NO:1, nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, nucleotides 15901-15924 of SEQ ID NO:1, nucleotides 16251-21749 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 21746-43519 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 43524-54920 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID

WO 99/66028

PCT/EP99/04171

NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, nucleotides 51534-52657 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, nucleotides 54935-62254 of SEQ ID NO:1, nucleotides 55028-56284 of SEQ ID NO:1, nucleotides 56600-57565 of SEQ ID NO:1, nucleotides 57593-58087 of SEQ ID NO:1, nucleotides 59366-60304 of SEQ ID NO:1, nucleotides 60362-61099 of SEQ ID NO:1, nucleotides 61211-61426 of SEQ ID NO:1, nucleotides 61427-62254 of SEQ ID NO:1, nucleotides 62369-63628 of SEQ ID NO:1, nucleotides 67334-68251 of SEQ ID NO:1, and nucleotides 1-68750 SEQ ID NO:1.

The present invention also provides a chimeric gene comprising a heterologous promoter sequence operatively linked to a nucleic acid molecule of the invention. Further, the present invention provides a recombinant vector comprising such a chimeric gene, wherein the vector is capable of being stably transformed into a host cell. Still further, the present invention provides a recombinant host cell comprising such a chimeric gene, wherein the host cell is capable of expressing the nucleotide sequence that encodes at least one polypeptide necessary for the biosynthesis of an epothilone. In a preferred embodiment, the recombinant host cell is a bacterium belonging to the order *Actinomycetales*, and in a more preferred embodiment the recombinant host cell is a strain of *Streptomyces*. In other embodiments, the recombinant host cell is any other bacterium amenable to fermentation, such as a pseudomonad or *E. coli*. Even further, the present invention provides a Bac clone comprising a nucleic acid molecule of the invention, preferably Bac clone pEPO15.

In another aspect, the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes an epothilone synthase domain.

According to one embodiment, the epothilone synthase domain is a β-ketoacyl-synthase (KS) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 11-437 of SEQ ID NO:2, amino acids 7-432 of SEQ ID NO:4, amino acids 39-457 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 35-454 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, and amino acids 32-450 of SEQ ID NO:7. According to this embodiment, said KS domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 11-437 of SEQ ID NO:2, amino acids 7-432 of SEQ ID NO:4, amino acids 39-457 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids

3024-3449 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 35-454 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, and amino acids 32-450 of SEQ ID NO:7. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, and nucleotides 55028-56284 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, and nucleotides 55028-56284 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is selected from the group consisting of: nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, and nucleotides 55028-56284 of SEQ ID NO:1.

According to another embodiment, the epothilone synthase domain is an acyltransferase (AT) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 543-864 of SEQ ID NO:2, amino acids 539-859 of SEQ ID NO:4, amino acids 563-884 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 561-881 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, and amino acids 556-877 of SEQ ID NO:7. According to this embodiment, said AT domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 543-864 of SEQ ID NO:2, amino acids 539-859 of SEQ ID NO:4, amino acids 563-884 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino

acids 3555-3876 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 561-881 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, and amino acids 556-877 of SEQ ID NO:7. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1. nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1. nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, and nucleotides 56600-57565 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, and nucleotides 56600-57565 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is selected from the group consisting of: nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, and nucleotides 56600-57565 of SEQ ID NO:1.

According to still another embodiment, the epothilone synthase domain is an enoyl reductase (ER) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 974-1273 of SEQ ID NO:2, amino acids 4433-4719 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, and amino acids 1478-1790 of SEQ ID NO:7. According to this embodiment, said ER domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 974-1273 of SEQ ID NO:2, amino acids 4433-4719 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, and amino acids 1478-1790 of SEQ ID NO:7. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 10529-11428 of

SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, and nucleotides 59366-60304 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, and nucleotides 59366-60304 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is selected from the group consisting of: nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, and nucleotides 59366-60304 of SEQ ID NO:1, and nucleotides 59366-60304 of SEQ ID NO:1, nucleotides

According to another embodiment, the epothilone synthase domain is an acyl carrier protein (ACP) domain, wherein said polypeptide comprises an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 1314-1385 of SEQ ID NO:2, amino acids 1722-1792 of SEQ ID NO:4, amino acids 1434-1506 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, amino acids 1430-1503 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, and amino acids 2093-2164 of SEQ ID NO:7. According to this embodiment, said ACP domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 1314-1385 of SEQ ID NO:2, amino acids 1722-1792 of SEQ ID NO:4, amino acids 1434-1506 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, amino acids 1430-1503 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, and amino acids 2093-2164 of SEQ ID NO:7. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, and nucleotides 61211-61426 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, and nucleotides 61211-61426 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is selected from the group consisting of: nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, and nucleotides 61211-61426 of SEQ ID NO:1.

According to another embodiment, the epothilone synthase domain is a dehydratase (DH) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 869-1037 of SEQ ID NO:4, amino acids 3886-4048 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 2383-2551 of SEQ ID NO:6, and amino acids 887-1051 of SEQ ID NO:7. According to this embodiment, said DH domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 869-1037 of SEQ ID NO:4, amino acids 3886-4048 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 2383-2551 of SEQ ID NO:6, and amino acids 887-1051 of SEQ ID NO:7. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, and nucleotides 57593-58087 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, and nucleotides 57593-58087 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is selected from the group consisting of: nucleotides 18855-19361 of SEQ ID NO:1,

nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, and nucleotides 57593-58087 of SEQ ID NO:1.

According to yet another embodiment, the epothilone synthase domain is a β-ketoreductase (KR) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 1439-1684 of SEQ ID NO:4, amino acids 1147-1399 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 1143-1393 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, and amino acids 1810-2055 of SEQ ID NO:7. According to this embodiment, said KR domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 1439-1684 of SEQ ID NO:4, amino acids 1147-1399 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 1143-1393 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, and amino acids 1810-2055 of SEQ ID NO:7. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, and nucleotides 60362-61099 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, and nucleotides 60362-61099 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is selected from the group consisting of: nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, and nucleotides 60362-61099 of SEQ ID NO:1.

According to an additional embodiment, the epothilone synthase domain is a methyltransferase (MT) domain comprising an amino acid sequence substantially similar to amino acids 2671-3045 of SEQ ID NO:6. According to this embodiment, said MT domain preferably comprises amino acids 2671-3045 of SEQ ID NO:6. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to nucleotides 51534-52657 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of nucleotides 51534-52657 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is nucleotides 51534-52657 of SEQ ID NO:1.

According to another embodiment, the epothilone synthase domain is a thioesterase (TE) domain comprising an amino acid sequence substantially similar to amino acids 2165-2439 of SEQ ID NO:7. According to this embodiment, said TE domain preferably comprises amino acids 2165-2439 of SEQ ID NO:7. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to nucleotides 61427-62254 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of nucleotides 61427-62254 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is nucleotides 61427-62254 of SEQ ID NO:1.

In still another aspect, the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes a non-ribosomal peptide synthetase, wherein said non-ribosomal peptide synthetase comprises an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: SEQ ID NO:3, amino acids 72-81 of SEQ ID NO:3, amino acids 118-125 of SEQ ID NO:3, amino acids 199-212 of SEQ ID NO:3, amino acids 353-363 of SEQ ID NO:3, amino acids 549-565 of SEQ ID NO:3, amino acids 588-603 of SEQ ID NO:3, amino acids 669-684 of SEQ ID NO:3, amino acids 815-821 of SEQ ID NO:3, amino acids 868-892 of SEQ ID NO:3, amino acids 903-912 of SEQ ID NO:3, amino acids 918-940 of SEQ ID NO:3, amino acids 1268-1274 of SEQ ID NO:3, amino acids 1285-1297 of SEQ ID NO:3, amino acids 973-1256 of SEQ ID NO:3, and amino acids 1344-1351 of SEQ ID NO:3. According to this

embodiment, said non-ribosomal peptide synthetase preferably comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:3, amino acids 72-81 of SEQ ID NO:3, amino acids 118-125 of SEQ ID NO:3, amino acids 199-212 of SEQ ID NO:3, amino acids 353-363 of SEQ ID NO:3, amino acids 549-565 of SEQ ID NO:3, amino acids 588-603 of SEQ ID NO:3, amino acids 669-684 of SEQ ID NO:3, amino acids 815-821 of SEQ ID NO:3, amino acids 868-892 of SEQ ID NO:3, amino acids 903-912 of SEQ ID NO:3, amino acids 918-940 of SEQ ID NO:3, amino acids 1268-1274 of SEQ ID NO:3, amino acids 1285-1297 of SEQ ID NO:3, amino acids 973-1256 of SEQ ID NO:3, and amino acids 1344-1351 of SEQ ID NO:3. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, and nucleotides 15901-15924 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, and nucleotides 15901-15924 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is selected from the group consisting of: nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 1246612507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, and nucleotides 15901-15924 of SEQ ID NO:1.

The present invention further provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:2-23.

In accordance with another aspect, the present invention also provides methods for the recombinant production of polyketides such as epothilones in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer. A specific advantage of these production methods is the chirality of the molecules produced; production in transgenic organisms avoids the generation of populations of racemic mixtures, within which some enantiomers may have reduced activity. In particular, the present invention provides a method for heterologous expression of epothilone in a recombinant host, comprising: (a) introducing into a host a chimeric gene comprising a heterologous promoter sequence operatively linked to a nucleic acid molecule of the invention that comprises a nucleotide sequence that encodes at least one polypeptide involved in the biosynthesis of epothilone; and (b) growing the host in conditions that allow biosynthesis of epothilone in the host. The present invention also provides a method for producing epothilone, comprising: (a) expressing epothilone in a recombinant host by the aforementioned method; and (b) extracting epothilone from the recombinant host.

According to still another aspect, the present invention provides an isolated polypeptide comprising an amino acid sequence that consists of an epothilone synthase domain.

According to one embodiment, the epothilone synthase domain is a β-ketoacyl-synthase (KS) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 11-437 of SEQ ID NO:2, amino acids 7-432 of SEQ ID NO:4, amino acids 39-457 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 35-454 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, and amino acids 32-450 of SEQ ID NO:7. According to this embodiment,

said KS domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 11-437 of SEQ ID NO:2, amino acids 7-432 of SEQ ID NO:4, amino acids 39-457 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 35-454 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, and amino acids 32-450 of SEQ ID NO:7.

According to another embodiment, the epothilone synthase domain is an acyltransferase (AT) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 543-864 of SEQ ID NO:2, amino acids 539-859 of SEQ ID NO:4, amino acids 563-884 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:6, amino acids 5631-5951 of SEQ ID NO:6, amino acids 561-881 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, and amino acids 556-877 of SEQ ID NO:7. According to this embodiment, said AT domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 543-864 of SEQ ID NO:2, amino acids 539-859 of SEQ ID NO:4, amino acids 563-884 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 561-881 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, and amino acids 556-877 of SEQ ID NO:7.

According to still another embodiment, the epothilone synthase domain is an enoyl reductase (ER) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 974-1273 of SEQ ID NO:2, amino acids 4433-4719 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, and amino acids 1478-1790 of SEQ ID NO:7. According to this embodiment, said ER domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 974-1273 of SEQ ID NO:2, amino acids 4433-4719 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, and amino acids 1478-1790 of SEQ ID NO:7.

According to another embodiment, the epothilone synthase domain is an acyl carrier protein (ACP) domain, wherein said polypeptide comprises an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 1314-1385 of SEQ ID NO:2, amino acids 1722-1792 of SEQ ID NO:4, amino acids 1434-1506 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, amino acids 1430-1503 of

SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, and amino acids 2093-2164 of SEQ ID NO:7. According to this embodiment, said ACP domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 1314-1385 of SEQ ID NO:2, amino acids 1722-1792 of SEQ ID NO:4, amino acids 1434-1506 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, amino acids 1430-1503 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, and amino acids 2093-2164 of SEQ ID NO:7.

According to another embodiment, the epothilone synthase domain is a dehydratase (DH) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 869-1037 of SEQ ID NO:4, amino acids 3886-4048 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 2383-2551 of SEQ ID NO:6, and amino acids 887-1051 of SEQ ID NO:7. According to this embodiment, said DH domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 869-1037 of SEQ ID NO:4, amino acids 3886-4048 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 2383-2551 of SEQ ID NO:6, and amino acids 887-1051 of SEQ ID NO:7.

According to yet another embodiment, the epothilone synthase domain is a β-keto-reductase (KR) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 1439-1684 of SEQ ID NO:4, amino acids 1147-1399 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:6, amino acids 6857-7101 of SEQ ID NO:5, amino acids 1143-1393 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, and amino acids 1810-2055 of SEQ ID NO:7. According to this embodiment, said KR domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 1439-1684 of SEQ ID NO:4, amino acids 1147-1399 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 1143-1393 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, and amino acids 1810-2055 of SEQ ID NO:7.

According to an additional embodiment, the epothilone synthase domain is a methyl-transferase (MT) domain comprising an amino acid sequence substantially similar to amino acids 2671-3045 of SEQ ID NO:6. According to this embodiment, said MT domain preferably comprises amino acids 2671-3045 of SEQ ID NO:6.

According to another embodiment, the epothilone synthase domain is a thioesterase (TE) domain comprising an amino acid sequence substantially similar to amino acids 2165-2439 of SEQ ID NO:7. According to this embodiment, said TE domain preferably comprises amino acids 2165-2439 of SEQ ID NO:7.

Other aspects and advantages of the present invention will become apparent to those skilled in the art from a study of the following description of the invention and non-limiting examples.

DEFINITIONS

In describing the present invention, the following terms will be employed, and are intended to be defined as indicated below.

Associated With / Operatively Linked: Refers to two DNA sequences that are related physically or functionally. For example, a promoter or regulatory DNA sequence is said to be "associated with" a DNA sequence that codes for an RNA or a protein if the two sequences are operatively linked, or situated such that the regulator DNA sequence will affect the expression level of the coding or structural DNA sequence.

Chimeric Gene: A recombinant DNA sequence in which a promoter or regulatory DNA sequence is operatively linked to, or associated with, a DNA sequence that codes for an mRNA or which is expressed as a protein, such that the regulator DNA sequence is able to regulate transcription or expression of the associated DNA sequence. The regulator DNA sequence of the chimeric gene is not normally operatively linked to the associated DNA sequence as found in nature.

Coding DNA Sequence: A DNA sequence that is translated in an organism to produce a protein.

Domain: That part of a polyketide synthase necessary for a given distinct activity. Examples include acyl carrier protein (ACP), β-ketosynthase (KS), acyltransferase (AT), βketoreductase (KR), dehydratase (DH), enoylreductase (ER), and thioesterase (TE) domains.

Epothilones: 16-membered macrocyclic polyketides naturally produced by the bacterium Sorangium cellulosum strain So ce90, which mimic the biological effects of taxol. In this application, "epothilone" refers to the class of polyketides that includes epothilone A and epothilone B, as well as analogs thereof such as those described in WO 98/25929.

Epothilone Synthase: A polyketide synthase responsible for the biosynthesis of epothilone.

Gene: A defined region that is located within a genome and that, besides the aforementioned coding DNA sequence, comprises other, primarily regulatory, DNA sequences responsible for the control of the expression, that is to say the transcription and translation, of the coding portion.

Heterologous DNA Sequence: A DNA sequence not naturally associated with a host cell into which it is introduced, including non-naturally occurring multiple copies of a naturally occurring DNA sequence.

Homologous DNA Sequence: A DNA sequence naturally associated with a host cell into which it is introduced.

Homologous Recombination: Reciprocal exchange of DNA fragments between homologous DNA molecules.

Isolated: In the context of the present invention, an isolated nucleic acid molecule or an isolated enzyme is a nucleic acid molecule or enzyme that, by the hand of man, exists apart from its native environment and is therefore not a product of nature. An isolated nucleic acid molecule or enzyme may exist in a purified form or may exist in a non-native environment such as, for example, a recombinant host cell.

Module: A genetic element encoding all of the distinct activities required in a single round of polyketide biosynthesis, i.e., one condensation step and all the β -carbonyl processing steps associated therewith. Each module encodes an ACP, a KS, and an AT activity to accomplish the condensation portion of the biosynthesis, and selected post-condensation activities to effect the β -carbonyl processing.

NRPS: A non-ribosomal polypeptide synthetase, which is a complex of enzymatic activities responsible for the incorporation of amino acids into secondary metabolites including, for example, amino acid adenylation, epimerization, N-methylation, cyclization, peptidyl carrier protein, and condensation domains. A functional NRPS is one that catalyzes the incorporation of an amino acid into a secondary metabolite.

NRPS gene: One or more genes encoding NRPSs for producing functional secondary metabolites, e.g., epothilones A and B, when under the direction of one or more compatible control elements.

Nucleic Acid Molecule: A linear segment of single- or double-stranded DNA or RNA that can be isolated from any source. In the context of the present invention, the nucleic acid molecule is preferably a segment of DNA.

ORF: Open Reading Frame.

PKS: A polyketide synthase, which is a complex of enzymatic activities (domains) responsible for the biosynthesis of polyketides including, for example, ketoreductase, dehydratase, acyl carrier protein, enoylreductase, ketoacyl ACP synthase, and acyltransferase. A functional PKS is one that catalyzes the synthesis of a polyketide.

PKS Genes: One or more genes encoding various polypeptides required for producing functional polyketides, e.g., epothilones A and B, when under the direction of one or more compatible control elements.

Substantially Similar: With respect to nucleic acids, a nucleic acid molecule that has at least 60 percent sequence identity with a reference nucleic acid molecule. In a preferred embodiment, a substantially similar DNA sequence is at least 80% identical to a reference DNA sequence; in a more preferred embodiment, a substantially similar DNA sequence is at least 90% identical to a reference DNA sequence; and in a most preferred embodiment, a substantially similar DNA sequence is at least 95% identical to a reference DNA sequence. A substantially similar DNA sequence preferably encodes a protein or peptide having substantially the same activity as the protein or peptide encoded by the reference DNA sequence. A substantially similar nucleotide sequence typically hybridizes to a reference nucleic acid molecule, or fragments thereof, under the following conditions: hybridization at 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO₄ pH 7.0, 1 mM EDTA at 50°C; wash with 2X SSC, 1% SDS, at 50°C. With respect to proteins or peptides, a substantially similar amino acid sequence is an amino acid sequence that is at least 90% identical to the amino acid sequence of a reference protein or peptide and has substantially the same activity as the reference protein or peptide.

Transformation: A process for introducing heterologous nucleic acid into a host cell or organism.

Transformed / Transgenic / Recombinant: Refers to a host organism such as a bacterium into which a heterologous nucleic acid molecule has been introduced. The nucleic acid molecule can be stably integrated into the genome of the host or the nucleic acid molecule can also be present as an extrachromosomal molecule. Such an extrachromosomal molecule can be auto-replicating. Transformed cells, tissues, or plants are understood to

encompass not only the end product of a transformation process, but also transgenic progeny thereof. A "non-transformed", "non-transgenic", or "non-recombinant" host refers to a wild-type organism, i.e., a bacterium, which does not contain the heterologous nucleic acid molecule.

Nucleotides are indicated by their bases by the following standard abbreviations: adenine (A), cytosine (C), thymine (T), and guanine (G). Amino acids are likewise indicated by the following standard abbreviations: alanine (ala; A), arginine (Arg; R), asparagine (Asn; N), aspartic acid (Asp; D), cysteine (Cys; C), glutamine (Gln; Q), glutamic acid (Glu; E), glycine (Gly; G), histidine (His; H), isoleucine (Ile; I), leucine (Leu; L), lysine (lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y), and valine (Val; V). Furthermore, (Xaa; X) represents any amino acid.

DESCRIPTION OF THE SEQUENCES IN THE SEQUENCE LISTING

SEQ ID NO:1 is the nucleotide sequence of a 68750 bp contig containing 22 open reading frames (ORFs), which comprises the epothilone biosynthesis genes.

SEQ ID NO:2 is the protein sequence of a type I polyketide synthase (EPOS A) encoded by *epo*A (nucleotides 7610-11875 of SEQ ID NO:1).

SEQ ID NO:3 is the protein sequence of a non-ribosomal peptide synthetase (EPOS P) encoded by *epo*P (nucleotides 11872-16104 of SEQ ID NO:1).

SEQ ID NO:4 is the protein sequence of a type I polyketide synthase (EPOS B) encoded by *epo*B (nucleotides 16251-21749 of SEQ ID NO:1).

SEQ ID NO:5 is the protein sequence of a type I polyketide synthase (EPOS C) encoded by *epo*C (nucleotides 21746-43519 of SEQ ID NO:1).

SEQ ID NO:6 is the protein sequence of a type I polyketide synthase (EPOS D) encoded by *epo*D (nucleotides 43524-54920 of SEQ ID NO:1).

SEQ ID NO:7 is the protein sequence of a type I polyketide synthase (EPOS E) encoded by *epo*E (nucleotides 54935-62254 of SEQ ID NO:1).

SEQ ID NO:8 is the protein sequence of a cytochrome P450 oxygenase homologue (EPOS F) encoded by *epo*F (nucleotides 62369-63628 of SEQ ID NO:1).

SEQ ID NO:9 is a partial protein sequence (partial Orf 1) encoded by *orf*1 (nucleotides 1-1826 of SEQ ID NO:1).

SEQ ID NO:10 is a protein sequence (Orf 2) encoded by *orf*2 (nucleotides 3171-1900 on the reverse complement strand of SEQ ID NO:1).

SEQ ID NO:11 is a protein sequence (Orf 3) encoded by *orf*3 (nucleotides 3415-5556 of SEQ ID NO:1).

SEQ ID NO:12 is a protein sequence (Orf 4) encoded by *orf*4 (nucleotides 5992-5612 on the reverse complement strand of SEQ ID NO:1).

SEQ ID NO:13 is a protein sequence (Orf 5) encoded by orf5 (nucleotides 6226-6675 of SEQ ID NO:1).

SEQ ID NO:14 is a protein sequence (Orf 6) encoded by *orf*6 (nucleotides 63779-64333 of SEQ ID NO:1).

SEQ ID NO:15 is a protein sequence (Orf 7) encoded by *orf*7 (nucleotides 64290-63853 on the reverse complement strand of SEQ ID NO:1).

SEQ ID NO:16 is a protein sequence (Orf 8) encoded by *orf*8 (nucleotides 64363-64920 of SEQ ID NO:1).

SEQ ID NO:17 is a protein sequence (Orf 9) encoded by *orf*9 (nucleotides 64727-64287 on the reverse complement strand of SEQ ID NO:1).

SEQ ID NO:18 is a protein sequence (Orf 10) encoded by *orf*10 (nucleotides 65063-65767 of SEQ ID NO:1).

SEQ ID NO:19 is a protein sequence (Orf 11) encoded by *orf*11 (nucleotides 65874-65008 on the reverse complement strand of SEQ ID NO:1).

SEQ ID NO:20 is a protein sequence (Orf 12) encoded by *orf*12 (nucleotides 66338-65871 on the reverse complement strand of SEQ ID NO:1).

SEQ ID NO:21 is a protein sequence (Orf 13) encoded by orf13 (nucleotides 66667-67137 of SEQ ID NO:1).

SEQ ID NO:22 is a protein sequence (Orf 14) encoded by *orf*14 (nucleotides 67334-68251 of SEQ ID NO:1).

SEQ ID NO:23 is a partial protein sequence (partial Orf 15) encoded by *orf*15 (nucleotides 68346-68750 of SEQ ID NO:1).

SEQ ID NO:24 is the universal reverse PCR primer sequence.

SEQ ID NO:25 is the universal forward PCR primer sequence.

SEQ ID NO:26 is the NH24 end "B" PCR primer sequence.

SEQ ID NO:27 is the NH2 end "A" PCR primer sequence.

SEQ ID NO:28 is the NH2 end "B" PCR primer sequence.

SEQ ID NO:29 is the pEPO15-NH6 end "B" PCR primer sequence. SEQ ID NO:30 is the pEPO15-H2.7 end "A" PCR primer sequence.

DEPOSIT INFORMATION

The following material has been deposited with the Agricultural Research Service,
Patent Culture Collection (NRRL), 1815 North University Street, Peoria, Illinois 61604, under
the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for
the Purposes of Patent Procedure. All restrictions on the availability of the deposited
material will be irrevocably removed upon the granting of a patent.

| Deposited Material | Accession Number | Deposit Date |
|--------------------|------------------|----------------|
| pEPO15 | NRRL B-30033 | June 11, 1998 |
| pEPO32 | NRRL B-30119 | April 16, 1999 |

DETAILED DESCRIPTION OF THE INVENTION

The genes involved in the biosynthesis of epothilones can be isolated using the techniques according to the present invention. The preferable procedure for the isolation of epothilone biosynthesis genes requires the isolation of genomic DNA from an organism identified as producing epothilones A and B, and the transfer of the isolated DNA on a suitable plasmid or vector to a host organism that does not normally produce the polyketide, followed by the identification of transformed host colonies to which the epothilone-producing ability has been conferred. Using a technique such as λ::Tn5 transposon mutagenesis (de Bruijn & Lupski, Gene 27: 131-149 (1984)), the exact region of the transforming epothiloneconferring DNA can be more precisely defined. Alternatively or additionally, the transforming epothilone-conferring DNA can be cleaved into smaller fragments and the smallest that maintains the epothilone-conferring ability further characterized. Whereas the host organism lacking the ability to produce epothilone may be a different species from the organism from which the polyketide derives, a variation of this technique involves the transformation of host DNA into the same host that has had its epothilone-producing ability disrupted by mutagenesis. In this method, an epothilone-producing organism is mutated and nonepothilone-producing mutants are isolated. These are then complemented by genomic DNA isolated from the epothilone-producing parent strain.

A further example of a technique that can be used to isolate genes required for epothilone biosynthesis is the use of transposon mutagenesis to generate mutants of an epothilone-producing organism that, after mutagenesis, fails to produce the polyketide. Thus, the region of the host genome responsible for epothilone production is tagged by the transposon and can be recovered and used as a probe to isolate the native genes from the parent strain. PKS genes that are required for the synthesis of polyketides and that are similar to known PKS genes may be isolated by virtue of their sequence homology to the biosynthetic genes for which the sequence is known, such as those for the biosynthesis of rifamycin or soraphen. Techniques suitable for isolation by homology include standard library screening by DNA hybridization.

Preferred for use as a probe molecule is a DNA fragment that is obtainable from a gene or another DNA sequence that plays a part in the synthesis of a known polyketide. A preferred probe molecule comprises a 1.2 kb *Smal* DNA fragment encoding the ketosynthase domain of the fourth module of the soraphen PKS (U.S. Patent No. 5,716,849), and a more preferred probe molecule comprises the β-ketoacyl synthase domains from the first and second modules of the rifamycin PKS (Schupp *et al.*, *FEMS Microbiology Letters* 159: 201-207 (1998)). These can be used to probe a gene library of an epothilone-producing microorganism to isolate the PKS genes responsible for epothilone biosynthesis.

Despite the well-known difficulties with PKS gene isolation in general and despite the difficulties expected to be encountered with the isolation of epothilone biosynthesis genes in particular, by using the methods described in the instant specification, biosynthetic genes for epothilones A and B can surprisingly be cloned from a microorganism that produces that polyketide. Using the methods of gene manipulation and recombinant production described in this specification, the cloned PKS genes can be modified and expressed in transgenic host organisms.

The isolated epothilone biosynthetic genes can be expressed in heterologous hosts to enable the production of the polyketide with greater efficiency than might be possible from native hosts. Techniques for these genetic manipulations are specific for the different available hosts and are known in the art. For example, heterologous genes can be expressed in *Streptomyces* and other actinomycetes using techniques such as those described in McDaniel et al., Science 262: 1546-1550 (1993) and Kao et al., Science 265: 509-512 (1994), both of which are incorporated herein by reference. See also, Rowe et al., Gene

216: 215-223 (1998); Holmes *et al.*, *EMBO Journal* 12(8): 3183-3191 (1993) and Bibb *et al.*, *Gene* 38: 215-226 (1985), all of which are incorporated herein by reference.

Alternately, genes responsible for polyketide biosynthesis, i.e., epothilone biosynthetic genes, can also be expressed in other host organisms such as pseudomonads and *E. coli*. Techniques for these genetic manipulations are specific for the different available hosts and are known in the art. For example, PKS genes have been successfully expressed in *E. coli* using the pT7-7 vector, which uses the T7 promoter. *See*, Tabor *et al.*, *Proc. Natl. Acad. Sci. USA* 82: 1074-1078 (1985), incorporated herein by reference. In addition, the expression vectors pKK223-3 and pKK223-2 can be used to express heterologous genes in *E. coli*, either in transcriptional or translational fusion, behind the *tac or trc* promoter. For the expression of operons encoding multiple ORFs, the simplest procedure is to insert the operon into a vector such as pKK223-3 in transcriptional fusion, allowing the cognate ribosome binding site of the heterologous genes to be used. Techniques for overexpression in gram-positive species such as *Bacillus* are also known in the art and can be used in the context of this invention (Quax *et al.*, in: *Industrial Microorganisms: Basic and Applied Molecular Genetics, Eds.* Baltz *et al.*, American Society for Microbiology, Washington (1993)).

Other expression systems that may be used with the epothilone biosynthetic genes of the invention include yeast and baculovirus expression systems. See, for example, "The Expression of Recombinant Proteins in Yeasts," Sudbery, P. E., Curr. Opin. Biotechnol. 7(5): 517-524 (1996); "Methods for Expressing Recombinant Proteins in Yeast," Mackay, et al., Editor(s): Carey, Paul R., Protein Eng. Des. 105-153, Publisher: Academic, San Diego, Calif (1996); "Expression of heterologous gene products in yeast," Pichuantes, et al., Editor(s): Cleland, J. L., Craik, C. S., Protein Eng. 129-161, Publisher: Wiley-Liss, New York, N. Y (1996); WO 98/27203; Kealey et al., Proc. Natl. Acad. Sci. USA 95: 505-509 (1998): "Insect Cell Culture: Recent Advances, Bioengineering Challenges And Implications In Protein Production," Palomares, et al., Editor(s): Galindo, Enrique; Ramirez, Octavio T., Adv. Bioprocess Eng. Vol. II, Invited Pap. Int. Symp., 2nd (1998) 25-52, Publisher: Kluwer, Dordrecht, Neth; "Baculovirus Expression Vectors," Jarvis, Donald L., Editor(s): Miller, Lois K., Baculoviruses 389-431, Publisher: Plenum, New York, N. Y. (1997); "Production Of Heterologous Proteins Using The Baculovirus/Insect Expression System," Grittiths, et al., Methods Mol. Biol. (Totowa, N. J.) 75 (Basic Cell Culture Protocols (2nd Edition)) 427-440 (1997); and "Insect Cell Expression Technology," Luckow, Verne A., Protein Eng. 183-218,

Publisher: Wiley-Liss, New York, N. Y. (1996); all of which are incorporated herein by reference.

Another consideration for expression of PKS genes in heterologous hosts is the requirement of enzymes for posttranslational modification of PKS enzymes by phosphopante-theinylation before they can synthesize polyketides. However, the enzymes responsible for this modification of type I PKS enzymes, phosphopantetheinyl (P-pant) transferases are not normally present in many hosts such as *E. coli*. This problem can be solved by coexpression of a P-pant transferase with the PKS genes in the heterologous host, as described by Kealey *et al.*, *Proc. Natl. Acad. Sci. USA* 95: 505-509 (1998), incorporated herein by reference.

Therefore, for the purposes of polyketide production, the significant criteria in the choice of host organism are its ease of manipulation, rapidity of growth (*i.e.* fermentation), possession or the proper molecular machinery for processes such as posttranslational modification, and its lack of susceptibility to the polyketide being overproduced. Most preferred host organisms are actinomycetes such as strains of *Streptomyces*. Other preferred host organisms are pseudomonads and *E. coli*. The above-described methods of polyketide production have significant advantages over the technology currently used in the preparation of the compounds. These advantages include the cheaper cost of production, the ability to produce greater quantities of the compounds, and the ability to produce compounds of a preferred biological enantiomer, as opposed to racemic mixtures inevitably generated by organic synthesis. Compounds produced by heterologous hosts can be used in medical (*e.g.* cancer treatment in the case of epothilones) as well as agricultural applications.

- 30 -

EXPERIMENTAL

The invention will be further described by reference to the following detailed examples. These examples are provided for purposes of illustration only, and are not intended to be limiting unless otherwise specified. Standard recombinant DNA and molecular cloning techniques used here are well known in the art and are described by Ausubel (ed.), Current Protocols in Molecular Biology, John Wiley and Sons, Inc. (1994); T. Maniatis, E. F. Fritsch and J. Sambrook, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor laboratory, Cold Spring Harbor, NY (1989); and by T.J. Silhavy, M.L. Berman, and L.W. Enquist, Experiments with Gene Fusions, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1984).

Example 1: Cultivation of an Epothilone-Producing Strain of Sorangium cellulosum

Sorangium cellulosum strain 90 (DSM 6773, Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig) is streaked out and grown (30°C) on an agar plate of SolE medium (0.35% glucose, 0.05% tryptone, 0.15% MgSO₄ x 7H₂O, 0.05% ammonium sulfate, 0.1% CaCl₂, 0.006% K₂HPO₄, 0.01% sodium dithionite, 0.0008% Fe-EDTA, 1.2% HEPES, 3.5% [vol/vol] supernatant of sterilized stationary *S. cellulosum* culture) pH ad. 7.4. Cells from about 1 square cm are picked and inoculated into 5 mls of G51t liquid medium (0.2% glucose, 0.5% starch, 0.2% tryptone, 0.1% probion S, 0.05% CaCl₂x2H₂O, 0.05% MgSO₄x7H₂O, 1.2% HEPES, pH ad. 7.4) and incubated at 30°C with shaking at 225 rpm. After 4 days, the culture is transferred into 50 mls of G51t and incubated as above for 5 days. This culture is used to inoculate 500 mls of G51t and incubated as above for 6 days. The culture is centrifuged for 10 minutes at 4000 rpm and the cell pellet is resuspended in 50 mls of G51t.

Example 2: Generation of a Bacterial Artificial Chromosome (Bac) Library

To generate a Bac library, *S. cellulosum* cells cultivated as described in Example 1 above are embedded into agarose blocks, lysed, and the liberated genomic DNA is partially digested by the restriction enzyme *HindIII*. The digested DNA is separated on an agarose gel by pulsed-field electrophoresis. Large (approximately 90-150 kb) DNA fragments are

isolated from the agarose gel and ligated into the vector pBelobacII. pBelobacII contains a gene encoding chloramphenicol resistance, a multiple cloning site in the *lacZ* gene providing for blue/white selection on appropriate medium, as well as the genes required for the replication and maintenance of the plasmid at one or two copies per cell. The ligation mixture is used to transform *Escherichia coli* DH10B electrocompetent cells using standard electroporation techniques. Chloramphenicol-resistant recombinant (white, *lacZ* mutant) colonies are transferred to a positively charged nylon membrane filter in 384 3X3 grid format. The clones are lysed and the DNA is cross-linked to the filters. The same clones are also preserved as liquid cultures at -80°C.

Example 3: Screening the Bac Library of *Sorangium cellulosum* 90 for the Presence of Type

I Polyketide Synthase-Related Sequences

The Bac library filters are probed by standard Southern hybridization procedures. The DNA probes used encode β-ketoacyl synthase domains from the first and second modules of the rifamycin polyketide synthase (Schupp et al., FEMS Microbiology Letters 159: 201-207 (1998)). The probe DNAs are generated by PCR with primers flanking each ketosynthase domain using the plasmid pNE95 as the template (pNE95 equals cosmid 2 described in Schupp et al. (1998)). 25 ng of PCR-amplified DNA is isolated from a 0.5% agarose gel and labeled with ³²P-dCTP using a random primer labeling kit (Gibco-BRL, Bethesda MD, USA) according to the manufacturer's instructions. Hybridization is at 65°C for 36 hours and membranes are washed at high stringency (3 times with 0.1x SSC and 0.5% SDS for 20 min at 65°C). The labeled blot is exposed on a phosphorescent screen and the signals are detected on a Phospholmager 445SI (screen and 445SI from Molecular Dynamics). This results in strong hybridization of certain Bac clones to the probes. These clones are selected and cultured overnight in 5 mls of Luria broth (LB) at 37°C. Bac DNA from the Bac clones of interest is isolated by a typical miniprep procedure. The cells are resuspended in 200 μl lysozyme solution (50mM glucose, 10 mM EDTA, 25 mM Tris-HCl. 5mg/ml lysozyme), lysed in 400 µl lysis solution (0.2 N NaOH and 2% SDS), the proteins are precipitated (3.0 M potassium acetate, adjusted to pH5.2 with acetic acid), and the Bac DNA is precipitated with isopropanol. The DNA is resuspended in 20µl of nuclease-free distilled water, restricted with BamHI (New England Biolabs, Inc.) and separated on a 0.7% agarose gel. The gel is blotted by Southern hybridization as described above and probed

under conditions described above, with a 1.2 kb *Smal* DNA fragment encoding the ketosynthase domain of the fourth module of the soraphen polyketide synthase as the probe (*see*, U.S. Patent No. 5,716,849). Five different hybridization patterns are observed. One clone representing each of the five patterns is selected and named pEPO15, pEPO20, pEPO30, pEPO31, and pEPO33, respectively.

Example 4: Subcloning of *Bam*HI Fragments from pEPO15, pEPO20, pEPO30, pEPO31, and pEPO33

The DNA of the five selected Bac clones is digested with BamHI and random fragments are subcloned into pBluescript II SK+ (Stratagene) at the BamHI site. Subclones carrying inserts between 2 and 10 kb in size are selected for sequencing of the flanking ends of the inserts and also probed with the 1.2 Smal probe as described above. Subclones that show a high degree of sequence homology to known polyketide synthases and/or strong hybridization to the soraphen ketosynthase domain are used for gene disruption experiments.

Example 5: Preparation of Streptomycin-Resistant Spontaneous Mutants of *Sorangium* cellulosum strain So ce90

0.1 ml of a three day old culture of *Sorangium cellulosum* strain So ce90, which is raised in liquid medium G52-H (0.2% yeast extract, 0.2% soyameal defatted, 0.8% potato starch, 0.2% glucose, 0.1% MgSO4 x7H2O, 0.1% CaCl2 x2H2O, 0.008% Fe-EDTA, pH ad 7.4 with KOH), is plated out on agar plates with SolE medium supplemented with 100 μg/ml streptomycin. The plates are incubated at 30°C for 2 weeks. The colonies growing on this medium are streptomycin-resistant mutants, which are streaked out and cultivated once more on the same agar medium with streptomycin for purification. One of these streptomycin-resistant mutants is selected and is called BCE28/2.

WO 99/66028 PCT/EP99/04171

- 33 -

Example 6: Gene Disruptions in *Sorangium cellulosum* BCE28/2 Using the Subcloned *Bam*HI Fragments

The BamHI inserts of the subclones generated from the five selected Bac clones as described above are isolated and ligated into the unique BamHI site of plasmid pCIB132 (see, U.S. Patent No. 5,716,849). The pCIB132 derivatives carrying the inserts are transformed into Escherichia coli ED8767 containing the helper plasmid pUZ8 (Hedges and Matthew, Plasmid 2: 269-278 (1979). The transformants are used as donors in conjugation experiments with Sorangium cellulosum BCE28/2 as recipient. For the conjugation, 5-10 x 109 cells of Sorangium cellulosum BCE28/2 from an early stationary phase culture (reaching about 5 x 108 cells/ml) grown at 30°C in liquid medium G51b (G51b equals medium G51t with tryptone replaced by peptone) are mixed in a 1:1 cellular ratio with a late-log phase culture (in LB liquid medium) of E. coli ED8767 containing pClB132 derivatives carrying the subcloned BamHI fragments and the helper plasmid pUZ8. The mixed cells are then centrifuged at 4000 rpm for 10 minutes and resuspended in 0.5 ml G51b medium. This cell suspension is then plated as a drop in the center of a plate with So1E agar containg 50 mg/l kanamycin. The cells obtained after incubation for 24 hours at 30°C are harvested and resuspended in 0.8 ml of G51b medium, and 0.1 to 0.3 ml of this suspension is plated out on a selective So1E solid medium containing phleomycin (30 mg/l), streptomycin (300 mg/l), and kanamycin (50 mg/l). The counterselection of the donor Escherichia coli strain takes place with the aid of streptomycin. The colonies that grow on this selective medium after an incubation time of 8-12 days at a temperature of 30°C are isolated with a plastic loop and streaked out and cultivated on the same agar medium for a second round of selection and purification. The colony-derived cultures that grow on this selective agar medium after 7 days at a temperature of 30°C are transconjugants of Sorangium cellulosum BCE28/2 that have acquired phleomycin resistance by conjugative transfer of the pCIB132 derivatives carrying the subcloned BamHI fragments.

Integration of the pCIB132-derived plasmids into the chromosome of *Sorangium cellulosum* BCE28/2 by homologous recombination is verified by Southern hybridization. For this experiment, complete DNA from 5-10 tranconjugants per transferred *Bam*HI fragment is isolated (from 10 ml cultures grown in medium G52-H for three days) applying the method described by Pospiech and Neumann, *Trends Genet.* 11: 217 (1995). For the Southern blot, the DNA isolated as described above is cleaved either with the restriction

enzymes Ball, Clal, or Notl, and the respective BamHI inserts or pClB132 are used as 32P labelled probes.

Example 7: Analysis of the Effect of the Integrated BamHI Fragments on Epothilone Production by Sorangium cellulosum After Gene Disruption

Transconjugant cells grown on about 1 square cm surface of the selective So1E plates of the second round of selection (see Example 6) are transferred by a sterile plastic loop into 10 ml of medium G52-H in an 50 ml Erlenmeyer flask. After incubation at 30°C and 180 rpm for 3 days, the culture is transfered into 50 ml of medium G52-H in an 200 ml Erlenmeyer flask. After incubation at 30°C and 180 rpm for 4-5 days, 10 ml of this culture is transfered into 50 ml of medium 23B3 (0.2 % glucose, 2 % potato starch, 1.6 % soya meal defatted, 0.0008 % Fe-EDTA Sodium salt, 0.5 % HEPES (4-(2-hydroxyethyl)-piperazine-1ethane-sulfonic-acid), 2 % vol/vol polysterole resin XAD16 (Rohm & Haas), pH adjusted to 7.8 with NaOH) in an 200 ml Erlenmeyer flask.

Quantitative determination of the epothilone produced takes place after incubation of the cultures at 30°C and 180 rpm for 7 days. The complete culture broth is filtered by suction through a 150 µm nylon filter. The resin remaining on the filter is then resuspended in 10 ml isopropanol and extracted by shaking the suspension at 180 rpm for 1 hour. 1 ml is removed from this suspension and centrifuged at 12,000 rpm in an Eppendorff Microfuge. The amount of epothilones A and B therein is determined by means of an HPLC and detection at 250 nm with a UV_DAD detector (HPLC with Waters -Symetry C18 column and a gradient of 0.02 % phosphoric acid 60%-0% and acetonitril 40%-100%).

Transconjugants with three different integrated BamHI fragments subcloned from pEPO15, namely transconjugants with the BamHI fragment of plasmid pEPO15-21, transconjugants with the BamHI fragment of plasmid pEPO15-4-5, and transconjugants with the BamHI fragment of plasmid pEPO15-4-1, are tested in the manner described above. HPLC analysis reveals that all transconjugants no longer produce epothilone A or B. By contrast, epothilone A and B are detectable in a concentration of 2-4 mg/l in transconjugants with BamHI fragments integrated that are derived from pEPO20, pEPO30, pEPO31, pEPO33, and in the parental strain BCE28/2.

Example 8: Nucleotide Sequence Determination of the Cloned Fragments and Construction of Contigs

A. BamHI Insert of Plasmid pEPO15-21

Plasmid DNA is isolated from the strain *Escherichia coli* DH10B [pEPO15-21], and the nucleotide sequence of the 2.3-kb *Bam*HI insert in pEPO15-21 is determined. Automated DNA sequencing is done on the double-stranded DNA template by the dideoxynucleotide chain termination method, using Applied Biosystems model 377 sequencers. The primers used are the universal reverse primer (5' GGA AAC AGC TAT GAC CAT G 3' (SEQ ID NO:24)) and the universal forward primer (5' GTA AAA CGA CGG CCA GT 3' (SEQ ID NO:25)). In subsequent rounds of sequencing reactions, custom-synthesized oligonucleotides, designed for the 3' ends of the previously determined sequences, are used to extend and join contigs. Both strands are entirely sequenced, and every nucleotide is sequenced at least two times. The nucleotide sequence is compiled using the program Sequencher vers. 3.0 (Gene Codes Corporation), and analyzed using the University of Wisconsin Genetics Computer Group programs. The nucleotide sequence of the 2213-bp insert corresponds to nucleotides 20779-22991 of SEQ ID NO:1.

B. BamHI Insert of Plasmid pEPO15-4-1

Plasmid DNA is isolated from the strain *Escherichia coli* DH10B [pEPO15-4-1], and the nucleotide sequence of the 3.9-kb *Bam*HI insert in pEPO15-4-1 is determined as described in (A) above. The nucleotide sequence of the 3909-bp insert corresponds to nucleotides 16876-20784 of SEQ ID NO:1.

C. BamHI Insert of Plasmid pEPO15-4-5

Plasmid DNA is isolated from the strain *Escherichia coli* DH10B [pEPO15-4-5], and the nucleotide sequence of the 2.3-kb *Bam*HI insert in pEPO15-4-5 is determined as described in (A) above. The nucleotide sequence of the 2233-bp insert corresponds to nucleotides 42528-44760 of SEQ ID NO:1.

Example 9: Subcloning and Ordering of DNA Fragments from pEPO15 Containing Epothilone Biosynthesis Genes

pEPO15 is digested to completion with the restriction enzyme *HindIII* and the resulting fragments are subcloned into pBluescript II SK- or pNEB193 (New England Biolabs) that has been cut with *HindIII* and dephosphorylated with calf intestinal alkaline phosphatase. Six different clones are generated and named pEPO15-NH1, pEPO15-NH2, pEPO15-NH6, pEPO15-NH24 (all based on pNEB193), and pEPO15-H2.7 and pEPO15-H3.0 (both based on pBluescript II SK-).

The *Bam*HI insert of pEPO15-21 is isolated and DIG-labeled (Non-radioactive DNA labeling and detection system, Boehringer Mannheim), and used as a probe in DNA hybridization experiments at high stringency against pEPO15-NH1, pEPO15-NH2, pEPO15-NH6, pEPO15-NH24, pEPO15-H2.7 and pEPO15-H3.0. Strong hybridization signal is detected for pEPO15-NH24, indicating that pEPO15-21 is contained within pEPO15-NH24.

The *Bam*HI insert of pEPO15-4-1 is isolated and DIG-labeled as above, and used as a probe in DNA hybridization experiments at high stringency against pEPO15-NH1, pEPO15-NH2, pEPO15-NH6, pEPO15-NH24, pEPO15-H2.7 and pEPO15-H3.0. Strong hybridization signals are detected for pEPO15-NH24 and pEPO15-H2.7. Nucleotide sequence data generated from one end each of pEPO15-NH24 and pEPO15-H2.7 are also in complete agreement with the previously determined sequence of the *Bam*HI insert of pEPO15-4-1. These experiments demonstrate that pEPO15-4-1 (which contains one internal *Hin*dIII site) overlaps pEPO15-H2.7 and pEPO15-NH24, and that pEPO15-H2.7 and pEPO15-NH24, in this order, are contiguous.

The *Bam*HI insert of pEPO15-4-5 is isolated and DIG-labeled as above, and used as a probe in DNA hybridization experiments at high stringency against pEPO15-NH1, pEPO15-NH2, pEPO15-NH6, pEPO15-NH24, pEPO15-H2.7 and pEPO15-H3.0. Strong hybridization signal is detected for pEPO15-NH2, indicating that pEPO15-21 is contained within pEPO15-NH2.

Nucleotide sequence data is generated from both ends of pEPO15-NH2 and from the end of pEPO15-NH24 that does not overlap with pEPO15-4-1. PCR primers NH24 end "B": GTGACTGGCGCCTGGAATCTGCATGAGC (SEQ ID NO:26), NH2 end "A": AGCGGGAGCTTGCTAGACATTCTGTTTC (SEQ ID NO:27), and NH2 end "B": GACGCGCCTCGGGCAGCGCCCCAA (SEQ ID NO:28), pointing towards the *HindIII* sites,

are designed based on these sequences and used in amplification reactions with pEPO15 and, in separate experiments, with *Sorangium cellulosum* So ce90 genomic DNA as the templates. Specific amplification is found with primer pair NH24 end "B" and NH2 end "A" with both templates. The amplimers are cloned into pBluescript II SK- and completely sequenced. The sequences of the amplimers are identical, and also agree completely with the end sequences of pEPO15-NH24 and pEPO15-NH2, fused at the *HindIII* site, establishing that the *HindIII* fragments of pEPO15-NH2 and pEPO15-NH24 are, in this order, contiguous.

The HindIII insert of pEPO15-H2.7 is isolated and DIG-labeled as above, and used as a probe in a DNA hybridization experiment at high stringency against pEPO15 digested by Notl. A Notl fragment of about 9 kb in size shows a strong a hybridization, and is further subcloned into pBluescript II SK- that has been digested with Notl and dephosphorylated with calf intestinal alkaline phosphatase, to yield pEPO15-N9-16. The Noth insert of pEPO15-N9-16 is isolated and DIG-labeled as above, and used as a probe in DNA hybridization experiments at high stringency against pEPO15-NH1, pEPO15-NH2, pEPO15-NH6, pEPO15-NH24, pEPO15-H2.7 and pEPO15-H3.0. Strong hybridization signals are detected for pEPO15-NH6, and also for the expected clones pEPO15-H2.7 and pEPO15-NH24. Nucleotide sequence data is generated from both ends of pEPO15-NH6 and from the end of pEPO15-H2.7 that does not overlap with pEPO15-4-1. PCR primers are designed pointing towards the HindIII sites and used in amplification reactions with pEPO15 and, in separate experiments, with Sorangium cellulosum So ce90 genomic DNA as the templates. Specific amplification is found with primer pair pEPO15-NH6 end "B": CACCGAAGCGTCGATCTGGTCCATC (SEQ ID NO:29) and pEPO15-H2.7 end "A": CGGTCAGATCGACGGCCTTTCC (SEQ ID NO:30) with both templates. The amplimers are cloned into pBluescript II SK- and completely sequenced. The sequences of the amplimers are identical, and also agree completely with the end sequences of pEPO15-NH6 and pEPO15-H2.7, fused at the HindllI site, establishing that the HindllI fragments of pEPO15-NH6 and pEPO15-H2.7 are, in this order, contiguous.

All of these experiments, taken together, establish a contig of *Hin*dIII fragments covering a region of about 55 kb and consisting of the *Hin*dIII inserts of pEPO15-NH6, pEPO15-H2.7, pEPO15-NH24, and pEPO15-NH2, in this order. The inserts of the remaining two *Hin*dIII subclones, namely pEPO15-NH1 and pEPO15-H3.0, are not found to be parts of this contig.

WO 99/66028

Example 10: Further Extension of the Subclone Contig Covering the Epothilone Biosynthesis Genes

An approximately 2.2 kb BamHI – HindIII fragment derived from the downstream end of the insert of pEPO15-NH2 and thus representing the downstream end of the subclone contig described in Example 9 is isolated, DIG-labeled, and used in Southern hybridization experiments against pEPO15 and pEPO15-NH2 DNAs digested with several enzymes. The strongly hybridizing bands are always found to be the same in size between the two target DNAs indicating that the Sorangium cellulosum So ce90 genomic DNA fragment cloned into pEPO15 ends with the HindIII site at the downstream end of pEPO15-NH2.

A cosmid DNA library of *Sorangium cellulosum* So ce90 is generated, using established procedures, in pScosTriplex-II (Ji, et al., Genomics 31: 185-192 (1996)). Briefly, high-molecular weight genomic DNA of *Sorangium cellulosum* So ce90 is partially digested with the restriction enzyme *Sau*3AI to provide fragments with average sizes of about 40 kb, and ligated to *Bam*HI and *Xba*I digested pScosTriplex-II. The ligation mix is packaged with Gigapack III XL (Stratagene) and used to transfect *E. coli* XL1 Blue MR cells.

The cosmid library is screened with the approximately 2.2 kb *BamHI – HindIII* fragment, derived from the downstream end of the insert of pEPO15-NH2, used as a probe in colony hybridization. A strongly hybridizing clone, named pEPO4E7 is selected.

pEPO4E7 DNA is isolated, digested with several restriction endonucleases, and probed in Southern hybridization experiments with the 2.2 kb *BamHI – HindIII* fragment. A strongly hybridizing *Not*I fragment of approximately 9 kb in size is selected and subcloned into pBluescript II SK- to yield pEPO4E7-N9-8. Further Southern hybridization experiments reveal that the approximately 9 kb *Not*I insert of pEPO4E7-N9-8 overlaps pEPO15-NH2 over 6 kb in a *Not*I – *HindIII* fragment, while the remaining approximately 3 kb *HindIII – Not*I fragment would extend the subclone contig described in Example 9. End sequencing reveals, however, that the downstream end of the insert of pEPO4E7-N9-8 contains the *BamHI – Not*I polylinker of pScosTriplex-II, thereby indicating that the genomic DNA insert of pEPO4E7 ends at a *Sau*3AI site within the extending *HindIII – Not*I fragment and that the *Not*I site is derived from pScosTriplex-II.

An approximately 1.6 kb *Pstl* – *Sall* fragment derived from the approximately 3 kb extending *Hin*dIII – *Not*l subfragment of pEPO4E7-N9-8, containing only *Sorangium*

cellulosum So ce90—derived sequences free of vector, is used as a probe against the bacterial artificial chromosome library described in Example 2. Besides the previously-isolated EPO15, a Bac clone, named EPO32, is found to strongly hybridize to the probe. pEPO32 is isolated, digested with several restriction endonucleases, and hybridized with the approximately 1.6 kb *Pstl – Sall* probe. A *HindIII – Eco*RV fragment of about 13 kb in size is found to strongly hybridize to the probe, and is subcloned into pBluescript II SK-digested with *HindIII* and *HincII* to yield pEPO32-HEV15.

Oligonucleotide primers are designed based on the downstream end sequence of pEPO15-NH2 and on the upstream (*HindIII*) end sequence derived from pEPO32-HEV15, and used in sequencing reactions with pEPO4E7-N9-8 as the template. The sequences reveal the existence of a small *HindIII* fragment (EPO4E7-H0.02) of 24 bp, undetectable in standard restriction analysis, separating the *HindIII* site at the downstream end of pEPO15-NH2 from the *HindIII* site at the upstream end of pEPO32-HEV15.

Thus, the subclone contig described in Example 9 is extended to include the *HindIII* fragment EPO4E7-H0.02 and the insert of pEPO32-HEV15, and constitutes the inserts of: pEPO15-NH6, pEPO15-H2.7, pEPO15-NH24, pEPO15-NH2, EPO4E7-H0.02 and pEPO32-HEV15, in this order.

Example 11: Nucleotide Sequence Determination of the Subclone Contig Covering the Epothilone Biosynthesis Genes

The nucleotide sequence of the subclone contig described in Example 10 is determined as follows.

pEPO15-H2.7. Plasmid DNA is isolated from the strain *Escherichia coli* DH10B [pEPO15-H2.7], and the nucleotide sequence of the 2.7-kb *Bam*HI insert in pEPO15-H2.7 is determined. Automated DNA sequencing is done on the double-stranded DNA template by the dideoxynucleotide chain termination method, using Applied Biosystems model 377 sequencers. The primers used are the universal reverse primer (5' GGA AAC AGC TAT GAC CAT G 3' (SEQ ID NO:24)) and the universal forward primer (5' GTA AAA CGA CGG CCA GT 3' (SEQ ID NO:25)). In subsequent rounds of sequencing reactions, custom-synthesized oligonucleotides, designed for the 3' ends of the previously determined sequences, are used to extend and join contigs.

pEPO15-NH6, pEPO15-NH24 and pEPO15-NH2. The *Hin*dIII inserts of these plasmids are isolated, and subjected to random fragmentation using a Hydroshear apparatus (Genomic Instrumentation Services, Inc.) to yield an average fragment size of 1-2 kb. The fragments are end-repaired using T4 DNA Polymerase and Klenow DNA Polymerase enzymes in the presence of desoxynucleotide triphosphates, and phosphorylated with T4 DNA Kinase in the presence of ribo-ATP. Fragments in the size range of 1.5-2.2 kb are isolated from agarose gels, and ligated into pBluescript II SK- that has been cut with *Eco*RV and dephosphorylated. Random subclones are sequenced using the universal reverse and the universal forward primers.

pEPO32-HEV15. pEPO32-HEV15 is digested with *HindIII* and *SspI*, the approximately 13.3 kb fragment containing the ~13 kb *HindIII* — *EcoRV* insert from *So. cellulosum* So ce90 and a 0.3 kb *HincII* — *SspI* fragment from pBluescript II SK- is isolated, and partially digested with *HaeIII* to yield fragments with an average size of 1-2 kb. Fragments in the size range of 1.5-2.2 kb are isolated from agarose gels, and ligated into pBluescript II SK- that has been cut with *EcoRV* and dephosphorylated. Random subclones are sequenced using the universal reverse and the universal forward primers.

The chromatograms are analyzed and assembled into contigs with the Phred, Phrap and Consed programs (Ewing, et al., Genome Res. 8(3): 175-185 (1998); Ewing, et al., Genome Res. 8(3): 195-202 (1998)). Contig gaps are filled, sequence discrepancies are resolved, and low-quality regions are resequenced using custom-designed oligonucleotide primers for sequencing on either the original subclones or selected clones from the random subclone libraries. Both strands are completely sequenced, and every basepair is covered with at least a minimum aggregated Phred score of 40 (confidence level of 99.99%).

The nucleotide sequence of the 68750 bp contig is shown as SEQ ID NO:1.

Example 12: Nucleotide Sequence Analysis of the Epothilone Biosynthesis Genes

SEQ ID NO:1 is found to contain 22 ORFs as detailed below in Table 1:

Table 1

| ORF | Start codon | Stop codon | Homology of deduced protein | Proposed function of deduced protein |
|---------|----------------------------------|----------------------------------|--|--|
| orfl | outside of sequenced range | 1826 | | |
| orf2 * | 3171 | 1900 | Hypothetical protein SP: Q11037; DD-peptidase SP:P15555 | |
| orf3 | 3415 | 5556 | Na/H antiporter PID: D1017724 | Transport |
| orf4 * | 5992 | 5612 | | |
| orf5 | 6226 | 6675 | | |
| epoA | 7610 | 11875 | Type I polyketide synthase | Epothilone synthase: Thiazole ring formation |
| epoP | 11872 | 16104 | Non-ribosomal peptide synthetase | Epothilone synthase: Thiazole ring formation |
| ероВ | 16251 | 21749 | Type I polyketide synthase | Epothilone synthase: Polyketide backbone formation |
| ероС | 21746 | 43519 | Type I polyketide synthase | Epothilone synthase: Polyketide backbone formation |
| epoD | 43524 | 54920 | Type I polyketide synthase | Epothilone synthase: Polyketide backbone formation |
| epoE | 54935 | 62254 | Type I polyketide synthase | Epothilone synthase: Polyketide backbone formation |
| epoF | 62369 | 63628 | Cytochrome P450 | Epothilone macrolactone oxidase |
| orf6 | 63779 | 64333 | | |
| orf7 * | 64290 | 63853 | | |
| orf8 | 64363 | 64920 | | |
| orf9 * | 64727 | 64287 | | |
| orf10 | 65063 | 65767 | | |
| orf11 * | 65874 | 65008 | | |
| orf12 * | 66338 | 65871 | | |
| orf13 | 66667 | 67137 | | |
| orf14 | 67334 | 68251 | Hypothetical protein GI:3293544; Cation efflux system protein GI:2623026 | Transport |
| orf15 | 68346 | outside of sequenced range | | |

^{*} On the reverse complementer strand. Numbering according to SEQ ID NO:1.

epoA (nucleotides 7610-11875 of SEQ ID NO:1) codes for EPOS A (SEQ ID NO:2), a type I polyketide synthase consisting of a single module, and harboring the following domains: β-ketoacyl-synthase (KS) (nucleotides 7643-8920 of SEQ ID NO:1, amino acids 11-

WO 99/66028

437 of SEQ ID NO:2); acyltransferase (AT) (nucleotides 9236-10201 of SEQ ID NO:1, amino acids 543-864 of SEQ ID NO:2); enoyl reductase (ER) (nucleotides 10529-11428 of SEQ ID NO:1, amino acids 974-1273 of SEQ ID NO:2); and acyl carrier protein homologous domain (ACP) (nucleotides 11549-11764 of SEQ ID NO:1, amino acids 1314-1385 of SEQ ID NO:2). Sequence comparisons and motif analysis (Haydock, et al. *FEBS Lett.* 374: 246-248 (1995); Tang, et al., *Gene* 216: 255-265 (1998)) reveal that the AT encoded by EPOS A is specific for malonyl-CoA. EPOS A should be involved in the initiation of epothilone biosynthesis by loading the acetate unit to the multienzyme complex that will eventually form part of the 2-methylthiazole ring (C26 and C20).

epoP (nucleotides 11872-16104 of SEQ ID NO:1) codes for EPOS P (SEQ ID NO:3), a non-ribosomal peptide synthetase containing one module. EPOS P harbors the following domains:

- peptide bond formation domain, as delineated by motif K (amino acids 72-81 [FPLTDIQESY] of SEQ ID NO:3, corresponding to nucleotide positions 12085-12114 of SEQ ID NO:1); motif L (amino acids 118-125 [VVARHDML] of SEQ ID NO:3, corresponding to nucleotide positions 12223-12246 of SEQ ID NO:1); motif M (amino acids 199-212 [SIDLINVDLGSLSI] of SEQ ID NO:3, corresponding to nucleotide positions 12466-12507 of SEQ ID NO:1); and motif O (amino acids 353-363 [GDFTSMVLLDI] of SEQ ID NO:3, corresponding to nucleotide positions 12928-12960 of SEQ ID NO:1);
- aminoacyl adenylate formation domain, as delineated by motif A (amino acids 549-565 [LTYEELSRRSRRLGARL] of SEQ ID NO:3, corresponding to nucleotide positions 13516-13566 of SEQ ID NO:1); motif B (amino acids 588-603 [VAVLAVLESGAAYVPI] of SEQ ID NO:3, corresponding to nucleotide positions 13633-13680 of SEQ ID NO:1); motif C (amino acids 669-684 [AYVIYTSGSTGLPKGV] of SEQ ID NO:3, corresponding to nucleotide positions 13876-13923 of SEQ ID NO:1); motif D (amino acids 815-821 [SLGGATE] of SEQ ID NO:3, corresponding to nucleotide positions 14313-14334 of SEQ ID NO:1); motif E (amino acids 868-892 [GQLYIGGVGLALGYWRDEEKTRKSF] of SEQ ID NO:3, corresponding to nucleotide positions 14473-14547 of SEQ ID NO:1); motif F (amino acids 903-912 [YKTGDLGRYL] of SEQ ID NO:3, corresponding to nucleotide positions 14578-14607 of SEQ ID NO:1); motif G (amino acids 918-940 [EFMGREDNQIKLRGYRVELGEIE] of SEQ ID NO:3, corresponding to nucleotide positions 14623-14692 of SEQ ID NO:1); motif H (amino acids 1268-1274 [LPEYMVP] of SEQ ID NO:3, corresponding to nucleotide positions 15673-15693 of SEQ ID NO:1); and

motif I (amino acids 1285-1297 [LTSNGKVDRKALR] of SEQ ID NO:3, corresponding to nucleotide positions 15724-15762 of SEQ ID NO:1);

- an unknown domain, inserted between motifs G and H of the aminoacyl adenylate formation domain (amino acids 973-1256 of SEQ ID NO:3, corresponding to nucleotide positions 14788-15639 of SEQ ID NO:1); and
- a peptidyl carrier protein homologous domain (PCP), delineated by motif J (amino acids 1344-1351 [GATSIHIV] of SEQ ID NO:3, corresponding to nucleotide positions 15901-15924 of SEQ ID NO:1).

It is proposed that EPOS P is involved in the activation of a cysteine by adenylation, binding the activated cysteine as an aminoacyl-S-PCP, forming a peptide bond between the enzyme-bound cysteine and the acetyl-S-ACP supplied by EPOS A, and the formation of the initial thiazoline ring by intramolecular heterocyclization. The unknown domain of EPOS P displays very weak homologies to NAD(P)H oxidases and reductases from Bacillus species. Thus, this unknown domain and/or the ER domain of EPOS A may be involved in the oxidation of the initial 2-methylthiazoline ring to a 2-methylthiazole.

epoB (nucleotides 16251-21749 of SEQ ID NO:1) codes for EPOS B (SEQ ID NO:4), a type I polyketide synthase consisting of a single module, and harboring the following domains: KS (nucleotides 16269-17546 of SEQ ID NO:1, amino acids 7-432 of SEQ ID NO:4); AT (nucleotides 17865-18827 of SEQ ID NO:1, amino acids 539-859 of SEQ ID NO:4); dehydratase (DH) (nucleotides 18855-19361 of SEQ ID NO:1, amino acids 869-1037 of SEQ ID NO:4); β-ketoreductase (KR) (nucleotides 20565-21302 of SEQ ID NO:1, amino acids 1439-1684 of SEQ ID NO:4); and ACP (nucleotides 21414-21626 of SEQ ID NO:1, amino acids 1722-1792 of SEQ ID NO:4). Sequence comparisons and motif analysis reveal that the AT encoded by EPOS B is specific for methylmalonyl-CoA. EPOS A should be involved in the first polyketide chain extension by catalysing the Claisen-like condensation of the 2-methyl-4-thiazolecarboxyl-S-PCP starter group with the methylmalonyl-S-ACP, and the concomitant reduction of the b-keto group of C17 to an enoyl.

epoC (nucleotides 21746-43519 of SEQ ID NO:1) codes for EPOS C (SEQ ID NO:5), a type I polyketide synthase consisting of 4 modules. The first module harbors a KS (nucleotides 21860-23116 of SEQ ID NO:1, amino acids 39-457 of SEQ ID NO:5); a malonyl CoAspecific AT (nucleotides 23431-24397 of SEQ ID NO:1, amino acids 563-884 of SEQ ID NO:5); a KR (nucleotides 25184-25942 of SEQ ID NO:1, amino acids 1147-1399 of SEQ ID NO:5); and an ACP (nucleotides 26045-26263 of SEQ ID NO:1, amino acids 1434-1506 of

SEQ ID NO:5). This module incorporates an acetate extender unit (C14-C13) and reduces the B-keto group at C15 to the hydroxyl group that takes part in the final lactonization of the epothilone macrolactone ring. The second module of EPOS C harbors a KS (nucleotides 26318-27595 of SEQ ID NO:1, amino acids 1524-1950 of SEQ ID NO:5); a malonyl CoAspecific AT (nucleotides 27911-28876 of SEQ ID NO:1, amino acids 2056-2377 of SEQ ID NO:5); a KR (nucleotides 29678-30429 of SEQ ID NO:1, amino acids 2645-2895 of SEQ ID NO:5); and an ACP (nucleotides 30539-30759 of SEQ ID NO:1, amino acids 2932-3005 of SEQ ID NO:5). This module incorporates an acetate extender unit (C12-C11) and reduces the β-keto group at C13 to a hydroxyl group. Thus, the nascent polyketide chain of epothilone corresponds to epothilone A, and the incorporation of the methyl side chain at C12 in epothilone B would require a post-PKS C-methyltransferase activity. The formation of the epoxi ring at C13-C12 would also require a post-PKS oxidation step. The third module of EPOS C harbors a KS (nucleotides 30815-32092 of SEQ ID NO:1, amino acids 3024-3449 of SEQ ID NO:5); a malonyl CoA-specific AT (nucleotides 32408-33373 of SEQ ID NO:1, amino acids 3555-3876 of SEQ ID NO:5); a DH (nucleotides 33401-33889 of SEQ ID NO:1, amino acids 3886-4048 of SEQ ID NO:5); an ER (nucleotides 35042-35902 of SEQ ID NO:1, amino acids 4433-4719 of SEQ ID NO:5); a KR (nucleotides 35930-36667 of SEQ ID NO:1, amino acids 4729-4974 of SEQ ID NO:5); and an ACP (nucleotides 36773-36991 of SEQ ID NO:1, amino acids 5010-5082 of SEQ ID NO:5). This module incorporates an acetate extender unit (C10-C9) and fully reduces the β-keto group at C11. The fourth module of EPOS C harbors a KS (nucleotides 37052-38320 of SEQ ID NO:1, amino acids 5103-5525 of SEQ ID NO:5); a methylmalonyl CoA-specific AT (nucleotides 38636-39598 of SEQ ID NO:1, amino acids 5631-5951 of SEQ ID NO:5); a DH (nucleotides 39635-40141 of SEQ ID NO:1, amino acids 5964-6132 of SEQ ID NO:5); an ER (nucleotides 41369-42256 of SEQ ID NO:1, amino acids 6542-6837 of SEQ ID NO:5); a KR (nucleotides 42314-43048 of SEQ ID NO:1, amino acids 6857-7101 of SEQ ID NO:5); and an ACP (nucleotides 43163-43378 of SEQ ID NO:1, amino acids 7140-7211 of SEQ ID NO:5). This module incorporates a propionate extender unit (C24 and C8-C7) and fully reduces the β-keto group at C9.

epoD (nucleotides 43524-54920 of SEQ ID NO:1) codes for EPOS D (SEQ ID NO:6), a type I polyketide synthase consisting of 2 modules. The first module harbors a KS (nucleotides 43626-44885 of SEQ ID NO:1, amino acids 35-454 of SEQ ID NO:6); a methylmalonyl CoA-specific AT (nucleotides 45204-46166 of SEQ ID NO:1, amino acids 561-881 of SEQ ID NO:6); a KR (nucleotides 46950-47702 of SEQ ID NO:1, amino acids

1143-1393 of SEQ ID NO:6); and an ACP (nucleotides 47811-48032 of SEQ ID NO:1, amino acids 1430-1503 of SEQ ID NO:6). This module incorporates a propionate extender unit (C23 and C6-C5) and reduces the β-keto group at C7 to a hydoxyl group. The second module harbors a KS (nucleotides 48087-49361 of SEQ ID NO:1, amino acids 1522-1946 of SEQ ID NO: 6); a methylmalonyl CoA-specific AT (nucleotides 49680-50642 of SEQ ID NO:1, amino acids 2053-2373 of SEQ ID NO:6); a DH (nucleotides 50670-51176 of SEQ ID NO:1, amino acids 2383-2551 of SEQ ID NO:6); a methyltransferase (MT, nucleotides 51534-52657 of SEQ ID NO:1, amino acids 2671-3045 of SEQ ID NO:6); a KR (nucleotides 53697-54431 of SEQ ID NO:1, amino acids 3392-3636 of SEQ ID NO:6); and an ACP (nucleotides 54540-54758 of SEQ ID NO:1, amino acids 3673-3745 of SEQ ID NO:6). This module incorporates a propionate extender unit (C21 or C22 and C4-C3) and reduces the β-keto group at C5 to a hydoxyl group. This reduction is somewhat unexpected, since epothilones contain a keto group at C5. Discrepancies of this kind between the deduced reductive capabilities of PKS modules and the redox state of the corresponding positions in the final polyketide products have been, however, reported in the literature (see, for example, Schwecke, et al., Proc. Natl. Acad. Sci. USA 92: 7839-7843 (1995) and Schupp, et al., FEMS Microbiology Letters 159: 201-207 (1998)). An important feature of epothilones is the presence of gem-methyl side groups at C4 (C21 and C22). The second module of EPOS D is predicted to incorporate a propionate unit into the growing polyketide chain, providing one methyl side chain at C4. This module also contains a methyltransferase domain integrated into the PKS between the DH and the KR domains, in an arrangement similar to the one seen in the HMWP1 yersiniabactin synthase (Gehring, A.M., DeMoll, E., Fetherston, J.D., Mori, I., Mayhew, G.F., Blattner, F.R., Walsh, C.T., and Perry, R.D.: Iron acquisition in plague: modular logic in enzymatic biogenesis of yersiniabactin by Yersinia pestis. Chem. Biol. 5, 573-586, 1998). This MT domain in EPOS D is proposed to be responsible for the incorporation of the second methyl side group (C21 or C22) at C4.

epoE (nucleotides 54935-62254 of SEQ ID NO:1) codes for EPOS E (SEQ ID NO:7), a type I polyketide synthase consisting of one module, harboring a KS (nucleotides 55028-56284 of SEQ ID NO:1, amino acids 32-450 of SEQ ID NO:7); a malonyl CoA-specific AT (nucleotides 56600-57565 of SEQ ID NO:1, amino acids 556-877 of SEQ ID NO:7); a DH (nucleotides 57593-58087 of SEQ ID NO:1, amino acids 887-1051 of SEQ ID NO:7); a probably nonfunctional ER (nucleotides 59366-60304 of SEQ ID NO:1, amino acids 1478-1790 of SEQ ID NO:7); a KR (nucleotides 60362-61099 of SEQ ID NO:1, amino acids 1810-2055

of SEQ ID NO:7); an ACP (nucleotides 61211-61426 of SEQ ID NO:1, amino acids 2093-2164 of SEQ ID NO:7); and a thioesterase (TE) (nucleotides 61427-62254 of SEQ ID NO:1, amino acids 2165-2439 of SEQ ID NO:7). The ER domain in this module harbors an active site motif with some highly unusual amino acid substitutions that probably render this domain inactive. The module incorporates an acetate extender unit (C2-C1), and reduces the β-keto at C3 to an enoyl group. Epothilones contain a hydroxyl group at C3, so this reduction also appears to be excessive as discussed for the second module of EPOS D. The TE domain of EPOS E takes part in the release and cyclization of the grown polyketide chain via lactonization between the carboxyl group of C1 and the hydroxyl group of C15.

Five ORFs are detected upstream of *epo*A in the sequenced region. The partially sequenced *orf*1 has no homologues in the sequence databanks. The deduced protein product (Orf 2, SEQ ID NO:10) of *orf*2 (nucleotides 3171-1900 on the reverse complement strand of SEQ ID NO:1) shows strong similarities to hypothetical ORFs from *Mycobacterium* and *Streptomyces coelicolor*, and more distant similarities to carboxypeptidases and DD-peptidases of different bacteria. The deduced protein product of *orf*3 (nucleotides 3415-5556 of SEQ ID NO:1), Orf 3 (SEQ ID NO:11), shows homologies to Na/H antiporters of different bacteria. Orf 3 might take part in the export of epothilones from the producer strain. *orf*4 and *orf*5 have no homologues in the sequence databanks.

Eleven ORFs are found downstream of *epo*E in the sequenced region. *epo*F (nucleotides 62369-63628 of SEQ ID NO:1) codes for EPOS F (SEQ ID NO:8), a deduced protein with strong sequence similarities to cytochrome P450 oxygenases. EPOS F may take part in the adjustment of the redox state of the carbons C12, C5, and/or C3. The deduced protein product of *orf*14 (nucleotides 67334-68251 of SEQ ID NO:1), Orf 14 (SEQ ID NO:22) shows strong similarities to GI:3293544, a hypothetic protein with no proposed function from *Streptomyces coelicolor*, and also to GI:2654559, the human embrionic lung protein. It is also more distantly related to cation efflux system proteins like GI:2623026 from *Methanobacterium thermoautotrophicum*, so it might also take part in the export of epothilones from the producing cells. The remaining ORFs (*orf*6-*orf*13 and *orf*15) show no homologies to entries in the sequence databanks.

Example 13: Recombinant Expression of Epothilone Biosynthesis Genes

Epothilone synthase genes according to the present invention are expressed in heterologous organisms for the purposes of epothilone production at greater quantities than can be accomplished by fermentation of *Sorangium cellulosum*. A preferable host for heterologous expression is *Streptomyces*, e.g. *Streptomyces coelicolor*, which natively produces the polyketide actinorhodin. Techniques for recombinant PKS gene expression in this host are described in McDaniel *et al.*, *Science* 262: 1546-1550 (1993) and Kao *et al.*, *Science* 265: 509-512 (1994). See also, Holmes *et al.*, *EMBO Journal* 12(8): 3183-3191 (1993) and Bibb *et al.*, *Gene* 38: 215-226 (1985), as well as U.S. Patent Nos. 5,521,077, 5,672,491, and 5,712,146, which are incorporated herein by reference.

According to one method, the heterologous host strain is engineered to contain a chromosomal deletion of the actinorhodin (act) gene cluster. Expression plasmids containing the epothilone synthase genes of the invention are constructed by transferring DNA from a temperature-sensitive donor plasmid to a recipient shuttle vector in E. coli (McDaniel et al. (1993) and Kao et al. (1994)), such that the synthase genes are built-up by homologous recombination within the vector. Alternatively, the epothilone synthase gene cluster is introduced into the vector by restriction fragment ligation. Following selection, e.g. as described in Kao et al. (1994), DNA from the vector is introduced into the act-minus Streptomyces coelicolor strain according to protocols set forth in Hopwood et al., Genetic Manipulation of Streptomyces. A Laboratory Manual (John Innes Foundation, Norwich, United Kingdom, 1985), incorporated herein by reference. The recombinant Streptomyces strain is grown on R2YE medium (Hopwood et al. (1985)) and produces epothilones. Alternatively, the epothilone synthase genes according to the present invention are expressed in other host organisms such as pseudomonads, Bacillus, yeast, insect cells and/or E. coli. PKS and NRPS genes are preferably expressed in E. coli using the pT7-7 vector, which uses the T7 promoter. See, Tabor et al., Proc. Natl. Acad. Sci. USA 82: 1074-1078 (1985). In another embodiment, the expression vectors pKK223-3 and pKK223-2 are used to express PKS and NRPS genes in E. coli, either in transcriptional or translational fusion, behind the tac or trc promoter. Expression of PKS and NRPS genes in heterologous hosts, which do not naturally have the phosphopantetheinyl (P-pant) transferases needed for posttranslational modification of PKS enzymes, requires the coexpression in the host of a Ppant transferase, as described by Kealey et al., Proc. Natl. Acad. Sci. USA 95: 505-509 (1998).

Example 14: Isolation of Epothilones from Producing Strains

Examples of cultivation, fermentation, and extraction procedures for polyketide isolation, which are useful for extracting epothilones from both native and recombinant hosts according to the present invention, are given in WO 93/10121, incorporated herein by reference, in Example 57 of U.S. Patent No. 5,639,949, in Gerth *et al.*, *J. Antibiotics* 49: 560-563 (1996), and in Swiss patent application no. 396/98, filed February 19, 1998, and U.S. patent application no. 09/248,910 (that discloses also preferred mutant strains of Sorangium cellulosum), both of which are incorporated herein by reference. The following are procedures that are useful for isolating epothilones from cultured *Sorangium cellulosum* strains such as So ce90, and may also be used for the isolation of epothilone from recombinant hosts.

A: Cultivation of epothilone-producing strains:

Strain:

Sorangium cellulosum Soce-90 or a recombinant host strain

according to the present invention.

Preservation of the strain: In liquid N2.

Media:

Precultures and intermediate cultures: G52

Main culture:

1B12

1 ml/l

G52 Medium:

EDTA-Fe(III)-Na salt (8 g/l)

| yeast extract, low in salt (BioSpringer, Maison Alfort, France) | 2 g/l |
|---|-------|
| MgSO₄ (7 H₂O) | 1 g/l |
| CaCl ₂ (2 H ₂ O) | 1 g/l |
| soya meal defatted Soyamine 50T (Lucas Meyer, Hamburg, | |
| Germany) | 2 g/l |
| potato starch Noredux A-150 (Blattmann, Waedenswil, | |
| Switzerland) | 8 g/l |
| glucose anhydrous | 2 g/l |

pH 7.4, corrected with KOH Sterilisation: 20 mins. 120 °C

1B12 Medium:

potato starch Noredux A-150 (Blattmann, Waedenswil,

Switzerland)

20 g/l

soya meal defatted Soyamine 50T (Lucas Meyer, Hamburg,

Germany)

11 g/l

EDTA-Fe(III)-Na salt

8 mg/l

pH 7.8, corrected with KOH Sterilisation: 20 mins. 120 °C

Addition of cyclodextrins and cyclodextrin derivatives:

Cyclodextrins (Fluka, Buchs, Switzerland, or Wacker Chemie, Munich, Germany) in different concentrations are sterilised separately and added to the 1B12 medium prior to seeding.

<u>Cultivation</u>: 1 ml of the suspension of *Sorangium cellulosum* Soce-90 from a liquid N₂ ampoule is transferred to 10 ml of G52 medium (in a 50 ml Erlenmeyer flask) and incubated for 3 days at 180 rpm in an agitator at 30°C, 25 mm displacement. 5 ml of this culture is added to 45 ml of G52 medium (in a 200 ml Erlenmeyer flask) and incubated for 3 days at 180 rpm in an agitator at 30°C, 25 mm displacement. 50 ml of this culture is then added to 450 ml of G52 medium (in a 2 litre Erlenmeyer flask) and incubated for 3 days at 180 rpm in an agitator at 30°C, 50 mm displacement.

Maintenance culture: The culture is overseeded every 3-4 days, by adding 50 ml of culture to 450 ml of G52 medium (in a 2 litre Erlenmeyer flask). All experiments and fermentations are carried out by starting with this maintenance culture.

Tests in a flask:

(I) Preculture in an agitating flask:

Starting with the 500 ml of maintenance culture, 1 x 450 ml of G52 medium are seeded with 50 ml of the maintenance culture and incubated for 4 days at 180 rpm in an agitator at 30°C, 50 mm displacement.

(ii) Main culture in the agitating flask:

40 ml of 1B12 medium plus 5 g/l 4-morpholine-propane-sulfonic acid (= MOPS) powder (in a 200 ml Erlenmeyer flask) are mixed with 5 ml of a 10x concentrated cyclodextrin solution, seeded with 10 ml of preculture and incubated for 5 days at 180 rpm in an agitator at 30°C, 50 mm displacement.

<u>Fermentation</u>: Fermentations are carried out on a scale of 10 litres, 100 litres and 500 litres. 20 litre and 100 litre fermentations serve as an intermediate culture step. Whereas the precultures and intermediate cultures are seeded as the maintenance culture 10% (v/v), the main cultures are seeded with 20% (v/v) of the intermediate culture. Important: In contrast to the agitating cultures, the ingredients of the media for the fermentation are calculated on the final culture volume including the inoculum. If, for example, 18 litres of medium + 2 litres of inoculum are combined, then substances for 20 litres are weighed in, but are only mixed with 18 litres.

Preculture in an agitating flask:

Starting with the 500 ml maintenance culture, 4 x 450 ml of G52 medium (in a 2 litre Erlenmeyer flask) are each seeded with 50 ml thereof, and incubated for 4 days at 180 rpm in an agitator at 30°C, 50 mm displacement.

Intermediate culture, 20 litres or 100 litres:

20 litres: 18 litres of G52 medium in a fermenter having a total volume of 30 litres are seeded with 2 litres of the preculture. Cultivation lasts for 3-4 days, and the conditions are: 30°C, 250 rpm, 0.5 litres of air per litre liquid per min, 0.5 bars excess pressure, no pH control.


100 litres: 90 litres of G52 medium in a fermenter having a total volume of 150 litres are seeded with 10 litres of the 20 litre intermediate culture. Cultivation lasts for 3-4 days, and the conditions are: 30°C, 150 rpm, 0.5 litres of air per litre liquid per min, 0.5 bars excess pressure, no pH control.

Main culture, 10 litres, 100 litres or 500 litres:

10 litres: The media substances for 10 litres of 1B12 medium are sterilised in 7 litres of water, then 1 litre of a sterile 10% 2-(hydroxypropyl) -β-cyclodextrin solution are added, and seeded with 2 litres of a 20 litre intermediate culture. The duration of the main culture is 6-7 days, and the conditions are: 30°C, 250 rpm, 0.5 litres of air per litre of liquid per min, 0.5 bars excess pressure, pH control with H₂SO₄/KOH to pH 7.6 +/- 0.5 (i.e. no control between pH 7.1 and 8.1).

100 litres: The media substances for 100 litres of 1B12 medium are sterilised in 70 litres of water, then 10 litres of a sterile 10% 2-(hydroxypropyl) - β -cyclodextrin solution are added, and seeded with 20 litres of a 20 litre intermediate culture. The duration of the main culture is 6-7 days, and the conditions are: 30°C, 200 rpm, 0.5 litres air per litre liquid per min., 0.5 bars excess pressure, pH control with H₂SO₄/KOH to pH 7.6 +/- 0.5. The chain of seeding for a 100 litre fermentation is shown schematically as follows:

maintenance culture (500ml)



500 litres: The media substances for 500 litres of 1B12 medium are sterilised in 350 litres of water, then 50 litres of a sterile 10% 2-(hydroxypropyl) -β-cyclodextrin solution are added, and seeded with 100 litres of a 100 litre intermediate culture. The duration of the main culture is 6-7 days, and the conditions are: 30°C, 120 rpm, 0.5 litres air per litre liquid per min., 0.5 bars excess pressure, pH control with H₂SO₄/KOH to pH 7.6 +/- 0.5.

Product analysis:

Preparation of the sample:

50 ml samples are mixed with 2 ml of polystyrene resin Amberlite XAD16 (Rohm + Haas. Frankfurt, Germany) and shaken at 180 rpm for one hour at 30°C. The resin is subsequently filtered using a 150 µm nylon sieve, washed with a little water and then added together with the filter to a 15 ml Nunc tube.

Elution of the product from the resin:

10 ml of isopropanol (>99%) are added to the tube with the filter and the resin. Afterwards, the sealed tube is shaken for 30 minutes at room temperature on a Rota-Mixer (Labinco BV, Netherlands). Then, 2 ml of the liquid are centrifuged off and the supernatant is added using a pipette to HPLC tubes.

HPLC analysis:

Column:

Waters-Symetry C18, 100 x 4 mm, 3.5 µm

WAT066220 + preliminary column 3.9 x 20 mm

WAT054225

Solvents:

A: 0.02 % phosphoric acid

Acetonitrile (HPLC-Quality)

Gradient:

41% B

from 0 to 7 min.

100% B

from 7.2 to 7.8 min.

41% B

from 8 to 12 min.

Oven temp.:

30°C

Detection:

250 nm, UV-DAD detection

Injection vol.:

10 µl

Retention time: Epo A: 4.30 min

Epo B: 5.38 min

B: Effect of the addition of cyclodextrin and cyclodextrin derivatives to the epothilone concentrations attained.

Cyclodextrins are cyclic (α -1,4)-linked oligosaccharides of α -D-glucopyranose with a relatively hydrophobic central cavity and a hydrophilic external surface area.

The following are distinguished in particular (the figures in parenthesis give the number of glucose units per molecule): α -cyclodextrin (6), β -cyclodextrin (7), γ - cyclodextrin (8), δ-cyclodextrin (9), ε- cyclodextrin (10), ζ-cyclodextrin (11), η-cyclodextrin (12), and θcyclodextrin (13). Especially preferred are δ-cyclodextrin and in particular α-cyclodextrin, βcyclodextrin or γ-cyclodextrin, or mixtures thereof.

Cyclodextrin derivatives are primarily derivatives of the above-mentioned cyclodextrins, especially of α-cyclodextrin, β-cyclodextrin or γ-cyclodextrin, primarily those in which one or more up to all of the hydroxy groups (3 per glucose radical) are etherified or esterified. Ethers are primarily alkyl ethers, especially lower alkyl, such as methyl or ethyl ether, also propyl or butyl ether; the aryl-hydroxyalkyl ethers, such as phenyl-hydroxy-lower-alkyl, especially phenyl-hydroxyethyl ether; the hydroxyalkyl ethers, in particular hydroxy-loweralkyl ethers, especially 2-hydroxyethyl, hydroxypropyl such as 2-hydroxypropyl or hydroxybutyl such as 2-hydroxybutyl ether; the carboxyalkyl ethers, in particular carboxy-lower-alkyl ethers, especially carboxymethyl or carboxyethyl ether; derivatised carboxyalkyl ethers, in particular derivatised carboxy-lower-alkyl ether in which the derivatised carboxy is etherified or amidated carboxy (primarily aminocarbonyl, mono- or di-lower-alkyl-aminocarbonyl, morpholino-, piperidino-, pyrrolidino- or piperazino-carbonyl, or alkyloxycarbonyl), in particular lower alkoxycarbonyl-lower-alkyl ether, for example methyloxycarbonylpropyl ether or ethyloxycarbonylpropyl ether; the sulfoalkyl ethers, in particular sulfo-lower-alkyl ethers, especially sulfobutyl ether; cyclodextrins in which one or more OH groups are etherified with a radical of formula

wherein alk is alkyl, especially lower alkyl, and n is a whole number from 2 to 12, especially 2 to 5, in particular 2 or 3; cyclodextrins in which one or more OH groups are etherified with a radical of formula

wherein R' is hydrogen, hydroxy, -O-(alk-O)z-H, -O-(alk(-R)-O-)p-H or

-O-(alk(-R)-O-)_q-alk-CO-Y; alk in all cases is alkyl, especially lower alkyl; m, n, p, q and z are a whole number from 1 to 12, preferably 1 to 5, in particular 1 to 3; and Y is OR_1 or NR_2R_3 , wherein R_1 , R_2 and R_3 independently of one another, are hydrogen or lower alkyl, or R_2 and R_3 combined together with the linking nitrogen signify morpholino, piperidino, pyrrolidino or piperazino;

or branched cyclodextrins, in which etherifications or acetals with other sugar molecules are present, especially glucosyl-, diglucosyl- (G_2 - β -cyclodextrin), maltosyl- or dimaltosyl-cyclodextrin, or N-acetylglucosaminyl-, glucosaminyl-, N-acetylgalactosaminyl- or galactosaminyl-cyclodextrin.

Esters are primarily alkanoyl esters, in particular lower alkanoyl esters, such as acetyl esters of cyclodextrins.

It is also possible to have cyclodextrins in which two or more different said ether and ester groups are present at the same time.

Mixtures of two or more of the said cyclodextrins and/or cyclodextrin derivatives may also exist.

Preference is given in particular to α -, β - or γ -cyclodextrins or the lower alkyl ethers thereof, such as methyl- β -cyclodextrin or in particular 2,6-di-O-methyl- β -cyclodextrin, or in particular the hydroxy lower alkyl ethers thereof, such as 2-hydroxypropyl- α -, 2-hydroxypropyl- β - or 2-hydroxypropyl- γ -cyclodextrin.

The cyclodextrins or cyclodextrin derivatives are added to the culture medium preferably in a concentration of 0.02 to 10, preferably 0.05 to 5, especially 0.1 to 4, for example 0.1 to 2 percent by weight (w/v).

Cyclodextrins or cyclodextrin derivatives are known or may be produced by known processes (see for example US 3,459,731; US 4,383,992; US 4,535,152; US 4,659,696; EP 0 094 157; EP 0 149 197; EP 0 197 571; EP 0 300 526; EP 0 320 032; EP 0 499 322; EP 0 503 710; EP 0 818 469; WO 90/12035; WO 91/11200; WO 93/19061; WO 95/08993; WO 96/14090; GB 2,189,245; DE 3,118,218; DE 3,317,064 and the references mentioned therein, which also refer to the synthesis of cyclodextrins or cyclodextrin derivatives, or also: T. Loftsson and M.E. Brewster (1996): Pharmaceutical Applications of Cyclodextrins: Drug Solubilization and Stabilisation: Journal of Pharmaceutical Science 85 (10):1017-1025; R.A. Rajewski and V.J. Stella(1996): Pharmaceutical Applications of Cyclodextrins: In Vivo Drug Delivery: Journal of Pharmaceutical Science 85 (11): 1142-1169).

All the cyclodextrin derivatives tested here are obtainable from the company Fluka, Buchs, CH. The tests are carried out in 200 ml agitating flasks with 50 ml culture volume. As controls, flasks with adsorber resin Amberlite XAD-16 (Rohm & Haas, Frankfurt, Germany) and without any adsorber addition are used. After incubation for 5 days, the following epothilone titres can be determined by HPLC:

Table 2:

| Addition | order | Conc | Epo A [mg/l] | Epo B [mg/l] |
|------------------------|-------|------------|--------------|--------------|
| | No. | [%w/v]¹ | | |
| Amberlite XAD-16 (v/v) | | 2.0 (%v/v) | 9.2 | 3.8 |

WO 99/66028

| Addition | order | Conc | Epo A [mg/l] | Epo B [mg/l] |
|---------------------------------|-------|---------------------|--------------|--------------|
| | No. | [%w/v] ¹ | | |
| 2-hydroxypropyl-β-cyclodextrin | 56332 | 0.1 | 2.7 | 1.7 |
| 2-hydroxypropyl-β-cyclodextrin | æ | 0.5 | 4.7 | 3.3 |
| 2-hydroxypropyl-β-cyclodextrin | u | 1.0 | 4.7 | 3.4 |
| 2-hydroxypropyl-β-cyclodextrin | 44 | 2.0 | 4.7 | 4.1 |
| 2-hydroxypropyl-β-cyclodextrin | 44 | 5.0 | 1.7 | 0.5 |
| 2-hydroxypropyl- α-cyclodextrin | 56330 | 0.5 | 1.2 | 1.2 |
| 2-hydroxypropyl- α-cyclodextrin | ı, | 1.0 | 1.2 | 1.2 |
| 2-hydroxypropyl- α-cyclodextrin | 11 | 5.0 | 2.5 | 2.3 |
| β-cyclodextrin | 28707 | 0.1 | 1.6 | 1.3 |
| β-cyclodextrin | u | 0.5 | 3.6 | 2.5 |
| β-cyclodextrin | 4 | 1.0 | 4.8 | 3.7 |
| β-cyclodextrin | " | 2.0 | 4.8 | 2.9 |
| β-cyclodextrin | | 5.0 | 1.1 | 0.4 |
| methyl-β-cyclodextrin | 66292 | 0.5 | 0.8 | <0.3 |
| methyl-β-cyclodextrin | 66 | 1.0 | <0.3 | <0.3 |
| methyl-β-cyclodextrin | 46 | 2.0 | <0.3 | <0.3 |
| 2,6 di-o-methyl-β-cyclodextrin | 39915 | 1.0 | <0.3 | <0.3 |
| 2-hydroxypropyl-γ-cyclodextrin | 56334 | 0.1 | 0.3 | <0.3 |
| 2-hydroxypropyl-γ-cyclodextrin | 44 | 0.5 | 0.9 | 0.8 |
| 2-hydroxypropyl-γ-cyclodextrin | 64 | 1.0 | 1.1 | 0.7 |
| 2-hydroxypropyl-γ-cyclodextrin | и | 2.0 | 2.6 | 0.7 |
| 2-hydroxypropyl-γ-cyclodextrin | 44 | 5.0 | 5.0 | 1.1 |
| no addition | | | 0.5 | 0.5 |

¹⁾ Apart from Amberlite (%v/v), all percentages are by weight (%w/v).

Few of the cyclodextrins tested (2,6-di-o-methyl- β -cyclodextrin, methyl- β -cyclodextrin) display no effect or a negative effect on epothilone production at the concentrations used. 1-2% 2-hydroxy-propyl- β -cyclodextrin and β -cyclodextrin increase epothilone production in the examples by 6 to 8 times compared with production using no cyclodextrins.

WO 99/66028 PCT/EP99/04171

- 56 -

C: 10 litre fermentation with 1% 2-(hydroxypropyl)-β-cyclodextrin):

Fermentation is carried out in a 15 litre glass fermenter. The medium contains 10 g/l of 2-(hydroxypropyl)- β -cyclodextrin from Wacker Chemie, Munich, Germany. The progress of fermentation is illustrated in Table 3. Fermentation is ended after 6 days and working up takes place.

Table 3: Progress of a 10 litre fermentation

| duration of culture [d] | Epothilone A [mg/l] | Epothilone B [mg/l] |
|-------------------------|---------------------|---------------------|
| 0 | 0 | 0 |
| 1 | 0 | 0 |
| 2 | 0.5 | 0.3 |
| 3 | 1.8 | 2.5 |
| 4 | 3.0 | 5.1 |
| 5 | 3.7 | 5.9 |
| 6 | 3.6 | 5.7 |

D: 100 litre fermentation with 1% 2-(hydroxypropyl)-β-cyclodextrin):

Fermentation is carried out in a 150 litre fermenter. The medium contains 10 g/l of 2-(Hydroxypropyl)- β -cyclodextrin. The progress of fermentation is illustrated in Table 4. The fermentation is harvested after 7 days and worked up.

Table 4: Progress of a 100 litre fermentation

| duration of culture [d] | Epothilone A [mg/l] | Epothilone B [mg/l] |
|----------------------------|------------------------|------------------------|
| 0 | 0 | 0 |
| 1 | 0 | 0 |
| 2 | 0.3 | 0 |

| 3 | 0.9 | 1.1 |
|---|-----|-----|
| 4 | 1.5 | 2.3 |
| 5 | 1.6 | 3.3 |
| 6 | 1.8 | 3.7 |
| 7 | 1.8 | 3.5 |

E: 500 litre fermentation with 1% 2-(hydroxypropyl)-β-cyclodextrin):

Fermentation is carried out in a 750 litre fermenter. The medium contains 10 g/l of 2-(Hydroxypropyl)- β -cyclodextrin. The progress of fermentation is illustrated in Table 5. The fermentation is harvested after 7 days and worked up.

Table 5: Progress of a 500 litre fermentation

| duration of culture [d] | Epothilone A [mg/l] | Epothilone B [mg/l] |
|-------------------------|------------------------|---------------------|
| 0 | 0 | 0 |
| 1 | 0 | 0 |
| 2 | 0 | 0 |
| 3 | 0.6 | 0.6 |
| 4 | 1.7 | 2.2 |
| 5 | 3.1 | 4.5 |
| 6 | 3.1 | 5.1 |

F: Comparison example 10 litre fermentation without adding an adsorber:

Fermentation is carried out in a 15 litre glass fermenter. The medium does not contain any cyclodextrin or other adsorber. The progress of fermentation is illustrated in Table 6. The fermentation is not harvested and worked up.

Table 6: Progress of a 10 litre fermentation without adsorber.

| duration of culture [d] | Epothilone A [mg/l] | Epothilone B [mg/l] |
|-------------------------|------------------------|------------------------|
| 0 | 0 | 0 |
| 1 | 0 | 0 |
| 2 | 0 | 0 |
| 3 | 0 | 0 |
| 4 | 0.7 | 0.7 |
| 5 | 0.7 | 1.0 |
| 6 | 0.8 | 1.3 |

G: Working up of the epothilones: Isolation from a 500 litre main culture:

The volume of harvest from the 500 litre main culture of example 2D is 450 litres and is separated using a Westfalia clarifying separator Type SA-20-06 (rpm = 6500) into the liquid phase (centrifugate + rinsing water = 650 litres) and solid phase (cells = ca. 15 kg). The main part of the epothilones are found in the centrifugate, The centrifuged cell pulp contains < 15% of the determined epothilone portion and is not further processed. The 650 litre centrifugate is then placed in a 4000 litre stirring vessel, mixed with 10 litres of Amberlite XAD-16 (centrifugate:resin volume = 65:1) and stirred. After a period of contact of ca. 2 hours, the resin is centrifuged away in a Heine overflow centrifuge (basket content 40 litres; rpm = 2800). The resin is discharged from the centrifuge and washed with 10-15 litres of deionised water. Desorption is effected by stirring the resin twice, each time in portions with 30 litres of isopropanol in 30 litre glass stirring vessels for 30 minutes. Separation of the isopropanol phase from the resin takes place using a suction filter. The isopropanol is then removed from the combined isopropanol phases by adding 15-20 litres of water in a vacuum-operated circulating evaporator (Schmid-Verdampfer) and the resulting water phase of ca. 10 litres is extracted 3x each time with 10 litres of ethyl acetate. Extraction is effected in 30 litre glass stirring vessels. The ethyl acetate extract is concentrated to 3-5 litres in a vacuum-operated circulating evaporator (Schmid-Verdampfer) and afterwards concentrated to dryness in a rotary evaporator (Büchi type) under vacuum. The result is an ethyl acetate extract of 50,2 g. The ethyl acetate extract is dissolved in

singlet; d = doublet; m = multiplet

500 ml of methanol, the insoluble portions filtered off using a folded filter, and the solution added to a 10 kg Sephadex LH 20 column (Pharmacia, Uppsala, Sweden) (column diameter 20 cm, filling level ca. 1.2 m). Elution is effected with methanol as eluant. Epothilone A and B is present predominantly in fractions 21-23 (at a fraction size of 1 litre). These fractions are concentrated to dryness in a vacuum on a rotary evaporator (total weight 9.0 g). These Sephadex peak fractions (9.0 g) are thereafter dissolved in 92 ml of acetonitrile:-water:-methylene chloride = 50:40:2, the solution filtered through a folded filter and added to a RP column (equipment Prepbar 200, Merck; 2. 0 kg LiChrospher RP-18 Merck, grain size 12μm, column diameter 10 cm, filling level 42 cm; Merck, Darmstadt, Germany). Elution is effected with acetonitrile:water = 3:7 (flow rate = 500 ml/min.; retention time of epothilone A = ca. 51-59 mins.; retention time of epothilone B = ca. 60-69 mins.). Fractionation is monitored with a UV detector at 250 nm. The fractions are concentrated to dryness under vacuum on a Büchi-Rotavapor rotary evaporator. The weight of the epothilone A peak fraction is 700 mg, and according to HPLC (external standard) it has a content of 75.1%. That of the epothilone B peak fraction is 1980 mg, and the content according to HPLC (external standard) is 86.6%. Finally, the epothilone A fraction (700 mg) is crystallised from 5 ml of ethyl acetate:toluene = 2:3, and yields 170 mg of epothilone A pure crystallisate [content according to HLPC (% of area) = 94.3%]. Crystallisation of the epothilone B fraction (1980 mg) is effected from 18 ml of methanol and yields 1440 mg of epothilone B pure crystallisate [content according to HPLC (% of area) = 99.2%]. m.p. (Epothilone B): e.g. 124-125 °C; ¹H-NMR data for Epothilone B: 500 MHz-NMR, solvent: DMSO-d6. Chemical displacement δ in ppm relative to TMS. s =

| δ | (Multi | plicity) | Integral (number of H) |
|---|--------|----------|------------------------|
| | 7.34 | (s) | 1 |
| | 6.50 | (s) | 1 |
| | 5.28 | (d) | 1 |
| | 5.08 | (d) | 1 |
| | 4.46 | (d) | 1 |
| | 4.08 | (m) | 1 |
| | | | |

WO 99/66028 PCT/EP99/04171

- 60 ~

| 3.47 (m) | 1 |
|---------------------------|--------|
| 3.11 (m) | 1 |
| 2.83 (dd) | 1 |
| 2.64 (s) | 3 |
| 2.36 (m) | 2 |
| 2.09 (s) | 3 |
| 2.04 (m) | 1 |
| 1.83 (m) | 1 |
| 1.61 (m) | 1 |
| 1.47 - 1.24 (m) | 4 |
| 1.18 (s) | 6 |
| 1.13 (m) | 2 |
| 1.06 (d) | 3 |
| 0.89 (d + s, overlapping) | 6 |
| | Σ = 41 |

Example 15: Medical Uses of Recombinantly Produced Epothilones

Pharmaceutical preparations or compositions comprising epothilones are used for example in the treatment of cancerous diseases, such as various human solid tumors. Such anticancer formulations comprise, for example, an active amount of an epothilone together with one or more organic or inorganic, liquid or solid, pharmaceutically suitable carrier materials. Such formulations are delivered, for example, enterally, nasally, rectally, orally, or parenterally, particularly intramuscularly or intravenously. The dosage of the active ingredient is dependent upon the weight, age, and physical and pharmacokinetical condition of the patient and is further dependent upon the method of delivery. Because epothilones mimic the biological effects of taxol, epothilones may be substituted for taxol in compositions and methods utilizing taxol in the treatment of cancer. See, for example, U.S.

Patent Nos. 5,496,804, 5,565,478, and 5,641,803, all of which are incorporated herein by reference.

For example, for treatments, epothilone B is supplied in individual 2 ml glass vials formulated as 1 mg/1 ml of clear, colorless intravenous concentrate. The substance is formulated in polyethylene glycol 300 (PEG 300) and diluted with 50 or 100 ml 0.9% Sodium Chloride Injection, USP, to achieve the desired final concentration of the drug for infusion. It is administered as a single 30-minute intravenous infusion every 21 days (treatment three-weekly) for six cycles, or as a single 30-minute intravenous infusion every 7 days (weekly treatment).

Preferably, for weekly treatment, the dose is between about 0.1 and about 6, preferably about 0.1 and about 5 mg/m², more preferably about 0.1 and about 3 mg/m², even more preferably 0.1 and 1.7 mg/m², most preferably about 0.3 and about 1 mg/m²; for three-weekly treatment (treatment every three weeks or every third week) the dose is between about 0.3 and about 18 mg/m², preferably about 0.3 and about 15 mg/m², more preferably about 0.3 and about 12 mg/m², even more preferably about 0.3 and about 7.5 mg/m², still more preferably about 0.3 and about 5 mg/m², most preferably about 1.0 and about 3.0 mg/m². This dose is preferably administered to the human by intravenous (i.v.) administration during 2 to 180 min, preferably 2 to 120 min, more preferably during about 5 to about 30 min, most preferably during about 10 to about 30 min, e.g. during about 30 min.

While the present invention has been described with reference to specific embodiments thereof, it will be appreciated that numerous variations, modifications, and embodiments are possible, and accordingly, all such variations, modifications and embodiments are to be regarded as being within the spirit and scope of the present invention.

BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSE OF PATENT PROCEDURES

INTERNATIONAL FORM

TO
Novartis AG
Novartis Corporation
Patent and Trademark Dept.
3054 Cornwallis Rd.
Research Triangle Park, NC 27709

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT issued pursuant to Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page

NAME AND ADDRESS OF DEPOSITOR

| 1. IDENTIFICATION OF THE MICROORGANISH | | | | |
|---|--|--|--|--|
| Identification reference given by the DEPOSITOR: | Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: | | | |
| Escherichia coli DH1OB (PEPO15) | NRRL B-30033 | | | |
| II. SCIENTIFIC DESCRIPTION AND/OR PROPOS | ED TAXONOMIC DESIGNATION | | | |
| The microorganism identified under I. abov | e was accompanied by: | | | |
| a scientific description | | | | |
| a proposed taxonomic designation | | | | |
| (Mark with a cross where applicable) | | | | |
| III. RECEIPT AND ACCEPTANCE | | | | |
| This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on June 11, 1998(date of the original deposit) | | | | |
| IV. RECEIPT OF REQUEST FOR CONVERSION | | | | |
| The microorganism identified under I. above was received by this International Depositary Authority on (date of the original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion). | | | | |
| V. INTERNATIONAL DEPOSITARY AUTHORITY | | | | |
| Name: Agricultural Research Gulture Collection (NRRL) International Depositary Authority | Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s): | | | |
| Address: 1815 N. University Street Peoria, Illinois 61504 U.S.A. Date: 7-2:-77 | | | | |

Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired.

TO

BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSE OF PATENT PROCEDURES

INTERNATIONAL PORM

Novatis AG c/o Novartis Agricultural Biotechnology Research, Inc. Patent & Trademark Department 3054 Cornwallis Road Research Triangle Fark, NC 27709

NAME AND ADDRESS OF DEPOSITOR RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT issued pursuant to Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page

| I. IDENTIFICATION OF THE MICROORGANISM | |
|---|--|
| Identification reference given by the DRPOSITOR: Bacherichia coli DH10B [pEP032] | Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: NRRL B-30119 |
| II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION | |
| The microorganism identified under I. above was accompanied by: | |
| a scientific description | |
| a proposed taxonomic designation | |
| (Mark with a cross where applicable) | |
| III. RECEIPT AND ACCEPTANCE | |
| This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on April 16, 1999 (date of the original deposit) 1 | |
| IV. RECEIPT OF REQUEST FOR CONVERSION | |
| The microorganism identified under I. above was received by this International Depositary Authority on (date of the original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion). | |
| V. INTERNATIONAL DEPOSITARY AUTHORITY | |
| Name: Agricultural Research Culture Collection (NRRL) International Depositary Authority | Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s): |
| Address: 1815 N. University Street Peorie, Illinois 61604 N.S.A. | Date: Sandy |

Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired.

What is claimed is:

- 1. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes at least one polypeptide involved in the biosynthesis of epothilone.
- 2. An isolated nucleic acid molecule according to claim 1, wherein said nucleotide sequence is isolated from a myxobacterium.
- 3. An isolated nucleic acid molecule according to claim 2, wherein said myxobacterium is *Sorangium cellulosum*.
- 4. A chimeric gene comprising a heterologous promoter sequence operatively linked to a nucleic acid molecule according to claim 1.
 - 5. A recombinant vector comprising a chimeric gene according to claim 4.
 - 6. A recombinant host cell comprising a chimeric gene according to claim 4.
 - 7. The recombinant host cell of claim 6, which is a bacteria.
 - 8. The recombinant host cell of claim 7, which is an Actinomycete.
 - 9. The recombinant host cell of claim 8, which is Streptomyces.
 - 10. A Bac clone comprising a nucleic acid molecule according to claim 1.
 - 11. The Bac clone of claim 10, which is pEPO15.
- 12. An isolated nucleic acid molecule according to claim 1, wherein said polypeptide comprises an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: SEQ ID NO:2, amino acids 11-437 of SEQ ID NO:2, amino acids 543-864 of SEQ ID NO:2, amino acids 974-1273 of SEQ ID NO:2, amino acids 1314-1385 of SEQ ID NO:2, SEQ ID NO:3, amino acids 72-81 of SEQ ID NO:3, amino acids

118-125 of SEQ ID NO:3, amino acids 199-212 of SEQ ID NO:3, amino acids 353-363 of SEQ ID NO:3, amino acids 549-565 of SEQ ID NO:3, amino acids 588-603 of SEQ ID NO:3, amino acids 669-684 of SEQ ID NO:3, amino acids 815-821 of SEQ ID NO:3, amino acids 868-892 of SEQ ID NO:3, amino acids 903-912 of SEQ ID NO:3, amino acids 918-940 of SEQ ID NO:3, amino acids 1268-1274 of SEQ ID NO:3, amino acids 1285-1297 of SEQ ID NO:3, amino acids 973-1256 of SEQ ID NO:3, amino acids 1344-1351 of SEQ ID NO:3, SEQ ID NO:4, amino acids 7-432 of SEQ ID NO:4, amino acids 539-859 of SEQ ID NO:4, amino acids 869-1037 of SEQ ID NO:4, amino acids 1439-1684 of SEQ ID NO:4, amino acids 1722-1792 of SEQ ID NO:4, SEQ ID NO:5, amino acids 39-457 of SEQ ID NO:5, amino acids 563-884 of SEQ ID NO:5, amino acids 1147-1399 of SEQ ID NO:5, amino acids 1434-1506 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 3886-4048 of SEQ ID NO:5, amino acids 4433-4719 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, SEQ ID NO:6, amino acids 35-454 of SEQ ID NO:6, amino acids 561-881 of SEQ ID NO:6, amino acids 1143-1393 of SEQ ID NO:6, amino acids 1430-1503 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, amino acids 2053-2373 of SEQ ID NO:6, amino acids 2383-2551 of SEQ ID NO:6, amino acids 2671-3045 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, SEQ ID NO:7, amino acids 32-450 of SEQ ID NO:7, amino acids 556-877 of SEQ ID NO:7, amino acids 887-1051 of SEQ ID NO:7, amino acids 1478-1790 of SEQ ID NO:7, amino acids 1810-2055 of SEQ ID NO:7, amino acids 2093-2164 of SEQ ID NO:7, amino acids 2165-2439 of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:22.

13. An isolated nucleic acid molecule according to claim 12, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:2, amino acids 11-437 of SEQ ID NO:2, amino acids 543-864 of SEQ ID NO:2, amino acids 974-1273 of SEQ ID NO:2, amino acids 1314-1385 of SEQ ID NO:2, SEQ ID NO:3, amino acids 72-81 of SEQ ID NO:3, amino acids 118-125 of SEQ ID NO:3, amino

acids 199-212 of SEQ ID NO:3, amino acids 353-363 of SEQ ID NO:3, amino acids 549-565 of SEQ ID NO:3, amino acids 588-603 of SEQ ID NO:3, amino acids 669-684 of SEQ ID NO:3, amino acids 815-821 of SEQ ID NO:3, amino acids 868-892 of SEQ ID NO:3, amino acids 903-912 of SEQ ID NO:3, amino acids 918-940 of SEQ ID NO:3, amino acids 1268-1274 of SEQ ID NO:3, amino acids 1285-1297 of SEQ ID NO:3, amino acids 973-1256 of SEQ ID NO:3, amino acids 1344-1351 of SEQ ID NO:3, SEQ ID NO:4, amino acids 7-432 of SEQ ID NO:4, amino acids 539-859 of SEQ ID NO:4, amino acids 869-1037 of SEQ ID NO:4, amino acids 1439-1684 of SEQ ID NO:4, amino acids 1722-1792 of SEQ ID NO:4, SEQ ID NO:5, amino acids 39-457 of SEQ ID NO:5, amino acids 563-884 of SEQ ID NO:5, amino acids 1147-1399 of SEQ ID NO:5, amino acids 1434-1506 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 3886-4048 of SEQ ID NO:5, amino acids 4433-4719 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, SEQ ID NO:6, amino acids 35-454 of SEQ ID NO:6, amino acids 561-881 of SEQ ID NO:6, amino acids 1143-1393 of SEQ ID NO:6, amino acids 1430-1503 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, amino acids 2053-2373 of SEQ ID NO:6, amino acids 2383-2551 of SEQ ID NO:6, amino acids 2671-3045 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, SEQ ID NO:7, amino acids 32-450 of SEQ ID NO:7, amino acids 556-877 of SEQ ID NO:7, amino acids 887-1051 of SEQ ID NO:7, amino acids 1478-1790 of SEQ ID NO:7, amino acids 1810-2055 of SEQ ID NO:7, amino acids 2093-2164 of SEQ ID NO:7, amino acids 2165-2439 of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:22.

14. An isolated nucleic acid molecule according to claim 12, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: the complement of nucleotides 1900-3171 of SEQ ID NO:1, nucleotides 3415-5556 of SEQ ID NO:1, nucleotides 7610-11875 of SEQ ID NO:1, nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 10529-11428 of SEQ

ID NO:1, nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, nucleotides 15901-15924 of SEQ ID NO:1, nucleotides 16251-21749 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 21746-43519 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 43524-54920 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, nucleotides 51534-52657 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, nucleotides 54935-62254 of SEQ ID NO:1, nucleotides 55028-56284 of SEQ ID NO:1, nucleotides 56600-57565 of SEQ ID NO:1, nucleotides 57593-58087 of SEQ ID NO:1, nucleotides 59366-60304 of SEQ ID NO:1, nucleotides 60362-61099 of SEQ ID NO:1, nucleotides 61211-61426 of SEQ ID NO:1, nucleotides 61427-62254 of SEQ ID NO:1, nucleotides 62369-63628 of SEQ ID NO:1, nucleotides 67334-68251 of SEQ ID NO:1, and nucleotides 1-68750 SEQ ID NO:1.

15. A nucleic acid molecule according to claim 12, wherein said nucleotide sequence is selected from the group consisting of: the complement of nucleotides 1900-3171 of SEQ ID NO:1, nucleotides 3415-5556 of SEQ ID NO:1, nucleotides 7610-11875 of SEQ ID NO:1, nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, nucleotides 15901-15924 of SEQ ID NO:1, nucleotides 16251-21749 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 21746-43519 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 43524-54920 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, nucleotides 51534-52657 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID

- NO:1, nucleotides 54935-62254 of SEQ ID NO:1, nucleotides 55028-56284 of SEQ ID NO:1, nucleotides 56600-57565 of SEQ ID NO:1, nucleotides 57593-58087 of SEQ ID NO:1, nucleotides 59366-60304 of SEQ ID NO:1, nucleotides 60362-61099 of SEQ ID NO:1, nucleotides 61211-61426 of SEQ ID NO:1, nucleotides 61427-62254 of SEQ ID NO:1, nucleotides 62369-63628 of SEQ ID NO:1, nucleotides 67334-68251 of SEQ ID NO:1, and nucleotides 1-68750 SEQ ID NO:1.
- 16. A chimeric gene comprising a heterologous promoter sequence operatively linked to a nucleic acid molecule according to claim 12.
 - 17. A recombinant vector comprising a chimeric gene according to claim 16.
 - 18. A recombinant host cell comprising a chimeric gene according to claim 16.
 - 19. The recombinant host cell of claim 18, which is a bacteria.
 - 20. The recombinant host cell of claim 19, which is an Actinomycete.
 - 21. The recombinant host cell of claim 20, which is Streptomyces.
- 22. An isolated nucleic acid molecule according to claim 1, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of a nucleotide sequence selected from the group consisting of: the complement of nucleotides 1900-3171 of SEQ ID NO:1, nucleotides 3415-5556 of SEQ ID NO:1, nucleotides 7610-11875 of SEQ ID NO:1, nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID

NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, nucleotides 15901-15924 of SEQ ID NO:1, nucleotides 16251-21749 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 21746-43519 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 43524-54920 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, nucleotides 51534-52657 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, nucleotides 54935-62254 of SEQ ID NO:1, nucleotides 55028-56284 of SEQ ID NO:1, nucleotides 56600-57565 of SEQ ID NO:1, nucleotides 57593-58087 of SEQ ID NO:1, nucleotides 59366-60304 of SEQ ID NO:1, nucleotides 60362-61099 of SEQ ID NO:1, nucleotides 61211-61426 of SEQ ID NO:1, nucleotides 61427-62254 of SEQ ID NO:1, nucleotides 62369-63628 of SEQ ID

PCT/EP99/04171

23. A chimeric gene comprising a heterologous promoter sequence operatively linked to a nucleic acid molecule according to claim 22.

NO:1, nucleotides 67334-68251 of SEQ ID NO:1, and nucleotides 1-68750 SEQ ID NO:1.

- 24. A recombinant vector comprising a chimeric gene according to claim 23.
- 25. A recombinant host cell comprising a chimeric gene according to claim 23.

- 26. The recombinant host cell of claim 25, which is a bacteria.
- 27. The recombinant host cell of claim 26, which is an Actinomycete.
- 28. The recombinant host cell of claim 27, which is Streptomyces.
- 29. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes at least one epothilone synthase domain.
- 30. An isolated nucleic acid molecule according to claim 29, wherein said epothilone synthase domain is a β-ketoacyl-synthase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 11-437 of SEQ ID NO:2, amino acids 7-432 of SEQ ID NO:4, amino acids 39-457 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 35-454 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO:6, and amino acids 32-450 of SEQ ID NO:7.
- 31. An isolated nucleic acid molecule according to claim 30, wherein said β -ketoacyl-synthase domain comprises an amino acid sequence selected from the group consisting of: amino acids 11-437 of SEQ ID NO:2, amino acids 7-432 of SEQ ID NO:4, amino acids 39-457 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 35-454 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, and amino acids 32-450 of SEQ ID NO:7.
- 32. An isolated nucleic acid molecule according to claim 30, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, and nucleotides 55028-56284 of SEQ ID NO:1.

- 33. An isolated nucleic acid molecule according to claim 30, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, and nucleotides 55028-56284 of SEQ ID NO:1.
- 34. An isolated nucleic acid molecule according to claim 30, wherein said nucleotide sequence is selected from the group consisting of: nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, and nucleotides 55028-56284 of SEQ ID NO:1.
- 35. An isolated nucleic acid molecule according to claim 29, wherein said epothilone synthase domain is a an acyltransferase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 543-864 of SEQ ID NO:2, amino acids 539-859 of SEQ ID NO:4, amino acids 563-884 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 561-881 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, and amino acids 556-877 of SEQ ID NO:7.
- 36. An isolated nucleic acid molecule according to claim 35, wherein said acyltransferase domain comprises an amino acid sequence selected from the group consisting of: amino acids 543-864 of SEQ ID NO:2, amino acids 539-859 of SEQ ID NO:4, amino acids 563-884 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:6, amino acids 561-881 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, and amino acids 556-877 of SEQ ID NO:7.

- 37. An isolated nucleic acid molecule according to claim 35, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, and nucleotides 56600-57565 of SEQ ID NO:1.
- 38. An isolated nucleic acid molecule according to claim 35, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, and nucleotides 56600-57565 of SEQ ID NO:1.
- 39. An isolated nucleic acid molecule according to claim 35, wherein said nucleotide sequence is selected from the group consisting of: nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, and nucleotides 56600-57565 of SEQ ID NO:1.
- 40. An isolated nucleic acid molecule according to claim 29, wherein said epothilone synthase domain is an enoyl reductase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 974-1273 of SEQ ID NO:2, amino acids 4433-4719 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, and amino acids 1478-1790 of SEQ ID NO:7.
- 41. An isolated nucleic acid molecule according to claim 40, wherein said enoyl reductase domain comprises an amino acid sequence selected from the group consisting

of: amino acids 974-1273 of SEQ ID NO:2, amino acids 4433-4719 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, and amino acids 1478-1790 of SEQ ID NO:7.

- 42. An isolated nucleic acid molecule according to claim 40, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, and nucleotides 59366-60304 of SEQ ID NO:1.
- 43. An isolated nucleic acid molecule according to claim 40, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, and nucleotides 59366-60304 of SEQ ID NO:1.
- 44. An isolated nucleic acid molecule according to claim 40, wherein said nucleotide sequence is selected from the group consisting of: nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, and nucleotides 59366-60304 of SEQ ID NO:1.
- 45. An isolated nucleic acid molecule according to claim 29, wherein said epothilone synthase domain is an acyl carrier protein domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 1314-1385 of SEQ ID NO:2, amino acids 1722-1792 of SEQ ID NO:4, amino acids 1434-1506 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, amino acids 1430-1503 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, and amino acids 2093-2164 of SEQ ID NO:7.
- 46. An isolated nucleic acid molecule according to claim 45, wherein said acyl carrier protein domain comprises an amino acid sequence selected from the group consisting of: amino acids 1314-1385 of SEQ ID NO:2, amino acids 1722-1792 of SEQ ID

NO:4, amino acids 1434-1506 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, amino acids 1430-1503 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, and amino acids 2093-2164 of SEQ ID NO:7.

- 47. An isolated nucleic acid molecule according to claim 45, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, and nucleotides 61211-61426 of SEQ ID NO:1.
- 48. An isolated nucleic acid molecule according to claim 45, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, and nucleotides 61211-61426 of SEQ ID NO:1.
- 49. An isolated nucleic acid molecule according to claim 45, wherein said nucleotide sequence is selected from the group consisting of: nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, and nucleotides 61211-61426 of SEQ ID NO:1.
- 50. An isolated nucleic acid molecule according to claim 29, wherein said epothilone synthase domain is a dehydratase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of:

amino acids 869-1037 of SEQ ID NO:4, amino acids 3886-4048 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 2383-2551 of SEQ ID NO:6, and amino acids 887-1051 of SEQ ID NO:7.

- 51. An isolated nucleic acid molecule according to claim 50, wherein said dehydratase domain comprises an amino acid sequence selected from the group consisting of: amino acids 869-1037 of SEQ ID NO:4, amino acids 3886-4048 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 2383-2551 of SEQ ID NO:6, and amino acids 887-1051 of SEQ ID NO:7.
- 52. An isolated nucleic acid molecule according to claim 50, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, and nucleotides 57593-58087 of SEQ ID NO:1.
- 53. An isolated nucleic acid molecule according to claim 50, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, and nucleotides 57593-58087 of SEQ ID NO:1.
- 54. An isolated nucleic acid molecule according to claim 50, wherein said nucleotide sequence is selected from the group consisting of: nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, and nucleotides 57593-58087 of SEQ ID NO:1.
- 55. An isolated nucleic acid molecule according to claim 29, wherein said epothilone synthase domain is a β-ketoreductase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 1439-1684 of SEQ ID NO:4, amino acids 1147-1399 of SEQ ID NO:5, amino

acids 2645-2895 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 1143-1393 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, and amino acids 1810-2055 of SEQ ID NO:7.

- 56. An isolated nucleic acid molecule according to claim 55, wherein said β-ketoreductase domain comprises an amino acid sequence selected from the group consisting of: amino acids 1439-1684 of SEQ ID NO:4, amino acids 1147-1399 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 1143-1393 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, and amino acids 1810-2055 of SEQ ID NO:7.
- 57. An isolated nucleic acid molecule according to claim 55, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, and nucleotides 60362-61099 of SEQ ID NO:1.
- 58. An isolated nucleic acid molecule according to claim 55, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, and nucleotides 60362-61099 of SEQ ID NO:1.
- 59. An isolated nucleic acid molecule according to claim 55, wherein said nucleotide sequence is selected from the group consisting of: nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID

NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, and nucleotides 60362-61099 of SEQ ID NO:1.

- 60. An isolated nucleic acid molecule according to claim 29, wherein said epothilone synthase domain is a methyltransferase domain comprising an amino acid sequence substantially similar to amino acids 2671-3045 of SEQ ID NO:6.
- 61. An isolated nucleic acid molecule according to claim 60, wherein said methyltransferase domain comprises amino acids 2671-3045 of SEQ ID NO:6.
- 62. An isolated nucleic acid molecule according to claim 60, wherein said nucleotide sequence is substantially similar to nucleotides 51534-52657 of SEQ ID NO:1.
- 63. An isolated nucleic acid molecule according to claim 60, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of nucleotides 51534-52657 of SEQ ID NO:1.
- 64. An isolated nucleic acid molecule according to claim 60, wherein said nucleotide sequence is nucleotides 51534-52657 of SEQ ID NO:1.
- 65. An isolated nucleic acid molecule according to claim 29, wherein said epothilone synthase domain is a thioesterase domain comprising an amino acid sequence substantially similar to amino acids 2165-2439 of SEQ ID NO:7.
- 66. An isolated nucleic acid molecule according to claim 65, wherein said thioesterase domain comprises amino acids 2165-2439 of SEQ ID NO:7.
- 67. An isolated nucleic acid molecule according to claim 65, wherein said nucleotide sequence is substantially similar to nucleotides 61427-62254 of SEQ ID NO:1.
- 68. An isolated nucleic acid molecule according to claim 65, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of nucleotides 61427-62254 of SEQ ID NO:1.

- 69. An isolated nucleic acid molecule according to claim 65, wherein said nucleotide sequence is nucleotides 61427-62254 of SEQ ID NO:1.
- 70. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes a non-ribosomal peptide synthetase, wherein said non-ribosomal peptide synthetase comprises an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: SEQ ID NO:3, amino acids 72-81 of SEQ ID NO:3, amino acids 118-125 of SEQ ID NO:3, amino acids 199-212 of SEQ ID NO:3, amino acids 353-363 of SEQ ID NO:3, amino acids 549-565 of SEQ ID NO:3, amino acids 588-603 of SEQ ID NO:3, amino acids 669-684 of SEQ ID NO:3, amino acids 815-821 of SEQ ID NO:3, amino acids 868-892 of SEQ ID NO:3, amino acids 903-912 of SEQ ID NO:3, amino acids 918-940 of SEQ ID NO:3, amino acids 1268-1274 of SEQ ID NO:3, amino acids 1285-1297 of SEQ ID NO:3, amino acids 973-1256 of SEQ ID NO:3, and amino acids 1344-1351 of SEQ ID NO:3.
- 71. An isolated nucleic acid molecule according to claim 70, wherein said non-ribosomal peptide synthetase comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:3, amino acids 72-81 of SEQ ID NO:3, amino acids 118-125 of SEQ ID NO:3, amino acids 199-212 of SEQ ID NO:3, amino acids 353-363 of SEQ ID NO:3, amino acids 549-565 of SEQ ID NO:3, amino acids 588-603 of SEQ ID NO:3, amino acids 669-684 of SEQ ID NO:3, amino acids 815-821 of SEQ ID NO:3, amino acids 868-892 of SEQ ID NO:3, amino acids 903-912 of SEQ ID NO:3, amino acids 918-940 of SEQ ID NO:3, amino acids 1268-1274 of SEQ ID NO:3, amino acids 1285-1297 of SEQ ID NO:3, amino acids 973-1256 of SEQ ID NO:3, and amino acids 1344-1351 of SEQ ID NO:3.
- 72. An isolated nucleic acid molecule according to claim 70, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID

NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, and nucleotides 15901-15924 of SEQ ID NO:1.

- 73. An isolated nucleic acid molecule according to claim 70, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, and nucleotides 15901-15924 of SEQ ID NO:1.
- 74. An isolated nucleic acid molecule according to claim 70, wherein said nucleotide sequence is selected from the group consisting of: nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, and nucleotides 15901-15924 of SEQ ID NO:1.
- 75. A method for heterologous expression of epothilone in a recombinant host, comprising:
 - (a) introducing a chimeric gene according to claim 4 into a host; and
 - (b) growing the host in conditions that allow biosynthesis of epothilone in the host.

- 76. A method for producing epothilone, comprising:
- (a) expressing epothilone in a recombinant host by the method of claim 75; and
- (b) extracting epothilone from the recombinant host.
- 77. An isolated polypeptide comprising an amino acid sequence that consists of an epothilone synthase domain.
- 78. An isolated polypeptide according to claim 77, wherein said epothilone synthase domain is a β-ketoacyl-synthase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 11-437 of SEQ ID NO:2, amino acids 7-432 of SEQ ID NO:4, amino acids 39-457 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 35-454 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, and amino acids 32-450 of SEQ ID NO:7.
- 79. An isolated polypeptide according to claim 78, wherein said β -ketoacyl-synthase domain comprises an amino acid sequence selected from the group consisting of: amino acids 11-437 of SEQ ID NO:2, amino acids 7-432 of SEQ ID NO:4, amino acids 39-457 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 35-454 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, and amino acids 32-450 of SEQ ID NO:7.
- 80. An isolated polypeptide according to claim 77, wherein said epothilone synthase domain is an acyltransferase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 543-864 of SEQ ID NO:2, amino acids 539-859 of SEQ ID NO:4, amino acids 563-884 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 561-881 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, and amino acids 556-877 of SEQ ID NO:7.
- 81. An isolated polypeptide according to claim 80, wherein said acyltransferase domain comprises an amino acid sequence selected from the group consisting of: amino

acids 543-864 of SEQ ID NO:2, amino acids 539-859 of SEQ ID NO:4, amino acids 563-884 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 561-881 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, and amino acids 556-877 of SEQ ID NO:7.

- 82. An isolated polypeptide according to claim 77, wherein said epothilone synthase domain is an enoyl reductase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 974-1273 of SEQ ID NO:2, amino acids 4433-4719 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, and amino acids 1478-1790 of SEQ ID NO:7.
- 83. An isolated polypeptide according to claim 82, wherein said enoyl reductase domain comprises an amino acid sequence selected from the group consisting of: amino acids 974-1273 of SEQ ID NO:2, amino acids 4433-4719 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, and amino acids 1478-1790 of SEQ ID NO:7.
- 84. An isolated polypeptide according to claim 77, wherein said epothilone synthase domain is an acyl carrier protein domain, wherein said polypeptide comprises an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 1314-1385 of SEQ ID NO:2, amino acids 1722-1792 of SEQ ID NO:4, amino acids 1434-1506 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, amino acids 1430-1503 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, and amino acids 2093-2164 of SEQ ID NO:7.
- 85. An isolated polypeptide according to claim 84, wherein said acyl carrier protein domain comprises an amino acid sequence selected from the group consisting of: amino acids 1314-1385 of SEQ ID NO:2, amino acids 1722-1792 of SEQ ID NO:4, amino acids 1434-1506 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, amino acids 1430-1503 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, and amino acids 2093-2164 of SEQ ID NO:7.

- 86. An isolated polypeptide according to claim 77, wherein said epothilone synthase domain is a dehydratase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 869-1037 of SEQ ID NO:4, amino acids 3886-4048 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 2383-2551 of SEQ ID NO:6, and amino acids 887-1051 of SEQ ID NO:7.
- 87. An isolated polypeptide according to claim 86, wherein said dehydratase domain comprises an amino acid sequence selected from the group consisting of: amino acids 869-1037 of SEQ ID NO:4, amino acids 3886-4048 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 2383-2551 of SEQ ID NO:6, and amino acids 887-1051 of SEQ ID NO:7.
- 88. An isolated polypeptide according to claim 77, wherein said epothilone synthase domain is a β-ketoreductase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 1439-1684 of SEQ ID NO:4, amino acids 1147-1399 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 1143-1393 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, and amino acids 1810-2055 of SEQ ID NO:7.
- 89. An isolated polypeptide according to claim 88, wherein said β-ketoreductase domain comprises an amino acid sequence selected from the group consisting of: amino acids 1439-1684 of SEQ ID NO:4, amino acids 1147-1399 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 1143-1393 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, and amino acids 1810-2055 of SEQ ID NO:7.
- 90. An isolated polypeptide according to claim 77, wherein said epothilone synthase domain is a methyltransferase domain comprising an amino acid sequence substantially similar to amino acids 2671-3045 of SEQ ID NO:6.
- 91. An isolated polypeptide according to claim 90, wherein said methyltransferase domain comprises amino acids 2671-3045 of SEQ ID NO:6.

- 92. An isolated polypeptide according to claim 77, wherein said epothilone synthase domain is a thioesterase domain comprising an amino acid sequence substantially similar to amino acids 2165-2439 of SEQ ID NO:7.
- 93. An isolated polypeptide according to claim 77, wherein said thioesterase domain comprises amino acids 2165-2439 of SEQ ID NO:7.

-1-

SEQUENCE LISTING

```
<110> Novartis AG
<120> GENES FOR THE BIOSYNTHESIS OF EPOTHILONES
<130> 4-30582A
<140>
<141>
<160> 30
<170> PatentIn Ver. 2.0
<210> 1
<211> 68750
<212> DNA
<213> Sorangium cellulosum
<400> 1
aagetteget egacgeeete ttegeeegeg ceacetetge eegtgtgete gatgatggee 60
acggccgggc cacggagcgg catgtgctcg ccgaggcgcg cgggatcgag gacctccgcg 120
ccctccgaga gcacctccgc atccaggaag gggggccgtc ctttcactgc atgtgcctcg 180
gegaeetgae ggtggagete etegegeaeg aecageeeet egegteeate agetteeaee 240
atgecegeag cetgaggeae eeegaetgga eeteggaege gatgetegte gaeggeeeeg 300
cyclogiccy grygologic gegegegeg cycegygtoc celeggegag tacgaagagg 360
cgatgtegee tgaagtegee gaggeegage ggegeeteeg egeetegtae gegaeteetg 540
agetegeetg tgeegegetg etegeetgge tegggaeggg egegggteee tggteeggat 600
atcocgecta egagatgetg ceagagaate tgeteetegg gtttggeete eegacegega 660
tegeogogo etcegegee ggcacategg aggeogotet eegeggegea gegeggetgt 720
tegectectg ggaggtegta tegageaaga agageeaget eggeaacate eeegaagece 780
tgtgggageg geteeggaeg ategteegeg egatgggeaa tgeegaeaac eteteteget 840
tegagegege egaggegate geggeggagg tgegeeget gegegeacag ceggegeect 900
tegeggeggg egeeggeetg geggtegetg gggteteete gageggeegg etetegggee 960
tegtgacega eggagaegca ttgtacteeg gegaeggcaa egacategte atgttecaae 1020
coggoogat orogoogto gracetog coggaacoga recentere gagerogeae 1080 egeceteag coagargere regregege acgecaacge gggeaceare recaaggree 1140
tgacggaagg cagcccctc atcgtgatgg caagaaacca ggcgcgaccg atgagcctcg 1200
tecaegeteg egggtteatg gegtgggtea accaggeeat ggtgeeegae eeegageggg 1260
gegegeeett egtegteeag egetegacea teatggaatt egageacece aegeetegtt 1320
gtetecaega gecegeegge agegetttet ecetegeetg egaegaggag cacetetaet 1380
ggtggggget tteggetgge eggetegage tatggegeea eeegeaceae egeeeeggeg 1440 eeeegageeg ettegegtae eteggegage aeeeeattge ggegaeetgg taceeetege 1500
teacecteaa tgegacecae gtgetgtggg cegacectga tegeagggee ateetegggg 1560
togacaagog cacoggogta gagoccatog tootogoga gaogogocat coccoggogo 1620
acgtcgtgtc cgaggaccgg gacatetteg cgettaccgg acagecegae tecegegaet 1680 ggcacgtega geacatecge teceggegeet ceacegtegt ggcegaetae cagegecage 1740 tatgggaccg ceetgacatg gtgeteaate ggegeggeet ettetteacg acgaacgaee 1800
geatectgae getegeeege agetgaeate getegaegee gggeegetea tegagggege 1860
ccggaccgag ctggcgaccc gccgctggcg ggccgcagct catgccgatt cggtggcgac 1920 gtagacgctg cgccagaaac gcccgagagc ccccgagaac aggaagccgg cggattgtgt 1980
catcacgate degateaget egeggeeegg atcattgate caggaegtee egaaceegee 2040
gteccaceca tagegeeegg geaceteega gacegegtee ggegeegtga ceaeggeeat 2100
cccataaccc caqccgtgcg totcgaagaa gcccgggaaa aacgaggacg ccgccttctg 2160
ggccggcgtg aggtgategg ccgtcatete gcgcaccgag gcggcgctca agagccgccg 2220 gccctcgtgc acaccgccgt tcatgagcat gcgcgcgaac aggaggtagt cgtccaccgt 2280
cgacacgago coggoggogo cogaagggaa cgccggoggg ctggcatagg cgctctcggo 2340
eccgtegega tecatgegeg tettetecce egtetgeteg teggtgaagt aacegeagee 2400
cgcgaaccga gcgagettgt ccgccgggac gtgaaagtcg gtgtcccgca tcccgagcgg 2460
egegaggatg egetegegea egaacgeate gaageeetgg teggeegege geeecacgag 2520
cacccetge accaggetee cegtgttgta catecactge geeeegget gatgeatgag 2580
eggeagegte cegageegee ggatecacte qtetggeeeg tgeggegtea teggeacegg 2640
```

ctgcgcgttg acgagcccga gctcgtcgat ggcccgctgg atcggcgacg atgcgtcgaa 2700 egagatteeg aageeeateg tgaaegteat eaggtegege acegtgateg geegeteege 2760 gggcaccgtc tcgtcgatcg gaccatcgat gcgcgccagc accttccggt tcgcgagctc 2820 cggcaaccat cggtcgacgg gggagtcgag gtcgagcttg cetteetega cgagcatcat 2880 caccgccgtc geggtgaccg cettegteat cgaggcgatc cggaagatcg tgtcccgccg 2940 catgggegeg etgeegeega geteggteae geccaeegeg tecaegtgea egtegtegee 3000 gegegegace agecagaceg eteceggeat etgeceegee gecaeeteeg eegecateae 3060 ctcgcgcgcg ggcgccagcg cgccggcccc cgcgtcctgc cctggctgcc cctcctcctc 3120 ggecccacce aacgegcace eeggegeege cacgetgate aaageteeca taaacteeeg 3180 cetteteatg acceptegatg cetetecegag egggggegee teceeteec gagageactg 3240 actgecegeg ecegaaaaaa teateggtge eeegteacga tegeegeegg gegtggetee 3300 geoeggeege cegeteggge geoegeeet ggacgagcaa agetegeeeg ceegegetea 3360 geacgecget tgccatgtcc ggcctgcacc cacaccgagg agccacccac cctgatgcac 3420 ggcctcaccg ageggcaggt cetgeteteg etegteacce tegegeteat cetegtgace 3480 gegegegeet eggegaget egegeggegg etgegeeage eegaggtget eggggagete 3540 tteggeggeg tegtgetggg ecceteegte gteggegege tegegeeegg gtteeatega 3600 gecetettee aggageegge ggteggggte gtgetetegg geateteetg gataggegeg 3660 ctcctcctgc tgctgatggc gggcatcgag gtcgacgtgg gcatcctgcg caaggaggcg 3720 cgccccgggg cgctctcggc gctcggcgcg atcgcgccc cgctcgcggc gggcgccgcc 3780 ttctcggcgc tcgtgctcga tcggcccctt ccgagcggcc tcttcctcgg gatcgtgctc 3840 teggtgaegg eggteagegt gategegaag gtgetgateg agegegagte gatgegeege 3900 agetatgege aggtgaeget egeggegggg gtggteageg aggtegetge etgggtgete 3960 gtcgcgatga cgtcgtcgag ctacggcgcg tcgcccgcgc tggcggtcgc ccggagcgcg 4020 ctcctggcga gcggattett gctgttcatg gtgctcgtcg ggcggcggct caccacctc 4080 gcgatgcgct gggtggccga cgcgacgcgc gtctccaagg gacaggtgtc gctcgtcctc 4140 gtcetcacgt teetggeege ggegetgaeg eageggeteg geetgeaeee getgetegge 4200 gegttegege teggegtget getcaacage getectegea ecaacegeee tetectegae 4260 ggcgtgcaga cgctcgtggc gggcctcttc gcgcctgtgt tcttcgtcct cgcgggcatg 4320 cgegtegaeg tgtegeaget gegeaegeeg geggegtggg ggaeggtege gttgetgetg 4380 gegaeegega eggeggegaa ggtegteeee geegegeteg gegegegget eggegggete 4440 aggggcageg aggcggcgct cgtggcggtg ggcctgaaca tgaagggcgg cacggacctc 4500 atcgtcgcga tcgtcggcgt cgagctcggg ctcctctcca acgaggctta tacgatgtac 4560 geogtegteg egetggteae ggtgaeegee teaecegege teetcatetg getegagaaa 4620 agggegeete egaegeagga ggagtegget egeetegage gegaggagge egegaggege 4680 gegtacatee eeggggtega geggateete gteeegateg tggegeaege cetgeeeggg 4740 ttcgccacgg acatcgtgga gagcatcgtc gcctccaagc gaaagctcgg cgagacggtc 4800 gacatcacgg agctctccgt ggagcagcag gcgcccggcc catcgcgcgc cgcgggggag 4860 gegageeggg ggetegegag geteggegeg egeeteegeg teggeatetg geggeaaagg 4920 egegagetge geggetegat ceaggegate etgegegeet egegggatea egatetgete 4980 grateggeg egegategee ggegegegeg egeggaatgt egtteggteg eergeaggae 5040 gcgatcgtcc agcgggccga gtccaacgtg ctcgtcgtgg tgggcgaccc tccggcggcg 5100 gagcgcgcct ccgcgcggcg gatcctcgtc ccgatcatcg gcctcgagta ctccttcgcc 5160 geogeogate tegeggeeea egtggegetg gegtgggaeg cegagetegt getgeteage 5220 agegegeaga eegateeggg egeggtegte tggegegate gegageeate eegggtgege 5280 geggtggege ggagegtegt egaegaggeg gtetteeggg ggegeegget eggegtgege 5340 greregrege gegregede egregeded egregeded agataacgeg ggagetegeg 5400 egegeeegt acgatetget egretegga tgetaegace atgggeeget eggeeggete 5460 taceteggea geaeggtega greggtggtg gteeggagee gggtgeeggt egegttgete 5520 gtcgcgcatg gagggactcg agagcaggtg aggtgagget tecacegege tegecegtga 5580 ggaagegage geceggetet geegaegate gteaeteeeg gteegtgtag gegategtge 5640 tgagcagcgc gttctccgcc tgacgcgagt cgagccgggt atgctgcacg acgatggggg 5700 cgtccgattc gatcacgctg gcatagtccg tatcgcgcgg gatcggctcg ggttcggtca 5760 gategttgaa eeggaegtge egggtgegee tegetggaac ggtcaccegg taaggeeegg 5820 eggggtegeg gtegetgaag taaaeggtga tggegaeetg egegteeegg teegaegeat 5880 tcaacaggca ggccgtctca tggctcgtca tctgcggctc aggtccgttg ctcccgcctg 5940 ggatgtagec ctctgcgatt gcacagegeg tecgcccgat eggettgtec atgtgtcctc 6000 cetectgget cetetttgge agectecete tgctgtecag gagegatgge etettegete 6060 gacgcgctcg gggatccatg gctgaggatc ctcgccgagc gctccctgcc gaccggcgcg 6120 ccgagcgccg acgggctttg aaagcgcgcg accggccagc ccggacgcgg gcccgagagg 6180 gacagtgggt ccgccgtgaa gcagagaggc gatcgaggtg gtgagatgaa acacgtcgac 6240 acgggccgac gattcggccg ccggataggg cacacgctcg gtcttctcgc gagcatggcg 6300 ctcgccggct gcggcggtcc gagcgagaaa accgtgcagg gcacgcggct cgcgcccggc 6360 geogatgege gegteacege egacgtegae ecegacgeeg egaceaegeg getggeggtg 6420 gacgtcgttc acctctcgcc gcccgagcgg ctcgaggccg gcagcgagcg gttcgtcgtc 6480 tggcagcgtc cgagccccga gtccccgtgg cgacgggtcg gagtgctcga ctacaatgct 6540

gacageegaa gaggeaaget ggeegagaeg acegtgeegt atgeeaactt egagetgete 6600 atcaccgccg agaagcagag cagccctcag tegecategt etgecgccgt categggeeg 6660 acgtetgteg ggtgacateg egetateage agegetgage cegecageag geeceaggge 6720 eetgeetega tggeettee cateaceet gegeateet ceagegaegg eegegageg 6780 acggccgcgt ccaagcaacc gccgtgccgg cgcggctcca cgcgcgcgac aggcgagcgt 6840 cctggcgcgg cctgcgcatc gctggaagga tcggcggagc atggatagag aatcgaggat 6900 cgcgatcttt gttgccatcg cagccaacgt ggcgatcgcg gcggtcaagt tcatcgccgc 6960 cgccgtgacc ggcagctcgg cgaggcgttt gccgacttcg gcggcgtccc gcgcgtgctg 7020 ctctacgaca acctcaagag cgccgtcgtc gagcgccacg gcgacgcgat ccggttccac 7080 cccacgctgc tggctctgtc ggcgcattac cgcttcgagc cgcgccccgt cgccgtcgcc 7140 cgcggcaacg agaagggccg cgtccagcgc gccatcacgg cgtggacgac atggcgcgga 7200 aacgtegteg taacegeeca geaatgteat gggaatggee cettgaaatg geeeettgag 7260 ggggctggcc ggggtcgacg atatcgcgcg atctccccgt caattcccga tggtaaaaga 7320 aaaatttgtc atagatcgta agctgtgata gtggtctgtc ttacgttgcg tcttccgcac 7380 ctcgagcgag ttctctcgga taactttcaa tttttccgag gggggcttgg tctctggttc 7440 ctcaggaagc ctgatcggga cgagctaatt cccatccatt tttttgaggc tctgctcaaa 7500 gggattagat cgagtgagac agttcttttg cagtgcgcga agaacctggg cctcgaccgg 7560 aggacgateg acgteegea gegggteage egetgaggat gtgeegteg tggeggateg 7620 teceategag egegeageeg aagateegat tgegategte ggagegagtt geegtetgee 7680 eggtggegtg ategatetga gegggttetg gaegeteete gagggetege gegacacegt 7740 eggegagte ecegegaac getgggatge ageagegtgg titigateeeg acceegatge 7800 cccggggaag acgcccgtta cgcgcgcatc tttcctgagc gacgtagcct gcttcgacgc 7860 ctecttette ggeatetege etegegaage getgeggatg gaceetgeae ategaetett 7920 getggaggtg tgetgggagg egetggagaa egeeggate getecategg egetegtegg 7980 tacggaaacg ggagtgttca tegggategg ecegteegaa tatgaggeeg egetgeegea 8040 agegaeggeg teegeagaga tegaegetea tggegggetg gggaegatge eeagegtegg 8100 agegggeega atetegtatg eeeteggget gegagggeeg tgtgtegegg tggataegge 8160 ctattegtee tegetggtgg cegtteatet ggeetgteag agettgeget eeggggaatg 8220 etecaeggee etggetggtg gggtateget gatgttgteg ecgageacee tegtgtgget 8280 ctcgaagace egggegetgg ccagggaegg tegetgeaag geattttegg eggaggeega 8340 tgggttcgga cgaggcgaag ggtgcgccgt cgtggtcctc aagcggctca gtggagcccg 8400 cgcggacggc gatcggatat tggcggtgat tcgaggatcc gcgatcaatc acgacggtgc 8460 gagcagcggt ctgaccgtgc cgaacgggag ctcccaagaa atcgtgctga aacgggccct 8520 ggcggacgca ggctgcgccg cgtcttcggt gggttatgtc gaggcacacg gcacgggcac 8580 gacgcttggt gaccccatcg aaatccaagc tctgaatgcg gtatacggcc tcgggcgaga 8640 tgtcgccacg ccgctgctga tcgggtcggt gaagaccaac cttggccatc ctgagtatgc 8700 gtoggggato actgggotgo tgaaggtogt ottgtocott cagoacgggo agattootgo 8760 gcacctccac gcgcaggcgc tgaacccccg gatctcatgg ggtgatcttc ggctgaccgt 8820 cacgegegee eggacacegt ggeeggactg gaataegeeg egaegggegg gggtgagete 8880 gttcggcatg agcgggacca acgcgcacgt ggtgctggaa gaggcgccgg cggcgacgtg 8940 cacaccgccg gcgccggagc gaccggcaga gctgctggtg ctgtcggcaa ggaccgcgtc 9000 agecetggat geacaggegg egeggetgeg egaceatetg gagacetace ettegeagtg 9060 tetgggegat gtggegttea gtetggegae gaegegeage gegatggage aeeggetege 9120 ggtggeggcg acgtegaggg aggggetgeg ggeageeetg gacgetgegg egcagggaca 9180 gacgtegece ggtgeggtge geagtatege egatteetea egeggeaage tegeetttet 9240 cttcaccgga cagggggcgc agacgctggg catgggccgt gggctgtacg atgtatggtc 9300 egegtteege gaggegtteg acetgtgegt gaggetgtte aaceaggage tegaceggee 9360 geteegegag gtgatgtggg eegaacegge cagegtegae geegegetge tegaecagae 9420 agectteace cageeggege tgtteacett egaatatgeg etegeegege tgtggeggte 9480 gtggggtgta gagccggagt tggtcgccgg ccatagcatc ggtgagctgg tggctgcctg 9540 cgtggcgggc gtgttctcgc ttgaggacgc ggtgttcctg gtggctgcgc gcgggcgcct 9600 gatgcaggcg ctgccggccg gcggggcgat ggtgtcgatc gaggcgccgg aggccgatgt 9660 ggetgetgeg gtggegeege aegeagegte ggtgtegate geegeggtea aegeteegga 9720 ccaggtggtc atcgcgggcg ccgggcaacc cgtgcatgcg atcgcggcgg cgatggccgc 9780 gegeggggeg egaaceaagg egeteeaegt etegeatgeg tteeaeteae egeteatgge 9840 cccgatgctg gaggcgttcg ggcgtgtggc cgagtcggtg agctaccggc ggccgtcgat 9900 cgtcctggtc agcaatctga gcgggaaggc ttgcacagac gaggtgagct cgccgggcta 9960 ttgggtgcgc cacgegcgag aggtggtgcg cttcgcggat ggagtgaagg cgctgcacgc 10020 ggccggtgcg ggcaccttcg tcgaggtcgg tccgaaatcg acgetgctcg gcctggtgcc 10080 tgeetgeatg ceggaegeee ggeeggeget getegeateg tegegegetg ggegtgaega 10140 geeggegace gigetegagg egeteggegg getetgggee gieggiggee iggieteeig 10200 ggccggcctc ttcccctcag gggggcggcg ggtgccgctg cccacgtacc cttggcagcg 10260 cgagcgctac tggatcgaca cgaaagccga cgacgcggcg cgtggcgacc gccgtgctcc 10320 gggagcgggt cacgacgagg tcgaggaggg gggcgcggtg cgcggcggcg accggcgcag 10380 cgctcggctc gaccatccgc cgcccgagag Cggacgccgg gagaaggtcg aggccgccgg 10440

cgaccgtccg ttccggctcg agatcgatga gccaggcgtg cttgatcacc tcgtgcttcg 10500 ggtcacggag cggcgcccc ctggtctggg cgaggtcgag atcgccgtcg acgcggcggg 10560 geteagette aatgatgtee agetegeget gggeatggtg eeegaegaee tgeegggaaa 10620 gcccaaccct cegetgctgc teggaggcga gtgcgccggg cgcatcgtcg cegtgggcga 10680 gggcgtgaac ggcctcgtgg tgggccaacc ggtcatcgcc ctttcggcgg gagcgtttgc 10740 tacccacgtc accacgtcggc ctgcgctggt gctgcctcgg cctcaggcgc tctcggcgat 10800 cgaggcggcc gccatgcccg tcgcgtacct gacggcatgg tacgcgctcg acagaatagc 10860 ccgccttcag ccgggggagc gggtgctgat ccatgcggcg accggcgggg tcggtctcgc 10920 egeggtgeag tgggegeage acgtgggage egaggteeat gegaeggeeg geaegeeega 10980 gaaacgcgcc tacctggagt cgctgggcgt gcggtatgtg agcgattccc gctcggaccg 11040 gttcgtcgcc gacgtgcgcg cgtggacgg cggcgaggga gtagacgtcg tgctcaactc 11100 geteteggge gagetgateg acaagagttt caateteetg egategeacg geeggtttgt 11160 ggagetegge aagegegaet gttaegegga taaceagete gggetgegge egtteetgeg 11220 caatetetee ttetegetgg tggateteeg ggggatgatg etegagegge eggegegggt 11280 ccgtgcgctc ttggaggagc tcctcggcct gatcgcggca ggcgtgttca cccctccccc 11340 catcgcgacg ctcccgatcg cccgtgtcgc cgatgcgttc cggagcatgg cgcaggcgca 11400 geatettggg aagetegtae teaegetggg tgaeeeggag gteeagatee gtatteeaac 11460 ccacgcagge geoggeocgt ccaccgggga tegggacetg etegacagge tegegtcage 11520 tgegeeggee gegegeggg eggegetgga ggegtteete egtacgeagg tetegeaggt 11580 getgegeacy eccgaaatea aggteggege ggaggegetg tteaceegee teggeatgga 11640 etegeteatg geegtggage tgegeaateg tategaggeg ageeteaage tgaagetgte 11700 gacgacgtte etgtecacgt ecceeaatat egeettgttg geecaaaace tgttggatge 11760 tetegecaca geteteteet tggagegggt ggeggeggag aacetaeggg eaggegtgea 11820 aaacgacttc gtctcatcgg gcgcagatca agactgggaa atcattgccc tatgacgatc 11880 aatcagette tgaacgaget egageaccag ggtateaage tggeggeega tggggagege 11940 etecagatae aggeeeccaa gaacgeeetg aaccegaace tgetegeteg aateteegag 12000 cacaaaagca cgatectgac gatgeteegt cagagactee cegeagaate categtgeec 12060 generated ageggeacge tengtheret etcacagada tenaagaate etactggetg 12120 ggccggacag gagcgtttac ggtcccagc gggatccacg cctatcgcga atacgactgt 12180 acggatctcg acgtgccgag gctgagccgc gcctttcgga aagtcgtcgc gcggcacgac 12240 atgcttcggg cccacacgct gcccgacatg atgcaggtga tcgagcctaa agtcgacgcc 12300 gacategaga teategatet gegegggete gaceggagea eaegggaage gaggetegtg 12360 tegttgegag atgegatgte geacegeate tatgacaceg agegecetee getetateae 12420 gtcgtcgccg ttcggctgga cgagcggcaa acccgtctcg tgctcagtat cgatctcatt 12480 aacgttgace taggeageet gtecateate tteaaggact ggeteagett ctacgaagat 12540 ceegagacet etetecetgt cetggagete tegtacegeg attatgtact egegetggag 12600 tetegeaaga agtetgagge geateaacga tegatggatt actggaageg gegeategee 12660 gageteecac eteegeegac getteegatg aaggeegate catetaceet gaaggagate 12720 cgcttccggc acacggagca atggctgccg tcggactcct ggggtcgatt gaagcggcgt 12780 greggggage gegggetgae cecgaegge greatering ergeattre egaggtgate 12840 gggegetgga gegegagee eeggtrace etcaacataa egetetteaa eeggeteece 12900 gtccatccgc gcgtgaacga tatcaccggg gaettcacgt cgatggtcct cctggacatc 12960 gacaccactc gegacaagag ettegaacag egegetaage gtatteaaga geagetgtgg 13020 gaagegatgg atcactgega egtaageggt ategaggtee agegagagge egeeegggte 13080 ctggggatcc aacgaggcgc attgtteecc gtggtgctca cgagegeget taaccagcaa 13140 gtegttggtg teacetegtt geagaggete ggaacteegg tgtacaccag caegeagaet 13200 cercagerge tgerggarea teagererae gageaegarg gggaeeregr ceregegrgg 13260 gacategteg aeggagtgtt eeegeeegae ettetggaeg acatgetega agegtaegte 13320 gtttttetee ggeggeteae tgagggaacea tggggtgaae aggtggete ttegetteeg 13380 cetgeceage tagaagegeg ggegagegea aacgegacea aeggetget gagegageat 13440 aegetgeaeg geetgttege ggeggggte gageagetge ceatgeaget egeegtggtg 13500 teggegegea agacgeteae gtaegaagag etttegegee gttegeggeg aettggegeg 13560 cggctgcgcg agcagggggc acgcccgaac acattggtcg cggtggtgat ggagaaaggc 13620 tgggagcagg ttgtcgcggt tctcgcggtg ctcgagtcag gcgcggccta cgtgccgatc 13680 gatgccgacc taccggcgga gcgtatccac tacctcctcg atcatggtga ggtaaagctc 13740 gtgctgacgc agccatggct ggatggcaaa ctgtcatggc cgccggggat ccagcggctg 13800 cregrageg aggeoggegt egaaggegae ggegaeeage etcegatgat geeeatteag 13860 acacettegg atetegegta tgteatetae acetegggat ceaeagggtt geceaagggg 13920 gtgatgateg atcategggg tgeegteaac accatectgg acateaacga gegettegaa 13980 atagggcccg gagacagggt gctggcgctc tcctcgctga gcttcgatct ctcggtctat 14040 gatgtgttcg ggatcctggc ggcgggcggt acgatcgtgg tgccggacgc gtccaagctg 14100 cgcgatccgg cgcattgggc agagttgatc gaacgagaga aggtgacggt gtggaactcg 14160 grgccggcgc rgargcggar gcrcgrcgag cattrigagg grcgccccga rrcgcrcgct 14220 aggreetetge ggettteget getgagegge gaetggatee eggtgggeet geetggegag 14280 etceaggeea teaggeeegg egtgteggtg ateageetgg geggggeeae egaagegteg 14340

atetgqteca tegggtacec egtgaggaac gtegacetat egtgggegag cateccetac 14400 ggccgtccgc tgcgcaacca gacgttccac gtgctcgatg aggcgctcga accgcgcccg 14460 gtctgggttc cggggcaact ctacattggc ggggtcgggc tggcactggg ctactggcgc 14520 gatgaagaga agacgegcaa gagetteete gtgcaeceeg agacegggga gegeetetae 14580 aagaccggcg atctgggccg ctacctgccc gatggaaaca tcgagttcat ggggcgtgag 14640 gacaaccaaa tcaagetteg eggatacege gttgageteg gggaaatega ggaaacgete 14700 aagtegeate egaaegtaeg egaegeggtg attgtgeeeg teggggaaega egeggegaae 14760 aageteette tageetatgt ggteeeggag ggeacaegga gaegegetge egageaggae 14820 gegageetea agacegageg gategaegeg agageacaeg eegeegaage ggaeggettg 14880 agegacggeg agagggtgea gttcaagete getegacaeg gaeteeggag ggaeetggae 14940 ggaaagcccg tcgtcgatct gaccgggcag gatccgcggg aggcggggct ggacgtctac 15000 gegegtegee gtagegteeg aacgtteett gaggeeeega tteegtttgt tgagtttggt 15060 cgattcctga getgettgag cagegtggag ccegaeggeg egaceettee caaatteegt 15120 tatecategg egggeageac gtaceeggtg caaacetacg egtatgteaa ateeggeege 15180 atcgagggg tggacgaggg cttctattat taccacccgt tcgagcaccg tttgctgaag 15240 ctctccgatc acgggatcga gcgcggagcg cacgttcggc aaaacttcga cgtgttcgat 15300 gaageggegt teaaceteet gttegtggge aggategaeg eeategagte getgtatgga 15360 tegtegtege gagaattttg cetgetggag geeggatata tggegeaget eetgatggag 15420 caggegeett cetgeaacat eggegtetgt ceggtgggge aatteaattt tgaacaggtt 15480 eggeeggtte tegacetgeg acatteggae gtttacgtge acggeatget gggeggegg 15540 gtagaeeege ggeagtteca ggtetgtacg eteggteagg attecteace gaggegege 15600 acgaegegeg gegeeettee eggeegegag eageaetteg eegatatget tegegaette 15660 ttgaggacca aactacccga gracatggtg cetacagtet tegtggaget egatgegttg 15720 cogetgacgt ccaacggcaa ggtcgatcgt aaggccetge gcgagcggaa ggatacetcg 15780 tegeogcgga attegggca cacggegeca cgggacgect tggaggagat cetegtege 15840 gtcgtacggg aggtgetegg getggaggtg gtcgggetee ageagagett cgtcgatett 15900 ggtgegaeat egatteaeat egttegeatg aggageetgt tgeagaagag getggatagg 15960 gagategeca teacegagtt gttecagtae eegaaceteg getegetege gteeggtttg 16020 egeegagaet egagagatet agateagegg cegaacatge aggacegagt ggaggttegg 16080 cgcaagggca ggagacgtag ctaagaggc cgaacaaaac caggccgagc gggccgatga 16140 gccgcaagcc cgcctgcgtc accctgggac tcatctgatc tgatcgcggg tacgcgtcgc 16200 gggtgtgcgc gttgagccgt gttgttcgaa cgctgaggaa cggtgagctc atggaagaac 16260 aagagteete egetategea gteateggea tgtegggeeg tttteegggg gegegggate 16320 tggaegaatt etggaggaac ettegagaeg geaeggagge egtgeagege tteteegage 16380 aggagetege ggegteegga gtegaeeeeg egetggtget ggaeeegge taegteeggg 16440 egggeagegt getggaagae gtegaeeggt tegaegetge tttettegge ateageeege 16500 gcgaggcaga gctcatggat ccgcagcacc ggatcttcat ggaatgcgcc tgggaggcgc 16560 tggagaacgc cggatacgac ccgacggctt acgagggctc tatcggcgtg tacgccggcg 16620 ccaacatgag ctcgtacttg acgtcgaacc tccacgagca cccagcgatg atgcggtggc 16680 ccggctggtt tcagacgttg atcggcaacg acaaggatta cctcgcgacc cacgtctcct 16740 acaggctgaa tctgagaggg ccgagcatct ccgttcaaac tgcctgctcc acctcgctcg 16800 tggcggttca cttggcgtgc atgagectec tggaccgcga gtgcgacatg gcgctggccg 16860 gegggattae egteeggate ecceategag eeggetatgt atatgetgag gggggeatet 16920 tetetecega eggecattge egggeetteg aegecaagge gaaeggeaeg atcatgggca 16980 acggctgcgg cgttgtcctc ctgaagccgc tggaccgggc gctctccgat ggtgatcccg 17040 tccgcgcggt tatccttggg tctgccacaa acaacgacgg agcgaggaag atcgggttca 17100 ctgcgcccag tgaggtgggc caggcgcaag cgatcatgga ggcgctggcg ctggcagggg 17160 tegaggeeeg gtecatecaa tacategaga eccaegggae eggeaggeeg 17220 ecategagae ggeggegetg eggegggtgt teggtegega egetteggee eggaggtett 17280 gegegategg etcegtgaag aceggeateg gacacetega ateggegget ggeategeeg 17340 gtttgatcaa gacggtettg gcgctggage accggcaget gccgcccage ctgaacttcg 17400 agtetectaa cccategate gatttegega gcagcccgtt ctacgtcaat acctetetta 17460 aggartggaa taccggctcg actccgcggc gggccggcgt cagctcgttc gggartcggcg 17520 gcaccaacgc ccatgtcgtg ctggaggaag cgcccgcggc gaagettcca gccgcggcgc 17580 cagagagate tagagagate tragtagter aggacaagag agagagagag atggatgacag 17640 eggeggeacg getacgagat catetgeagg egcaecaggg gatttegttg ggegaegteg 17700 cetteageet ggegaegaeg egeageeca tggageaceg getegegatg geggegeegt 17760 egegegagge gttgegagag gggetegaeg eageggegeg aggeeagaee eegeegggeg 17820 cogragoging cogetactic coaggeaacg tgccgaaggt ggtettegte tttcccggcc 17880 agggetetea graggtegge atgggeegge agetectgge tgaggaacce gtettccacg 17940 cggcgctttc ggcgtgcgac cgggccatcc aggccgaagc tggttggtcg ctgctcgcgg 18000 agctcgccgc cgacgaaggg tcctcccagc tcgagcgcat cgacgtggtg cagccggtgc 18060 tgttcgccct cgcggtggca tttgcggcgc tgtggcggtc gtgggggtgtc gcgcccgacg 18120 tegtgategg ceacageate acetgeegge geageegget geteeggeg aceageggte 18180 agggcgagat ggcggtgace gagctgtege tggccgagge cgaggcggcg etecgagget 18300 acgaggateg ggtgagegtg geegtgagea acageeegeg etegaeggtg etetegggeg 18360 ageoggeage gateggegag gtgetgtegt ceetgaacge gaagggggtg ttetgeegte 18420 gggtgaaggt ggatgtegee agceacagee egeaggtega eeegetgege gaggacetet 18480 tggeageeet gggegggete eggeegggtg eggetgeggt geegatgege tegaeggtga 18540 eggegecat ggtageggge eeggageteg gagegaatta etggatgaac aaceteagge 18600 agccagtgcg cttcgccgag gtagtccagg cgcagctcca aggcggccac ggtctgttcg 18660 tggagatgag cccgcatccg atcctaacga cttcggtcga ggagatgcgg cgcgcggccc 18720 agegggeggg egeageggtg ggetegetge ggegggggea ggaegagege eeggegatge 18780 tggaggeget gggeaegetg tgggegeagg getaeeetgt accetggggg eggetgttte 18840 ccgcgggggg gcggcggta ccgctgccga cctatccctg gcagcgcgag cggtactgga 18900 tegaagegee ggecaagage geegegggeg ategeegegg egtgegtgeg ggeggteace 18960 cgctcctcgg tgaaatgcag accctgtcaa cccagacgag cacgcggctg tgggagacga 19020 cgctggatct caagcggctg ccgtggctcg gcgaccaccg ggtgcaggga gcggtcgtgt 19080 ttccgggcgc ggcgtacctg gagatggcga tttcgtcggg ggccgaggct ttgggcgatg 19140 gccctttgca gataactgac gtggtgctcg ccgaggcgct ggccttcgcg ggcgacgcgg 19200 eggtgttggt ccaggtggtg acgaeggage ageegteggg geggetgeag ttecagateg 19260 egageeggge geegggeget ggeeacgegt cetteegggt ccaegetege ggegegttge 19320 teegagtgga gegeacegag gteeeggetg ggettaeget tteegetgtg egegegegge 19380 tecaggecag cataceegec geggecacet aegeggaget gacegagatg gggetgeagt 19440 aeggeetge ettecagggg attgetgage tatgeeggg tgaaggegag gegetgggae 19500 gggtacgect geoegaegeg geoggetegg cageggagta teggttgeat cetgegetge 19560 tggacgcgtg ettecagate gteggcagee tettegeeeg cagtggegag gegacgeegt 19620 gggtgcccgt ggagttgggc tcgctgcggc tcttgcagcg gccttcgggg gagctgtggt 19680 gccatgcgcg cgtcgtgaac catgggcacc aaacccccga tcggcaggc gccgactttt 19740 gggtggtcga cagctcgggt gcagtggtcg ccgaagtttg cgggctcgtg gcgcagcggc 19800 ttccgggagg ggtgcgccgg cgcgaagaag acgattggtt cctggagctc gagtgggaac 19860 ccgcagcggt cggcacagcc aaggtcaacg cgggccggtg gctgctcctc ggcggcggcg 19920 gtgggctcgg cgccgcgttg cgcgcgatgc tggaggccgg cggccatgcc gtcgtgcatg 19980 eggeagagaa caacacgage getgeeggeg taegegeget cetggeaaag geetttgaeg 20040 gecaggetee gaeggeggtg gtgeaceteg geageetega tgggggtgge gagetegaee 20100 cagggetegg ggegeaagge geattggaeg egeeeeggag egeegaegte agteeegatg 20160 ccctcgatcc ggcgctggta cgtggctgcg acagcgtgct ctggaccgtg caggccctgg 20220 ccggcatggg ctttcgagac gccccgcgat tgtggctttt gacccgcggc gcacaggccg 20280 teggegeegg egacgtetee grgacacagg cacegetget ggggetggge egegteateg 20340 ccatggagea egeggatetg egetgegete gggtegaeet egatecagee eggeeegagg 20400 gggagetege tgecetgetg geegagetge tggeegaega egeegaageg gaagtegegt 20460 tgegeggtgg cgagegatge gtegetegga tegteegeeg geageeegag acceggeeee 20520 gggggaggat cgagagetge gttecgaceg acgteaceat cegegeggae ageacetace 20580 ttgtgaccgg cggtctgggt gggctcggtc tgagcgtggc cggatggctg gccgagcgcg 20640 gegetggtea cetggtgetg gtgggeeget eeggegegge gagegtggag caaegggeag 20700 ccgtcgcggc gctcgaggcc cgcggcgcgc gcgtcaccgt ggcgaaggcg gatgtcgccg 20760 ategggegea getegagegg atecteegeg aggttaceae gteggggatg cegetgeggg 20820 gegtegteca tgeggeegge atettggaeg aegggetget gatgeageag acteeegege 20880 ggtttegtaa ggtgatggeg eecaaggtee agggggeett geacetgeae gegttgaege 20940 gegaagegee gettteette ttegtgetgt aegetteggg agtagggete ttgggetege 21000 egggecaggg caactaegee geggecaaca egtteetega egetetggeg caccaeegga 21060 gggcgcaggg gctgccagcg ttgagcgtcg actggggcct gttcgcggag gtgggcatgg 21120 cggccgcgca ggaagatcgc ggcgcgcgc tggtctcccg cggaatgcgg agcctcaccc 21180 ccgacgaggg gctgtccgct ctggcacggc tgctcgaaag cggccgcgct caggtggggg 21240 tqatgccggt gaacccgcgg ctgtgggtgg agctctaccc cgcggcggcg tcttcgcgaa 21300 tgttgtegeg cetggtgaeg gegeategeg egagegeegg egggeeagee ggggaegggg 21360 acctgeteeg eegeetegee getgeegage egagegeeg gagegegete etggageege 21420 tecteegege geagateteg eaggtgetge geeteecega gggeaagate gaggtggaeg 21480 ecceptical gageetggge atgaactege tgatgggget egagetgege aacegeateg 21540 aggecatget gggcatcace graceggeaa egetgttgtg gacetatece aeggtggegg 21600 egetgagegg gcatetggeg egggaggeat gegaageege teetgtggag teaecgeaca 21660 ccaccgccga ctctgccgtc gagatcgagg agatgtcgca ggacgatctg acgcagttga 21720 togcagcaaa attoaaggog ottacatgac tactogoggt octacggoac agcagaatco 21780 gctgaaacaa gcggccatca tcattcagcg gctggaggag cggctcgctg ggctcgcaca 21840 ggcggagctg gaacggaccg agccgatcgc catcgtcggt atcggctgcc gcttccctgg 21900 cggtgcggac gctccggaag cgttttggga gctgctcgac gcggagcgcg acgcggtcca 21960 geogetegae atgegetegg egetegtegg tetegetece etegaggeeg tecegeacte 22020 ggcggggctg crcaccgage cgaragattg ettegatget gegttetteg geatetegee 22080 tegggaggeg egategeteg accegeagea tegtetgttg etggaggteg ettgggaggg 22140

getegaggae geeggtatee egeeeeggte categaeggg ageegeaeeg gtgtgttegt 22200 cggcgctttc acggcggact acgcgcgcac ggtcgctcgg ctgccgcgcg aggagcgaga 22260 cgcgtacage gccaccggca acatgctcag catcgccgcc ggacggctgt cgtacacgct 22320 ggggttgcag ggaccttgcc tgaccgtcga cacggcgtgc tcgtcatcgc tggtggcgat 22380 tcacetegee tgeegeagee tgegegeagg agagagegat etegegetegg egggaggggt 22440 cagegegete etetececeg acatgatgga ageegeggeg egeaegeaag egetgtegee 22500 cgatggtcgt tgccggacct tcgatgcttc ggccaacggg ttcgtccgtg gcgagggctg 22560 tggcctggtc gtcctcaaac ggctctccga cgcgcaacgg gatggcgacc gcatctgggc 22620 gctgatccgg ggctcggcca tcaaccatga tggccggtcg accgggttga ccgcgccaa 22680 cgtgctggct caggagacgg tcttgcgcga ggcgctgcgg agcgcccacg tcgaagctgg 22740 ggccgtcgat tacgtcgaga cccacggaac agggacctcg ctgggcgatc ccatcgaggt 22800 cgaggegetg egggegaegg tggggeegge gegeteegae ggeacaeget gegtgetggg 22860 cgcggtgaag accaacatcg gccatctcga ggccgcggca ggcgtagcgg gcctgatcaa 22920 ggcagcgctt tcgctgacgc acgagcgcat cccgagaaac ctcaacttcc gcacgctcaa 22980 teegeggate eggetegagg geagegeget egegttggeg acegageegg tgeegtggee 23040 gegeaeggae egecegeget tegegggggt gagetegtte gggatgageg gaaegaaege 23100 gcatgtggtg ctggaagagg cgccggcggt ggagctgtgg cctgccgcgc cggagcgctc 23160 ggcggagctt ttggtgctgt cgggcaagag cgagggggcg ctcgatgcgc aggcggcgcg 23220 gctgcgcgag cacctggaca tgcacccgga gctcgggctc ggggacgtgg cgttcagcct 23280 ggcgacgacg cgcagcgcga tgagccaccg gctcgcggtg gcggtgacgt cgcgcgaggg 23340 getgetggeg gegetetegg cegtggegea ggggcagaeg ceggeggggg eggegegetg 23400 categogage testegogog geaagetgge gtteetgtte aceggacagg gegegeagae 23460 gccgggcatg ggccggggc tttgcgcggc gtggccagcg ttccgggagg cgttcgaccg 23520 gtgcgtggcg ctgttcgacc gggagctgga ccgcccgctg cgcgaggtga tgtgggcgga 23580 ggeggggage geegagtegt tgttgetega ceagaeggeg ttcacceage eegegetett 23640 cgcggtggag tacgcgctga cggcgctgtg gcggtcgtgg ggcgtagagc cggagctcct 23700 ggttgggcat agcatcgggg agctggtgg ggcgtgcgtg gcgggggtgt tctcgctgga 23760 agatggggtg aggetegtgg eggegegeg geggetgatg caggggetet eggeggggg 23820 egegatggtg tegeteggag egeeggagge ggaggtggeg geggeggtgg egeegeacge 23880 ggegteggtg tegategegg eggteaatgg geeggageag gtggtgateg egggegtgga 23940 gcaageggtg caggegateg eggeggggtt egeggegege ggegegegea ccaagegget 24000 geatgteteg eacgegttee actegeeget gatggaaceg atgetggagg agttegggeg 24060 ggtggcggcg tcggtgacgt accggcggcc aagcgtttcg ctggtgagca acctgagcgg 24120 gaaggtggtc acggacgagc tgagcgccc ggggtactgg gtgcggcacg tgcgggaggc 24180 ggtgcgcttc gcggacgggg tgaaggcgct gcacgaagcc ggcgcgggga cgttcgtcga 24240 agtgggcccg aagccgacgc tgctcgggct gttgccagcc tgcctgccgg aggcggagcc 24300 gacgetgetg gegtegttge gegeegggeg egaggagget gegggggtge tegaggeget 24360 gggcaggctg tgggccgccg gcggctcggt cagctggccg ggcgtcttcc ccaccggctgg 24420 gcggcgggtg ccgctgccga cctatccgtg gcagcggcag cggtactgga tcgaggcgcc 24480 ggccgaaggg ctcggagcca cggccgccga tgcgctggcg cagtggttct accgggtgga 24540 ctggcccgag atgcctcgct catccgtgga ttcgcggcga gcccggtccg gcgggtggct 24600 ggtgctggcc gaccggggtg gagtcgggga ggggcctcc gcggttgccg acgagggcc 24780 cgtcgtggag gcgggggcat cggccgaaga ggtcgccaaa gtcacccatc ttgccgcggc 24840 geogytycte gegetyatte aggegetegg caegyggeeg egeteacece ggetetygat 24900 cgtgacccga ggggcctgca cggtgggcgg cgagcctgac gctgccccct gtcaggcggc 24960 getgtggggt atgggecggg tegeggeget agageateee ggeteetggg gegggetegt 25020 ggaeetggat eeggaggaga geeegaegga ggtegaggee etggtggeeg agetgettte 25080 geeggaegee gaggateage tggeatteeg eeaggggege eggegegeag egeggettgt 25140 ggccgcccca ccggagggaa acgcagegce ggtgtcgctg tctgcggagg ggagttactt 25200 ggtgacgggt gggctgggcg cccttggcct cctcgttgcg cggtggttgg tggagcgcgg 25260 ggeggggeae ettgtgetga teageeggea eggattgeee gaeegegagg aatggggeeg 25320 agatcagceg ceagaggtge gegegegeat tgeggegate gaggegetgg aggegeaggg 25380 cgcgcgggtc accgtggcgg cggtcgacgt ggccgatgcc gaaggcatgg cggcgctctt 25440 ggcggccgtc gagccgccgc tgcggggggt agtgcacgcc gcgggtctgc tcgacgacgg 25500 gctgctggcc caccaggacg ctggtcggct cgcccgggtg ttgcgccca aggtggaggg 25560 ggcatgggtg ctgcacaccc ttacccgcga gcagccgctg gacctcttcg tactgttttc 25620 cteggegteg ggegtetteg getegategg ceagggeage taegeggeag geaatgeett 25680 tttggacgeg etggeggace teegeegaac geaggggete geegeeetga geategeetg 25740 gggcctgtgg gcggaggggg ggatgggctc gcaggcgcag cgccgggaac acgaggcatc 25800 gggaatctgg gcgatgccga cgagtcgggc cctggcggcg atggaatggc tgctcggtac 25860 gcgcgcgacg cagcgcgtgg tcatccagat ggattgggcc catgcgggag cggcgccgcg 25920 cgacgcgage cgaggccgct totgggateg gctggtaact gccacgaaag aggcctcctc 25980 ctcggccgtg ccagctgtgg agcgctggcg caacgcgtct gttgtggaga cccgctcggc 26040 getetacgag ettgtgegeg gegtggtege eggggtgatg ggetttaceg accagggeae 26100 getegacgtg egacgagget tegecgagea gggeetegae teeetgatgg eegtggagat 26160 eegcaaaegg etteagggtg agetgggtat geegetgteg gegaegetag egttegaeea 26220 tecgacegtg gageggetgg tggaataett getgageeag gegetggage tgeaggaceg 26280 cacegaegtg eggagegtte ggttgeegge gacagaggae eegategeea tegtgggtge 26340 cgcctgccgc ttcccgggcg gggtcgagga cctggagtcc tactggcagc tgttgaccga 26400 gggcgtggtg gtcagcaccg aggtgccggc cgaccggtgg aatggggcag acgggcgcgt 26460 ccccggctcg ggagaggcac agagacagac ctacgtgccc aggggtggct ttctgcgcga 26520 ggtggagacg ttcgatgcgg cgttcttcca catctcgcct cgggaggcga tgagcctgga 26580 cccqcaacag cggctgctgc tggaagtgag ctgggaggcg atcgagcgcg cgggccagga 26640 cccgtcggcg ctgcgcgaga gccccacggg cgtgttcgtg ggcgcgggcc ccaacgaata 26700 tgccgagcgg gtgcaggaac tcgccgatga ggcggcgggg ctctacagcg gcaccggcaa 26760 catgeteage gttgeggegg gaeggetate attitteetg ggeetgeaeg ggeegaeeet 26820 qqctqtqqat acggcqtqct cetegteget ggtggcgctg cacetegget gccagagett 26880 gcgacggggc gagtgcgacc aagccctggt tggcggggtc aacatgctgc tctcgccgaa 26940 gacettegeg etgeteteae ggatgeaege aetttegece ggegggeggt geaagaegtt 27000 cteggeegae geggaegget aegegeggge egagggetge geegtggtgg tgeteaageg 27060 geteteegae gegeagegeg acegegaece cateetggeg gtgateeggg gtaeggegat 27120 caatcatgat ggcccgagca gcgggctgac agtgcccagc ggccctgccc aggaggcgct 27180 gttacgccag gcgctggcgc acgcaggggt ggttccggcc gacgtcgatt tcgtggaatg 27240 ccacgggacc gggacggcgc tgggcgaccc gatcgaggtg cgtgcgctga gcgacgtgta 27300 cgggcaagec cgccctgcgg accgaccgct gatectggga geegecaagg ccaacettgg 27360 gcacatggag cccgcggcgg gcctggccgg cttgctcaag gcggtgctcg cgctggggca 27420 agagcaaata ccagcccage eggageteggg egageteaac cegetettge egtgggagge 27480 gctgccggtg gcggtggcc gcgcagcggt gcctgcgcgc cgcacggacc gcccgcgctt 27540 cgcggggtg agctcgttcg ggatgagcgg aacgaacgcg catgtggtgc tggaagaggc 27600 geoggeggtg gagetgtgge etgeegegee ggagegeteg geggagettt tggtgetgte 27660 gggcaagage gagggggege tegatgegea ggeggegegg etgegegage aeetggacat 27720 gcacceggag ctegggeteg gggaegtgge gtteageetg gegaegaege geagegegat 27780 gaaccaccgg ctcgcggtgg cggtgacgtc gcgcgagggg ctgcttggcgg cgctttcggc 27840 cgtggcgcag gggcagacgc cgccgggggc ggcgctgc atcgcgagct cgtcgcgcgg 27900 caagctggcg ttcctgttca ccggacaggg cgcgcagacg ccggggcatgg gccgggggct 27960 ttgcgcggcg tggccagcgt tccgggaggc gttcgaccgg tgcgtggcgc tgttcgaccg 28020 qqaqctqqac cqccqctqc gcqaqqtqat qtqqqcqqaq ccqqqqqqcq ccqaqtcqtt 28080 gttgctcgac cagacggcgt tcacccagce cgcgctcttc acggtggagt acgcgctgac 28140 ggcgctgtgg cggtcgtggg gcgtagagcc ggagctggtg gctgggcata gcgccgggga 28200 gctggtggcg gcgtgcgtgg cgggggtgtt ctcgctggaa gatggggtga ggctcgtggc 28260 ggcgcgcggg cggctgatgc aggggctctc ggcgggcggc gcgatggtgt cgctcggagc 28320 geoggaggeg gaggtggegg eggeggtgge geogeacgeg gegteggtgt egategege 28380 ggtcaatggg ccggagcagg tggtgatcgc gggcgtggag caagcggtgc aggcgatcgc 28440 ggcggggttc gcggcgcgcg gcgcgcgcac caagcggctg catgtctcgc acgcgtccca 28500 ctegeegetg atggaacega tgetggagga gttegggegg gtggeggegt eggtgaegta 28560 ccggcggcca agcgtttcgc tggtgagcaa cctgagcggg aaggtggtcg cggacgagct 28620 gagcgcgccg gggtactggg tgcggcacgt gcgggaggcg gtgcgcttcg cggacggggt 28680 gaaggcgctg cacgaagccg gtgcgggcac gttcgtcgaa gtgggcccga agccgacgct 28740 gctcgggctg ttgccagcct gcctgccgga ggcggagccg acgctgctgg cgtcgttgcg 28800 cgccqqqcqc qaggaggctg cgggggtgct cgaggcgctg ggcaggctgt gggccgccgg 28860 eggeteggte agetggeegg gegtetteee caeggetggg eggegggtge egetgeegae 28920 ctatccgtgg cagcggcagc ggtactggcc cgacatcgag cctgacagcc gtcgccacgc 28980 agccgcggat ccgacccaag gctggttcta tcgcgtggac tggccggaga tacctcgcag 29040 cetecagaaa teagaggagg egageegegg gagetggetg gtattggegg ataagggtgg 29100 agteggegag geggtegetg cagegetgte gacaegtgga ettecatgeg tegtgeteca 29160 tgegeeggea gagaeateeg egaeegeega getggtgaee gaggetgeeg geggtegaag 29220 egattggeag gtagtgetet acetgtgggg tetggaegee gtegteggtg eggaggegte 29280 gategatgag ateggegacg egaceegteg tgetaeegeg eeggtgeteg gettggeteg 29340 gtttctgagc accgtgtctt gttcgccccg actctgggtc gtgacccggg gggcatgcat 29400 cgttggcgac gagcctgcga tcgccccttg tcaggcggcg ttatggggca tgggccgggt 29460 ggcggcgctc gagcatcccg gggcctgggg cgggctcgtg gacctggatc cccgagcgag 29520 cccgcccaa gccagcccga tcgacggcga gatgetcgtc accgagctat tgtegcagga 29580 gaccgaggat cagetegeet teegeeatgg gegeeggeac geggeaegge tggtggeege 29640 cccgccacag gggcaagcgg caccggtgtc gctgtctgcg gaggcgagct acctggtgac 29700 gggaggcctc ggtggctgg gcctgatcgt ggcccagtgg ctggtggagc tgggagcgcg 29760 gractinging organization of the contraction of the gccgcctgag atccgcgcg ggatcgcagc ggtcgaggcg ctggaggcgc ggggtgcacg 29880 ggtgaccgtg gcagcggtgg acgtggccga cgtcgaaccg atgacagcgc tggtttcgtc 29940 ggtcgagccc ccgctgcgag gggtggtgca cgccgctggc gtcagcgtca tgcgtccact 30000 ggcggagacg gacgagaccc tgctcgagtc ggtgctccgt cccaaggtgg ccgggagctg 30060 getgetgeac eggetgetge aeggeeggee tetegaeetg ttegtgetgt tetegteggg 30120 cgcagcggtg tggggtagcc atagccaggg tgcgtacgcg gcggccaacg ctttcctcga 30180 egggetegeg catettegge gttegeaate getgeetgeg ttgagegteg egtggggtet 30240 gtgggccgag ggaggcatgg cggacgcgga ggetcatgca cgtctgagcg acatcggggt 30300 totgoccatg togacgtogg cagogttgto ggogetocag ogcotggtgg agacoggogo 30360 ggeteagege aeggtgaeee ggatggaetg ggegegette gegeeggtgt acaeegeteg 30420 agggegtege accetgettt eggegetggt egcagggege gacateateg egeetteece 30480 teeggeggea geaaceegga actggegtgg cetgteegtt geggaageee gegtggetet 30540 gcacgagate gtccatgggg ccgtcgctcg ggtgctgggc ttcctcgacc cgagcgcgct 30600 cgatcctggg atggggttca atgagcaggg cctcgactcg ttgatggcgg tggagatccg 30660 caaceteett caggetgage tggacgtgeg getttegaeg acgetggeet ttgateatee 30720 qacqqtacaq cggctggtgg agcatctgct cgtcgatgta ctgaagctgg aggatcgcag 30780 cgacacccag catgttcggt cgttggcgtc agacgagccc atcgccatcg tgggagccgc 30840 ctgccgcttc ccgggcgggg tggaggacct ggagtcctac tggcagctat tggccgaggg 30900 cgtggtggtc agcgccgagg tgccggccga ccggtgggat gcggcggact ggtacgaccc 30960 tgatccggag atcccaggcc ggacttacgt gaccaaaggc gccttcctgc gcgatttgca 31020 gagattggat gegacettet teegeatete geetegegag gegatgagee tegaceegea 31080 gcagcggttg ctcctggagg taagctggga agcgctcgag agcgcgggta tcgctccgga 31140 tacgctgcga gatagcccca ccggggtgtt cgtgggtgcg gggcccaatg agtactacac 31200 geageggetg egaggettea eegaeggage ggeagggttg taeggeggea eegggaacat 31260 getcagegtt aeggetggae ggetgtegtt ttteetgggt etgeaeggee egaegetgge 31320 catggatacg gegtgetegt catecetggt egegetgeac etegeetgee agageetgeg 31380 actgggcgag tgcgatcaag cgctggttgg cggggtcaac gtgctgctcg cgccggagac 31440 cttcgtgctg ctctcacgga tgcgcgcgct ttcgcccgac gggcggtgca agacgttctc 31500 ggeegaegeg gaeggetaeg egeggggega ggggtgegee gtggtggtge teaagegget 31560 gegegatgeg cagegegeg gegactecat cetggegetg atceggggaa gegeggtgaa 31620 ccacgacggc ccgagcagcg ggctgaccgt acccaacgga cccgcccagc aagcattgct 31680 gcgccaggcg ctttcgcaag caggcgtgtc tccggtcgac gttgattttg tggagtgtca 31740 cgggacaggg acggcgctgg gcgacccgat cgaggtgcag gcgctgagcg aggtgtatgg 31800 tccagggcgc tccggggacc gaccgctggt gctgggggcc gccaaggcca acgtcgcgca 31860 tetggagge geatetgget tggeeagest geteaaggee gtgettgege tgeggeaega 31920 geagateceg geceageegg agetggggga geteaaceeg caettgeegt ggaacaeget 31980 geeggtggeg gtgccacgta aggeggtgee gtgggggege ggegeaegee egegteggge 32040 eggegtgage gegttegggt tgageggaae caacgtgeat gtegtgetgg aggaggeaee 32100 ggaggtggag coggcgcccg cggcgccggc gcgaccggtg gagctggtcg tgctatcggc 32160 caagagcgcg gcggcgctgg acgccgcggc ggcacggctc tcggcgcacc tgtccgcgca 32220 cccggagctg agcctcggcg acgtggcgtt cagcctggcg acgacgcgca gcccgatgga 32280 gcaccggctc gccatcgcga cgacctcgcg cgaggccctg cgaggcgcgc tggacgccgc 32340 ggcgcagcaa aagacgccgc agggcgcggt gcgcggcaag gccgtgtcct cacgcggtaa 32400 getggettte etgtteaceg gaeagggege geaaatgeeg ggeatgggee gtgggetgta 32460 cgaaacgtgg cctgcgttcc gggaggcgtt cgaccggtgc gtggcgctct tcgatcggga 32520 gategaceag cetetgegeg aggtgatgtg ggetgegeeg ggeetegete aggeggegeg 32580 getegateag acegegtaeg egeageegge tetetttgeg etggagtaeg egetggetge 32640 cetgtggegt tegtggggeg tggageegea egtactgete ggteatagea teggegaget 32700 qqtcqccqcc tgcgtqqcqq qcgtgttctc gctcgaagat gcggtgaggt tggtggccgc 32760 gegegggegg etgatgeagg egetaceege eggeggtgee atggtageea tegeagegte 32820 cgaggccgag gtggccgcct ccgtggcgcc ccacgccgcc acggtgtcga tcgccgcggt 32880 caacggtcct gacgccgtcg tgatcgccgg cgccgaggta caggtgctcg ccctcggcgc 32940 qacqttcgcg gcgcgtggga tacgcacgaa gaggctcgcc gtctcccatg cgttccactc 33000 geogeteatg gateegatge tggaagaett ccagegggte getgegaega tegegtaeeg 33060 egegecagae egeeeggtgg tgtegaatgt caceggecae gtegeaggee eegagatege 33120 cacgeeegag tartgggtee ggeatgtgeg aagegeegtg egetteggeg aeggggeaaa 33180 qqcqttqcat qccqcqggtq ccqccacqtt cqtcqagqtt gqcccqaaqc cqqtcctqct 33240 cgggctgttg ccagcgtgcc tcggggaagc ggacgcggtc ctcgtgccgt cgctacgcgc 33300 ggaccgctcg gaatgcgagg tggtcctcgc ggcgctcggg gcttggtatg cctggggggg 33360 tgcgctcgac tggaagggcg tgttccccga tggcgcgcgc cgcgtggctc tgcccatgta 33420 tccatggcag cgtgagcgcc attggatgga cctcaccccg cgaagcgccg cgcctgcagg 33480 gategeaggt egetggeege tggetggtgt egggetetge atgeeeggeg etgtgttgea 33540 ccacqtqctc tcgatcgqac cacqccatca gcccttcctc ggtgatcacc tcgtgtttgg 33600 caaggtggtg gtgcccggcg cctttcatgt cgcggtgatc ctcagcatcg ccgccgagcg 33660 ctggcccgag cgggcgatcg agctgacagg cgtggagttc ctgaaggcca tcgcgatgga 33720 georgaceag gaggtegage tecacgeegt geteaceece gaageegeeg gggatggeta 33780 cetgttegag etggegacee tggeggegee ggagacegaa egeorgatgga egacecaege 33840 WO 99/66028

cogoggtogg gtgcagcoga cagacggcgc gcccggcgcg ttgccgcgcc tcgaggtgct 33900 ggaggacege gegatecage ceetegactt egeeggatte etegacaggt tateggeggt 33960 geggategge tggggteege tttggegatg getgeaggae gggegegteg gegaegagge 34020 ctogettgee accetegtge egacetatee gaacgeecae gaegtggege cettgeacec 34080 gatectgetg gacaacgget ttgeggtgag cetgetgtea acceggageg ageeggagga 34140 cgacgggacg cccccgetgc cgttcgccgt ggaacgggtg cggtggtggc gggcgccggt 34200 tggaaggtg cggtgtggcg gcgtgccgcg gtcgcaggca ttcggtgtct cgagcttcgt 34260 gctggtcgac gaaactggcg aggtggtcgc cgaggtggag ggatttgtt gccgccgggc 34320 gccgcgagag gtgttcctgc ggcaggagtc gggcgcgtcg actgcagcct tgtaccgcct 34380 cgactggccc gaagcgccct tgcccgatgc gcctgcggaa cggatcgagg agagctgggt 34440 cgtggtggca gcacctggct cggagatggc cgcggggcgc tcaaccgctg 34500 cgtcctcgcc gaacccaaag gcctcgaggc ggcctcgcg ggggtgtctc ccgcaggtgt 34560 gatctgcctc tgggaggctg gagcccacga ggaagctccg gcggcggc agcgtgtgc 34620 gaccgagggc ctctcggtgg tgcaggcgct cagggaccgc gcggtgcgcc tgtggtgggt 34680 gaccatgggc gcagtggccg tcgaggccgg tgagcggrafg caggtcgca cagcgccggt 34740 atggggcctc ggccggacag tgatgcagga gcgcccggag ctcagctgca ctctggtgga 34800 tttggagccg gaggccgatg cagcgcgctc agctgacgtt ctgttgcggg agctcggtcg 34860 cgctgacgac gagacacagg tggctttccg ttccggaaag cgccgcgtag cgcggctggt 34920 caaagegaeg accecegaag ggcteetggt ceetgaegea gagteetate gaetggagge 34980 tgggcagaag ggcacattgg accagetecg cetegegeeg geacagegee gggcacetgg 35040 eeegggegag gtegagatea aggtaacege eteggggete aaetteegga eegteetege 35100 tgtgctggga atgtatccgg gcgacgccgg gccgatgggc ggagattgtg ccggtgtcgc 35160 cacggeggtg ggccaggggg tgcgccacgt cgcggtcggc gatgctgtca tgacgctggg 35220 gacgttgcat cgattcgtca cggtcgacgc gcggctggtg gtccggcagc Ctgcagggct 35280 gactcocgcg caggcageta cggtgccggt cgcgttcctg acggcctggc tcgctctgca 35340 cgacctgggg aatctgcggc gcggcgagcg ggtgctgatc catgctgcgg ccggcggtgt 35400 gggcatggcc gcggtgcaaa tcgcccgatg gataggggcc gaggtgttcg ccacggcgag 35460 cccgtccaag tgggcagcgg ttcaggccat gggcgtgccg cgcacgcaca tcgccagctc 35520 geggaegetg gagtttgetg agaegtteeg geaggteace ggeggeeggg gegtggaegt 35580 ggtgctcaac gcgctggccg gcgagttcgt ggacgcgagc ctgtccctgc tgtcgacggg 35640 cgggcggttc ctcgagatgg gcaagaccga catacgggat cgagccgcgg tcgcggcggc 35700 geateeggt gttegetate gggtattega cateetggag etegeteegg ategaacteg 35760 agagateete gagegegtgg tegagggett tgetgeggga catetgeggg cattgeeggt 35820 gcatgcgttc gcgatcacca aggccgaggc agcgtttcgg ttcatggcgc aagcgcggca 35880 teagggeaag gtegtgetge tgeeggegee etcegeage cecttggege egaegggeae 35940 egtaetgetg accggtggge tgggagegtt ggggeteeae gtggeeeget ggetegeea 36000 gragggggtg cegracatgg tgctcacagg teggegggge etggataege egggegetge 36060 caaagccgtc gcggagatcg aagcgctcgg cgctcgggtg acgatcgcgg cgtcggatgt 36120 cgccgatcgg aatgcgctgg aggctgtgct ccaggccatt ccggcggagt ggccgttaca 36180 gggcgtgatc catgcagccg gagcgctcga tgatggtgtg cttgatgagc agaccaccga 36240 ccgcttctcg cgggtgctgg caccgaaggt gactggcgcc tggaatctgc atgagctcac 36300 ggegggeaac gatetegett tettegtget gtteteetee atgtegggge tettgggete 36360 ggccgggcag tccaactatg cggcggccaa caccttcctc gacgcgctgg ccgcgcatcg 36420 gegggeegaa ggeetggegg egeagageet egegtgggge eeatggtegg acggaggeat 36480 ggcagcgggg ctcagcgcgg cgctgcaggc gcggctcgct cggcatggga tgggagctct 36540 gtcgccggct cagggcaccg cgctgctcgg gcaggcgctg gctcggccgg aaacgcagct 36600 eggggegatg tegetegaeg tgegtgegge aagecaaget tegggagegg eagtgeegee 36660 tgtgtggcgc gcgttggtgc gcgcggaggc gcgccatacg gcggctgggg cgcaggggc 36720 attggccgcq cgtcttgggg cgctgccga qqcqcgtcgc gccgacgagg tqcgcaaggt 36780 cgtgcaggcc gagatcgcgc gcgtgctttc atggagcgcc gcgagcgccg tgcccgtcga 36840 teggeegetg teggaettgg geetegaete geteaeggeg gtggagetge geaaegtget 36900 cggccagegg gtgggtgega cgctgeegge gaegetggea ttegateace egaeggtega 36960 egegeteacy egetggetge tegataaggt cetggeegtg geegageega gegtategte 37020 egeaaagteg tegeegeagg tegeeetega egageecatt geeateateg geateggetg 37080 ccgtttccca ggcggcgtgg ccgatccgga gtcgttttgg cggctgctcg aagagggcag 37140 cgatgccgtc gtcgaggtgc cgcatgagcg atgggacatc gacgcgttct atgatccgga 37200 teeggatgtg egeggeaaga tgaegacaeg etttggegge tteetgteeg atategaeeg 37260 gttcgatccg gccttcttcg gcatctcgcc gcgcgaagcg acgaccatgg atccgcagca 37320 geggetgete etggagaega getgggagge gttegagege geegggattt tgeeegageg 37380 getgatggge agegataceg gegtgttegt ggggetette taccaggagt acgetgeget 37440 egeeggegge ategaggegt tegatggeta tetaggeace ggeaceacgg ecagegtege 37500 ctegggeagg atetettatg tgeteggget aaaggggeeg ageetgaegg tggacaeege 37560 gtgctcctcg tcgctgqtcq cqqtgcacct ggcctgccag gcgctgcggc ggggcgagtg 37620 tteggtggeg etggeeggeg gegtggeget gatgeteacg eeggegaegt tegtggagtt 37680 cageeggetg egaggeetgg etceegaegg aeggtgeaag agettetegg eegeageega 37740

eggegtgggg tggagegaag getgegeeat geteetgete aaacegette gegatgegea 37800 gegegatggg gateegatee tggeggtgat cegeggeace geggtgaace aggatgggeg 37860 cagcaacggg ctgacggcgc ccaacgggtc gtcgcagcaa gaggtgatcc gtcgggccct 37920 ggagcaggeg gggctggctc cggcggacgt cagctacgtc gagtgccacg gcaccggcac 37980 gacgttgggc gaccccatcg aagtgcaggc cctgggcgcc gtgctggcac aggggcgacc 38040 ctoggacogg cogotogtga togggtoggt gaagtecaat atoggacata cgcaggotge 38100 ggcgggggtg gccggtgtca tcaaggtggc gctggcgctc gagcgcgggc ttatcccgag 38160 gagcctgcat ttcgacgcgc ccaatccgca cattccgtgg tcggagctcg ccgtgcaggt 38220 ggccgccaaa cccgtcgaat ggacgagaaa cggcgtgccg cgacgagccg gggtgagctc 38280 gtttggcgtc agcgggacca acgcgcacgt ggtgctggag gaggcgccag cggcggcgtt 38340 cgcgcccgcg gcggcgcgtt cagcggagct tttcgtgctg tcggcgaaga gcgccgcggc 38400 gctggacgcg caggcggcg ggctttcggc gcacgtcgt gcgcacccgg agctcggcct 38460 cggcgacctg gcgttcagcc tggcgacgac ccgcagcccg atgacgtacc ggctcgcggt 38520 ggeggegace tegegegagg egetgtetge egegetegae acageggege aggggeagge 38580 gccgcccgca gcggctcgcg gccacgcttc cacaggcagc gccccaaaagg tggttttcgt 38640 ctttcctggc cagggctcc agtggctggg catgggccaa aagctcctct cggaggagcc 38700 egtetteege gaegegetet eggegtgtga eegagegatt eaggeegaag eeggetggte 38760 getgetegee gagetegegg cegatgagae cacetegeag eteggeegea tegaegtggt 38820 geageeggeg etgttegega tegaggtege getgteggeg etgtggeggt egtggggegt 38880 cgagccggat gcagtggtag gccacagcat gggcgaagtg gcggcgcgc acgtcgcgg 38940 cgccctgtcg ctcgaggatg ctgtagcgat catctgccgg cgcagcctgc tgctgcggcg 39000 gatcagegge caaggegaga tggeggtegt egagetttee etggeegagg eegaggeage 39060 gctcctgggc tacgaagacc ggctcagcgt ggcggtgagc aacagcccgc gctcgacggt 39120 gctggcgggc gagccggcag cgctcgcaga ggtgctggcg atccttgcgg caaagggggt 39180 gttctgccgt cgagtcaagg tggacgtcgc cagcacage ccacagatcg acccgctgcg 39240 cgacgageta ttggcagcat tgggcgaget cgagccgcga caagcgaccg tgtcgatgcg 39300 ctcgacggtg acgagcacga tcatggcggg cccggagctc gtggcgagct actgggcgga 39360 caacgttega cageeggtge gettegeega ageggtgeaa tegttgatgg aagaeggtea 39420 tgggctgttc gtggagatga gcccgcatcc gatcctgacg acatcggtcg aggagatccg 39480 acggcgacg aagcggagg gagtcgcgt gggctcgttg cggcgtggac aggacgagcg 39540 cctgccatg ttggagcgc tgggagcgct ctgggtacac ggccaggcg tgggctggga 39600 geggetgite teegegggeg gegegggeet eegtegegig eegetgeega eetateeetg 39660 gcagcgcgag cggtactggg tcgatgcgcc gaccggcggc gcggcgggcg gcagccgctt 39720 tgeteatgeg ggeagteace egeteetggg tgaaatgeag accetgtega eecagaggag 39780 cacgoggtg tgggagacga cyctggatet caaacggetg ccgtggeteg gcgateaccg 39840 ggtgcagggg gcggtegtgt tecegggege ggegtacetg gagatggege tttegteegg 39900 ggeegaggee ttgggtgaeg gteegeteea ggteagegat gtggtgeteg eegaggeget 39960 ggeettegeg gatgataege eggeggeggt geaggteatg gegaeegagg agegaeeagg 40020 cogectycaa ttocacgtty cyayeegggt geegggcac ggeggtgety eetitegaag 40080 ccatgecege ggggtgetge gecagatega gegegeegag gteeeggea ggetggatet 40140 ggeegegett egtgeegge tteaggeeag egeaceeget geggetaeet atgeggeget 40200 ggccgagatg gggctcgagt acggcccagc gttccagggg cttgtcgagc tgtggcgggg 40260 ggagggggag gcgctgggac gtgtgcggct ccccgaggcc gccggctccc cagccgcgtg 40320 coggetecae ecogogetet togatgogtg ettecaegtg ageagegeet tegetgaceg 40380 cggcgaggcg acgccatggg tacccgtgga aatcggctcg ctgcggtggt tccagcggcc 40440 gtcgggggag ctgtggtgt atgcgcggag tgtgagccac ggaaagccaa cacccgaccg 40500 geggagtace gaettetggg tggtegaeag caegggegeg ategtegeeg agateteegg 40560 getegtggeg cageggeteg egggaggtgt acgeeggege gaagaagaeg actggtteat 40620 ggagccggct tgggaaccga ccgcggtccc cggatccgag gtcatggcgg gccggtggt 40680 gctcatcggc tcgggcgcg ggctcggcg tgcgctcac tcggcgctga cggaagctg 40740 ccattccgtc gtcacgcga cagggcgcg cacgagcgc gccgggttgc aggcactctt 40800 gacggcgtcc ttcgacggcc aggccccgac gtcggtggtg cacctcggca gcctcgatga 40860 gegrag gegeggetge gacagegtge tetggacegt geaggeegtg geeggggegg getteegaga 40980 tecteogogg trgregereg tgacaegogg egeteaggee ateggegeeg gegaegtete 41040 tgtggcgcaa gcgccgctcc tggggctggg ccgcgttatc gccttggagc acgccgagct 41100 gcgctgcgct cggatcgacc tcgatccagc gcggcgcgac ggagaagtcg atgagctgct 41160 tgccgagctg ttggccgacg acgccgagga ggaagtcgcg tttcgcggcg gtgagcggcg 41220 cgtggcccgg ctcgtccgaa ggctgcccga gaccgactgc cgagagaaaa tcgagcccgc 41280 ggaaggccgg ccgttccggc tggagatcga tgggtccggc gtgctcgacg acctggtgct 41340 ccgagccacg gagcggcgc ctcctggccc gggcgaggtc gagatcgccg tcgaggcgc 41400 ggggctcaac tttctcgacg tgatgagggc catggggatc taccctgggc ccggggacgg 41460 tecggttqcg etgggegeeq aqtqeteegg eegaattgte gegatgggeg aaggtgtega 41520 gageettegt ateggeeagg aegtegtgge egtegegeee treagttteg geacceaegt 41580 caccategae geeeggatge tegeaceteg eccepeggeg etgaeggeeg egeaggeage 41640

WO 99/66028 PCT/EP99/04171

egegetgeee gtegeattea tgaeggeetg gtaeggtete gteeatetgg ggaggeteeg 41700 ggccggcgag cgcgtgctca tccactcggc gacgggggc accgggctcg ctgctgtgca 41760 gatcgcccgc cacctcggcg cggagatatt tgcgaccgct ggtacaccgg agaagcgggc 41820 gtggctgcgc gagcagggga tcgcgcacgt gatggactcg cggtcgctgg acttcgccga 41880 gcaagtgetg gccgcgacga agggcgaggg ggtcgacgte gtgttgaact cgctgtctgg 41940 cgccgcgate gacgcgagec tttcgaccet cgtgccggac ggccgcttca tcgagctcgg 42000 caagacggac atctatgcag atcgctcgct ggggctcgct cacttcagga agagcctgtc 42060 ctacagegee gtegatettg egggettgge egtgegtegg ecegagegeg tegeageget 42120 gctggcggag gtggtggacc tgctcgcacg gggagcgctg cagccgcttc cggtagagat 42180 cttececete tegeggeeg eggaegegtt eeggaaaatg gegeaagege ageatetegg 42240 gaagetegtg etegegetgg aggaecegga egtgeggate egegtteegg gegaateegg 42300 egregecate egegeggaeg gegeetaeet egrgaeegge ggtergggg ggereggtet 42360 gagcgtggct ggatggctgg ccgagcaggg ggctgggcat ctggtgctgg tgggccgctc 42420 cggcgcggtg agcgcggage agcagacggc tgtcgccgcg ctcgaggcgc acggcgcgc 42480 tgtcacggta gcgagggcag acgtcgccga tcgggcgcag atggagcgga tcctccgcga 42540 ggttaccgcg tcggggatgc cgctccgcgg cgtcgttcat gcggccggaa tcctggacga 42600 egggetgetg atgeagcaaa eeceegegeg gtteegegeg gtcatggege eeaaggteeg 42660 agggeettg cacetgeatg cgttgacacg cgaagegeeg eteteettet tegtgetgta 42720 cgcttcggga gcagggctct tgggctcgcc gggccagggc aactacgccg cggccaacac 42780 gttcttegac gcactggcac accaceggag ggcgcagggg ctgccagcat tgagcatega 42840 ctggggcetg ttegeggacg tgggtttggc cgcegggcag caaaatcgcg gcgcaeggct 42900 ggtcaccege gggaegegga geeteaceee egaegaaggg etgtgggege tegagegeet 42960 gctcgacggc gatcgcaccc aggccggggt catgccgttc gacgtgcggc agtgggtgga 43020 cctctccgaa ggcaagctcg acgtggatgc gccgctcacg agcctgggaa tggactcgct 43260 gatggggeta gagetgegea acegeatega ggeegtgete ggeateacea tgeeggegae 43320 cetgetgtgg acetaceca eggtggeage getgagtgeg catetggett etcatgtegt 43380 etctacgggg gatggggaat eeggegeee geeggataca gggagegtgg etceaacgae 43440 ccacgaagte gettegeteg acgaagaegg gttgttegeg ttgattgatg agteactege 43500 gegegeggga aagaggtgat tgegtgaeag aeegagaagg ceageteetg gagegettge 43560 gtgaggttac tetggeeett egeaagaege tgaaegageg egataceetg gagetegaga 43620 agaccgagec gategecate gtggggateg getgeegett ecceggegga gegggeacte 43680 eggaggegtt etgggagetg etegaegaeg ggegegaege gateeggeeg etegaggage 43740 getgggeget egtaggtgte gaeceaggeg acgaegtaee gegetgggeg gggetgetea 43800 ccgaggccat cgacggcttc gacgccgcgt tcttcggtat cgccccccgg gaggcacggt 43860 cgctcgacc gcagcatcgc ctgctgctgg aggtcgcctg ggaggggttc gaagacgccg 43920 gcatcccgcc caggtcctc gtcgggagcc gcaccggcgt gttcgtcgg gtctgcgcca 43980 cggagtacct ccacgccgc gtcgcgacc agccgcgcga agagcgggac gcgtacagca 44040 ccaccggcaa catgetcage ategeegeeg gaeggetate gtacaegetg gggetgeagg 44100 quectigeet gaeegtegat aeggegtget egteateget ggtggeeatt cacctegeet 44160 gccgcagcct gcgcgctcga gagagcgatc tcgcgctggc gggaggggtc aacatgcttc 44220 tctcccccga cacgatgcga gctctggcgc gcacccaggc gctgtcgccc aatggccgtt 44280 gecagacett egaegegteg gecaaegggt tegteegtgg ggagggetge ggtetgateg 44340 tgctcaagcg attgagcgac gcgcggcggg atggggaccg gatctgggcg ctgatccgag 44400 gatcggccat caatcaggac ggccggtcga cggggttgac ggcgcccaac gtgctcgccc 44460 agggggggt cttgcgcga gcgctgcgga acgccggcgt cgaggccgag gccatcggtt 44520 acatcgagac ccacggggcg gcaacctcgc tgggcgaccc catcgagatc gaagcgctgc 44580 gcgctgtggt ggggccggcg cgagccgacg gagcgcgctg cgtgctgggc gcggtgaaga 44640 ccaacetegg ccaectggag ggcgetgccg gcgtggcggg cctgatcaag gcgacgcttt 44700 cgctacatca cgagcgcatc ccgaggaacc tcaactttcg tacgctcaat ccgcggatcc 44760 ggarcgaggg gaccgcgctc gcgtrggcga ccgaaccggt gcccrggccg cggacgggcc 44820 ggacgcgctt cgcgggagtg agctcgttcg ggatgagcgg gaccaacgcg catgtggtgt 44880 tggaggaggc gccggggtg gagcctgagg ccgcggcccc cgagcgcgca gcggagctgt 44940 togtoctgto ggogaagago goggoggogo tggatgogoa ggoagocogg ctgogggaco 45000 acctggagaa gcacgtcgag cttggcctcg gcgatgtggc gttcagcctg gcgacgacgc 45060 gcagcgcgat ggagcaccgg ctggcggtgg ccgcgagctc gcgcgaggcg ctgcgagggg 45120 cgetttegge egeagegeag gggeaeaege egeegggage egtgegtggg egggeetegg 45180 geggeagege geegaaggtg gtettegtgt tteeeggtea gggetegeag tgggtgggea 45240 tgggccgaaa gctcatggcc gaagagccgg tcttccgggc ggcgctggag ggttgcgacc 45300 gggccatcga ggcggaageg ggctggtege tgctegggga geteteegee gacgaggeeg 45360 cctcgcagct cgggcgcatc gacgtggttc agccggtgct cttcgccatg gaagtagcgc 45420 tttctgcgct gtggcggtcg tggggagtgg agccggaagc ggtggtgggc cacagcatgg 45480 gcgaggttgc ggcggcgcac gtggccggcg cgctgtcgct cgaggacgcg gtggcgatca 45540 tetgeeggeg cageeggetg etgeggegga teageggtea gggggagatg gegetggteg 45600 agctgteget ggaggaggec gaggeggege tgegtggeea tgagggtegg etgagegtgg 45660 eggtgageaa cageeegege tegaeegtge tegeeggega geeggeggeg eteteggagg 45720 tgctggcggc gctgacggcc aagggggtgt tctggcggca ggtgaaggtg gacgtcgcca 45780 gccatagccc gcaggtcgac ccgctgcgcg aagagctgat cgcggcgctg ggagcgatcc 45840 ggccgcgagc ggctgcggtg ccgatgcgct cgacggtgac gggcggggtg atcgcgggtc 45900 cggagetegg tgegagetae tgggeggaea acetteggea geeggtgege ttegetgegg 45960 cggcgcaage getgetggag ggtggeeeeg egetgtteat egagatgage eegeaeeega 46020 tectggtgee geeeetggae gagateeaga eggeggeega geaaggggge getgeggtgg 46080 gctcgctgcg gcgagggcag gacgagcgcg cgacgctgct ggaggcgctg gggacgctgt 46140 gggcgtccgg ctatccggtg agctgggctc ggctgttccc cgcgggcggc aggcgggttc 46200 cgctgccgac ctatccctgg cagcacgagc ggtgctggat cgaggtcgag cctgacgccc 46260 geogeotege egeageegae eccaecaagg actggtteta eegaaeggae tggeeegagg 46320 tgccccgcgc cgccccgaaa tcggagacag ctcatgggag ctggctgctg ttggccgaca 46380 ggggtggggt cggtgaggcg gtcgctgcag cgctgtcgac gcgcggactt tcctgcaccg 46440 tgcttcatgc gtcggctgac gcctccaccg tcgccgagca ggtatccgaa gctgccagtc 46500 gccgaaacga ctggcaggga gtcctctacc tgtggggcct cgacgccgtc gtcgatgctg 46560 gggcatcggc cgacgaagtc agcgaggcta cccgccgtgc caccgcaccc gtccttgggc 46620 tggttcgatt cctgagcgct gcgcccatc ctcctcgctt ctgggtggtg acccgcgggg 46680 catgcacggt gggcggcgag ccagaggcct ctctttgcca agcggcgttg tggggcctcg 46740 cgcgcgtcgc ggcgctggag caccccgctg cctggggtgg cctcgtggac ctggatcctc 46800 agaagageee gaeggagate gageeeetgg tggeegaget getttegeeg gaegeegagg 46860 atcaactgge gtteegage ggtegeagge acgeageaeg cettgtagee geeeegeegg 46920 agggcgacgt cgcaccgata tcgctgtccg cggaggggag ctacctggtg acgggcgggc 46980 tgggtggcet tggtctgctc gtggctcggt ggctggtgga gcggggagct cgacatctgg 47040 tgctcaccag ccggcacggg ctgccagagc gacaggcgtc gggcggagag cagccgccgg 47100 aggcccgcgc gcgcatcgca gcggtcgagg ggctggaagc gcagggcgcg cgggtgaccg 47160 tggcagcggt ggatgtcgcc gaggccgatc ccatgacggc gctgctggcc gccatcgagc 47220 ccccgttgcg cggggtggtg cacgccgccg gcgtcttccc cgtgcgtcac ctggcggaga 47280 cggacgagge cetgetggag teggtgetec gteceaaggt ggeegggage tggetget 47340 accggetget gegegacegg cetetegace tgttegtget gttetegteg ggegeggegg 47400 tgtggggtgg caaaggccaa ggcgcatacg ccgcggccaa tgcgttcctc gacgggctcg 47460 cgcaccatcg ccgcgcgcac tcgctgccgg cgttgagcct cgcctggggc ttatgggccg 47520 agggaggcat ggttgatgca aaggetcatg cacgtetgag cgacateggg gtcetgecca 47580 tggccacggg gccggccttg tcggcgctgg agcgcctggt gaacaccagc gctgtccagc 47640 gttcggtcac acggatggac tgggcgcgt tcgcgccggt ctatgccgcg cgagggcggc 47700 geaacttget tteggetetg gtegeggagg acgagegege tgegteteec eeggtgeega 47760 cggcaaaccg gatctggcgc ggcctgtccg ttgcggagag ccgctcagcc ctctacgagc 47820 tcgttcgcgg catcgtcgcc cgggtgctgg gcttctccga cccgggcgcg ctcgacgtcg 47880 geogaggett egeogageag gggetegaet ecetgatgge tetggagate egtaacegee 47940 ttcagcgcga gctgggcgaa cggctgtcgg cgactctggc cttcgaccac ccgacggtgg 48000 agcggctggt ggcgcatctc ctcaccgacg tgctgaagct ggaggaccgg agcgacaccc 48060 ggcacatccg gtcggtggcg gcggatgacg acatcgcat cgtcggtgcc gcctgcggt 48120 tccagcaccga ggtgccagcc gaccggtggc gcgcggtgacat actggcgga tctggccgag ggcatggtgg 48180 tcagcaccga ggtgccagcc gaccggtggc gcgcggcgga ctggtacgac cccgatccgg 48240 aggttccggg ccggacctat gtggccaagg gtgccttcct ccgcgatgtg cgcagcttgg 48300 atgcggcgtt cttcgccatt tcccctcgtg aggcgatgag cctggacccg caacagcggc 48360 tgttgctgga ggtgagctgg gaggcgatcg agcgcgctgg ccaggacccg atggcgctgc 48420 gcgagagcgc cacgggcgtg ttcgtgggca tgatcgggag cgagcacgcc gagcgggtgc 48480 agggettega egaegaegeg gegttgetgt aeggeaceae eggeaacetg eteagegteg 48540 eegetggaeg getgtegtte tteetgggte tgeaeggeee gaegatgaeg gtggaeaceg 48600 cetgetegte gtegetggtg gegttgcace tegeetgeca gageetgega ttgggegagt 48660 gcgaccaggc cctggccggc gggtccagcg tgcttttgtc gccgcggtca ttcgtcgcgg 48720 cgtcgcgcat gcgtttgctt tcgccagatg ggcggtgcaa gacgttctcg gccgctgcag 48780 acggctttgc gcgggccgag ggctgcgccg tggtggtgct caagcggctc cgtgacgcgc 48840 agegegaceg egaceceate etggeggtgg teaggageae ggegateaae caegatggee 48900 cgagcagcgg gctcacggtg cccagcggtc ctgcccagca ggcgttgcta cgccaggcgc 48960 tggcgcaagc gggcgtggcg ccggccgagg tcgatttcgt ggagtgccac gggacgggga 49020 cagegetggg tgaccegate gaggtgeagg egetgggege ggtgtaeggg eggggeegee 49080 eegeggageg geegetetgg etgggegetg teaaggeeaa eeteggeeae etggaggeeg 49140 cggcgggctt ggccgcgtg ctcaaggtgc tcttggcgct ggagcacgag cagattccgg 49200 ctcaaccgg gccgcacgag ctcaaccgc acateccgtg ggcagagctg ccagtggccg 49200 ttgtccgcag ggcggtccc tggcgcgcg gggggggcgcg ggggggagcg 49320 ctttcggcct gagcgggacc aacgcgcatg tggtgttgga ggaggggcg ggggtggagc 49380 ctgtggccgc ggcccccgag cgcgcagcgg agctgttcgt cctgtcggcg aagagcgcgg 49440

cggcgctgga tgcgcaggca gcccggctgc gggaccacct ggagaagcat gtcgagcttg 49500 genteggega tgtggegtte agentggega egacgegeag egegatggag caceggetgg 49560 cggtggccgc gagctcgcgc gaggcgctgc gaggggcgct ttcggccgca gcgcaggggc 49620 acacgccgcc gggagccgtg cgtgggcggg cctcgggcgg cagcgcgcg aaggtggtct 49680 togtgtttee eggeeaggge tegeagtggg tgggeatggg cegaaagete atggeegaag 49740 ageeggtett eegggeggeg etggagggtt gegaeeggge categaggeg gaageggget 49800 ggtcgctgct cggggagctc tccgccgacg aggccgcctc gcagctcggg cgcatcgacg 49860 tggttcagcc ggtgctgttc gccatggaag tagcgctttc tgcgctgtgg cggtcgtggg 49920 gagtggagcc ggaagcggtg gtgggccaca gcatgggcga ggttgcggcg gcgcacgtgg 49980 ccggcgcgct gtcgctcgag gacgcggtgg cgatcatctg ccggcgcagc cggctgctgc 50040 ggcggatcag cggtcagggg gagatggcgc tggtcgagct gtcgctggag gaggccgagg 50100 eggegetgeg tggccatgag ggteggetga gegtggeggt gageaacage eegegetega 50160 ccgtgctcgc cggcgagccg gcggcgctct cggaggtgct ggcggcgctg acggccaagg 50220 gggtgttctg gcggcaggtg aaggtggacg tcgccagcca tagcccgcag gccgacccgc 50280 tgcgcgaaga gctgatcgcg gcgctgggag cgatccggcc gcgagcggct gcggtgccga 50340 tgegetegae ggtgaeggge ggggtgateg egggteegga geteggtgeg agetaetggg 50400 eggacaacet teggeageeg gtgegetteg etgeggegge geaagegetg etggagggtg 50460 geceegeget giteategag atgageeege accegateet ggitgeegee etggaegaga 50520 tecagaegge ggeegageaa gggggegetg eggtgggete getgeggega gggeaggaeg 50580 agegegegae getgetggag gegetgggga egetgtggge gteeggetat eeggtgaget 50640 gggetegget gtteecegeg ggeggeagge gggtteeget geegaectat eeetggeage 50700 acgageggta etggategag gacagegtge atgggtegaa gecetegetg eggettegge 50760 agettegeaa eggegeeaeg gaccateege tgetegggge tecattgete gteteggege 50820 gacccggage teacttgtgg gagcaagege tgagegacga gaggetatee tacetttegg 50880 aacatagggt ccatggcgaa gccgtgttgc ccagcgcggc gtatgtagag atggcgctcg 50940 ccgccggcgt agatctctat ggcacggcga cgctggtgct ggagcagctg gcgctcgagc 51000 gagecetege egtgeeetee gaaggeggae geategtgea agtggeeete agegaagaag 51060 gtcccggtcg ggcctcattc caggtatcga gtcgtgagga ggcaggtagg agctgggtgc 51120 ggcacgccac ggggcacgty tgtagcggcc agagctcagc ggtgggagcg ttgaaggaag 51180 ctccgtggga gattcaacgg cgatgtccga gcgtcctgtc gtcggaggcg ctctatccgc 51240 tgctcaacga gcacgccctc gactatggtc cctgcttcca gggcgtggag caggtgtggc 51300 teggeaeggg ggaggtgete ggeegggtae gettgeeagg agacatggea teeteaagtg 51360 gegectaceg gatteatece geettgttgg atgeatgttt teaggtgetg acagegetge 51420 tcaccacgec ggaatecate gagattegga ggeggetgae ggatetecae gaaccggate 51480 tecegeggte cagggeteeg gtgaateaag eggtgagtga caeetggetg tgggaegeeg 51540 egetggaegg tggaeggeg cagagegega gegtgeeegt egaeetggtg eteggeaget 51600 tccatgcgaa gtgggaggtc atggagcgcc tcgcgcaggc gtacatcatc ggcactctcc 51660 gcatatggaa cgtcttctgc gctgctggag agcgtcacac gatagacgag ttgctcgtca 51720 ggcttcaaat ctctgtcgtc tacaggaagg tcatcaagcg atggatggaa caccttgtcg 51780 cgatcggcat ccttgtaggg gacggagagc attttgtgag ctctcagccg ctgccggagc 51840 ctgatttggc ggcggtgctc gaggaggccg ggagggtgtt cgccgacctc ccagtcctat 51900 ttgagtggtg caagtttgcc ggggaacggc tcgcggacgt attgaccggt aagacgctcg 51960 egetegagat eetetteeet ggtggetegt tegatatgge ggagegaate tategagatt 52020 cgcccatcgc ccgttactcg aacggcatcg tgcgcggtgt cgtcgagtcg gcggcgcggg 52080 tggtagcacc gtcgggaatg ttcagcatct tggagatcgg agcagggacg ggcgcgacca 52140 ecgeegeegt ceteceggtg ttgetgeetg accggaegga gtaccattte accgatgttt 52200 etecgetett cettgetege geggageaaa gatttegaga ttatecatte etgaagtatg 52260 geattetgga tgtegaceag gageeagetg geeagggata egeacateag aggtttgaeg 52320 tcatcgtcgc ggccaatgtc atccatgcga cccgcgatat aagagccacg gcgaagcgtc 52380 tcctgtcgtt gctcgcgccc ggaggccttc tggtgctggt cgagggcaca gggcatccga 52440 totggttoga tatcaccacg ggattgattg aggggtggca gaagtacgaa gatgatcttc 52500 gtategaeca teegeteetg eetgetegga eetggtgtga egteetgege egggtagget 52560 ttgcggacgc cgtgagtctg ccaggcgacg gatctccggc ggggatcctc ggacagcacg 52620 tgatectete gegegegeg ggcatageag gagecgettg tgacagetee ggtgagtegg 52680 cgaccgaate geeggeege egtgeagtae ggcaggaatg ggcegatgge teegetgaeg 52740 tegtecateg gatggettg gagaggatgt acttecaceg ceggeeggge eggeaggttt 52800 gggtccacgg tegattgcgt accggtggag gcgcgttcac gaaggcgctc gctggagatc 52860 tgctcctgtt cgaagacacc gggcaggtcg tggcagaggt tcaggggctc cgcctgccqc 52920 agetegagge tretgerric gegeegeggg accegeggga agagtggtrg tacgetrigg 52980 aatggcagcg caaagaccct ataccagagg ctccggcagc cgcgtcttct tcctccgcgg 53040 gggettgget egtgetgatg gaccagggeg ggacaggege tgegetegta tegetgetgg 53100 aagggegagg cgaggegtge gtgegegtea tegegggtae ggeataegee tgeetegege 53160 cggggctgta tcaagtcgat ccggcgcagc cagatggctt tcataccctg ctccgcgatg 53220 catteggega ggaceggatt tgtegegegg tagtgeatat gtggageett gatgegaegg 53280 cagcagggga gagggcgaca gcggagtcgc ttcaggccga tcaactcctg gggagcctga 53340

gegegettte tetggtgeag gegetggtge geeggaggtg gegeaacatg eegeggettt 53400 ggetettgae eegegeegtg eatgeggtgg gegeggagga egeageggee teggtggege 53460 aggegeeggt gtggggeete ggteggaege tegegetega geateeagag etgeggtgea 53520 cgctcgtgga cgtgaacccg gcgccgtctc cagaggacgc agccgcactg gcggtggagc 53580 toggggcgag cgacagagag gaccaggtog cattgogoto ggatggcogo tacgtggcgc 53640 geetegtgeg gageteettt teeggeaage etgetaegga ttgeggeate egggeggaeg 53700 gcagctatgt gatcaccgat ggcatgggga gagtggggct ctcggtcgcg caatggatgg 53760 tgatgeaggg ggecegecat gtggtgeteg tggategegg eggegettee gaggeatece 53820 gggatgeet eeggteeatg geegagget gegeggaggt geagategtg gaggeegaeg 53880 tggeteggeg egaegatgte geteggetee tetegaagat egaacegteg atgeegeege 53940 ttegggggat egtgtaegtg gaegggaeet teeagggega eteetegatg etggagetgg 54000 atgeeegteg etteaaggag tggatgtate ceaaggtget eggagegtgg aacetgeacg 54060 egetgaecag ggatagateg etggaettet tegteetgta tteeteggge acetegette 54120 tgggcttgcc aggacagggg agccgcgccg ccggtgacgc cttettggac gccatcgcgc 54180 atcaccygtg caaggtgggc cttacagcga tgagcatcaa ctggggattg ctctccgaag 54240 catcatcgcc ggcgaccccg aacgacggcg gagcacggct cgaataccgg gggatggaag 54300 geetcaeget ggageaggga geggeggege tegggegett getegeaega eecagggege 54360 aggtaggggt gatgeggetg aatetgegee agtggttgga gttetateee aacgeggeee 54420 gattggeget gtgggggag etgetgaagg agegtgaeeg egeegaeega ggegegtega \$4480 aegegtegaa eetgegegag gegetgeaga gegeeaggee egaagategt eagttgatte \$4540 tggagaagca cttgagcgag ctgttggggc gggggctgcg ccttccgccg gagaggatcg 54600 ageggeaegt geegtteage aateteggea tggaeteget gataggeetg gageteegea 54660 acegeatega ggeegegete ggeateaceg tgeeggegae eetgetatgg acetaceeta 54720 acgtagcage tetgageggg agettgetag acattetgtt teegaatgee ggegegaeee 54780 acgeteegge cacegagegg gagaagaget tegagaaega tgeegeagat etegaggete 54840 tgcggggcat gacggacgag cagaaggacg cgttgctcgc cgaaaaagctg gcgcagctcg 54900 cgcagatcgt tggtgagtaa gggaccgagg gagtatggcg accacgaatg ccgggaagct 54960 tgagcatgcc cttctgctca tggacaagct tgcgaaaaag aacgcgtctt tggagcaaga 55020 geggacegag eegategeea tegtaggeat tggetgeege tteeceggeg gageggacae 55080 teeggaggea ttetgggage tgetegacte aggeegagae geggteeage egetegaeeg 55140 gegetgggeg etggteggeg tecateeeag egaggaggtg eegegetggg eeggaetget 55200 caccgaggeg gtggacgget tegacgeege gttetttgge acetegeete gggaggegeg 55260 gtegetegat ceteageaac geetgetget ggaggteace tgggaaggge tegaggaege 55320 cggcatcgca ccccagtccc tcgacggcag ccgcaccggg gtgttcctgg gcgcatgcag 55380 cagegactac tegeataceg ttgegeaaca geggegegaa gageaggaeg cataegaeat 55440 caeeggeaat aegeteageg tegeegegg aeggttgtet tataegetag ggetgeaggg 55500 accetgeetg accetegaca eggeetgete gtegtegete gteggeeatee accttgeetg 55560 eegeageetg egegetegeg agagegatet egegeteggeg ggaggegtea acatgeteet 55620 ttegtecaag aegatgataa tgetggggeg catecaggeg etgtegeeeg atggeeaetg 55680 coggacatto gaogootogg coaacgggtt ogtoogtggg gagggotgcg gtatggtogt \$5740 gotoaaacgg ototoogacg cocagogaca oggogatogg atotgggoto tgatoogggg \$5800 treggeearg aareaggarg geeggregae agggrigarg geaceeaarg rgeregerea 55860 ggaggegete ttgegegagg egetgeagag egetegegte gaegeegggg ecateggtta 55920 tgtcgagacc cacggaacgg ggacctcgct cggcgacccg atcgaggtcg aggcgctgcg 55980 tgccgtgttg gggccggcgc gggccgatgg gagccgctgc gtgctgggcg cagtgaagac 56040 aaacctcggc cacctggagg gcgctgcagg cgtggcggt ttgatcaagg cggcgctggc 56100 tetgeaceae gaactgatee egegaaaeet eeattteeae aegeteaate egeggateeg 56160 gategagggg acegegeteg egetggegae ggageeggtg eegtggeege gggegggeeg 56220 accgegette gegggggtga gegegttegg ceteagegge accaaegtee atgtegtget 56280 ggaggaggeg ceggecaegg tgetegeaee ggegaegeeg gggegeteag eggagetttt 56340 categoegeg tacceggage agggtetegg agacgtegeg tteageetgg tategaegeg 56460 tagecegatg gageacegge tegeggtgge ggegaeeteg egegaggege tgegaagege 56520 ctcgcccggc aagctcgcct tcctgttcgc cgggcagggc gcgcaggtgc cgggcatggg 56640 ccgtgggttg tgggaggcgt ggccggcgtt ccgcgagacc ttcgaccggt gcgtcacgct 56700 cttcgaccgg gagetecate ageogetetg egaggtgatg tgggccgage egggcageag 56760 caggingting tightggace aganggegit cacecageng gegeteting egenggagia 56820 egegetggee gegetettee ggtegtgggg egtggageeg gagetegteg etggeeatag 56880 ceteggegag etggtggeeg cetgegtgge gggtgtgte teeetegagg aegeegtgeg 56940 cttggtggtc gcgcgggcc ggttgatgca ggcgctgccg gccggcggcg cgatggtatc 57000 gatcgccgcg ccggaggccg acgtggctgc cgcggtggcg ccgcacgcag cgttggtgtc 57060 garcgcggca greaarggge eggageaggt ggrgarcgeg ggegeegaga aarregtgea 57120 gcagategeg geggegtteg eggegegggg ggegegaace aaacegetge atgtetegea 57180 cgcgttccac tcgccgctca tggatccgat gctggaggcg ttccggcggg tgactgagtc 57240

ggtgacgtac cggcggcctt cgatcgcgct ggtgagcaac ctgagcggga agccctgcac 57300 cgatgaggtg agcgcccgg gttactgggt gcgtcacgcg cgagaggcgg tgcgcttcgc 57360 ggacggagtg aaggcgctgc acgcggccgg tgcgggcctc ttcgtcgagg tggggccgaa 57420 geogaegetg eteggeettg tgeeggeetg eetgeeggat geeaggeegg tgetgeteee 57480 agegtegege geegggegtg acgaggetge gagegegeta gaggegetgg gtgggttetg 57540 ggtegteggt ggateggtea cetggteggg tgtetteeet tegggeggae ggegggtaee 57600 getgecaace tatecetgge agegegageg ttactggate gaagegeegg tegategtga 57660 ggeggaegge aceggeegtg etegggeggg gggeeaecec ettetgggtg aagtettite 57720 cgtgtcgacc catgccggtc tgcgcctgtg ggagacgacg ctggaccgaa agcggctgcc 57780 gtggctcggc gagcaccggg cgcaggggga ggtcgtgttt cctggcgccg ggtacctgga 57840 gatggcgctg tcgtcggggg ccgagatctt gggcgatgga ccgatccagg tcacggatgt 57900 ggtgctcatc gagacgctga ccttcgcggg cgatacggcg gtaccggtcc aggtggtgac 57960 gaccgaggag cgaccgggac ggctgcggtt ccaggtagcg agtcgggagc cgggggaacg 58020 tegegegece tteeggatee aegeeegegg egtgetgege eggateggge gegtegagae 58080 cccggcgagg tcgaacctcg ccgccctgcg cgcccggctt catgccgccg tgcccgctgc 58140 ggctatctat ggtgcgctcg ccgagatggg gcttcaatac ggcccggcgt tgcgggggct 58200 egeegagetg tggegggtg agggegagge getgggeagg gtgagaetge etgaggeege 58260 eggeteegeg acagectace agetgeatee ggtgetgetg gaegegtgeg tecaaatgat 58320 tgttggegeg ttegeegate gegatgagge gaegeegtgg gegeeggtgg aggtgggete 58380 ggtgeggetg ttecageggt etectgggga getatggtge catgegegeg tegtgagega 58440 tggteaacag geetecagee ggtggagege egaetttgag ttgatggaeg gtaegggege 58500 ggtggtcgcc gagatctccc ggctggtggt ggagcggctt gcgagcggtg tacgccggcg 58560 cgacgcagac gactggttcc tggagctgga ttgggagccc gcggcgctcg gtgggcccaa 58620 gatcacagec ggccggtggc tgctgctcgg cgagggtggt gggctcgggc gctcgttgtg 58680 ctcggcgctg aaggccgccg gccatgtcgt cgtccacgcc gcgggggacg acacgagcac 58740 tgcaggaatg cgcgcgctcc tggccaacgc gttcgacggc caggccccga cggccgtggt 58800 gcacctcagc agcctcgacg ggggcggcca gctcggcccg gggctcgggg cgcagggcgc 58860 getegaegeg eeceggagee eagatgtega tgeegatgee etegaategg egetgatgeg 58920 tggttgcgac agcgtgctct ccctggtgca agcgctggtc ggcatggacc tccgaaacgc 58980 geogeggetg tggetettga eeegegggge teaggeggee geogeeggeg atgteteegt 59040 ggtgeaageg eegetgttgg ggetgggeeg caccategee ttggageacg eegagetgeg 59100 ctgtateagc gtcgacctcg atccagccga gcctgaaggg gaagccgatg ctttgctggc 59160 cgagetaett geagatgatg eegaggagga ggtegegetg egeggtggeg aeeggetegt 59220 tgcgcggctc gtccaccggc tgcccgacgc tcagcgccgg gagaaggtcg agcccgccgg 59280 tgacaggccg ttccggctag agatcgatga acceggcgcg ctggaccaac tggtgctccg 59340 agccacgggg cggcgccc ctggtccggg cgaggtcgag atctccgtcg aagcggcggg 59400 getegactee ategacatee agetggegtt gggegttget cecaatgate tgeetggaga 59460 agaaatcgag ccgttggtgc tcggaagcga gtgcgccggg cgcatcgtcg ctgtgggcga 59520 gggcgtgaac ggccttgtgg tgggccagcc ggtgatcgcc cttgcggcgg gagtatttgc 59580 tacccatgte accaegtegg ccaegetggt gttgcetegg cetetgggge teteggegae 59640 egaggeggee gegatgeece tegegtattt gaeggeetgg tacgceeteg acaaggtege 59700 ccacctgcag gcgggggagc gggtgctgat ccatgcggag gccggtggtg tcggtctttg 59760 cgeggtgega tgggegeage gegtgggege egaggtgtat gegaeegeeg acaegeeega 59820 gaaccgtgcc tacctggagt cgctgggcgt gcggtacgtg agcgattccc gctcgggccg 59880 gttcgtcaca gacgtgcatg catggacgga cggcgagggt gtggacgtcg tgctcgactc 59940 gettteggge gagegeateg acaagageet catggteetg egegeetgtg gtegeettgt 60000 gaagetggge aggegegaeg aetgegeega caegeageet gggetgeege egeteetaeg 60060 gaatttttcc ttctcgcagg tggacttgcg gggaatgatg ctcgatcaac cggcgaggat 60120 ccgtgcgctc ctcgacgagc tgttcgggtt ggtcgcagcc ggtgccatca gcccactggg 60180 gtcggggttg cgcgttggcg gatccctcac gccaccgccg gtcgagacct tcccgatctc 60240 tcgcgcagcc gaggcattcc ggaggatggc gcaaggacag catctcggga agctcgtgct 60300 cacgetggae gaceeggagg tgeggateeg egeteeggee gaateeageg tegeegteeg 60360 cgcggaegge acctacettg tgaccggegg tetgggtgge eteggtetge gegtggeegg 60420 atggctggcc gageggggcg eggggcaact ggtgctggtg ggccgctccg gtgcggcgag 60480 cgcagagcag cgagccgccg tggcgcgct ggaggcccac ggcgcgcgcg tcacggtggc 60540 gaaagcggac gtcgccgatc ggtcacagat cgagcgggtc ctccgcgagg ttaccgcgtc 60600 ggggatgeeg etgeggggtg tegtgeatge ggeaggtete gtggatgaeg ggetgetgat 60660 gcagcagact ccggcgcggt tccgcacggt gatgggacct aaggtccagg gggccttgca 60720 cttgcacacg ctgacacgcg aagegeetet tteettette gtgctgtacg cttetgcage 60780 tgggctttte ggctcgccag gccagggcaa ctatgccgca gccaacgcgt tcctcgacgc 60840 cetttegeat cacegaaggg egeagggeet geeggegetg ageategaet ggggeatgtt 60900 cacggaggtg gggatggccg ttgcgcaaga aaaccgtggc gcgcggcaga tctctcgcgg 60960 gatgcggggc atcacccccg atgagggtct greageterg gegegetrge tegagggtga 61020 tegegtgcag acgggggtga taccgateae teegeggeag tgggtggagt tetaccegge 61080 aacageggee teaeggaggt tgtegegget ggtgaccacg cagegeggg tegetgateg 61140

gaccgccggg gatcgggacc tgctcgaaca gcttgcgtcg gctgagccga gcgcgcgggc 61200 ggggctgctg caggacgtcg tgcgcgtgca ggtctcgcat gtgctgcgtc tccctgaaga 61260 caagatcgag gtggatgccc cgctctcgag catgggcatg gactcgctga tgagcctgga 61320 getgegeaac egeategagg etgegetggg egtegeegeg eetgeageet tggggtggac 61380 gtacccaacg gtagcagcga taacgcgetg getgetegac gacgcceteg tegteegget 61440 tggcgggggg tcggacacgg acgaatcgac ggcgagcgcc ggttcgttcg tccacgtcct 61500 ccgctttcgt cctgtcgtca agccgcgggc tcgtctcttc tgttttcacg gttctggcgg 61560 ctcgcccgag ggcttccgtt cctggtcgga gaagtctgag tggagcgatc tggaaatcgt 61620 ggccatgtgg cacgategca geetegeete egaggaegeg cetggtaaga agtaegteea 61680 agaggcggcc tegetgatte ageactatge agacgcaceg tttgcgttag tagggttcag 61740 cetgggtgte eggttegtea tggggacage egtggagete gecagtegtt eeggegeace 61800 ggeteegetg geegtettea egttgggegg eagettgate tettetteag agateacece 61860 ggagatggag accgatataa tagccaaget ettetteega aatgeegegg gtttegtgeg 61920 atccacccaa caagtccagg ccgatgctcg cgcagacaag gtcatcacag acaccatggt 61980 ggctccggcc cccggggact cgaaggagcc gcccgtgaag atcgcggtcc ctatcgtcgc 62040 categorgge teggacgatg tgategtgee teegagegac gttcaggate tacaateteg 62100 caccaeggag egettetata tgcateteet teeeggagat caegaattte tegtegateg 62160 agggegegag atcatgeaca tegtegaete geateteaat eegetgeteg eegegaggae 62220 gacgtcgtca ggccccgcgt tcgaggcaaa atgatggcag cctccctcgg gcgcgcgaga 62280 gatcgagege etgagagagg caacceccat ettetaetgg gatgaaggee geteetgggt 62520 ceteaceega taccaegaeg tgteggeggt gtteegegae gaaegetteg eggteagteg 62580 agaagagtgg gaatcgagcg cggagtactc gtcggccatt cccgagctca gcgatatgaa 62640 gaagtacgga ttgtteggge tgeegeegga ggateaeget egggteegea agetegteaa 62700 cccgtcgttt acgtcacgcg ccatcgacct gctgcgcgcc gaaatacagc gcaccgtcga 62760 ccagctgete gatgeteget eeggacaaga ggagttegae gttgtgeggg attaegegga 62820 gggaatcccg atgcgcgcga tcagcgctct gttgaaggtt ccggccgagt gtgacgagaa 62880 gttccgtcgc ttcggctcgg cgactgcgc cgcgctcggc gtgggtttgg tgccccaggt 62940 cgatgaggag accaagaccc tggtegegte cgteaccgag gggetegege tgetecatga 63000 cgteetegat gageggegea ggaacceget cgaaaatgac gtettgacga tgetgettea 63060 ggccgaggcc gacggcagca ggctgagcac gaaggagctg gtcgcgctcg tgggtgcgat 63120 tategetget ggeacegata ecaegateta cettategeg ttegetgtge teaacetget 63180 geggtegeee gaggegeteg agetggtgaa ggeegageee gggeteatga ggaaegeget 63240 egatgaggtg etcegetteg acaatateet cagaatagga aetgtgegtt tegecaggea 63300 ggacctggag tactgegggg categateaa gaaaggggag atggtettte teetgateee 63360 gagegeeetg agagatggga etgtattete eaggeeagae gtgtttgatg tgegaeggga 63420 cacqqqcqcq agcctcqcqt acqqtaqaqq cccccatqtc tqccccqqqq tqtcccttqc 63480 togoctogag goggagatog cogtgggcac catottocgt aggttococg agatgaagot 63540 gaaagaaact cccgtgtttg gataccacce cgcgttccgg aacatcgaat cactcaacgt 63600 catcttgaag ccctccaaag ctggataget cgcgggggta tcgcttcccg aacctcattc 63660 ceteatgata eagetegege gegggtgetg tetgeegegg gtgegatteg atecagegga 63720 caageceatt gteagegege gaagategaa teeaeggeee ggagaagage eegteegggt 63780 gacgtcggaa gaagtgccgg gcgccgcct gggagcgcaa agctcgctcg ttcgcgctca 63840 gcacgccgct cgtcatgtcc ggcctgcac ccggccgag gagccgcccg ccctgatgca 63900 cggcctcacc gagcggcagg ttctgctctc gctcgtcgcc ctcgcgctcg tcctcctgac 63960 egegegegee tteggegage teggeggeg getgegeeag eeegaggtge teggegaget 64020 ctteggegge gtggtgetgg geoegteegt egteggegeg etegeteetg ggtteeateg 64080 agtectette caggateegg eggteggggt egtgetetee ggcateteet ggataggege 64140 getegteetg etgeteatgg egggtatega ggtegatgtg ageateetge geaaggagge 64200 gegeeeeggg gegetetegg egeteggege gategegee eegetgegea egeeggggee 64260 getggtgeag egeatgeagg gegegtteae gtgggatete gaegtetege egegaegete 64320 tgegeaagee tgageetegg egeetgeteg tacacetege eggtgetege teegeeegeg 64380 gacatccggc cgcccgccgc ggcccagctc gagccggact cgccggatga cgaggccgac 64440 gaggeegaeg aggegeteeg eeegtteege gaegegateg eegegtaete ggaggeegtt 64500 cggtgggcgg aggcggcaca gcggccgcgg ctggagagcc tcgtgcggct cgcgatcgtg 64560 cggctgggca aggcgctcga caaggtccct ttcgcgcaca cgacggccgg cgtctcccag 64620 ategeeggea gacteeagaa egatgeggte tggttegatg tegeegeeeg gtaegegage 64680 ttccgcgcgg cgacggagca cgcgctccgc gacgcggcgt cggccatgga ggcgctcgcg 64740 geoggeoogt accgeggate gageegegtg teegetgeeg taggggagtt teggggggag 64800 geggegegee tteacceege ggaeegtgta ecegegteeg accageagat cetgaeegeg 64860 ctgcgcgcag ccgagcgggc gctcatcgcg ctctacactg cgttcgcccg tgaggagtga 64920 gcctctctcg ggcgcagccg agcggcggcg tgccggtggt tccctcttcg caaccatgac 64980 cggagccgcg ctcggtccgc gcagcggcta gcgcgcgtcg cggcagagat cgctggagcg 65040 acaggcgacg accegecega gggtgtegaa eggattgeeg cageceteat tgeggateee 65100 ctccagacac tegiticaget gettiggegic gatgeegect gggcactege egaaggicag 65160 ctcgtcgcgc cactcggate ggatcttgtt cgagcacgcg tccttgctcg aatactcccg 65220 gtettgteeg atgttgttge acegegeete geggtegeac egegeegeea egatgetate 65280 gaeggegetg eegactggea eeggegeete geeetgegeg ceaecegggg tttgegeete 65340 cccgcctgac cgcttttcgc cgccgcacgc cgcgagcagg ctcattcccg acaccgagat 65400 caggectacg accagettee caggaatett ttgcatgget teceeteet cacgacaegt 65460 cacatcagag actotocgot oggotogtog gttogacago oggogacggo cacgagoaga 65520 acceptococy accagaacay ocycatycyy gtttctcyca acatyccocy acatecttyc 65580 gactaycyty cotocyctoy tyceyayate gyetytecty tycyacyyca atatectycy 65640 ateggeeggg caggaggtae egacaeggge geegggeggg aggtgeegee aegggetega 65700 aatgtgetge ggeaggegee tecatgeeeg cageegggaa egeggegeee ggeeageete 65760 ggggtgacgc cgcaaacggg agatgctccc ggagaggcgc cgggcacagc cgagcgccgt 65820 caccacegtg cgcactcgtg agctccagct cctcggcata gaagagaccg tcactcccgg 65880 tccgtgtagg cgatcgtgct gatcagcgcg ttctccgcct gacgcgagtc gagccgggta 65940 tgctgcacga caatgggaac gtccgattcg atcacgctgg catagtccgt atcgcgcggg 66000 ateggetegg gtteggteag ategttgaac eggacgtgce gggtgegeet egetgggacg 66060 gtcacceggt acggcccggc ggggtcgcgg tcgctgaagt agacggtgat ggcgacctgc 66120 gegteeeggt cegacgeatt caacaggcag gecgteteat ggetegteat etgeggeteg 66180 ggteegttge teeggeetgg gatgtageee tetgegattg cecagegegt cegecegate 66240 agegaeggee tetteteeeg aegegetegg ggateeatgg etgaggatee tegeegageg 66360 ctccttgccg accggcgcgc cgagcgccga cgggctttga aagcacgcga ccggacacgt 66420 gatgccggcg cgacgaggcc gccccgcgtc tgatcccgat cgtgacatcg cgacgtccgc 66480 cggcgcctct gcaggccggc ctgagcgttg cgcggtcatg gtcgtcctcg cgtcaccgcc 66540 accegecgat teacatecca eegeggeacg acgettgete aaacegegge gagaeggeeg 66600 ggeggetgtg gtaceggeea geeeggaege gaggeeegag agggaeagtg ggteegeegt 66660 gaagcagtga ggcgatcgag gtggcagatg aaacacgttg acacgggccg acgagtcggc 66720 cgccggatag ggctcacgct cggtctcctc gcgagcatgg cgctcgccgg ctgtggcggc 66780 ccgagcgaga aaatcgtgca gggcacgcgg ctcgcgcccg gcgccgatgc gcacgtcgcc 66840 geogacyteg accocyacyc cycyaccacy cygetygegy tygacyteyt teacetetey 66900 ccgcccgagc gcatcgaggc cggcagcgag cggttcgtcg tctggcagcg tccgagctcc 66960 gagtececgt ggcaacgggt eggagtgete gactacaacg etgccageeg aagaggcaag 67020 ctggccgaga cgaccgtgcc gcatgccaac ttcgagctgc tcatcaccgt cgagaagcag 67080 agcagccctc agtctccatc ttctgccgcc gtcatcgggc cgacgtccgt cgggtaacat 67140 cgegetatea geagegetga geeegeeage aggeeecaga geeetgeete gategeette 67200 tecatcatat catcectgcg tactectcca gegaeggeeg egtegaagea acegeegtge 67260 eggegeget etacgtgege gacaggagag egteetggeg eggeetgege ategetggaa 67320 ggatcggcgg agcatggaga aagaatcgag gatcgcgatc tacggcgcca tcgcagccaa 67380 cgtggcgatc gcggcggtca agttcatcgc cgccgccgtg accggcagct cggcgatgct 67440 ctccgagggc gtgcactccc tcgtcgatac tgcagacggg ctcctcctcc tgctcggcaa 67500 geaceggage geacgeege cegacgeega geateegtte ggecacggea aggageteta 67560 tttctggacg ctgatcgtcg ccatcatgat cttcgccgcg ggcggcggcg tctcgatcta 67620 cgaagggate ttgcacctet tgcaccegeg ccagategag gatecgaegt ggaactaegt 67680 cgtcetegge geageggeeg tettegaggg gacgtegete atcatetega tecaegagtt 67740 caagaagaag gacggacagg gctacctcgc ggcgatgcgg tccagcaagg acccgacgac 67800 gttcacgate gtcctggagg actccgcggc gctcgccggg ctcaccatcg ccttcctcgg 67860 egtetggete gggeaeegee tgggaaaeee etacetegae ggegeggegt egateggeat 67920 cggcctcgtg ctcgccgcgg tcgcggtctt cctcgccagc cagagccgtg ggctcctcgt 67980 gggggagagc gcggacaggg agctcctcgc cgcgatccgc gcgctcgcca gcgcagatcc 68040 tggcgtgtcg gcggtggggc ggcccctgac gatgcacttc ggtccgcacg aagtcctggt 68100 cgtgctgcgc atcgagttcg acgccgcgct cacggcgtcc ggggtcgcgg aggcgatcga 68160 gegeategag acceggatae ggagegageg accegaegtg aagcacatet acgtegagge 68220 caggtegete caecagegeg egagggegtg acgegecettg gagagacege gegeggeete 68280 egecateete egeggegee gggeteaggt ggeeetegea geagggegeg eetggegge 68340 aaaccgtgca gacgtcgtcc ttcgacgcga ggtacgctgg ttgcaagtcg tcacgccgta 68400 caggettega gaggggegac gtcatgagga aggccaggge gcatggggcg atgctcggcg 68520 ggcgagatga cggctggcgt cgcggcctcc ccggcgccgg cgcgcttcgc gccgcgctcc 68580 agegeggteg ctegegegat etegecegge geeggeteat egeeteegtg teeetegeeg 68640 geggegeeag catggeggte gtetegetgt tecagetegg gateategag egeetgeeeg 68700 atcotcoget tocagggtto gattoggoca aggtgacgag otcogatato

<212> PRT <213> Sorangium cellulosum

<400> 2 Val Ala Asp Arg Pro Ile Glu Arg Ala Ala Glu Asp Pro Ile Ala Ile Val Gly Ala Ser Cys Arg Leu Pro Gly Gly Val Ile Asp Leu Ser Gly 20 25 30 Phe Trp Thr Leu Leu Glu Gly Ser Arg Asp Thr Val Gly Arg Val Pro 35 45 Ala Glu Arg Trp Asp Ala Ala Ala Trp Phe Asp Pro Asp Pro Asp Ala 50 60 Pro Gly Lys Thr Pro Val Thr Arg Ala Ser Phe Leu Ser Asp Val Ala 65 70 75 80 Cys Phe Asp Ala Ser Phe Phe Gly Ile Ser Pro Arg Glu Ala Leu Arg Met Asp Pro Ala His Arg Leu Leu Leu Glu Val Cys Trp Glu Ala Leu 100 105 110 Glu Asn Ala Ala Ile Ala Pro Ser Ala Leu Val Gly Thr Glu Thr Gly 115 120 125 Val Phe Ile Gly Ile Gly Pro Ser Glu Tyr Glu Ala Ala Leu Pro Gln 130 140 Ala Thr Ala Ser Ala Glu Ile Asp Ala His Gly Gly Leu Gly Thr Met 145 150 155 Leu Gly Thr Met 160Pro Ser Val Gly Ala Gly Arg Ile Ser Tyr Ala Leu Gly Leu Arg Gly 165 170 175 Pro Cys Val Ala Val Asp Thr Ala Tyr Ser Ser Ser Leu Val Ala Val 180 185 190 His Leu Ala Cys Gln Ser Leu Arg Ser Gly Glu Cys Ser Thr Ala Leu Ala Gly Gly Val Ser Leu Met Leu Ser Pro Ser Thr Leu Val Trp Leu 215 Ser Lys Thr Arg Ala Leu Ala Arg Asp Gly Arg Cys Lys Ala Phe Ser 225 230 235 Ala Glu Ala Asp Gly Phe Gly Arg Gly Glu Gly Cys Ala Val Val Val 245 250 255Leu Lys Arg Leu Ser Gly Ala Arg Ala Asp Gly Asp Arg Ile Leu Ala 260 265 270 Val Ile Arg Gly Ser Ala Ile Asn His Asp Gly Ala Ser Ser Gly Leu Thr Val Pro Asn Gly Ser Ser Gln Glu Ile Val Leu Lys Arg Ala Leu Ala Asp Ala Gly Cys Ala Ala Ser Ser Val Gly Tyr Val Glu Ala His 305 310 315 320 Cly Thr Gly Thr Thr Leu Gly Asp Pro Ile Glu Ile Gln Ala Leu Asn - 20 -

| | | | | 325 | | | | | 330 | | | | | 335 | |
|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|
| Ala | Val | Tyr | Gly 340 | Leu | Gly | Arg | Asp | Val 345 | Ala | Thr | Pro | Leu | Leu 350 | Ile | Gly |
| Ser | Val | Lys 355 | Thr | Asn | Leu | Gly | His 360 | Pro | Glu | Tyr | Ala | Ser 365 | Gly | Ile | Thr |
| Gly | Leu 370 | Leu | Lys | Val | Val | Leu 375 | Ser | Leu | Gln | His | Gly 380 | Gln | Ile | Pro | Ala |
| His 385 | Leu | His | Ala | Gln | Ala 390 | Leu | Asn | Pro | Arg | Ile 395 | Ser | Trp | Gly | Asp | Leu 400 |
| Arg | Leu | Thr | Val | Thr 405 | Arg | Ala | Arg | Thr | Pro 410 | Trp | Pro | Asp | Trp | Asn 415 | Thr |
| Pro | Arg | Arg | Ala 420 | Gly | Val | Ser | Ser | Phe 425 | Gly | Met | Ser | Gly | Thr 430 | Asn | Ala |
| His | Val | Val 435 | Leu | Glu | Glu | Ala | Pro 440 | Ala | Ala | Thr | Cys | Thr 445 | Pro | Pro | Ala |
| Pro | Glu 450 | Arg | Pro | Ala | Glu | Leu 455 | Leu | Val | Leu | Ser | Ala 460 | Arg | Thr | Ala | Ser |
| Ala 465 | Leu | qzA | Ala | Gln | Ala 470 | Ala | Arg | Leu | Arg | Asp 475 | His | Leu | Glu | Thr | Tyr 480 |
| Pro | ser | Gln | Cys | Leu 485 | Gly | Asp | Val | Ala | Phe 490 | Ser | Leu | Ala | Thr | Thr 495 | Arg |
| Ser | Ala | Met | Glu 500 | His | Arg | Leu | Ala | Val 505 | Ala | Ala | Thr | Ser | Arg 510 | Glu | Gly |
| Leu | Arg | Ala 515 | Ala | Leu | qzA | Ala | Ala 520 | Ala | Gln | Gly | Gln | Thr 525 | Ser | Pro | Gly |
| | 530 | | | | Ala | 535 | | | | | 540 | | | | |
| 545 | | | | | Ala 550 | | | | | 555 | | | | | 560 |
| Asp | Val | Trp | Ser | Ala 565 | Phe | Arg | Glu | Ala | Phe 570 | | Leu | Суз | Val | Arg 575 | Leu |
| Phe | Asn | Gln | Glu 580 | Leu | Asp | Arg | Pro | Leu 585 | | Glu | Val | Met | Trp 590 | Ala | Glu |
| Pro | Ala | Ser 595 | Val | Asp | Ala | Ala | Leu 600 | | . Asp | Gln | Thr | Ala 605 | | Thr | Gln |
| Pro | Ala 610 | | Phe | Thr | Phe | Glu 615 | | Ala | Leu | Ala | Ala 620 | | Trp | Arg | Ser |
| Trp 625 | | Val | Glu | Pro | Glu 630 | | Val | . Ala | Gly | His 635 | | Ile | Gly | Glu | Leu 640 |
| Val | Ala | Ala | . Cys | Val 645 | Ala | Gly | v Val | . Phe | Ser 650 | | Glu | Asp | Ala | Val 655 | Phe |
| Leu | Val | . Ala | Ala 660 | | Gly | Arg | J Lev | Met 665 | | Ala | Leu | Pro | Ala 670 | Gly | Gly |

WO 99/66028 PCT/EP99/04171

Ala Met Val Ser Ile Glu Ala Pro Glu Ala Asp Val Ala Ala Ala Val Ala Pro His Ala Ala Ser Val Ser Ile Ala Ala Val Asn Ala Pro Asp Gln Val Val Ile Ala Gly Ala Gly Gln Pro Val His Ala Ile Ala Ala 705 710 715 720 Ala Met Ala Ala Arg Gly Ala Arg Thr Lys Ala Leu His Val Ser His 725 730 735Ala Phe His Ser Pro Leu Met Ala Pro Met Leu Glu Ala Phe Gly Arg
740 745 750 Val Ala Glu Ser Val Ser Tyr Arg Arg Pro Ser Ile Val Leu Val Ser 755 760 765 Asn Leu Ser Gly Lys Ala Cys Thr Asp Glu Val Ser Ser Pro Gly Tyr 770 780 Trp Val Arg His Ala Arg Glu Val Val Arg Phe Ala Asp Gly Val Lys 785 790 795 800 Ala Leu His Ala Ala Gly Ala Gly Thr Phe Val Glu Val Gly Pro Lys Ser Thr Leu Leu Gly Leu Val Pro Ala Cys Met Pro Asp Ala Arg Pro 820 825 830Ala Leu Leu Ala Ser Ser Arg Ala Gly Arg Asp Glu Pro Ala Thr Val Leu Glu Ala Leu Gly Gly Leu Trp Ala Val Gly Gly Leu Val Ser Trp 850 860Ala Gly Leu Phe Pro Ser Gly Gly Arg Arg Val Pro Leu Pro Thr Tyr 865 870 870 880 Pro Trp Gln Arg Glu Arg Tyr Trp Ile Asp Thr Lys Ala Asp Asp Ala Ala Arg Gly Asp Arg Ala Pro Gly Ala Gly His Asp Glu Val Glu 900 905 910 Glu Gly Gly Ala Val Arg Gly Gly Asp Arg Arg Ser Ala Arg Leu Asp 915 920 925 His Pro Pro Pro Glu Ser Gly Arg Arg Glu Lys Val Glu Ala Ala Gly 930 935 940 Asp Arg Pro Phe Arg Leu Glu Ile Asp Glu Pro Gly Val Leu Asp His 945 955 960 Leu Val Leu Arg Val Thr Glu Arg Arg Ala Pro Gly Leu Gly Glu Val 965 970 975 Glu Ile Ala Val Asp Ala Ala Gly Leu Ser Phe Asn Asp Val Gln Leu Ala Leu Gly Met Val Pro Asp Asp Leu Pro Gly Lys Pro Asn Pro Pro Leu Leu Gly Gly Glu Cys Ala Gly Arg Ile Val Ala Val Gly Glu 1020

Gly Val Asn Gly Leu Val Val Gly Gln Pro Val Ile Ala Leu Ser Ala 1025 1030 1035 1040

Gly Ala Phe Ala Thr His Val Thr Thr Ser Ala Ala Leu Val Leu Pro 1045 1050 1055

Arg Pro Gln Ala Leu Ser Ala Ile Glu Ala Ala Ala Met Pro Val Ala 1060 1065 1070

Tyr Leu Thr Ala Trp Tyr Ala Leu Asp Arg Ile Ala Arg Leu Gln Pro 1075 1080 1085

Gly Glu Arg Val Leu Ile His Ala Ala Thr Gly Gly Val Gly Leu Ala 1090 1095 1100

Ala Val Gln Trp Ala Gln His Val Gly Ala Glu Val His Ala Thr Ala 1105 1110 1115 1120

Gly Thr Pro Glu Lys Arg Ala Tyr Leu Glu Ser Leu Gly Val Arg Tyr 1125 1130 1135

Val Ser Asp Ser Arg Ser Asp Arg Phe Val Ala Asp Val Arg Ala Trp
1140 1145 1150

Thr Gly Gly Glu Gly Val Asp Val Leu Asn Ser Leu Ser Gly Glu 1155 1160 1165

Leu Ile Asp Lys Ser Phe Asn Leu Leu Arg Ser His Gly Arg Phe Val 1170 \$1175\$

Glu Leu Gly Lys Arg Asp Cys Tyr Ala Asp Asn Gln Leu Gly Leu Arg 1185 1190 1195 1200

Pro Phe Leu Arg Asn Leu Ser Phe Ser Leu Val Asp Leu Arg Gly Met 1205 1210 1215

Met Leu Glu Arg Pro Ala Arg Val Arg Ala Leu Leu Glu Glu Leu Leu 1220 1225 1230

Gly Leu Ile Ala Ala Gly Val Phe Thr Pro Pro Pro Ile Ala Thr Leu 1235 1240 1245

Pro Ile Ala Arg Val Ala Asp Ala Phe Arg Ser Met Ala Gln Ala Gln 1250 1260

His Leu Gly Lys Leu Val Leu Thr Leu Gly Asp Pro Glu Val Gln Ile 1265 1270 1275 1280

Arg Ile Pro Thr His Ala Gly Ala Gly Pro Ser Thr Gly Asp Arg Asp

Leu Leu Asp Arg Leu Ala Ser Ala Ala Pro Ala Ala Arg Ala Ala Ala 1300 1305 1310

Leu Glu Ala Phe Leu Arg Thr Gln Val Ser Gln Val Leu Arg Thr Pro 1315 1320 1325

Glu Ile Lys Val Gly Ala Glu Ala Leu Phe Thr Arg Leu Gly Met Asp 1330 1335 1340

Ser Leu Met Ala Val Glu Leu Arg Asn Arg Ile Glu Ala Ser Leu Lys 1345 1350 1355 1360

Leu Lys Leu Ser Thr Thr Phe Leu Ser Thr Ser Pro Asn Ile Ala Leu

WO 99/66028

1365

1370

- 23 -

1375

Leu Ala Gln Asn Leu Leu Asp Ala Leu Ala Thr Ala Leu Ser Leu Glu 1380 1385 1390

Arg Val Ala Ala Glu Asn Leu Arg Ala Gly Val Gln Asn Asp Phe Val 1395 1400 1405

Ser Ser Gly Ala Asp Gln Asp Trp Glu Ile Ile Ala Leu 1410 1415 1420

<210> 3

<211> 1410

<212> PRT

<213> Sorangium cellulosum

<400> 3

Met Thr Ile Asn Gln Leu Leu Asn Glu Leu Glu His Gln Gly Ile Lys 1 5 10 15

Leu Asn Pro Asn Leu Leu Ala Arg Ile Ser Glu His Lys Ser Thr Ile 35 40 45

Leu Thr Met Leu Arg Gln Arg Leu Pro Ala Glu Ser Ile Val Pro Ala 50 60

Pro Ala Glu Arg His Ala Pro Phe Pro Leu Thr Asp Ile Gln Glu Ser 65 70 75 80

Tyr Trp Leu Gly Arg Thr Gly Ala Phe Thr Val Pro Ser Gly Ile His 85 90 95

Arg Ala Phe Arg Lys Val Val Ala Arg His Asp Met Leu Arg Ala His 115 120 125

Thr Leu Pro Asp Met Met Gln Val Ile Glu Pro Lys Val Asp Ala Asp 130 135 140

Ile Glu Ile Ile Asp Leu Arg Gly Leu Asp Arg Ser Thr Arg Glu Ala 145 150 155 160

Arg Leu Val Ser Leu Arg Asp Ala Met Ser His Arg Ile Tyr Asp Thr 165 170 175

Glu Arg Pro Pro Leu Tyr His Val Val Ala Val Arg Leu Asp Glu Arg

Gln Thr Arg Leu Val Leu Ser Ile Asp Leu Ile Asn Val Asp Leu Gly 195 200 205

Ser Leu Ser Ile Ile Phe Lys Asp Trp Leu Ser Phe Tyr Glu Asp Pro 210 215 220

Glu Thr Ser Leu Pro Val Leu Glu Leu Ser Tyr Arg Asp Tyr Val Leu 225 230 235 240

Ala Leu Glu Ser Arg Lys Lys Ser Glu Ala His Gln Arg Ser Met Asp 245 250 255

Tyr Trp Lys Arg Arg Ile Ala Glu Leu Pro Pro Pro Pro Thr Leu Pro Met Lys Ala Asp Pro Ser Thr Leu Lys Glu Ile Arg Phe Arg His Thr Glu Gln Trp Leu Pro Ser Asp Ser Trp Gly Arg Leu Lys Arg Arg Val Gly Glu Arg Gly Leu Thr Pro Thr Gly Val Ile Leu Ala Ala Phe Ser Glu Val Ile Gly Arg Trp Ser Ala Ser Pro Arg Phe Thr Leu Asn Ile Thr Leu Phe Asn Arg Leu Pro Val His Pro Arg Val Asn Asp Ile Thr Gly Asp Phe Thr Ser Met Val Leu Leu Asp Ile Asp Thr Thr Arg Asp Lys Ser Phe Glu Gln Arg Ala Lys Arg Ile Gln Glu Gln Leu Trp Glu Ala Met Asp His Cys Asp Val Ser Gly Ile Glu Val Gln Arg Glu Ala Ala Arg Val Leu Gly Ile Gln Arg Gly Ala Leu Phe Pro Val Val Leu Thr Ser Ala Leu Asn Gln Gln Val Val Gly Val Thr Ser Leu Gln Arg Leu Gly Thr Pro Val Tyr Thr Ser Thr Gln Thr Pro Gln Leu Leu Leu 440 Asp His Gln Leu Tyr Glu His Asp Gly Asp Leu Val Leu Ala Trp Asp Ile Val Asp Gly Val Phe Pro Pro Asp Leu Leu Asp Asp Met Leu Glu Ala Tyr Val Val Phe Leu Arg Arg Leu Thr Glu Glu Pro Trp Gly Glu Gln Val Arg Cys Ser Leu Pro Pro Ala Gln Leu Glu Ala Arg Ala Ser 500 505 510 Ala Asn Ala Thr Asn Ala Leu Leu Ser Glu His Thr Leu His Gly Leu Phe Ala Ala Arg Val Glu Gln Leu Pro Met Gln Leu Ala Val Val Ser Ala Arg Lys Thr Leu Thr Tyr Glu Glu Leu Ser Arg Arg Ser Arg Arg 545 550 560 Leu Gly Ala Arg Leu Arg Glu Gln Gly Ala Arg Pro Asn Thr Leu Val Ala Val Val Met Glu Lys Gly Trp Glu Gln Val Val Ala Val Leu Ala Val Leu Glu Ser Gly Ala Ala Tyr Val Pro Ile Asp Ala Asp Leu Pro

595 600 605 Ala Glu Arg Ile His Tyr Leu Leu Asp His Gly Glu Val Lys Leu Val Leu Thr Gln Pro Trp Leu Asp Gly Lys Leu Ser Trp Pro Pro Gly Ile Gln Arg Leu Leu Val Ser Glu Ala Gly Val Glu Gly Asp Gly Asp Gln Pro Pro Met Met Pro Ile Gln Thr Pro Ser Asp Leu Ala Tyr Val Ile 660 665 670 Tyr Thr Ser Gly Ser Thr Gly Leu Pro Lys Gly Val Met Ile Asp His Arg Gly Ala Val Asn Thr Ile Leu Asp Ile Asn Glu Arg Phe Glu Ile Gly Pro Gly Asp Arg Val Leu Ala Leu Ser Ser Leu Ser Phe Asp Leu 705 710 715 720 Ser Val Tyr Asp Val Phe Gly Ile Leu Ala Ala Gly Gly Thr Ile Val 725 730 735 Val Pro Asp Ala Ser Lys Leu Arg Asp Pro Ala His Trp Ala Glu Leu 740 745 750Ile Glu Arg Glu Lys Val Thr Val Trp Asn Ser Val Pro Ala Leu Met 755 760 765 Arg Met Leu Val Glu His Phe Glu Gly Arg Pro Asp Ser Leu Ala Arg 770 780 Ser Leu Arg Leu Ser Leu Leu Ser Gly Asp Trp Ile Pro Val Gly Leu 785 790 795 800 Pro Gly Glu Leu Gln Ala Ile Arg Pro Gly Val Ser Val Ile Ser Leu 805 810 815 Gly Gly Ala Thr Glu Ala Ser Ile Trp Ser Ile Gly Tyr Pro Val Arg 820 825 830Asn Val Asp Leu Ser Trp Ala Ser Ile Pro Tyr Gly Arg Pro Leu Arg Asn Gln Thr Phe His Val Leu Asp Glu Ala Leu Glu Pro Arg Pro Val Trp Val Pro Gly Gln Leu Tyr Ile Gly Gly Val Gly Leu Ala Leu Gly Tyr Trp Arg Asp Glu Glu Lys Thr Arg Lys Ser Phe Leu Val His Pro 885 890 895 Glu Thr Gly Glu Arg Leu Tyr Lys Thr Gly Asp Leu Gly Arg Tyr Leu $900 \hspace{1.5cm} 905 \hspace{1.5cm} 910 \hspace{1.5cm}$ Pro Asp Gly Asn Ile Glu Phe Met Gly Arg Glu Asp Asn Gln Ile Lys 920 Leu Arg Gly Tyr Arg Val Glu Leu Gly Glu Ile Glu Glu Thr Leu Lys

- Ser His Pro Asn Val Arg Asp Ala Val Ile Val Pro Val Gly Asn Asp 945 950 955 960
- Ala Ala Asn Lys Leu Leu Leu Ala Tyr Val Val Pro Glu Gly Thr Arg 965 970 975
- Arg Arg Ala Ala Glu Gln Asp Ala Ser Leu Lys Thr Glu Arg Ile Asp 980 985 990
- Ala Arg Ala His Ala Ala Glu Ala Asp Gly Leu Ser Asp Gly Glu Arg 995 1000 1005
- Val Gln Phe Lys Leu Ala Arg His Gly Leu Arg Arg Asp Leu Asp Gly 1010 1015 1020
- Lys Pro Val Val Asp Leu Thr Gly Gln Asp Pro Arg Glu Ala Gly Leu 1025 1030 1035 1040
- Asp Val Tyr Ala Arg Arg Arg Ser Val Arg Thr Phe Leu Glu Ala Pro 1045 1050 1055
- Ile Pro Phe Val Glu Phe Gly Arg Phe Leu Ser Cys Leu Ser Ser Val 1060 1065 1070
- Glu Pro Asp Gly Ala Thr Leu Pro Lys Phe Arg Tyr Pro Ser Ala Gly 1075 1080 1085
- Ser Thr Tyr Pro Val Gln Thr Tyr Ala Tyr Val Lys Ser Gly Arg Ile 1090 1095 1100
- Glu Gly Val Asp Glu Gly Phe Tyr Tyr Tyr His Pro Phe Glu His Arg 1105 1110 1115 1120
- Leu Leu Lys Leu Ser Asp His Gly Ile Glu Arg Gly Ala His Val Arg 1125 1130 1135
- Gln Asn Phe Asp Val Phe Asp Glu Ala Ala Phe Asn Leu Leu Phe Val 1140 1145 1150
- Gly Arg Ile Asp Ala Ile Glu Ser Leu Tyr Gly Ser Ser Ser Arg Glu 1155 1160 1165
- Phe Cys Leu Leu Glu Ala Gly Tyr Met Ala Gln Leu Leu Met Glu Gln 1170 1180
- Ala Pro Ser Cys Asn Ile Gly Val Cys Pro Val Gly Gln Phe Asn Phe 1185 1190 1195 1200
- Glu Gln Val Arg Pro Val Leu Asp Leu Arg His Ser Asp Val Tyr Val 1205 1210 1215
- His Gly Met Leu Gly Gly Arg Val Asp Pro Arg Gln Phe Gln Val Cys 1220 1225 1230
- Thr Leu Gly Gln Asp Ser Ser Pro Arg Arg Ala Thr Thr Arg Gly Ala 1235 1240 1245
- Pro Pro Gly Arg Glu Gln His Phe Ala Asp Met Leu Arg Asp Phe Leu 1250 1260
- Arg Thr Lys Leu Pro Glu Tyr Met Val Pro Thr Val Phe Val Glu Leu 1265 1270 1275 1280
- Asp Ala Leu Pro Leu Thr Ser Asn Gly Lys Val Asp Arg Lys Ala Leu 1285 1290 1295

WO 99/66028 PCT/EP99/04171

- 27 -

Arg Glu Arg Lys Asp Thr Ser Ser Pro Arg His Ser Gly His Thr Ala 1300 1305 1310

Pro Arg Asp Ala Leu Glu Glu Ile Leu Val Ala Val Val Arg Glu Val 1315 1320 1325

Leu Gly Leu Glu Val Val Gly Leu Gln Gln Ser Phe Val Asp Leu Gly 1330 1335 1340

Ala Thr Ser Ile His Ile Val Arg Met Arg Ser Leu Leu Gln Lys Arg 1345 1350 1355 1360

Leu Asp Arg Glu Ile Ala Ile Thr Glu Leu Phe Gln Tyr Pro Asn Leu 1365 1370 1375

Gly Ser Leu Ala Ser Gly Leu Arg Arg Asp Ser Arg Asp Leu Asp Gln 1380 1385 1390

Arg Pro Asn Met Gln Asp Arg Val Glu Val Arg Arg Lys Gly Arg Arg 1395 1400 1405

Arg Ser 1410

<210> 4

<211> 1832

<212> PRT

<213> Sorangium cellulosum

<400> 4

Met Glu Glu Gln Glu Ser Ser Ala Ile Ala Val Ile Gly Met Ser Gly
1 5 10 15

Arg Phe Pro Gly Ala Arg Asp Leu Asp Glu Phe Trp Arg Asn Leu Arg 20 25 30

Asp Gly Thr Glu Ala Val Gln Arg Phe Ser Glu Gln Glu Leu Ala Ala 35 40 45

Ser Gly Val Asp Pro Ala Leu Val Leu Asp Pro Ser Tyr Val Arg Ala 50 60

Gly Ser Val Leu Glu Asp Val Asp Arg Phe Asp Ala Ala Phe Phe Gly 65 70 75

Ile Ser Pro Arg Glu Ala Glu Leu Met Asp Pro Gln His Arg Ile Phe

Met Glu Cys Ala Trp Glu Ala Leu Glu Asn Ala Gly Tyr Asp Pro Thr 100 105 110

Ala Tyr Glu Gly Ser Ile Gly Val Tyr Ala Gly Ala Asn Met Ser Ser 115 120 125

Tyr Leu Thr Ser Asn Leu His Glu His Pro Ala Met Met Arg Trp Pro 130 135 140

Gly Trp Phe Gln Thr Leu Ile Gly Asn Asp Lys Asp Tyr Leu Ala Thr 145 150 155 160

His Val Ser Tyr Arg Leu Asn Leu Arg Gly Pro Ser Ile Ser Val Gln 165 170 175

Thr Ala Cys Ser Thr Ser Leu Val Ala Val His Leu Ala Cys Met Ser Leu Leu Asp Arg Glu Cys Asp Met Ala Leu Ala Gly Gly Ile Thr Val 195 200 205 Arg Ile Pro His Arg Ala Gly Tyr Val Tyr Ala Glu Gly Gly Ile Phe 210 220 Ser Pro Asp Gly His Cys Arg Ala Phe Asp Ala Lys Ala Asn Gly Thr 225 230 235 240 Ile Met Gly Asn Gly Cys Gly Val Val Leu Leu Lys Pro Leu Asp Arg 245 250 255 Ala Leu Ser Asp Gly Asp Pro Val Arg Ala Val Ile Leu Gly Ser Ala 260 265 270 Val Gly Gln Ala Gln Ala Ile Met Glu Ala Leu Ala Leu Ala Gly Val 290 295 300 Glu Ala Arg Ser Ile Gln Tyr Ile Glu Thr His Gly Thr Gly Thr Leu Leu Gly Asp Ala Ile Glu Thr Ala Ala Leu Arg Arg Val Phe Gly Arg 325 330 335 Asp Ala Ser Ala Arg Arg Ser Cys Ala Ile Gly Ser Val Lys Thr Gly 340 345 350Ile Gly His Leu Glu Ser Ala Ala Gly Ile Ala Gly Leu Ile Lys Thr 355 360 365Val Leu Ala Leu Glu His Arg Gln Leu Pro Pro Ser Leu Asn Phe Glu Ser Pro Asn Pro Ser Ile Asp Phe Ala Ser Ser Pro Phe Tyr Val Asn Thr Ser Leu Lys Asp Trp Asn Thr Gly Ser Thr Pro Arg Arg Ala Gly 405 410 415 Val Ser Ser Phe Gly Ile Gly Gly Thr Asn Ala His Val Val Leu Glu Glu Ala Pro Ala Ala Lys Leu Pro Ala Ala Pro Ala Arg Ser Ala Glu Leu Phe Val Val Ser Ala Lys Ser Ala Ala Ala Leu Asp Ala Ala Ala Ala Arg Leu Arg Asp His Leu Gln Ala His Gln Gly Ile Ser Leu Gly Asp Val Ala Phe Ser Leu Ala Thr Thr Arg Ser Pro Met Glu His Arg Leu Ala Met Ala Ala Pro Ser Arg Glu Ala Leu Arg Glu Gly Leu 500 505 510Asp Ala Ala Arg Gly Gln Thr Pro Pro Gly Ala Val Arg Gly Arg 515 520 525

| Cys | Ser 530 | Pro | Gly | Asn | Val | Pro 535 | Lys | Val | Val | Phe | Val 540 | Phe | Pro | Gly | Gln |
|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|
| Gly 545 | Ser | Gln | Trp | Val | Gly 550 | Met | Gly | Arg | Gln | Leu 555 | Leu | Ala | Glu | Glu | Pro 560 |
| Val | Phe | His | Ala | Ala 565 | Leu | Ser | Ala | Cys | Asp 570 | Arg | Ala | Ile | Gln | Ala 575 | Glu |
| Ala | Gly | Trp | Ser 580 | Leu | Leu | Ala | Glu | Leu 585 | Ala | Ala | Asp | Glu | Gly 590 | Ser | Ser |
| Gln | Leu | Glu 595 | Arg | Ile | Asp | Val | Val 600 | Gln | Pro | Val | Leu | Phe 605 | Ala | Leu | Ala |
| Val | Ala 610 | Phe | Ala | Ala | Leu | Trp 615 | Arg | Ser | Trp | Gly | Val 620 | Ala | Pro | Asp | Val |
| Val 625 | Ile | Gly | His | Ser | Met 630 | Gly | Glu | Val | Ala | Ala 635 | Ala | His | Val | Ala | Gly 640 |
| Ala | Leu | Ser | Leu | Glu 645 | Asp | Ala | Val | Ala | Ile 650 | Ile | Cys | Arg | Arg | Ser 655 | Arg |
| Leu | Leu | Arg | Arg 660 | Ile | Ser | Gly | Gln | Gly 665 | Glu | Met | Ala | Val | Thr 670 | Glu | Leu |
| Ser | Leu | Ala 675 | Glu | Ala | Glu | Ala | Ala 680 | Leu | Arg | Gly | Tyr | Glu 685 | Asp | Arg | Val |
| Ser | Val 690 | Ala | Val | Ser | Asn | Ser 695 | Pro | Arg | Ser | Thr | Val 700 | Leu | Ser | Gly | Glu |
| Pro 705 | Ala | Ala | Ile | Gly | Glu 710 | Val | Leu | Ser | Ser | Leu 715 | Asn | Ala | Lys | Gly | Val 720 |
| Phe | Cys | Arg | Arg | Val 725 | Lys | Val | Asp | Val | Ala 730 | Ser | His | Ser | Pro | Gln 735 | Val |
| Asp | Pro | Leu | Arg 740 | Glu | Asp | Leu | Leu | Ala 745 | Ala | Leu | Gly | Gly | Leu 750 | Arg | Pro |
| Gly | Ala | Ala 755 | Ala | Val | Pro | Met | Arg 760 | Ser | Thr | Val | Thr | Gly 765 | Ala | Met | Val |
| Ala | Gly 770 | Pro | Glu | Leu | Gly | Ala 775 | Asn | Tyr | Trp | Met | Asn 780 | Asn | Leu | Arg | Gln |
| Pro 785 | Val | Arg | Phe | Ala | Glu 790 | Val | Val | Gln | Ala | Gln 795 | Leu | Gln | Gly | Gly | His 800 |
| Gly | Leu | Phe | Val | Glu 805 | Met | Ser | Pro | His | Pro 810 | Ile | Leu | Thr | Thr | Ser 815 | Val |
| Glu | Glu | Met | Arg 820 | Arg | Ala | Ala | Gln | Arg 825 | Ala | Gly | Ala | Ala | Val 830 | Gly | Ser |
| Leu | Arg | Arg 835 | Gly | Gln | Asp | Glu | Arg 840 | | Ala | Met | Leu | Glu 845 | Ala | Leu | Gly |
| Thr | Leu 850 | | Ala | Gln | Gly | Тут 855 | Pro | Val | Pro | Trp | Gly 860 | Arg | Leu | Phe | Pro |
| Ala | Gly | Gly | Arg | Arg | Val | Pro | Leu | Pro | Thr | Туг | Pro | Trp | Gln | Arg | Gli |

PCT/EP99/04171 WO 99/66028

- 30 -

| 865 | | | | | 870 | | | | | 875 | | | | | 880 |
|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| Arg | Tyr | Trp | Ile | Glu 885 | Ala | Pro | Ala | Lys | Ser 890 | Ala | Ala | Gly | Asp | Arg 895 | Arg |
| Gly | Val | Arg | Ala 900 | Gly | Gly | His | Pro | Leu 905 | Leu | Gly | Glu | Met | Gln 910 | Thr | Leu |
| Ser | Thr | Gln 915 | Thr | Ser | Thr | Arg | Leu 920 | Trp | Glu | Thr | Thr | Leu 925 | Asp | Leu | Lys |
| Arg | Leu 930 | Pro | Trp | Leu | Gly | Asp 935 | His | Arg | Val | Gln | Gly 940 | Ala | Val | Val | Phe |
| Pro 945 | Gly | Ala | Ala | Tyr | Leu 950 | Glu | Met | Ala | Ile | Ser 955 | Ser | Gly | Ala | Glu | Ala 960 |
| Leu | Gly | qzA | Gly | Pro 965 | Leu | Gln | Ile | Thr | Asp 970 | Val | Val | Leu | Ala | Glu 975 | Ala |
| Leu | Ala | Phe | Ala 980 | Gly | Asp | Ala | Ala | Val 985 | Leu | Val | Gln | Val | Val 990 | Thr | Thr |
| Glu | Gln | Pro 995 | Ser | Gly | Arg | | Gln 1000 | Phe | Gln | Ile | | Ser L005 | Arg | Ala | Pro |
| | Ala 010 | Gly | His | Ala | | Phe 1015 | Arg | Val | His | | Arg 1020 | Gly | Ala | Leu | Leu |
| Arg 1025 | | Glu | Arg | | G1u L030 | Val | Pro | Ala | | Leu 1035 | Thr | Leu | Ser | | Val 1040 |
| Arg | Ala | Arg | | Gln 1045 | Ala | Ser | Ile | | Ala 1050 | Ala | Ala | Thr | | Ala LO55 | Glu |
| Leu | Thr | | Met 1060 | Gly | Leu | Gln | Tyr | Gly 1065 | Pro | Ala | Phe | | Gly 1070 | Ile | Ala |
| Glu | | Trp 1075 | Arg | Gly | Glu | | Glu 1080 | Ala | Leu | Gly | | Val 1085 | Arg | Leu | Pro |
| | Ala 1090 | Ala | Gly | Ser | | Ala 1095 | Glu | Tyr | Arg | | His 1100 | Pro | Ala | Leu | Leu |
| Asp 110 | | Cys | Phe | | Ile 1110 | Val | Gly | Ser | | Phe 1115 | Ala | Arg | Ser | | Glu 1120 |
| Ala | Thr | Pro | | Val 1125 | Pro | Val | Glu | | Gly 1130 | Ser | Leu | Arg | | Leu 1135 | Gln |
| Arg | Pro | | Gly 1140 | Glu | Leu | Trp | Cys | His 1145 | Ala | Arg | Val | Val | Asn 1150 | His | Gly |
| His | | Thr 1155 | Pro | Asp | Arg | Gln | Gly 1160 | | Asp | Phe | Trp | Val 1165 | Val | Asp | Ser |
| | Gly 1170 | | Val | Val | | Glu 1175 | Val | Cys | Gly | Leu | Val 1180 | | Gln | Arg | Leu |
| Pro 118 | | Gly | Val | | Arg 1190 | | Glu | Glu | Asp | Asp 1195 | | Phe | Leu | | Leu 1200 |
| Glu | Trp | Glu | Pro | Ala 1205 | | Val | Gly | Thr | Ala 1210 | | Val | Asr | Ala | Gly 1215 | |

- Trp Leu Leu Gly Gly Gly Gly Leu Gly Ala Ala Leu Arg Ala
- Met Leu Glu Ala Gly Gly His Ala Val Val His Ala Ala Glu Asn Asn
- Thr Ser Ala Ala Gly Val Arg Ala Leu Leu Ala Lys Ala Phe Asp Gly 1255
- Gln Ala Pro Thr Ala Val Val His Leu Gly Ser Leu Asp Gly Gly Gly
- Glu Leu Asp Pro Gly Leu Gly Ala Gln Gly Ala Leu Asp Ala Pro Arg
- Ser Ala Asp Val Ser Pro Asp Ala Leu Asp Pro Ala Leu Val Arg Gly
- Cys Asp Ser Val Leu Trp Thr Val Gln Ala Leu Ala Gly Met Gly Phe
- Arg Asp Ala Pro Arg Leu Trp Leu Leu Thr Arg Gly Ala Gln Ala Val 1335
- Gly Ala Gly Asp Val Ser Val Thr Gln Ala Pro Leu Gly Leu Gly
- Arg Val Ile Ala Met Glu His Ala Asp Leu Arg Cys Ala Arg Val Asp
- Leu Asp Pro Ala Arg Pro Glu Gly Glu Leu Ala Ala Leu Leu Ala Glu
- Leu Leu Ala Asp Asp Ala Glu Ala Glu Val Ala Leu Arg Gly Gly Glu
- Arg Cys Val Ala Arg Ile Val Arg Arg Gln Pro Glu Thr Arg Pro Arg 1415 1420
- Gly Arg Ile Glu Ser Cys Val Pro Thr Asp Val Thr Ile Arg Ala Asp 1430
- Ser Thr Tyr Leu Val Thr Gly Gly Leu Gly Leu Gly Leu Ser Val
- Ala Gly Trp Leu Ala Glu Arg Gly Ala Gly His Leu Val Leu Val Gly
- Arg Ser Gly Ala Ala Ser Val Glu Gln Arg Ala Ala Val Ala Ala Leu
- Glu Ala Arg Gly Ala Arg Val Thr Val Ala Lys Ala Asp Val Ala Asp 1500
- Arg Ala Gln Leu Glu Arg Ile Leu Arg Glu Val Thr Thr Ser Gly Met 1510 1515
- Pro Leu Arg Gly Val Val His Ala Ala Gly Ile Leu Asp Asp Gly Leu
- Leu Met Gln Gln Thr Pro Ala Arg Phe Arg Lys Val Met Ala Pro Lys 1545
- Val Gln Gly Ala Leu His Leu His Ala Leu Thr Arg Glu Ala Pro Leu 1560 1555

Ser Phe Phe Val Leu Tyr Ala Ser Gly Val Gly Leu Leu Gly Ser Pro 1570 1575 1580

Gly Gln Gly Asn Tyr Ala Ala Ala Asn Thr Phe Leu Asp Ala Leu Ala 1585 1590 1595 1600

His His Arg Arg Ala Gln Gly Leu Pro Ala Leu Ser Val Asp Trp Gly 1605 1610 1615

Leu Phe Ala Glu Val Gly Met Ala Ala Ala Gln Glu Asp Arg Gly Ala 1620 1625 1630

Arg Leu Val Ser Arg Gly Met Arg Ser Leu Thr Pro Asp Glu Gly Leu 1635 1640 1645

Ser Ala Leu Ala Arg Leu Leu Glu Ser Gly Arg Ala Gln Val Gly Val 1650 1655 1660

Met Pro Val Asn Pro Arg Leu Trp Val Glu Leu Tyr Pro Ala Ala Ala 1665 1670 1675 1680

Ser Ser Arg Met Leu Ser Arg Leu Val Thr Ala His Arg Ala Ser Ala 1685 1690 1695

Gly Gly Pro Ala Gly Asp Gly Asp Leu Leu Arg Arg Leu Ala Ala Ala , 1700 1705 1710

Glu Pro Ser Ala Arg Ser Ala Leu Leu Glu Pro Leu Leu Arg Ala Gln 1715 1720 1725

Ile Ser Gln Val Leu Arg Leu Pro Glu Gly Lys Ile Glu Val Asp Ala 1730 1735 1740

Pro Leu Thr Ser Leu Gly Met Asn Ser Leu Met Gly Leu Glu Leu Arg 1745 1750 1755 1760

Asn Arg Ile Glu Ala Met Leu Gly Ile Thr Val Pro Ala Thr Leu Leu 1765 1770 1775

Trp Thr Tyr Pro Thr Val Ala Ala Leu Ser Gly His Leu Ala Arg Glu 1780 1785 1790

Ala Cys Glu Ala Ala Pro Val Glu Ser Pro His Thr Thr Ala Asp Ser 1795 1800 1805

Ala Val Glu Ile Glu Glu Met Ser Gln Asp Asp Leu Thr Gln Leu Ile 1810 1815 1820

Ala Ala Lys Phe Lys Ala Leu Thr 1825 1830

<210> 5

<211> 7257

<212> PRT

<213> Sorangium cellulosum

<400> 5

Met Thr Thr Arg Gly Pro Thr Ala Gln Gln Asn Pro Leu Lys Gln Ala

Ala Ile Ile Gl
n Arg Leu Glu Glu Arg Leu Ala Gly Leu Ala Gl
n 20 25 30

Ala Glu Leu Glu Arg Thr Glu Pro Ile Ala Ile Val Gly Ile Gly Cys 35 40 45Arg Phe Pro Gly Gly Ala Asp Ala Pro Glu Ala Phe Trp Glu Leu Leu 50 60Asp Ala Glu Arg Asp Ala Val Gln Pro Leu Asp Met Arg Trp Ala Leu 65 70 75 80 Val Gly Val Ala Pro Val Glu Ala Val Pro His Trp Ala Gly Leu Leu 85 90 95 Thr Glu Pro Ile Asp Cys Phe Asp Ala Ala Phe Phe Gly Ile Ser Pro Arg Glu Ala Arg Ser Leu Asp Pro Gln His Arg Leu Leu Glu Val Ala Trp Glu Gly Leu Glu Asp Ala Gly Ile Pro Pro Arg Ser Ile Asp 130 135 140 Gly Ser Arg Thr Gly Val Phe Val Gly Ala Phe Thr Ala Asp Tyr Ala 145 150 155 160 Arg Thr Val Ala Arg Leu Pro Arg Glu Glu Arg Asp Ala Tyr Ser Ala Thr Gly Asn Met Leu Ser Ile Ala Ala Gly Arg Leu Ser Tyr Thr Leu 180 185 Leu 190Gly Leu Gln Gly Pro Cys Leu Thr Val Asp Thr Ala Cys Ser Ser Ser Leu Val Ala Ile His Leu Ala Cys Arg Ser Leu Arg Ala Gly Glu Ser 210 215 220 Met Glu Ala Ala Arg Thr Gln Ala Leu Ser Pro Asp Gly Arg Cys Arg Thr Phe Asp Ala Ser Ala Asn Gly Phe Val Arg Gly Glu Gly Cys 260 265 270Gly Leu Val Val Leu Lys Arg Leu Ser Asp Ala Gln Arg Asp Gly Asp Arg Ile Trp Ala Leu Ile Arg Gly Ser Ala Ile Asn His Asp Gly Arg Ser Thr Gly Leu Thr Ala Pro Asn Val Leu Ala Gln Glu Thr Val Leu Arg Glu Ala Leu Arg Ser Ala His Val Glu Ala Gly Ala Val Asp Tyr Val Glu Thr His Gly Thr Gly Thr Ser Leu Gly Asp Pro Ile Glu Val Glu Ala Leu Arg Ala Thr Val Gly Pro Ala Arg Ser Asp Gly Thr Arg 355 360 365 Cys Val Leu Gly Ala Val Lys Thr Asn Ile Gly His Leu Glu Ala Ala Ala Gly Val Ala Gly Leu Ile Lys Ala Ala Leu Ser Leu Thr His Glu 390 Arg Ile Pro Arg Asn Leu Asn Phe Arg Thr Leu Asn Pro Arg Ile Arg 410 Leu Glu Gly Ser Ala Leu Ala Leu Ala Thr Glu Pro Val Pro Trp Pro Arg Thr Asp Arg Pro Arg Phe Ala Gly Val Ser Ser Phe Gly Met Ser Gly Thr Asn Ala His Val Val Leu Glu Glu Ala Pro Ala Val Glu Leu Trp Pro Ala Ala Pro Glu Arg Ser Ala Glu Leu Leu Val Leu Ser Gly Lys Ser Glu Gly Ala Leu Asp Ala Gln Ala Ala Arg Leu Arg Glu His Leu Asp Met His Pro Glu Leu Gly Leu Gly Asp Val Ala Phe Ser Leu Ala Thr Thr Arg Ser Ala Met Ser His Arg Leu Ala Val Ala Val Thr Ser Arg Glu Gly Leu Leu Ala Ala Leu Ser Ala Val Ala Gln Gly Gln Thr Pro Ala Gly Ala Ala Arg Cys Ile Ala Ser Ser Ser Arg Gly Lys 545 550 560 Leu Ala Phe Leu Phe Thr Gly Gln Gly Ala Gln Thr Pro Gly Met Gly Arg Gly Leu Cys Ala Ala Trp Pro Ala Phe Arg Glu Ala Phe Asp Arg Cys Val Ala Leu Phe Asp Arg Glu Leu Asp Arg Pro Leu Arg Glu Val Met Trp Ala Glu Ala Gly Ser Ala Glu Ser Leu Leu Asp Gln Thr Ala Phe Thr Gln Pro Ala Leu Phe Ala Val Glu Tyr Ala Leu Thr Ala Leu Trp Arg Ser Trp Gly Val Glu Pro Glu Leu Leu Val Gly His Ser 645 650 655 Ile Gly Glu Leu Val Ala Ala Cys Val Ala Gly Val Phe Ser Leu Glu Asp Gly Val Arg Leu Val Ala Ala Arg Gly Arg Leu Met Gln Gly Leu Ser Ala Gly Gly Ala Met Val Ser Leu Gly Ala Pro Glu Ala Glu Val Ala Ala Ala Val Ala Pro His Ala Ala Ser Val Ser Ile Ala Ala Val Asn Gly Pro Glu Gln Val Val Ile Ala Gly Val Glu Gln Ala Val Gln

in the

| | | | | 725 | | | | | 730 | | | | | 735 | |
|------------|---------------|------------|------------|-------------|------------|---------------|------------|------------|---------------|--------------------|------------|-------------|---------------|------------|---------------|
| Ala | Ile | Ala | Ala 740 | Gly | Phe | Ala | Ala | Arg 745 | Gly | Ala | Arg | Thr | Lys 750 | Arg | Leu |
| His | : Val | Ser 755 | His | Ala | Phe | His | Ser 760 | Pro | Leu | Met | Glu | Pro 765 | Met | Leu | Glu |
| Glu | 770 | Gly | Arg | Val | Ala | Ala 775 | Ser | Val | Thr | Tyr | Arg 780 | Arg | Pro | Ser | Val |
| Ser 785 | Leu | Val | Ser | Asn | Leu 790 | Ser | Gly | Lys | Val | Val 795 | Thr | Asp | Glu | Leu | Ser 800 |
| Ala | Pro | Gly | Tyr | Trp 805 | Val | Arg | His | Val | Arg 810 | Glu | Ala | Val | Arg | Phe 815 | Ala |
| Asp | Gly | Val | Lys 820 | Ala | Leu | His | Glu | Ala 825 | Gly | Ala | Gly | Thr | Phe 830 | Val | Glu |
| Val | Gly | Pro 835 | Lys | Pro | Thr | Leu | Leu 840 | Gly | Leu | Leu | Pro | Ala 845 | Cys | Leu | Pro |
| Glu | 850 | Glu | Pro | Thr | Leu | Leu 855 | Ala | Ser | Leu | Arg | Ala 860 | Gly | Arg | Glu | Glu |
| A1a 865 | a Ala | Gly | Val | Leu | Glu 870 | Ala | Leu | Gly | Arg | Leu 875 | Trp | Ala | Ala | Gly | Gly 880 |
| Sei | c Val | Ser | Trp | Pro 885 | Gly | Val | Phe | Pro | Thr 890 | Ala | Gly | Arg | Arg | Val 895 | Pro |
| Let | ı Pro | Thr | Туг 900 | Pro | Trp | Gln | Λrg | Gln 905 | | Туг | Trp | Ile | Glu 910 | Ala | Pro |
| Ala | a Glu | Gly 915 | | Gly | Ala | Thr | Ala 920 | Ala | Asp | Ala | Leu | Ala 925 | | Trp | Phe |
| Ту | r Arg 930 | | Asp | Trp | Pro | Glu 935 | | Pro | Arg | Ser | Ser 940 | | Asp | Ser | Arg |
| Are 94 | g Ala 5 | Arg | Ser | Gly | Gly 950 | Trp | Leu | Val | Leu | Ala 955 | _ | Arg | G1y | Gly | Val 960 |
| Gl | y Glu | Ala | Ala | Ala 965 | Ala | Ala | Leu | Ser | 970 | | Gly | Cys | Ser | Суs 975 | |
| Va | l Leu | His | 980 | | Ala | Glu | Ala | Ser 985 | | Val | Ala | Glu | 990 | | Thr |
| Gl | n Ala | 995 | | Gly | Arg | Asr | 1000 | | Glr | ı Gly | v Val | Let 1009 | | Let | Trp |
| Gl | y Let 1010 | | Ala | val | . Val | . Glv 1015 | | G1) | / Ala | a Ser | 1020 | | ı Glu | ı Va] | Ala |
| | rs Val 125 | l Thi | c His | s Let | 1030 | | a Ala | a Pro | o Vai | l Let 103 | | a Lei | ı Ile | e Glr | 1 Ala 1040 |
| L€ | eu Gl | y Th | r Gly | Pro 1045 | | ; Se: | r Pro |) Ar | g Let 1050 | и Тх <u>г</u> О | ıle | e Va | l Thi | 105 | g Gly |
| A. | la Cy | s Th | r Vai | l Gly | / Gly | / Gl | u Pro | 2 As | p Ala | a Ala | a Pro | Cy: | s Glr 1070 | n Ala | a Ala |

- Leu Trp Gly Met Gly Arg Val Ala Ala Leu Glu His Pro Gly Ser Trp 1080
- Gly Gly Leu Val Asp Leu Asp Pro Glu Glu Ser Pro Thr Glu Val Glu 1095
- Ala Leu Val Ala Glu Leu Leu Ser Pro Asp Ala Glu Asp Gln Leu Ala 1110
- Phe Arg Gln Gly Arg Arg Arg Ala Ala Arg Leu Val Ala Ala Pro Pro 1130
- Glu Gly Asn Ala Ala Pro Val Ser Leu Ser Ala Glu Gly Ser Tyr Leu
- Val Thr Gly Gly Leu Gly Ala Leu Gly Leu Leu Val Ala Arg Trp Leu
- Val Glu Arg Gly Ala Gly His Leu Val Leu Ile Ser Arg His Gly Leu 1175
- Pro Asp Arg Glu Glu Trp Gly Arg Asp Gln Pro Pro Glu Val Arg Ala
- Arg Ile Ala Ala Ile Glu Ala Leu Glu Ala Gln Gly Ala Arg Val Thr 1205 1210
- Val Ala Ala Val Asp Val Ala Asp Ala Glu Gly Met Ala Ala Leu Leu
- Ala Ala Val Glu Pro Pro Leu Arg Gly Val Val His Ala Ala Gly Leu
- Leu Asp Asp Gly Leu Leu Ala His Gln Asp Ala Gly Arg Leu Ala Arg 1255
- Val Leu Arg Pro Lys Val Glu Gly Ala Trp Val Leu His Thr Leu Thr
- Arg Glu Gln Pro Leu Asp Leu Phe Val Leu Phe Ser Ser Ala Ser Gly 1285 1290
- Val Phe Gly Ser Ile Gly Gln Gly Ser Tyr Ala Ala Gly Asn Ala Phe
- Leu Asp Ala Leu Ala Asp Leu Arg Arg Thr Gln Gly Leu Ala Ala Leu
- Ser Ile Ala Trp Gly Leu Trp Ala Glu Gly Gly Met Gly Ser Gln Ala 1335
- Gln Arg Arg Glu His Glu Ala Ser Gly Ile Trp Ala Met Pro Thr Ser
- Arg Ala Leu Ala Ala Met Glu Trp Leu Leu Gly Thr Arg Ala Thr Gln
- Arg Val Val Ile Gln Met Asp Trp Ala His Ala Gly Ala Ala Pro Arg 1385
- Asp Ala Ser Arg Gly Arg Phe Trp Asp Arg Leu Val Thr Ala Thr Lys 1400
- Glu Ala Ser Ser Ser Ala Val Pro Ala Val Glu Arg Trp Arg Asn Ala 1420

- Ser Val Val Glu Thr Arg Ser Ala Leu Tyr Glu Leu Val Arg Gly Val 1430 1435 1425
- Val Ala Gly Val Met Gly Phe Thr Asp Gln Gly Thr Leu Asp Val Arg 1450 1445
- Arg Gly Phe Ala Glu Gln Gly Leu Asp Ser Leu Met Ala Val Glu Ile
- Arg Lys Arg Leu Gln Gly Glu Leu Gly Met Pro Leu Ser Ala Thr Leu 1480
- Ala Phe Asp His Pro Thr Val Glu Arg Leu Val Glu Tyr Leu Leu Ser 1495
- Gln Ala Leu Glu Leu Gln Asp Arg Thr Asp Val Arg Ser Val Arg Leu 1510 1515
- Pro Ala Thr Glu Asp Pro Ile Ala Ile Val Gly Ala Ala Cys Arg Phe 1530
- Pro Gly Gly Val Glu Asp Leu Glu Ser Tyr Trp Gln Leu Leu Thr Glu
- Gly Val Val Val Ser Thr Glu Val Pro Ala Asp Arg Trp Asn Gly Ala 1560
- Asp Gly Arg Val Pro Gly Ser Gly Glu Ala Gln Arg Gln Thr Tyr Val
- Pro Arg Gly Gly Phe Leu Arg Glu Val Glu Thr Phe Asp Ala Ala Phe 1590 1595
- Phe His Ile Ser Pro Arg Glu Ala Met Ser Leu Asp Pro Gln Gln Arg 1605 1610
- Leu Leu Leu Glu Val Ser Trp Glu Ala Ile Glu Arg Ala Gly Gln Asp
- Pro Ser Ala Leu Arg Glu Ser Pro Thr Gly Val Phe Val Gly Ala Gly 1640
- Pro Asn Glu Tyr Ala Glu Arg Val Gln Glu Leu Ala Asp Glu Ala Ala
- Gly Leu Tyr Ser Gly Thr Gly Asn Met Leu Ser Val Ala Ala Gly Arg
- Leu Ser Phe Phe Leu Gly Leu His Gly Pro Thr Leu Ala Val Asp Thr 1690
- Ala Cys Ser Ser Ser Leu Val Ala Leu His Leu Gly Cys Gln Ser Leu 1705
- Arg Arg Gly Glu Cys Asp Gln Ala Leu Val Gly Gly Val Asn Met Leu 1720
- Leu Ser Pro Lys Thr Phe Ala Leu Leu Ser Arg Met His Ala Leu Ser
- Pro Gly Gly Arg Cys Lys Thr Phe Ser Ala Asp Ala Asp Gly Tyr Ala 1755
- Arg Ala Glu Gly Cys Ala Val Val Leu Lys Arg Leu Ser Asp Ala

1765 1770 1775

- Gln Arg Asp Arg Asp Pro Ile Leu Ala Val Ile Arg Gly Thr Ala Ile 1780 1785 1790
- Asn His Asp Gly Pro Ser Ser Gly Leu Thr Val Pro Ser Gly Pro Ala 1795 1800 1805
- Gln Glu Ala Leu Leu Arg Gln Ala Leu Ala His Ala Gly Val Val Pro 1810 1815 1820
- Ala Asp Val Asp Phe Val Glu Cys His Gly Thr Gly Thr Ala Leu Gly 1825 1830 1835 1840
- Asp Pro Ile Glu Val Arg Ala Leu Ser Asp Val Tyr Gly Gln Ala Arg 1845 1850 1855
- Pro Ala Asp Arg Pro Leu Ile Leu Gly Ala Ala Lys Ala Asn Leu Gly 1860 1865 1870
- His Met Glu Pro Ala Ala Gly Leu Ala Gly Leu Leu Lys Ala Val Leu 1875 1880 1885
- Ala Leu Gly Gln Glu Gln Ile Pro Ala Gln Pro Glu Leu Gly Glu Leu 1890 1895 1900
- Asn Pro Leu Leu Pro Trp Glu Ala Leu Pro Val Ala Val Ala Arg Ala 1905 1910 1915 1920
- Ala Val Pro Trp Pro Arg Thr Asp Arg Pro Arg Phe Ala Gly Val Ser 1925 1930 1935
- Ser Phe Gly Met Ser Gly Thr Asn Ala His Val Val Leu Glu Glu Ala 1940 1945 1950
- Pro Ala Val Glu Leu Trp Pro Ala Ala Pro Glu Arg Ser Ala Glu Leu 1955 1960 1965
- Leu Val Leu Ser Gly Lys Ser Glu Gly Ala Leu Asp Ala Gln Ala Ala 1970 1975 1980
- Arg Leu Arg Glu His Leu Asp Met His Pro Glu Leu Gly Leu Gly Asp 1985 1990 1995 2000
- Val Ala Phe Ser Leu Ala Thr Thr Arg Ser Ala Met Asn His Arg Leu 2005 2010 2015
- Ala Val Ala Val Thr Ser Arg Glu Gly Leu Leu Ala Ala Leu Ser Ala 2020 2025 2030
- Val Ala Gln Gly Gln Thr Pro Pro Gly Ala Ala Arg Cys Ile Ala Ser 2035 2040 2045
- Ser Ser Arg Gly Lys Leu Ala Phe Leu Phe Thr Gly Gln Gly Ala Gln 2050 2055 2060
- Thr Pro Gly Met Gly Arg Gly Leu Cys Ala Ala Trp Pro Ala Phe Arg 2065 2070 2075 2080
- Glu Ala Phe Asp Arg Cys Val Ala Leu Phe Asp Arg Glu Leu Asp Arg 2085 2090 2095
- Pro Leu Arg Glu Val Met Trp Ala Glu Pro Gly Ser Ala Glu Ser Leu 2100 2105 2110

WO 99/66028 PCT/EP99/04171

Leu Leu Asp Gln Thr Ala Phe Thr Gln Pro Ala Leu Phe Thr Val Glu 2115 2120 2125

Tyr Ala Leu Thr Ala Leu Trp Arg Ser Trp Gly Val Glu Pro Glu Leu 2130 2135 2140

Val Ala Gly His Ser Ala Gly Glu Leu Val Ala Ala Cys Val Ala Gly 2145 2150 2155 2160

Val Phe Ser Leu Glu Asp Gly Val Arg Leu Val Ala Ala Arg Gly Arg 2165 2170 2175

Pro Glu Ala Glu Val Ala Ala Ala Val Ala Pro His Ala Ala Ser Val 2195 2200 2205

Ser Ile Ala Ala Val Asn Gly Pro Glu Gln Val Val Ile Ala Gly Val 2210 2215 2220

Glu Gln Ala Val Gln Ala Ile Ala Ala Gly Phe Ala Ala Arg Gly Ala 2225 2230 2235 2240

Arg Thr Lys Arg Leu His Val Ser His Ala Ser His Ser Pro Leu Met 2245 2250 2255

Glu Pro Met Leu Glu Glu Phe Gly Arg Val Ala Ala Ser Val Thr Tyr $2260 \hspace{1.5cm} 2265 \hspace{1.5cm} 2270$

Arg Arg Pro Ser Val Ser Leu Val Ser Asn Leu Ser Gly Lys Val Val 2275 2280 2285

Ala Asp Glu Leu Ser Ala Pro Gly Tyr Trp Val Arg His Val Arg Glu 2290 2295 2300

Ala Val Arg Phe Ala Asp Gly Val Lys Ala Leu His Glu Ala Gly Ala 2305 2310 2315 2320

Gly Thr Phe Val Glu Val Gly Pro Lys Pro Thr Leu Leu Gly Leu Leu 2325 2330 2335

Pro Ala Cys Leu Pro Glu Ala Glu Pro Thr Leu Leu Ala Ser Leu Arg 2340 2345 2350

Ala Gly Arg Glu Glu Ala Ala Gly Val Leu Glu Ala Leu Gly Arg Leu 2355 2360 2365

Trp Ala Ala Gly Gly Ser Val Ser Trp Pro Gly Val Phe Pro Thr Ala 2370 2375 2380

Gly Arg Arg Val Pro Leu Pro Thr Tyr Pro Trp Gln Arg Gln Arg Tyr 2385 2390 2395 2400

Trp Pro Asp Ile Glu Pro Asp Ser Arg Arg His Ala Ala Ala Asp Pro 2405 2410 2415

Thr Gln Gly Trp Phe Tyr Arg Val Asp Trp Pro Glu Ile Pro Arg Ser 2420 2425 2430

Leu Gln Lys Ser Glu Glu Ala Ser Arg Gly Ser Trp Leu Val Leu Ala 2435 2440 2445

Asp Lys Gly Gly Val Gly Glu Ala Val Ala Ala Ala Leu Ser Thr Arg 2450 2455 2460 Gly Leu Pro Cys Val Val Leu His Ala Pro Ala Glu Thr Ser Ala Thr 2465 2470 2475 2480

Ala Glu Leu Val Thr Glu Ala Ala Gly Gly Arg Ser Asp Trp Gln Val 2485 2490 2495

Val Leu Tyr Leu Trp Gly Leu Asp Ala Val Val Gly Ala Glu Ala Ser 2500 2505 2510

Ile Asp Glu Ile Gly Asp Ala Thr Arg Arg Ala Thr Ala Pro Val Leu 2515 2520 2525

Gly Leu Ala Arg Phe Leu Ser Thr Val Ser Cys Ser Pro Arg Leu Trp 2530 2535 2540

Val Val Thr Arg Gly Ala Cys Ile Val Gly Asp Glu Pro Ala Ile Ala 2545 2550 2555 2560

Pro Cys Gln Ala Ala Leu Trp Gly Met Gly Arg Val Ala Ala Leu Glu 2565 2570 2575

His Pro Gly Ala Trp Gly Gly Leu Val Asp Leu Asp Pro Arg Ala Ser 2580 2585 2590

Pro Pro Gln Ala Ser Pro Ile Asp Gly Glu Met Leu Val Thr Glu Leu 2595 2600 2605

Leu Ser Gln Glu Thr Glu Asp Gln Leu Ala Phe Arg His Gly Arg Arg 2610 2615 2620

His Ala Ala Arg Leu Val Ala Ala Pro Pro Gln Gly Gln Ala Ala Pro 2625 2630 2635 2640

Val Ser Leu Ser Ala Glu Ala Ser Tyr Leu Val Thr Gly Gly Leu Gly 2645 2650 2655

Gly Leu Gly Leu Ile Val Ala Gln Trp Leu Val Glu Leu Gly Ala Arg 2660 2665 2670

His Leu Val Leu Thr Ser Arg Arg Gly Leu Pro Asp Arg Gln Ala Trp 2675 2680 2685

Cys Glu Gln Gln Pro Pro Glu Ile Arg Ala Arg Ile Ala Ala Val Glu 2690 2695 2700

Ala Leu Glu Ala Arg Gly Ala Arg Val Thr Val Ala Ala Val Asp Val 2705 2710 2715 2720

Ala Asp Val Glu Pro Met Thr Ala Leu Val Ser Ser Val Glu Pro Pro 2725 2730 2735

Leu Arg Gly Val Val His Ala Ala Gly Val Ser Val Met Arg Pro Leu 2740 2745 2750

Ala Glu Thr Asp Glu Thr Leu Leu Glu Ser Val Leu Arg Pro Lys Val 2755 2760 2765

Ala Gly Ser Trp Leu Leu His Arg Leu Leu His Gly Arg Pro Leu Asp 2770 2780

Leu Phe Val Leu Phe Ser Ser Gly Ala Ala Val Trp Gly Ser His Ser 2785 2790 2795 2800

Gln Gly Ala Tyr Ala Ala Ala Asn Ala Phe Leu Asp Gly Leu Ala His

2805 2810 2815

Leu Arg Arg Ser Gln Ser Leu Pro Ala Leu Ser Val Ala Trp Gly Leu 2820 2825 2830

Trp Ala Glu Gly Gly Met Ala Asp Ala Glu Ala His Ala Arg Leu Ser 2835 2840 2845

Asp Ile Gly Val Leu Pro Met Ser Thr Ser Ala Ala Leu Ser Ala Leu 2850 2855 2860

Gln Arg Leu Val Glu Thr Gly Ala Ala Gln Arg Thr Val Thr Arg Met 2865 2870 2875 2880

Asp Trp Ala Arg Phe Ala Pro Val Tyr Thr Ala Arg Gly Arg Arg Asn 2885 2890 2895

Leu Leu Ser Ala Leu Val Ala Gly Arg Asp Ile Ile Ala Pro Ser Pro 2900 2905 2910

Pro Ala Ala Ala Thr Arg Asn Trp Arg Gly Leu Ser Val Ala Glu Ala 2915 2920 2925

Arg Val Ala Leu His Glu Ile Val His Gly Ala Val Ala Arg Val Leu 2930 2935 2940

Gly Phe Leu Asp Pro Ser Ala Leu Asp Pro Gly Met Gly Phe Asn Glu 2945 2950 2955 2960

Gln Gly Leu Asp Ser Leu Met Ala Val Glu Ile Arg Asn Leu Leu Gln 2965 2970 2975

Ala Glu Leu Asp Val Arg Leu Ser Thr Thr Leu Ala Phe Asp His Pro 2980 2985 2990

Thr Val Gln Arg Leu Val Glu His Leu Leu Val Asp Val Leu Lys Leu 2995 3000 3005

Glu Asp Arg Ser Asp Thr Gln His Val Arg Ser Leu Ala Ser Asp Glu 3010 3015 3020

Pro Iie Ala Ile Val Gly Ala Ala Cys Arg Phe Pro Gly Gly Val Glu 3025 3030 3035 3040

Asp Leu Glu Ser Tyr Trp Gln Leu Leu Ala Glu Gly Val Val Ser 3045 3050 3055

Ala Glu Val Pro Ala Asp Arg Trp Asp Ala Ala Asp Trp Tyr Asp Pro 3060 3065 3070

Asp Pro Glu Ile Pro Gly Arg Thr Tyr Val Thr Lys Gly Ala Phe Leu 3075 3080 3085

Arg Asp Leu Gln Arg Leu Asp Ala Thr Phe Phe Arg Ile Ser Pro Arg 3090 3095 3100

Glu Ala Met Ser Leu Asp Pro Gln Gln Arg Leu Leu Leu Glu Val Ser 3105 3110 3115 3120

Trp Glu Ala Leu Glu Ser Ala Gly Ile Ala Pro Asp Thr Leu Arg Asp 3125 3130 3135

Ser Pro Thr Gly Val Phe Val Gly Ala Gly Pro Asn Glu Tyr Tyr Thr 3140 3145 3150

- Gln Arg Leu Arg Gly Phe Thr Asp Gly Ala Ala Gly Leu Tyr Gly Gly 3155 3160 3165
- Thr Gly Asn Met Leu Ser Val Thr Ala Gly Arg Leu Ser Phe Phe Leu 3170 3175 3180
- Gly Leu His Gly Pro Thr Leu Ala Met Asp Thr Ala Cys Ser Ser Ser 3185 3190 3195 3200
- Leu Val Ala Leu His Leu Ala Cys Gln Ser Leu Arg Leu Gly Glu Cys 3205 3210 3215
- Asp Gln Ala Leu Val Gly Gly Val Asn Val Leu Leu Ala Pro Glu Thr 3220 3225 3230
- Phe Val Leu Leu Ser Arg Met Arg Ala Leu Ser Pro Asp Gly Arg Cys 3235 3240 3245
- Lys Thr Phe Ser Ala Asp Ala Asp Gly Tyr Ala Arg Gly Glu Gly Cys 3250 3255 3260
- Ala Val Val Val Leu Lys Arg Leu Arg Asp Ala Gln Arg Ala Gly Asp 3265 3270 3275 3280
- Ser Ile Leu Ala Leu Ile Arg Gly Ser Ala Val Asn His Asp Gly Pro 3285 3290 3295
- Ser Ser Gly Leu Thr Val Pro Asn Gly Pro Ala Gln Gln Ala Leu Leu 3300 3305 3310
- Arg Gln Ala Leu Ser Gln Ala Gly Val Ser Pro Val Asp Val Asp Phe 3315 3320 3325
- Val Glu Cys His Gly Thr Gly Thr Ala Leu Gly Asp Pro Ile Glu Val 3330 3340
- Leu Val Leu Gly Ala Ala Lys Ala Asn Val Ala His Leu Glu Ala Ala 3365 3370 3375
- Ser Gly Leu Ala Ser Leu Leu Lys Ala Val Leu Ala Leu Arg His Glu 3380 3385 3390
- Gln Ile Pro Ala Gln Pro Glu Leu Gly Glu Leu Asn Pro His Leu Pro 3395 3400 3405
- Trp Asn Thr Leu Pro Val Ala Val Pro Arg Lys Ala Val Pro Trp Gly 3410 3415 3420
- Arg Gly Ala Arg Pro Arg Arg Ala Gly Val Ser Ala Phe Gly Leu Ser 3425 3430 3435 3440
- Gly Thr Asn Val His Val Val Leu Glu Glu Ala Pro Glu Val Glu Pro 3445 3450 3455
- Ala Pro Ala Ala Pro Ala Arg Pro Val Glu Leu Val Val Leu Ser Ala 3460 3465 3470
- Lys Ser Ala Ala Ala Leu Asp Ala Ala Ala Ala Arg Leu Ser Ala His 3475 3480 3485
- Leu Ser Ala His Pro Glu Leu Ser Leu Gly Asp Val Ala Phe Ser Leu 3490 3495 3500

Ala Thr Thr Arg Ser Pro Met Glu His Arg Leu Ala Ile Ala Thr Thr 3505 3510 3515 3520

Ser Arg Glu Ala Leu Arg Gly Ala Leu Asp Ala Ala Ala Gln Gln Lys 3525 3530 3535

Thr Pro Gln Gly Ala Val Arg Gly Lys Ala Val Ser Ser Arg Gly Lys 3540 3545 3550

Leu Ala Phe Leu Phe Thr Gly Gln Gly Ala Gln Met Pro Gly Met Gly 3555 3560 3565

Arg Gly Leu Tyr Glu Thr Trp Pro Ala Phe Arg Glu Ala Phe Asp Arg 3570 3580

Cys Val Ala Leu Phe Asp Arg Glu Ile Asp Gln Pro Leu Arg Glu Val 3585 3590 3595 3600

Met Trp Ala Ala Pro Gly Leu Ala Gln Ala Ala Arg Leu Asp Gln Thr 3605 3610 3615

Ala Tyr Ala Gln Pro Ala Leu Phe Ala Leu Glu Tyr Ala Leu Ala Ala 3620 3625 3630

Leu Trp Arg Ser Trp Gly Val Glu Pro His Val Leu Leu Gly His Ser 3635 3640 3645

Ile Gly Glu Leu Val Ala Ala Cys Val Ala Gly Val Phe Ser Leu Glu 3650 3660

Asp Ala Val Arg Leu Val Ala Ala Arg Gly Arg Leu Met Gln Ala Leu 3665 3670 3680

Pro Ala Gly Gly Ala Met Val Ala Ile Ala Ala Ser Glu Ala Glu Val 3685 3690 3695

Ala Ala Ser Val Ala Pro His Ala Ala Thr Val Ser Ile Ala Ala Val 3700 3705 3710

Asn Gly Pro Asp Ala Val Val Ile Ala Gly Ala Glu Val Gln Val Leu 3715 3720 3725

Ala Leu Gly Ala Thr Phe Ala Ala Arg Gly Ile Arg Thr Lys Arg Leu 3730 3735 3740

Ala Val Ser His Ala Phe His Ser Pro Leu Met Asp Pro Met Leu Glu 3745 3750 3760

Asp Phe Gln Arg Val Ala Ala Thr Ile Ala Tyr Arg Ala Pro Asp Arg 3765 3770 3775

Pro Val Val Ser Asn Val Thr Gly His Val Ala Gly Pro Glu Ile Ala 3780 3785 3790

Thr Pro Glu Tyr Trp Val Arg His Val Arg Ser Ala Val Arg Phe Gly 3795 3800 3805

Asp Gly Ala Lys Ala Leu His Ala Ala Gly Ala Ala Thr Phe Val Glu 3810 3815 3820

Val Gly Pro Lys Pro Val Leu Leu Gly Leu Leu Pro Ala Cys Leu Gly 3825 3830 3835 3840

Glu Ala Asp Ala Val Leu Val Pro Ser Leu Arg Ala Asp Arg Ser Glu

| | | | | | | | | | | | | , | | |
|-----------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|---------------|-------------|-------------|-------------|-------------|-------------|
| | | 3 | 845 | | | | 3 | 850 | | | | 3 | 855 | |
| Cys Glu | | Val 860 | Leu | Ala | Ala | | Gly 865 | Ala | Trp | Tyr | | Trp 870 | Gly | Gly |
| Ala Leu 3 | Asp ' | rrp | Lys | Gly | | Phe 880 | Pro | Asp | Gly | | Arg 1885 | Arg | Val | Ala |
| Leu Pro 3890 | Met ' | Гух | Pro | | Gln 895 | Arg | Glu | Arg | | Trp 900 | Met | Asp | Leu | Thr |
| Pro Arg 3905 | Ser : | Ala | | Pro 910 | Ala | Gly | Ile | | Gly 3915 | Arg | Trp | Pro | | Ala 920 |
| Gly Val | Gly : | | Cys 925 | Met | Pro | Gly | | Val 3930 | Leu | His | His | | Leu 1935 | Ser |
| Ile Gly | | Arg 940 | His | Gln | Pro | | Leu 945 | Gly | Asp | His | | Val 3950 | Phe | Gly |
| Lys Val | Val 3955 | Val | Pro | Gly | | Phe 1960 | His | Val | Ala | | Ile 3965 | Leu | Ser | Ile |
| Ala Ala 3970 | Glu . | Arg | Trp | | Glu 3975 | Arg | Ala | Ile | | Leu 3980 | Thr | Gly | Val | Glu |
| Phe Leu 3985 | Lys | Ala | | Ala 3990 | Met | Glu | Pro | | Gln 3995 | Glu | Val | Glu | | His 1000 |
| Ala Val | Leu | | Pro 1005 | Glu | Ala | Ala | | Asp 4010 | Gly | Tyr | Leu | | Glu 4015 | Leu |
| Ala Thr | | Ala 020 | Ala | Pro | Glu | | Glu 4025 | Arg | Arg | Trp | | Thr 4030 | His | Ala |
| Arg Gly | Arg 4035 | Val | Gln | Pro | | Asp 4040 | Gly | Ala | Pro | | Ala 4045 | Leu | Pro | Arg |
| Leu Glu 4050 | Val | Leu | Glu | | Arg 4055 | Ala | Ile | Gln | | Leu 4060 | | Phe | Ala | Gly |
| Phe Leu 4065 | Asp | Arg | | Ser 4070 | Ala | Val | Arg | | Gly 4075 | Trp | Gly | Pro | Leu | Trp 4080 |
| Arg Trp | Leu | | Asp 4085 | Gly | Arg | Val | | Asp 4090 | | Ala | Ser | | Ala 4095 | Thr |
| Leu Val | | Thr 1100 | | Pro | Asn | | His 4105 | | Val | Ala | Pro | Leu 4110 | | Pro |
| Ile Leu | Leu 4115 | Asp | Asn | Gly | Phe | Ala 4120 | | Ser | Leu | Leu | Ser 4125 | | Arg | Ser |
| Glu Pro 4130 | | Asp | Asp | Gly | Thr 4135 | | Pro | Let | Pro | Phe 4140 | | Val | Glu | Arg |
| Val Arg | Trp | Trp | Arg | Ala 4150 | | Val | . Gly | / Arg | y Val 4155 | Arg | g Cys | Gl) | Gly | Val |

Pro Arg Ser Gln Ala Phe Gly Val Ser Ser Phe Val Leu Val Asp Glu 4165 4170 4175

Thr Gly Glu Val Val Ala Glu Val Glu Gly Phe Val Cys Arg Arg Ala 4180 4185 4190

Pro Arg Glu Val Phe Leu Arg Gln Glu Ser Gly Ala Ser Thr Ala Ala 4195 4200 4205

Leu Tyr Arg Leu Asp Trp Pro Glu Ala Pro Leu Pro Asp Ala Pro Ala 4210 4215 4220

Glu Arg Ile Glu Glu Ser Trp Val Val Val Ala Ala Pro Gly Ser Glu 4225 4230 4235 4240

Met Ala Ala Leu Ala Thr Arg Leu Asn Arg Cys Val Leu Ala Glu 4245 4250 4255

Pro Lys Gly Leu Glu Ala Ala Leu Ala Gly Val Ser Pro Ala Gly Val 4260 4265 4270

11e Cys Leu Trp Glu Ala Gly Ala His Glu Glu Ala Pro Ala Ala Ala
4275 4280 4285

Gln Arg Val Ala Thr Glu Gly Leu Ser Val Val Gln Ala Leu Arg Asp 4290 4295 4300

Arg Ala Val Arg Leu Trp Trp Val Thr Met Gly Ala Val Ala Val Glu 4305 4310 4315 4320

Ala Gly Glu Arg Val Gln Val Ala Thr Ala Pro Val Trp Gly Leu Gly
4325 4330 4335

Arg Thr Val Met Gln Glu Arg Pro Glu Leu Ser Cys Thr Leu Val Asp 4340 4345 4350

Leu Glu Pro Glu Ala Asp Ala Ala Arg Ser Ala Asp Val Leu Leu Arg 4355 4360 4365

Glu Leu Gly Arg Ala Asp Asp Glu Thr Gln Val Ala Phe Arg Ser Gly 4370 4375 4380

Lys Arg Arg Val Ala Arg Leu Val Lys Ala Thr Thr Pro Glu Gly Leu 4385 4390 4395 4400

Leu Val Pro Asp Ala Glu Ser Tyr Arg Leu Glu Ala Gly Gln Lys Gly
4405 4410 4415

Thr Leu Asp Gln Leu Arg Leu Ala Pro Ala Gln Arg Arg Ala Pro Gly
4420 4425 4430

Pro Gly Glu Val Glu Ile Lys Val Thr Ala Ser Gly Leu Asn Phe Arg 4435 4440 4445

Thr Val Leu Ala Val Leu Gly Met Tyr Pro Gly Asp Ala Gly Pro Met 4450 4460

Gly Gly Asp Cys Ala Gly Val Ala Thr Ala Val Gly Gln Gly Val Arg
4465 4470 4475 4480

His Val Ala Val Gly Asp Ala Val Met Thr Leu Gly Thr Leu His Arg 4485 4490 4495

Phe Val Thr Val Asp Ala Arg Leu Val Val Arg Gln Pro Ala Gly Leu 4500 4505 4510

Thr Pro Ala Gln Ala Ala Thr Val Pro Val Ala Phe Leu Thr Ala Trp 4515 4520 4525

Leu Ala Leu His Asp Leu Gly Asn Leu Arg Arg Gly Glu Arg Val Leu 4530 4535 4540 Ile His Ala Ala Ala Gly Gly Val Gly Met Ala Ala Val Gln Ile Ala 4545 4550 4555 4560

Arg Trp Ile Gly Ala Glu Val Phe Ala Thr Ala Ser Pro Ser Lys Trp 4565 4570 4575

Ala Ala Val Gln Ala Met Gly Val Pro Arg Thr His Ile Ala Ser Ser 4580 4585 4590

Arg Thr Leu Glu Phe Ala Glu Thr Phe Arg Gln Val Thr Gly Gly Arg 4595 4600 4605

Gly Val Asp Val Val Leu Asn Ala Leu Ala Gly Glu Phe Val Asp Ala 4610 4615 4620

Ser Leu Ser Leu Leu Ser Thr Gly Gly Arg Phe Leu Glu Met Gly Lys 4625 4630 4635 4640

Thr Asp Ile Arg Asp Arg Ala Ala Val Ala Ala Ala His Pro Gly Val
4645 4650 4655

Arg Tyr Arg Val Phe Asp Ile Leu Glu Leu Ala Pro Asp Arg Thr Arg 4660 4665 4670

Glu Ile Leu Glu Arg Val Val Glu Gly Phe Ala Ala Gly His Leu Arg 4675 4680 4685

Ala Leu Pro Val His Ala Phe Ala Ile Thr Lys Ala Glu Ala Ala Phe 4690 4695 4700

Arg Phe Met Ala Gln Ala Arg His Gln Gly Lys Val Val Leu Leu Pro 4705 4710 4715 4720

Ala Pro Ser Ala Ala Pro Leu Ala Pro Thr Gly Thr Val Leu Leu Thr
4725 4730 4735

Gly Gly Leu Gly Ala Leu Gly Leu His Val Ala Arg Trp Leu Ala Gln 4740 4745 4750

Gln Gly Val Pro His Met Val Leu Thr Gly Arg Arg Gly Leu Asp Thr 4755 4760 4765

Pro Gly Ala Ala Lys Ala Val Ala Glu Ile Glu Ala Leu Gly Ala Arg 4770 4780

Val Thr Ile Ala Ala Ser Asp Val Ala Asp Arg Asn Ala Leu Glu Ala 4785 4790 4795 4800

Val Leu Gln Ala Ile Pro Ala Glu Trp Pro Leu Gln Gly Val Ile His 4805 4810 4815

Ala Ala Gly Ala Leu Asp Asp Gly Val Leu Asp Glu Gln Thr Thr Asp 4820 4825 4830

Arg Phe Ser Arg Val Leu Ala Pro Lys Val Thr Gly Ala Trp Asn Leu 4835 4840 4845

His Glu Leu Thr Ala Gly Asn Asp Leu Ala Phe Phe Val Leu Phe Ser 4850 4855 4860

Ser Met Ser Gly Leu Leu Gly Ser Ala Gly Gln Ser Asn Tyr Ala Ala 4865 4870 4875 4880

Ala Asn Thr Phe Leu Asp Ala Leu Ala Ala His Arg Arg Ala Glu Gly

| | | | 4 | 1885 | | | | 4 | 890 | | | | 4 | 895 | |
|-------------|-------------|-------------|-------------|---------------|-------------|-------------|-------------|-------------|-------------|-------------|---------------|-------------|-------------|-------------|-------------|
| Leu | Ala | | Gln 900 | Ser | Leu | Ala | | Gly 905 | Pro | Trp | Ser | | Gly 910 | Gly | Met |
| Ala | | Gly 1915 | Leu | Ser | Ala | | Leu 1920 | Gln | Ala | Arg | | Ala 1925 | Arg | His | Gly |
| | Gly 930 | Ala | Leu | Ser | | Ala 935 | Gln | Gly | Thr | | Leu 940 | Leu | Gly | Gln | Ala |
| Leu 4945 | | Arg | Pro | Glu 4 | Thr 1950 | Gln | Leu | Gly | | Met 955 | Ser | Leu | Asp | | Arg 1960 |
| Ala | Ala | Ser | | Ala 1965 | Ser | Gly | Ala | | Val 1970 | Pro | Pro | Val | | Arg 1975 | Ala |
| Leu | Val | | Ala 980 | Glu | Ala | Arg | | Thr 1985 | Ala | Ala | Gly | | Gln 1990 | Gly | Ala |
| Leu | | Ala 1995 | Arg | Leu | Gly | | Leu 5000 | Pro | Glu | Ala | | Arg 5005 | Ala | Asp | Glu |
| | Arg 010 | Lys | Val | Val | | Ala 015 | Glu | Ile | Ala | | Val 5020 | Leu | Ser | Trp | Ser |
| Ala 5025 | | Ser | Ala | Val | Pro 5030 | Val | Asp | Arg | | Leu 5035 | Ser | Asp | Leu | | Leu 5040 |
| Asp | Ser | Leu | | Ala 5045 | Val | Glu | Leu | | Asn 5050 | Val | Leu | Gly | | Arg 5055 | Val |
| Gly | Ala | | Leu 5060 | Pro | Ala | Thr | | Ala 5065 | Phe | Asp | His | | Thr 5070 | Val | qzA |
| Ala | | Thr 5075 | Arg | Trp | Leu | | 4sp 080 | Lys | Val | Leu | | Val 5085 | Ala | Glu | Pro |
| | Val 090 | Ser | Ser | Ala | | Ser 5095 | Ser | Pro | Gln | | Ala 5100 | Leu | Asp | Glu | Pro |
| Ile 5105 | | Ile | Ile | Gly | Ile 5110 | Gly | Cys | Arg | | Pro 5115 | Gly | Gly | Val | | Asp 5120 |
| Pro | Glu | Ser | | Trp 5125 | Arg | Leu | Leu | | Glu 5130 | Gly | Ser | Asp | | Val 5135 | Val |
| Glu | Val | | His 5140 | Glu | Arg | Trp | Asp | 11e 5145 | | Ala | Phe | Tyr | Asp 5150 | | Asp |
| Pro | Asp | Val 5155 | | Gly | Lys | Met | Thr 5160 | | Árg | Phe | Gly | Gly 5165 | | Leu | Ser |
| _ | 11e 5170 | | Arg | Phe | Asp | Pro 5175 | | Phe | Phe | Gly | 7 Ile 5180 | | Pro | Arg | Glu |
| Ala 518 | | Thr | Met | . Asp | 9rc 5190 | | ı Glr | ı Arg | Leu | Leu 5195 | | ı Glu | Thr | Ser | Trp 5200 |
| Glu | Ala | Phe | Glu | 1 Arg 5205 | | Gly | / Ile | e Leu | Pro 5210 | | ı Arç | j Leu | Met | Gly 5215 | |

Asp Thr Gly Val Phe Val Gly Leu Phe Tyr Gln Glu Tyr Ala Ala Leu 5220 5235 5230

- Ala Gly Gly Ile Glu Ala Phe Asp Gly Tyr Leu Gly Thr Gly Thr Thr 5235 5240 5245
- Ala Ser Val Ala Ser Gly Arg Ile Ser Tyr Val Leu Gly Leu Lys Gly 5250 5255 5260
- Pro Ser Leu Thr Val Asp Thr Ala Cys Ser Ser Ser Leu Val Ala Val 5265 5270 5275 5280
- His Leu Ala Cys Gln Ala Leu Arg Gly Glu Cys Ser Val Ala Leu 5285 5290 5295
- Ala Gly Gly Val Ala Leu Met Leu Thr Pro Ala Thr Phe Val Glu Phe 5300 5305 5310
- Ser Arg Leu Arg Gly Leu Ala Pro Asp Gly Arg Cys Lys Ser Phe Ser 5315 5320 5325
- Ala Ala Asp Gly Val Gly Trp Ser Glu Gly Cys Ala Met Leu Leu 5330 5335 5340
- Leu Lys Pro Leu Arg Asp Ala Gln Arg Asp Gly Asp Pro Ile Leu Ala 5345 5350 5360
- Val Ile Arg Gly Thr Ala Val Asn Gln Asp Gly Arg Ser Asn Gly Leu 5365 5370 5375
- Thr Ala Pro Asn Gly Ser Ser Gln Gln Glu Val Ile Arg Arg Ala Leu 5380 5385 5390
- Glu Gln Ala Gly Leu Ala Pro Ala Asp Val Ser Tyr Val Glu Cys His 5395 5400 5405
- Gly Thr Gly Thr Thr Leu Gly Asp Pro Ile Glu Val Gln Ala Leu Gly 5410 5415 5420
- Ala Val Leu Ala Gln Gly Arg Pro Ser Asp Arg Pro Leu Val Ile Gly 5425 5430 5435 5440
- Ser Val Lys Ser Asn Ile Gly His Thr Gln Ala Ala Gly Val Ala 5445 5450 5455
- Gly Val Ile Lys Val Ala Leu Ala Leu Glu Arg Gly Leu Ile Pro Arg 5460 5465 5470
- Ser Leu His Phe Asp Ala Pro Asn Pro His Ile Pro Trp Ser Glu Leu 5475 5480 5485
- Ala Val Gl
n Val Ala Ala Lys Pro Val Glu Tr
p Thr Arg Asn Gly Val5490 5495 5500
- Pro Arg Arg Ala Gly Val Ser Ser Phe Gly Val Ser Gly Thr Asn Ala 5505 5510 5520
- His Val Val Leu Glu Glu Ala Pro Ala Ala Ala Phe Ala Pro Ala Ala 5525 5530 5535
- Ala Arg Ser Ala Glu Leu Phe Val Leu Ser Ala Lys Ser Ala Ala Ala 5540 5545 5550
- Leu Asp Ala Gln Ala Ala Arg Leu Ser Ala His Val Val Ala His Pro 5555 5560 5565
- Glu Leu Gly Leu Gly Asp Leu Ala Phe Ser Leu Ala Thr Thr Arg Ser 5570 5580

- Pro Met Thr Tyr Arg Leu Ala Val Ala Ala Thr Ser Arg Glu Ala Leu 5585 5590 5595 5600
- Ser Ala Ala Leu Asp Thr Ala Ala Gln Gly Gln Ala Pro Pro Ala Ala 5605 5610 5615
- Phe Pro Gly Gln Gly Ser Gln Trp Leu Gly Met Gly Gln Lys Leu Leu 5635 5640 5645
- Ser Glu Glu Pro Val Phe Arg Asp Ala Leu Ser Ala Cys Asp Arg Ala 5650 5655 5660
- Ile Gln Ala Glu Ala Gly Trp Ser Leu Leu Ala Glu Leu Ala Ala Asp 5665 5670 5675 5680
- Glu Thr Thr Ser Gln Leu Gly Arg Ile Asp Val Val Gln Pro Ala Leu 5685 5690 5695
- Phe Ala Ile Glu Val Ala Leu Ser Ala Leu Trp Arg Ser Trp Gly Val 5700 5705 5710
- Glu Pro Asp Ala Val Val Gly His Ser Met Gly Glu Val Ala Ala Ala 5715 5720 5725
- His Val Ala Gly Ala Leu Ser Leu Glu Asp Ala Val Ala Ile Ile Cys 5730 5740
- Arg Arg Ser Leu Leu Leu Arg Arg Ile Ser Gly Gln Gly Glu Met Ala 5745 5750 5755 5760
- Val Val Glu Leu Ser Leu Ala Glu Ala Glu Ala Leu Leu Gly Tyr 5765 5770 5775
- Glu Asp Arg Leu Ser Val Ala Val Ser Asn Ser Pro Arg Ser Thr Val 5780 5785 5790
- Leu Ala Gly Glu Pro Ala Ala Leu Ala Glu Val Leu Ala Ile Leu Ala 5795 5800 5805
- Ala Lys Gly Val Phe Cys Arg Arg Val Lys Val Asp Val Ala Ser His 5810 5815 5820
- Ser Pro Gln Ile Asp Pro Leu Arg Asp Glu Leu Leu Ala Ala Leu Gly 5825 5830 5840
- Glu Leu Glu Pro Arg Gln Ala Thr Val Ser Met Arg Ser Thr Val Thr 5845 5850 5855
- Ser Thr Ile Met Ala Gly Pro Glu Leu Val Ala Ser Tyr Trp Ala Asp 5860 5865 5870
- Asn Val Arg Gln Pro Val Arg Phe Ala Glu Ala Val Gln Ser Leu Met 5875 5880 5885
- Glu Asp Gly His Gly Leu Phe Val Glu Met Ser Pro His Pro Ile Leu 5890 5895 5900
- Thr Thr Ser Val Glu Glu Ile Arg Arg Ala Thr Lys Arg Glu Gly Val 5905 5910 5915 5920
- Ala Val Gly Ser Leu Arg Arg Gly Gln Asp Glu Arg Leu Ser Met Leu

5925 5930 5935

Glu Ala Leu Gly Ala Leu Trp Val His Gly Gln Ala Val Gly Trp Glu 5940 5945 5950

Arg Leu Phe Ser Ala Gly Gly Ala Gly Leu Arg Arg Val Pro Leu Pro 5955 5960 5965

Thr Tyr Pro Trp Gln Arg Glu Arg Tyr Trp Val Asp Ala Pro Thr Gly 5970 5980

Gly Ala Ala Gly Gly Ser Arg Phe Ala His Ala Gly Ser His Pro Leu 5985 5990 5995 6000

Leu Gly Glu Met Gln Thr Leu Ser Thr Gln Arg Ser Thr Arg Val Trp 6005 6010 6015

Glu Thr Thr Leu Asp Leu Lys Arg Leu Pro Trp Leu Gly Asp His Arg 6020 6030

Val Gln Gly Ala Val Val Phe Pro Gly Ala Ala Tyr Leu Glu Met Ala 6035 6040 6045

Leu Ser Ser Gly Ala Glu Ala Leu Gly Asp Gly Pro Leu Gln Val Ser 6050 6055 6060

Asp Val Val Leu Ala Glu Ala Leu Ala Phe Ala Asp Asp Thr Pro Ala 6065 6070 6075 6080

Ala Val Gln Val Met Ala Thr Glu Glu Arg Pro Gly Arg Leu Gln Phe 6085 6090 6095

His Val Ala Ser Arg Val Pro Gly His Gly Gly Ala Ala Phe Arg Ser 6100 6105 6110

His Ala Arg Gly Val Leu Arg Gln Ile Glu Arg Ala Glu Val Pro Ala 6115 6120 6125

Arg Leu Asp Leu Ala Ala Leu Arg Ala Arg Leu Gln Ala Ser Ala Pro 6130 6135 6140

Ala Ala Ala Thr Tyr Ala Ala Leu Ala Glu Met Gly Leu Glu Tyr Gly 6145 6150 6155 6160

Pro Ala Phe Gln Gly Leu Val Glu Leu Trp Arg Gly Glu Gly Glu Ala 6165 6170 6175

Leu Gly Arg Val Arg Leu Pro Glu Ala Ala Gly Ser Pro Ala Ala Cys 6180 6185 6190

Arg Leu His Pro Ala Leu Leu Asp Ala Cys Phe His Val Ser Ser Ala 6195 6200 6205

Phe Ala Asp Arg Gly Glu Ala Thr Pro Trp Val Pro Val Glu Ile Gly 6210 6220

Ser Leu Arg Trp Phe Gln Arg Pro Ser Gly Glu Leu Trp Cys His Ala 6225 6230 6235 6240

Arg Ser Val Ser His Gly Lys Pro Thr Pro Asp Arg Arg Ser Thr Asp 6245 6250 6255

Phe Trp Val Val Asp Ser Thr Gly Ala Ile Val Ala Glu Ile Ser Gly 6260 6265 6270

- Leu Val Ala Gln Arg Leu Ala Gly Gly Val Arg Arg Arg Glu Glu Asp 6280
- Asp Trp Phe Met Glu Pro Ala Trp Glu Pro Thr Ala Val Pro Gly Ser 6295
- Glu Val Met Ala Gly Arg Trp Leu Leu Ile Gly Ser Gly Gly Leu 6305
- Gly Ala Ala Leu His Ser Ala Leu Thr Glu Ala Gly His Ser Val Val 6325 6330
- His Ala Thr Gly Arg Gly Thr Ser Ala Ala Gly Leu Gln Ala Leu Leu 6345
- Thr Ala Ser Phe Asp Gly Gln Ala Pro Thr Ser Val Val His Leu Gly 6360
- Ser Leu Asp Glu Arg Gly Val Leu Asp Ala Asp Ala Pro Phe Asp Ala 6370 6380
- Asp Ala Leu Glu Glu Ser Leu Val Arg Gly Cys Asp Ser Val Leu Trp
- Thr Val Gln Ala Val Ala Gly Ala Gly Phe Arg Asp Pro Pro Arg Leu 6410
- Trp Leu Val Thr Arg Gly Ala Gln Ala Ile Gly Ala Gly Asp Val Ser
- Val Ala Gln Ala Pro Leu Leu Gly Leu Gly Arg Val Ile Ala Leu Glu 6440
- His Ala Glu Leu Arg Cys Ala Arg Ile Asp Leu Asp Pro Ala Arg Arg 6455
- Asp Gly Glu Val Asp Glu Leu Leu Ala Glu Leu Leu Ala Asp Asp Ala
- Glu Glu Glu Val Ala Phe Arg Gly Gly Glu Arg Arg Val Ala Arg Leu 6490
- Val Arg Arg Leu Pro Glu Thr Asp Cys Arg Glu Lys Ile Glu Pro Ala 6505
- Glu Gly Arg Pro Phe Arg Leu Glu Ile Asp Gly Ser Gly Val Leu Asp 6520
- Asp Leu Val Leu Arg Ala Thr Glu Arg Arg Pro Pro Gly Pro Gly Glu 6535
- Val Glu Ile Ala Val Glu Ala Ala Gly Leu Asn Phe Leu Asp Val Met 6550 6545
- Arg Ala Met Gly Ile Tyr Pro Gly Pro Gly Asp Gly Pro Val Ala Leu
- Gly Ala Glu Cys Ser Gly Arg Ile Val Ala Met Gly Glu Gly Val Glu 6585
- Ser Leu Arg Ile Gly Gln Asp Val Val Ala Val Ala Pro Phe Ser Phe
- Gly Thr His Val Thr Ile Asp Ala Arg Met Leu Ala Pro Arg Pro Ala 6620

- Ala Leu Thr Ala Ala Gln Ala Ala Ala Leu Pro Val Ala Phe Met Thr 6625 6630 6635 6640
- Ala Trp Tyr Gly Leu Val His Leu Gly Arg Leu Arg Ala Gly Glu Arg 6645 6650 6655
- Val Leu Ile His Ser Ala Thr Gly Gly Thr Gly Leu Ala Ala Val Gln 6660 6665 6670
- Ile Ala Arg His Leu Gly Ala Glu Ile Phe Ala Thr Ala Gly Thr Pro 6675 6680 6685
- Glu Lys Arg Ala Trp Leu Arg Glu Gln Gly Ile Ala His Val Met Asp 6690 6695 6700
- Ser Arg Ser Leu Asp Phe Ala Glu Gln Val Leu Ala Ala Thr Lys Gly 6705 6710 6715 6720
- Glu Gly Val Asp Val Val Leu Asn Ser Leu Ser Gly Ala Ala Ile Asp 6725 6730 6735
- Ala Ser Leu Ser Thr Leu Val Pro Asp Gly Arg Phe Ile Glu Leu Gly
 6740 6745 6750
- Lys Thr Asp Ile Tyr Ala Asp Arg Ser Leu Gly Leu Ala His Phe Arg 6755 6760 6765
- Lys Ser Leu Ser Tyr Ser Ala Val Asp Leu Ala Gly Leu Ala Val Arg 6770 6775 6780
- Arg Pro Glu Arg Val Ala Ala Leu Leu Ala Glu Val Val Asp Leu Leu 6785 6790 6795 6800
- Ala Arg Gly Ala Leu Gln Pro Leu Pro Val Glu Ile Phe Pro Leu Ser 6805 6810 6815
- Arg Ala Ala Asp Ala Phe Arg Lys Met Ala Gln Ala Gln His Leu Gly 6820 6830
- Lys Leu Val Leu Ala Leu Glu Asp Pro Asp Val Arg Ile Arg Val Pro 6835 6840 6845
- Gly Glu Ser Gly Val Ala Ile Arg Ala Asp Gly Ala Tyr Leu Val Thr 6850 6860
- Gly Gly Leu Gly Gly Leu Gly Leu Ser Val Ala Gly Trp Leu Ala Glu 6865 6870 6875 6880
- Gln Gly Ala Gly His Leu Val Leu Val Gly Arg Ser Gly Ala Val Ser 6885 6890 6895
- Ala Glu Gln Gln Thr Ala Val Ala Ala Leu Glu Ala His Gly Ala Arg 6900 6905 6910
- Val Thr Val Ala Arg Ala Asp Val Ala Asp Arg Ala Gln Met Glu Arg 6915 6920 6925
- Ile Leu Arg Glu Val Thr Ala Ser Gly Met Pro Leu Arg Gly Val Val 6930 6935 6940
- His Ala Ala Gly Ile Leu Asp Asp Gly Leu Leu Met Gln Gln Thr Pro 6945 6950 6955 6960
- Ala Arg Phe Arg Ala Val Met Ala Pro Lys Val Arg Gly Ala Leu His

6965 6970 6975

Leu His Ala Leu Thr Arg Glu Ala Pro Leu Ser Phe Phe Val Leu Tyr

Ala Ser Gly Ala Gly Leu Leu Gly Ser Pro Gly Gln Gly Asn Tyr Ala 6995 7000 7005

Ala Ala Asn Thr Phe Leu Asp Ala Leu Ala His His Arg Arg Ala Gln 7010 7015 7020

Gly Leu Pro Ala Leu Ser Ile Asp Trp Gly Leu Phe Ala Asp Val Gly 7025 7030 7035 7040

Leu Ala Ala Gly Gln Gln Asn Arg Gly Ala Arg Leu Val Thr Arg Gly 7045 7050 7055

Thr Arg Ser Leu Thr Pro Asp Glu Gly Leu Trp Ala Leu Glu Arg Leu 7060 7065 7070

Leu Asp Gly Asp Arg Thr Gln Ala Gly Val Met Pro Phe Asp Val Arg 7075 7080 7085

Gln Trp Val Glu Phe Tyr Pro Ala Ala Ala Ser Ser Arg Arg Leu Ser 7090 7095 7100

Arg Leu Met Thr Ala Arg Arg Val Ala Ser Gly Arg Leu Ala Gly Asp 7105 7110 7115 7120

Arg Asp Leu Leu Glu Arg Leu Ala Thr Ala Glu Ala Gly Ala Arg Ala 7125 7130 7135

Gly Met Leu Gln Glu Val Val Arg Ala Gln Val Ser Gln Val Leu Arg 7140 7145 7150

Leu Ser Glu Gly Lys Leu Asp Val Asp Ala Pro Leu Thr Ser Leu Gly $7155 \hspace{1cm} 7160 \hspace{1cm} 7165$

Met Asp Ser Leu Met Gly Leu Glu Leu Arg Asn Arg Ile Glu Ala Val7170 7175 7180

Leu Gly Ile Thr Met Pro Ala Thr Leu Leu Trp Thr Tyr Pro Thr Val 7185 7190 7195 7200

Ala Ala Leu Ser Ala His Leu Ala Ser His Val Val Ser Thr Gly Asp
7205 7210 7215

Gly Glu Ser Ala Arg Pro Pro Asp Thr Gly Ser Val Ala Pro Thr Thr 7220 7225 7230

His Glu Val Ala Ser Leu Asp Glu Asp Gly Leu Phe Ala Leu Ile Asp 7235 7240 7245

Glu Ser Leu Ala Arg Ala Gly Lys Arg 7250 7255

<210> 6

<211> 3798

<212> PRT

<213> Sorangium cellulosum

<400> 6

Val Thr Asp Arg Glu Gly Gln Leu Leu Glu Arg Leu Arg Glu Val Thr

Leu Ala Leu Arg Lys Thr Leu Asn Glu Arg Asp Thr Leu Glu Leu Glu 20 25 30Lys Thr Glu Pro Ile Ala Ile Val Gly Ile Gly Cys Arg Phe Pro Gly 35 40 45 Gly Ala Gly Thr Pro Glu Ala Phe Trp Glu Leu Leu Asp Asp Gly Arg Asp Ala Ile Arg Pro Leu Glu Glu Arg Trp Ala Leu Val Gly Val Asp 65 70 75 80 Pro Gly Asp Asp Val Pro Arg Trp Ala Gly Leu Leu Thr Glu Ala Ile $85 \hspace{1.5cm} 90 \hspace{1.5cm} 95$ Asp Gly Phe Asp Ala Ala Phe Phe Gly Ile Ala Pro Arg Glu Ala Arg 100 105 110 Ser Leu Asp Pro Gln His Arg Leu Leu Leu Glu Val Ala Trp Glu Gly Phe Glu Asp Ala Gly Ile Pro Pro Arg Ser Leu Val Gly Ser Arg Thr 130 135 140 Gly Val Phe Val Gly Val Cys Ala Thr Glu Tyr Leu His Ala Ala Val 145 $$ 150 $$ 155 $$ 160 Ala His Gln Pro Arg Glu Glu Arg Asp Ala Tyr Ser Thr Thr Gly Asn 165 170 175Met Leu Ser Ile Ala Ala Gly Arg Leu Ser Tyr Thr Leu Gly Leu Gln
180 185 190 Gly Pro Cys Leu Thr Val Asp Thr Ala Cys Ser Ser Ser Leu Val Ala Ile His Leu Ala Cys Arg Ser Leu Arg Ala Arg Glu Ser Asp Leu Ala 210 215 220 Leu Ala Gly Gly Val Asn Met Leu Leu Ser Pro Asp Thr Met Arg Ala Leu Ala Arg Thr Gln Ala Leu Ser Pro Asn Gly Arg Cys Gln Thr Phe Asp Ala Ser Ala Asn Gly Phe Val Arg Gly Glu Gly Cys Gly Leu Ile 260 265 270 Val Leu Lys Arg Leu Ser Asp Ala Arg Arg Asp Gly Asp Arg Ile Trp Ala Leu Ile Arg Gly Ser Ala Ile Asn Gln Asp Gly Arg Ser Thr Gly 290 295 300 Leu Thr Ala Pro Asn Val Leu Ala Gln Gly Ala Leu Leu Arg Glu Ala Leu Arg Asn Ala Gly Val Glu Ala Glu Ala Ile Gly Tyr Ile Glu Thr 325 330 335 His Gly Ala Ala Thr Ser Leu Gly Asp Pro Ile Glu Ile Glu Ala Leu Arg Ala Val Val Gly Pro Ala Arg Ala Asp Gly Ala Arg Cys Val Leu

| | | 355 | | | | | 360 | | | | | 365 | | | |
|------------|--------------------|------------|------------|------------|------------|------------|------------|-------------------|------------|------------|------------|------------|------------|------------|------------|
| Gly | Ala 370 | Va1 | Lys | Thr | Asn | Leu 375 | Gly | His | Leu | Glu | Gly 380 | Ala | Ala | Gly | Val |
| Ala 385 | Gly | Leu | Ile | Lys | Ala 390 | Thr | Leu | Ser | Leu | His 395 | His | Glu | Arg | Ile | Pro 400 |
| Arg | Asn | Leu | Asn | Phe 405 | Arg | Thr | Leu | Asn | Pro 410 | Arg | Ile | Arg | Ile | Glu 415 | Gly |
| Thr | Ala | Leu | Ala 420 | Leu | Ala | Thr | Glu | Pro 425 | Val | Pro | Trp | Pro | Arg 430 | Thr | Gly |
| Arg | Thr | Arg 435 | Phe | Ala | Gly | Val | Ser 440 | Ser | Phe | Gly | Met | Ser 445 | Gly | Thr | Asn |
| Ala | His 4 50 | Val | Val | Leu | Glu | Glu 455 | Ala | Pro | Ala | Val | Glu 460 | Pro | Glu | Ala | Ala |
| Ala 465 | Pro | Glu | Arg | Ala | Ala 470 | Glu | Leu | Phe | Val | Leu 475 | Ser | Ala | Lys | Ser | Ala 480 |
| Ala | Ala | Leu | Asp | Ala 485 | Gln | Ala | Ala | Arg | Leu 490 | Arg | Asp | His | Leu | Glu 495 | Lys |
| His | Val | Glu | Leu 500 | Gly | Leu | Gly | Asp | Val 505 | Ala | Phe | Ser | Leu | Ala 510 | Thr | Thr |
| Arg | Ser | Ala 515 | Met | Glu | His | Arg | Leu 520 | Ala | Val | Ala | Ala | Ser 525 | Ser | Arg | Glu |
| Ala | Leu 530 | Arg | Gly | Ala | Leu | Ser 535 | Ala | Ala | Ala | Gln | Gly 540 | His | Thr | Pro | Pro |
| Gly 545 | Ala | Val | Arg | Gly | Arg 550 | Ala | Ser | Gly | Gly | Ser 555 | Ala | Pro | Lys | Val | Val 560 |
| Phe | Val | Phe | Pro | Gly 565 | Gln | Gly | Ser | Gln | Trp 570 | | Gly | Met | GŢĀ | Arg 575 | Lys |
| Leu | Met | Ala | Glu 580 | Glu | Pro | Val | Phe | Arg 585 | Ala | Ala | Leu | Glu | Gly 590 | Cys | Asp |
| Arg | Ala | Ile 595 | Glu | Ala | Glu | Ala | Gly 600 | Trp | Ser | Leu | Leu | Gly 605 | Glu | Leu | Ser |
| Ala | Asp 610 | | Ala | Ala | Ser | Gln 615 | Leu | Gly | Arg | Ile | Asp 620 | | Val | Gln | Pro |
| Val 625 | | . Phe | Ala | Met | Glu 630 | | Ala | Leu | Ser | Ala 635 | | Trp | Arg | Ser | Tr: 640 |
| Gly | Val | Glu | Pro | G1u 645 | | . Val | . Val | Gly | His 650 | | Met | Gly | Glu | Val 655 | Ala |
| Ala | Ala | His | Val 660 | | Gly | Ala | Leu | Ser 665 | | ı Glu | Asp | Ala | 670 | Ala | 110 |
| Ile | Cys | 675 | | ser | Arg | Leu | 680 | | Arg | ; Ile | e Ser | Gly 685 | Glr. | Gly | Gl: |
| Met | Ala 690 | | ı Val | . Glu | Leu | Ser 695 | c Lev | Glu | ı Glı | ı Ala | Gli 700 | | Ala | Lev | Ar |

| Gly 705 | His | Glu | Gly | Arg | Leu 710 | Ser | Val | Ala | Val | Ser 715 | Asn | Ser | Pro | Arg | Ser 720 |
|------------|-------------|------------|------------|-------------|--------------------|-------------|-------------|------------|------------|-------------|-------------|-------------|------------|-------------|-------------|
| Thr | Val | Leu | Ala | Gly 725 | Glu | Pro | Ala | Ala | Leu 730 | Ser | Glu | Val | Leu | Ala 735 | Ala |
| Leu | Thr | Ala | Lys 740 | Gly | Val | Phe | Trp | Arg 745 | Gln | Val | Lys | Val | Asp 750 | Val | Ala |
| Ser | His | Ser 755 | Pro | Gln | Val | Asp | Pro 760 | Leu | Arg | Glu | Glu | Leu 765 | Ile | Ala | Ala |
| Leu | Gly 770 | Ala | Ile | Arg | Pro | Arg 775 | Ala | Ala | Ala | Val | Pro 780 | Met | Arg | Ser | Thr |
| Val 785 | Thr | Gly | Gly | Val | Ile 790 | Ala | Gly | Pro | Glu | Leu 795 | Gly | Ala | Ser | Tyr | Trp 800 |
| Ala | Asp | Asn | Leu | Arg 805 | Gln | Pro | Val | Arg | Phe 810 | Ala | Ala | Ala | Ala | Gln 815 | Ala |
| Leu | Leu | Glu | Gly 820 | Gly | Pro | Ala | Leu | Phe 825 | Ile | Glu | Met | Ser | Pro 830 | His | Pro |
| Ile | Leu | Val 835 | Pro | Pro | Leu | qzA | Glu 840 | Ile | Gln | Thr | Ala | Ala 845 | Glu | Gln | Gly |
| Gly | Ala 850 | Ala | Val | Gly | Ser | Leu 855 | Arg | Arg | Gly | Gln | Asp 860 | Glu | Arg | Ala | Thr |
| Leu 865 | Leu | Glu | Ala | Leu | Gly 870 | Thr | Leu | Trp | Ala | Ser 875 | Gly | Tyr | Pro | Val | Ser 880 |
| Trp | Ala | Arg | Leu | Phe 885 | Pro | Ala | Gly | Gly | Arg 890 | Arg | Val | Pro | Leu | Pro 895 | Thr |
| Tyr | Pro | Trp | Gln 900 | His | Glu | Arg | Cys | Trp 905 | Ile | Glu | Val | Glu | Pro 910 | Asp | Ala |
| Arg | Arg | Leu 915 | Ala | Ala | Ala | Asp | Pro 920 | Thr | Lys | Asp | Trp | Phe 925 | Tyr | Arg | Thr |
| Asp | Trp 930 | Pro | Glu | Val | Pro | Arg 935 | Ala | Ala | Pro | Lys | Ser 940 | Glu | Thr | Ala | His |
| Gly 945 | Ser | Trp | Leu | Leu | Leu 9 50 | Ala | Asp | Arg | Gly | Gly 955 | Val | Gly | Glu | Ala | Val 960 |
| Ala | Ala | Ala | Leu | Ser 965 | Thr | Arg | Gly | Leu | Ser 970 | Cys | Thr | Val | Leu | His 975 | Ala |
| Ser | Ala | Asp | Ala 980 | | Thr | Val | Ala | Glu 985 | | Val | Ser | Glu | Ala 990 | | Ser |
| Arg | Arg | Asn 995 | | Trp | Gln | Gly | Val 1000 | | Tyr | Leu | Trp | Gly 1005 | | Asp | Ala |
| Val | Val 1010 | | Ala | Gly | Ala | Ser 1015 | | Asp | Glu | Val | Ser 1020 | | Ala | Thr | Arg |
| Arg 102 | | Thr | Ala | Pro | Val 1030 | Lev | Gly | Leu | Val | Arg 1035 | | Leu | Ser | | Ala 1040 |
| Pro | His | Pro | Pro | Arg 1045 | | Tr | Val | . Val | Thr | | g Gly | Ala | Cys | Thr 1055 | |

- Gly Glu Pro Glu Ala Ser Leu Cys Gln Ala Ala Leu Trp Gly Leu
- Ala Arg Val Ala Ala Leu Glu His Pro Ala Ala Trp Gly Gly Leu Val 1080 1085
- Asp Leu Asp Pro Gln Lys Ser Pro Thr Glu Ile Glu Pro Leu Val Ala 1095
- Glu Leu Leu Ser Pro Asp Ala Glu Asp Gln Leu Ala Phe Arg Ser Gly 1110
- Arg Arg His Ala Ala Arg Leu Val Ala Ala Pro Pro Glu Gly Asp Val 1130
- Ala Pro Ile Ser Leu Ser Ala Glu Gly Ser Tyr Leu Val Thr Gly Gly 1145
- Leu Gly Gly Leu Gly Leu Leu Val Ala Arg Trp Leu Val Glu Arg Gly
- Ala Arg His Leu Val Leu Thr Ser Arg His Gly Leu Pro Glu Arg Gln 1175
- Ala Ser Gly Gly Glu Gln Pro Pro Glu Ala Arg Ala Arg Ile Ala Ala 1190
- Val Glu Gly Leu Glu Ala Gln Gly Ala Arg Val Thr Val Ala Ala Val
- Asp Val Ala Glu Ala Asp Pro Met Thr Ala Leu Leu Ala Ala Ile Glu 1225
- Pro Pro Leu Arg Gly Val Val His Ala Ala Gly Val Phe Pro Val Arg
- His Leu Ala Glu Thr Asp Glu Ala Leu Leu Glu Ser Val Leu Arg Pro
- Lys Val Ala Gly Ser Trp Leu Leu His Arg Leu Leu Arg Asp Arg Pro 1270
- Leu Asp Leu Phe Val Leu Phe Ser Ser Gly Ala Ala Val Trp Gly Gly 1290
- Lys Gly Gln Gly Ala Tyr Ala Ala Ala Asn Ala Phe Leu Asp Gly Leu 1305
- Ala His His Arg Arg Ala His Ser Leu Pro Ala Leu Ser Leu Ala Trp 1320
- Gly Leu Trp Ala Glu Gly Gly Met Val Asp Ala Lys Ala His Ala Arg
- Leu Ser Asp Ile Gly Val Leu Pro Met Ala Thr Gly Pro Ala Leu Ser 1355
- Ala Leu Glu Arg Leu Val Asn Thr Ser Ala Val Gln Arg Ser Val Thr 1370
- Arg Met Asp Trp Ala Arg Phe Ala Pro Val Tyr Ala Ala Arg Gly Arg 1385
- Arg Asn Leu Leu Ser Ala Leu Val Ala Glu Asp Glu Arg Ala Ala Ser

1395 1400 1405

- Pro Pro Val Pro Thr Ala Asn Arg Ile Trp Arg Gly Leu Ser Val Ala 1410 1415 1420
- Glu Ser Arg Ser Ala Leu Tyr Glu Leu Val Arg Gly Ile Val Ala Arg 1425 1430 1435 1440
- Val Leu Gly Phe Ser Asp Pro Gly Ala Leu Asp Val Gly Arg Gly Phe 1445 1450 1455
- Ala Glu Gln Gly Leu Asp Ser Leu Met Ala Leu Glu Ile Arg Asn Arg 1460 1465 1470
- Leu Gln Arg Glu Leu Gly Glu Arg Leu Ser Ala Thr Leu Ala Phe Asp 1475 1480 1485
- His Pro Thr Val Glu Arg Leu Val Ala His Leu Leu Thr Asp Val Leu 1490 1495 1500
- Lys Leu Glu Asp Arg Ser Asp Thr Arg His Ile Arg Ser Val Ala Ala 1505 1510 1515 1520
- Asp Asp Asp Ile Ala Ile Val Gly Ala Ala Cys Arg Phe Pro Gly Gly 1525 1530 1535
- Asp Glu Gly Leu Glu Thr Tyr Trp Arg His Leu Ala Glu Gly Met Val 1540 1545 Leu Ala Glu Gly Met Val
- Val Ser Thr Glu Val Pro Ala Asp Arg Trp Arg Ala Ala Asp Trp Tyr 1555 1560 1565
- Asp Pro Asp Pro Glu Val Pro Gly Arg Thr Tyr Val Ala Lys Gly Ala 1570 1580
- Phe Leu Arg Asp Val Arg Ser Leu Asp Ala Ala Phe Phe Ala Ile Ser 1585 1590 1595 1600
- Pro Arg Glu Ala Met Ser Leu Asp Pro Gln Gln Arg Leu Leu Glu 1605 1610 1615
- Val Ser Trp Glu Ala Ile Glu Arg Ala Gly Gln Asp Pro Met Ala Leu 1620 1625 1630
- Arg Glu Ser Ala Thr Gly Val Phe Val Gly Met Ile Gly Ser Glu His 1635 1640 1645
- Ala Glu Arg Val Gln Gly Leu Asp Asp Asp Ala Ala Leu Leu Tyr Gly 1650 1660
- Thr Thr Gly Asn Leu Leu Ser Val Ala Ala Gly Arg Leu Ser Phe Phe 1665 1670 1675 1680
- Leu Gly Leu His Gly Pro Thr Met Thr Val Asp Thr Ala Cys Ser Ser 1685 1690 1695
- Ser Leu Val Ala Leu His Leu Ala Cys Gln Ser Leu Arg Leu Gly Glu 1700 1705 1710
- Cys Asp Gln Ala Leu Ala Gly Gly Ser Ser Val Leu Leu Ser Pro Arg
- Ser Phe Val Ala Ala Ser Arg Met Arg Leu Leu Ser Pro Asp Gly Arg 1730 1735 1740

- Cys Lys Thr Phe Ser Ala Ala Ala Asp Gly Phe Ala Arg Ala Glu Gly 1745 1750 1755 1760
- Cys Ala Val Val Leu Lys Arg Leu Arg Asp Ala Gln Arg Asp Arg 1765 1770 1775
- Asp Pro Ile Leu Ala Val Val Arg Ser Thr Ala Ile Asn His Asp Gly 1780 1785 1790
- Pro Ser Ser Gly Leu Thr Val Pro Ser Gly Pro Ala Gln Gln Ala Leu 1795 1800 1805
- Leu Arg Gln Ala Leu Ala Gln Ala Gly Val Ala Pro Ala Glu Val Asp 1810 1815 1820
- Phe Val Glu Cys His Gly Thr Gly Thr Ala Leu Gly Asp Pro Ile Glu 1825 1830 1835 1840
- Val Gln Ala Leu Gly Ala Val Tyr Gly Arg Gly Arg Pro Ala Glu Arg 1845 1850 1855
- Pro Leu Trp Leu Gly Ala Val Lys Ala Asn Leu Gly His Leu Glu Ala 1860 1865 1870
- Ala Ala Gly Leu Ala Gly Val Leu Lys Val Leu Leu Ala Leu Glu His 1875 1880 1885
- Glu Gln Ile Pro Ala Gln Pro Glu Leu Asp Glu Leu Asn Pro His Ile 1890 1895 1900
- Pro Trp Ala Glu Leu Pro Val Ala Val Val Arg Arg Ala Val Pro Trp 1905 1910 1915 1920
- Pro Arg Gly Ala Arg Pro Arg Arg Ala Gly Val Ser Ala Phe Gly Leu 1925 1930 1935
- Ser Gly Thr Asn Ala His Val Val Leu Glu Glu Ala Pro Ala Val Glu 1940 1945 1950
- Pro Val Ala Ala Pro Glu Arg Ala Ala Glu Leu Phe Val Leu Ser
- Ala Lys Ser Ala Ala Ala Leu Asp Ala Gln Ala Ala Arg Leu Arg Asp 1970 1975 1980
- His Leu Glu Lys His Val Glu Leu Gly Leu Gly Asp Val Ala Phe Ser 1985 1990 1995 2000
- Leu Ala Thr Thr Arg Ser Ala Met Glu His Arg Leu Ala Val Ala Ala 2005 2010 2015
- Ser Ser Arg Glu Ala Leu Arg Gly Ala Leu Ser Ala Ala Gln Gly 2020 2025 2030
- His Thr Pro Pro Gly Ala Val Arg Gly Arg Ala Ser Gly Gly Ser Ala 2035 2040 2045
- Pro Lys Val Val Phe Val Phe Pro Gly Gln Gly Ser Gln Trp Val Gly 2050 2055 2060
- Met Gly Arg Lys Leu Met Ala Glu Glu Pro Val Phe Arg Ala Ala Leu 2065 2070 2075 2080
- Glu Gly Cys Asp Arg Ala Ile Glu Ala Glu Ala Gly Trp Ser Leu Leu 2085 2090 2095

- Gly Glu Leu Ser Ala Asp Glu Ala Ala Ser Gln Leu Gly Arg Ile Asp 2100 2105 2110
- Val Val Gln Pro Val Leu Phe Ala Met Glu Val Ala Leu Ser Ala Leu 2115 2120 2125
- Trp Arg Ser Trp Gly Val Glu Pro Glu Ala Val Val Gly His Ser Met 2130 2140
- Gly Glu Val Ala Ala Ala His Val Ala Gly Ala Leu Ser Leu Glu Asp 2145 2150 2155 2160
- Ala Val Ala Ile Ile Cys Arg Arg Ser Arg Leu Leu Arg Arg Ile Ser 2165 2170 2175
- Gly Gln Gly Glu Met Ala Leu Val Glu Leu Ser Leu Glu Glu Ala Glu 2180 2185 2190
- Ala Ala Leu Arg Gly His Glu Gly Arg Leu Ser Val Ala Val Ser Asn $2195 \\ 2200 \\ 2205$
- Ser Pro Arg Ser Thr Val Leu Ala Gly Glu Pro Ala Ala Leu Ser Glu 2210 2215 2220
- Val Leu Ala Ala Leu Thr Ala Lys Gly Val Phe Trp Arg Gln Val Lys 2225 2230 2235 2240
- Val Asp Val Ala Ser His Ser Pro Gln Val Asp Pro Leu Arg Glu Glu 2245 2250 2255
- Leu Ile Ala Ala Leu Gly Ala Ile Arg Pro Arg Ala Ala Ala Val Pro 2260 2265 2270
- Met Arg Ser Thr Val Thr Gly Gly Val Ile Ala Gly Pro Glu Leu Gly 2275 2280 2285
- Ala Ser Tyr Trp Ala Asp Asn Leu Arg Gln Pro Val Arg Phe Ala Ala 2290 2295 2300
- Ala Ala Gln Ala Leu Leu Glu Gly Gly Pro Ala Leu Phe Ile Glu Met 2305 2310 2315 2320
- Ser Pro His Pro Ile Leu Val Pro Pro Leu Asp Glu Ile Gln Thr Ala 2325 2330 2335
- Ala Glu Gln Gly Gly Ala Ala Val Gly Ser Leu Arg Arg Gly Gln Asp 2340 2345 2350
- Glu Arg Ala Thr Leu Leu Glu Ala Leu Gly Thr Leu Trp Ala Ser Gly 2355 2360 2365
- Tyr Pro Val Ser Trp Ala Arg Leu Phe Pro Ala Gly Gly Arg Arg Val 2370 2380
- Pro Leu Pro Thr Tyr Pro Trp Gln His Glu Arg Tyr Trp Ile Glu Asp 2385 2390 2395 2400
- Ser Val His Gly Ser Lys Pro Ser Leu Arg Leu Arg Gln Leu Arg Asn 2405 2410 2415
- Gly Ala Thr Asp His Pro Leu Leu Gly Ala Pro Leu Leu Val Ser Ala 2420 2425 2430
- Arg Pro Gly Ala His Leu Trp Glu Gln Ala Leu Ser Asp Glu Arg Leu

- 61 -

| | 2435 | | | | 2 | 440 | | | | 2 | 445 | | | |
|-----------------|---------------|-------------|----------------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|----------------------|-------------|-------------|
| Ser Ty: 2450 | | Ser | Glu | | Arg 455 | Val | His | Gly | | Ala 460 | Val | Leu | Pro | Ser |
| Ala Ala 2465 | a Tyr | Val | | Met 470 | Ala | Leu | Ala | | Gly 1475 | Val | Asp | Leu | | Gly 480 |
| Thr Ala | a Thr | | Val 485 | Leu | Glu | Gln | | Ala 490 | Leu | Glu | Arg | | Leu 495 | Ala |
| Val Pro | | Glu 2500 | Gly | Gly | Arg | | Val 505 | Gln | Val | Ala | | Ser 510 | Glu | Glu |
| Gly Pro | 2515 | Arg | Ala | Ser | | Gln 520 | Val | Ser | Ser | | Glu !525 | Glu | Ala | Gly |
| Arg Sei 2530 | | Val | Arg | | Ala 535 | Thr | Gly | His | | Cys 540 | Ser | Gly | Gln | Ser |
| Ser Ala 2545 | a Val | Gly | | Leu 550 | Lys | Glu | Ala | | Trp 2555 | Glu | Ile | Gln | | Arg 560 |
| Cys Pro | o Ser | | Leu 2565 | Ser | Ser | Glu | | Leu 1570 | Tyr | Pro | Leu | | Asn 575 | Glu |
| His Al | | Asp 2580 | Tyr | Gly | Pro | | Phe 2585 | Gln | Gly | Val | | Gln 2590 | Val | Trp |
| Leu Gl | y Thr 2595 | Gly | Glu | Val | | Gly 600 | Arg | Val | Arg | | Pro 2605 | Gly | Asp | Met |
| Ala Se 261 | | Ser | Gly | | Туг 2615 | Arg | Ile | His | | Ala 2620 | Leu | Leu | Asp | Ala |
| Cys Ph 2625 | e Gln | Val | | Thr 2630 | Ala | Leu | Leu | | Thr 2635 | Pro | Glu | Ser | | Glu 2640 |
| Ile Ar | g Arg | | Leu 2645 | Thr | qzA | Leu | | Glu 2650 | Pro | Asp | Leu | | Arg 2655 | Ser |
| Arg Al | | Val 2660 | Asn | Gln | Ala | | Ser 2665 | Asp | Thr | Trp | | Trp 2 67 0 | Asp | Ala |
| Ala Le | u Asp 2675 | | Gly | Arg | | Gln 2680 | Ser | Ala | Ser | | Pro 2685 | Val | Asp | Leu |
| Val Le 269 | - | Ser | Phe | | Ala 2695 | Lys | Trp | Glu | | Met 2700 | Glu | Arg | Leu | Ala |
| Gln Al 2705 | a Tyr | Ile | | Gly 2710 | Thr | Leu | Arg | Tle | Trp 2715 | Asn | Val | Phe | Cys | Ala 2720 |
| Ala Gl | y Glu | | His 2 72 5 | Thr | Ile | Asp | | Leu 2730 | | Val | Arg | Leu | Gln 2735 | Ile |
| Ser Va | ıl Val | Tyr 2740 | | Lys | Val | Ile | Lys 2745 | Arg | Trp | Met | Glu | His 2750 | Leu | Va1 |
| Ala Il | e Gly 2755 | | Leu | Val | Gly | Asp 2760 | Gly | Glu | His | Phe | Val 2765 | Ser | Ser | Gln |

Pro Leu Pro Glu Pro Asp Leu Ala Ala Val Leu Glu Glu Ala Gly Arg 2770 2775 2780

Val Phe Ala Asp Leu Pro Val Leu Phe Glu Trp Cys Lys Phe Ala Gly 2785 2790 2795 2800

Glu Arg Leu Ala Asp Val Leu Thr Gly Lys Thr Leu Ala Leu Glu Ile 2805 2810 2815

Leu Phe Pro Gly Gly Ser Phe Asp Met Ala Glu Arg Ile Tyr Arg Asp 2820 2825 2830

Ser Pro Ile Ala Arg Tyr Ser Asn Gly Ile Val Arg Gly Val Val Glu 2835 2840 2845

Ser Ala Ala Arg Val Val Ala Pro Ser Gly Met Phe Ser Ile Leu Glu 2850 2855 2860

Ile Gly Ala Gly Thr Gly Ala Thr Thr Ala Ala Val Leu Pro Val Leu 2865 2870 2875 2880

Leu Pro Asp Arg Thr Glu Tyr His Phe Thr Asp Val Ser Pro Leu Phe 2885 2890 2895

Leu Ala Arg Ala Glu Gln Arg Phe Arg Asp Tyr Pro Phe Leu Lys Tyr 2900 2905 2910

Gly Ile Leu Asp Val Asp Gln Glu Pro Ala Gly Gln Gly Tyr Ala His 2915 2920 2925

Gln Arg Phe Asp Val Ile Val Ala Ala Asn Val Ile His Ala Thr Arg 2930 2935 2940

Asp Ile Arg Ala Thr Ala Lys Arg Leu Leu Ser Leu Leu Ala Pro Gly 2945 2950 2960

Gly Leu Leu Val Leu Val Glu Gly Thr Gly His Pro Ile Trp Phe Asp 2965 2970 2975

Ile Thr Thr Gly Leu Ile Glu Gly Trp Gln Lys Tyr Glu Asp Asp Leu 2980 2985 2990

Arg Ile Asp His Pro Leu Leu Pro Ala Arg Thr Trp Cys Asp Val Leu 2995 3000 3005

Arg Arg Val Gly Phe Ala Asp Ala Val Ser Leu Pro Gly Asp Gly Ser 3010 3015 3020

Pro Ala Gly Ile Leu Gly Gln His Val Ile Leu Ser Arg Ala Pro Gly 3025 3030 3035 3040

Ile Ala Gly Ala Ala Cys Asp Ser Ser Gly Glu Ser Ala Thr Glu Ser 3045 3050 3055

Pro Ala Ala Arg Ala Val Arg Gln Glu Trp Ala Asp Gly Ser Ala Asp 3060 3065 3070

Val Val His Arg Met Ala Leu Glu Arg Met Tyr Phe His Arg Arg Pro 3075 3080 3085

Gly Arg Gln Val Trp Val His Gly Arg Leu Arg Thr Gly Gly Gly Ala 3090 3095 3100

Phe Thr Lys Ala Leu Ala Gly Asp Leu Leu Leu Phe Glu Asp Thr Gly 3105 3110 3115 3120

Gln Val Val Ala Glu Val Gln Gly Leu Arg Leu Pro Gln Leu Glu Ala 3125 3130 3135

- Ser Ala Phe Ala Pro Arg Asp Pro Arg Glu Glu Trp Leu Tyr Ala Leu 3140 3145 3150
- Glu Trp Gln Arg Lys Asp Pro Ile Pro Glu Ala Pro Ala Ala Ser 3155 3160 3165
- Ser Ser Ser Ala Gly Ala Trp Leu Val Leu Met Asp Gln Gly Gly Thr 3170 3175 3180
- Gly Ala Ala Leu Val Ser Leu Leu Glu Gly Arg Gly Glu Ala Cys Val 3185 3190 3195 3200
- Arg Val Ile Ala Gly Thr Ala Tyr Ala Cys Leu Ala Pro Gly Leu Tyr 3205 3210 3215
- Gln Val Asp Pro Ala Gln Pro Asp Gly Phe His Thr Leu Leu Arg Asp 3220 3225 3230
- Ala Phe Gly Glu Asp Arg Ile Cys Arg Ala Val Val His Met Trp Ser 3235 3240 3245
- Leu Asp Ala Thr Ala Ala Gly Glu Arg Ala Thr Ala Glu Ser Leu Gln 3250 3255 3260
- Ala Asp Gln Leu Leu Gly Ser Leu Ser Ala Leu Ser Leu Val Gln Ala 3265 3270 3275 3280
- Leu Val Arg Arg Trp Arg Asn Met Pro Arg Leu Trp Leu Leu Thr 3285 3290 Leu Trp Leu Leu Thr
- Arg Ala Val His Ala Val Gly Ala Glu Asp Ala Ala Ala Ser Val Ala
 3300 3305 3310
- Gln Ala Pro Val Trp Gly Leu Gly Arg Thr Leu Ala Leu Glu His Pro 3315 3320 3325
- Glu Leu Arg Cys Thr Leu Val Asp Val Asn Pro Ala Pro Ser Pro Glu 3330 3335 3340
- Asp Ala Ala Ala Leu Ala Val Glu Leu Gly Ala Ser Asp Arg Glu Asp 3345 3350 3355 3360
- Gln Val Ala Leu Arg Ser Asp Gly Arg Tyr Val Ala Arg Leu Val Arg 3365 3370 3375
- Ser Ser Phe Ser Gly Lys Pro Ala Thr Asp Cys Gly Ile Arg Ala Asp 3380 3385 3390
- Gly Ser Tyr Val Ile Thr Asp Gly Met Gly Arg Val Gly Leu Ser Val 3395 3400 3405
- Ala Gln Trp Met Val Met Gln Gly Ala Arg His Val Val Leu Val Asp 3410 3415 3420
- Arg Gly Gly Ala Ser Glu Ala Ser Arg Asp Ala Leu Arg Ser Met Ala 3425 3430 3435 3440
- Glu Ala Gly Ala Glu Val Gln Ile Val Glu Ala Asp Val Ala Arg Arg 3445 3450 3455
- Asp Asp Val Ala Arg Leu Leu Ser Lys Ile Glu Pro Ser Met Pro Pro 3460 3465 3470
- Leu Arg Gly Ile Val Tyr Val Asp Gly Thr Phe Gln Gly Asp Ser Ser

3475

3480

3489

Met Leu Glu Leu Asp Ala Arg Arg Phe Lys Glu Trp Met Tyr Pro Lys 3490 3495 3500

Val Leu Gly Ala Trp Asn Leu His Ala Leu Thr Arg Asp Arg Ser Leu 3505 3510 3515 3520

Asp Phe Phe Val Leu Tyr Ser Ser Gly Thr Ser Leu Leu Gly Leu Pro 3525 3530 3535

Gly Gln Gly Ser Arg Ala Ala Gly Asp Ala Phe Leu Asp Ala Ile Ala 3540 3545 3550

His His Arg Cys Lys Val Gly Leu Thr Ala Met Ser Ile Asn Trp Gly 3555 3560 3565

Leu Leu Ser Glu Ala Ser Ser Pro Ala Thr Pro Asn Asp Gly Gly Ala 3570 3580

Arg Leu Glu Tyr Arg Gly Met Glu Gly Leu Thr Leu Glu Gln Gly Ala 3585 3590 3595 3600

Ala Ala Leu Gly Arg Leu Leu Ala Arg Pro Arg Ala Gln Val Gly Val 3605 3610 3615

Met Arg Leu Asn Leu Arg Gl
n Trp Leu Glu Phe Tyr Pro Asn Ala Ala 3620 3625 3630

Arg Leu Ala Leu Trp Ala Glu Leu Leu Lys Glu Arg Asp Arg Ala Asp 3635 3640 3645

Arg Gly Ala Ser Asn Ala Ser Asn Leu Arg Glu Ala Leu Gln Ser Ala 3650 3655 3660

Arg Pro Glu Asp Arg Gln Leu Ile Leu Glu Lys His Leu Ser Glu Leu 3665 3670 3680

Leu Gly Arg Gly Leu Arg Leu Pro Pro Glu Arg Ile Glu Arg His Val 3685 3690 3695

Pro Pne Ser Asn Leu Gly Met Asp Ser Leu Ile Gly Leu Glu Leu Arg 3700 3705 3710

Asn Arg Ile Glu Ala Ala Leu Gly Ile Thr Val Pro Ala Thr Leu Leu $3715 \hspace{1cm} 3720 \hspace{1cm} 3725$

Trp Thr Tyr Pro Asn Val Ala Ala Leu Ser Gly Ser Leu Leu Asp Ile 3730 3735 3740

Leu Phe Pro Asn Ala Gly Ala Thr His Ala Pro Ala Thr Glu Arg Glu 3745 3750 3755 3760

Lys Ser Phe Glu Asn Asp Ala Ala Asp Leu Glu Ala Leu Arg Gly Met 3765 3770 3775

Thr Asp Glu Gln Lys Asp Ala Leu Leu Ala Glu Lys Leu Ala Gln Leu

Ala Gln Ile Val Gly Glu 3795

<210> 7 <211> 2439 <212> PRT

<213> Sorangium cellulosum

<400> 7

Met Ala Thr Thr Asn Ala Gly Lys Leu Glu His Ala Leu Leu Met 1 5 10 15

Asp Lys Leu Ala Lys Lys Asn Ala Ser Leu Glu Gln Glu Arg Thr Glu 20 25 30

Pro Ile Ala Ile Val Gly Ile Gly Cys Arg Phe Pro Gly Gly Ala Asp $35 \hspace{1cm} 40 \hspace{1cm} 45$

Thr Pro Glu Ala Phe Trp Glu Leu Leu Asp Ser Gly Arg Asp Ala Val $50 \hspace{1.5cm} 55 \hspace{1.5cm} 60$

Gln Pro Leu Asp Arg Arg Trp Ala Leu Val Gly Val His Pro Ser Glu 65 70 75 80

Glu Val Pro Arg Trp Ala Gly Leu Leu Thr Glu Ala Val Asp Gly Phe 85 90 95

Asp Ala Ala Phe Phe Gly Thr Ser Pro Arg Glu Ala Arg Ser Leu Asp 100 105 110

Pro Gln Gln Arg Leu Leu Glu Val Thr Trp Glu Gly Leu Glu Asp 115 120 125

Ala Gly Ile Ala Pro Gln Ser Leu Asp Gly Ser Arg Thr Gly Val Phe 130 135 140

Leu Gly Ala Cys Ser Ser Asp Tyr Ser His Thr Val Ala Gln Gln Arg 145 150 155 160

Arg Glu Glu Gln Asp Ala Tyr Asp Ile Thr Gly Asn Thr Leu Ser Val

Ala Ala Gly Arg Leu Ser Tyr Thr Leu Gly Leu Gln Gly Pro Cys Leu 180 185 190

Thr Val Asp Thr Ala Cys Ser Ser Ser Leu Val Ala Ile His Leu Ala 195 200 205

Cys Arg Ser Leu Arg Ala Arg Glu Ser Asp Leu Ala Leu Ala Gly Gly 210 215 220

Val Asn Met Leu Leu Ser Ser Lys Thr Met Ile Met Leu Gly Arg Ile 225 230

Gln Ala Leu Ser Pro Asp Gly His Cys Arg Thr Phe Asp Ala Ser Ala 245 250 255

Asn Gly Phe Val Arg Gly Glu Gly Cys Gly Met Val Val Leu Lys Arg 260 265 270

Leu Ser Asp Ala Gln Arg His Gly Asp Arg Ile Trp Ala Leu Ile Arg 275 280 285

Gly Ser Ala Met Asn Gln Asp Gly Arg Ser Thr Gly Leu Met Ala Pro

Asn Val Leu Ala Gln Glu Ala Leu Leu Arg Glu Ala Leu Gln Ser Ala 305 310 315 320

Arg Val Asp Ala Gly Ala Ile Gly Tyr Val Glu Thr His Gly Thr Gly

| | | | | 325 | | | | | 330 | | | | | 335 | |
|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|--------------|------------|------------|------------|------------|------------|
| Thr | Ser | Leu | Gly 340 | Asp | Pro | Ile | Glu | Val 345 | Glu | Ala | Leu | Arg | Ala 350 | Val | Leu |
| Gly | Pro | Ala 355 | Arg | Ala | Asp | Gly | Ser 360 | Arg | Суз | Val | Leu | Gly 365 | Ala | Val | Lys |
| Thr | Asn 370 | Leu | Gly | His | Leu | Glu 375 | Gly | Ala | Ala | Gly | Val 380 | Ala | Gly | Leu | Ile |
| Lys 385 | Ala | Ala | Leu | Ala | Leu 390 | His | His | Glu | Leu | Ile 395 | Pro | Arg | Asn | Leu | His 400 |
| Phe | His | Thr | Leu | Asn 405 | Pro | Arg | Ile | Arg | Ile 410 | Glu | Gly | Thr | Ala | Leu 415 | Ala |
| Leu | Ala | Thr | Glu 420 | Pro | Val | Pro | Trp | Pro 425 | Arg | Ala | Gly | Arg | Pro 430 | Arg | Phe |
| Ala | Gly | Val 435 | Ser | Ala | Phe | Gly | Leu 440 | Ser | Gly | Thr | Asn | Val 445 | His | Val | Val |
| Leu | Glu 450 | Glu | Ala | Pro | Ala | Thr 455 | Val | Leu | Ala | Pro | Ala 460 | Thr | Pro | Gly | Arg |
| Ser 465 | Ala | Glu | Leu | Leu | Val 470 | Leu | Ser | Ala | Lys | Ser 475 | Ala | Ala | Ala | Leu | Asp 480 |
| Ala | Gln | Ala | Ala | Arg 485 | Leu | Ser | Ala | His | Ile 490 | Ala | Ala | Tyr | Pro | Glu 495 | Gln |
| Gly | Leu | Gly | Asp 500 | Val | Ala | Phe | Ser | Leu 505 | Va1 | Ser | Thr | Arg | Ser 510 | Pro | Met |
| Glu | His | Arg 515 | Leu | Ala | Val | Ala | Ala 520 | | Ser | Arg | Glu | Ala 525 | Leu | Arg | Ser |
| Ala | Leu 530 | Glu | Val | Ala | Ala | Gln 535 | Gly | Gln | Thr | Pro | Ala 540 | Gly | Ala | Ala | Arg |
| Gly 545 | Arg | Ala | Ala | Ser | Ser 550 | Pro | GŢĀ | Lys | Leu | Ala 555 | Phe | Leu | Phe | Ala | Gly 560 |
| Gln | Gly | Ala | Gln | Val 565 | Pro | Gly | Met | Gly | Arg 570 | | Leu | Trp | Glu | Ala 575 | |
| Pro | Ala | Phe | Arg 580 | Glu | Thr | Phe | Asp | Arg 585 | | Val | Thr | Leu | Phe 590 | _ | Arg |
| Glu | Leu | His 595 | Gln | Pro | Leu | Cys | Glu 600 | | Met | Trp | Ala | Glu 605 | | Gly | Ser |
| Ser | Arg 610 | | Ser | Leu | Leu | Asp 615 | | Thr | Ala | Ph∈ | 620 | | Pro | Ala | Leu |
| Phe 625 | | Leu | Glu | Туг | 630 | | Ala | a Ala | Let | 2 Phe 635 | | g Ser | Trp | Gly | Val 640 |
| Glu | Pro | Glu | ı Lev | (Va) | | Gly | / His | s Sex | 650 | | / Glu | ı Let | ı Val | Ala 655 | |
| Суз | : Val | Ala | Gly 660 | | Phe | s Ser | : Let | ı Glu | | Ala | a Val | l Arg | Lev 670 | | l Val |

Ala Arg Gly Arg Leu Met Gln Ala Leu Pro Ala Gly Gly Ala Met Val Ser Ile Ala Ala Pro Glu Ala Asp Val Ala Ala Ala Val Ala Pro His Ala Ala Leu Val Ser Ile Ala Ala Val Asn Gly Pro Glu Gln Val Val 705 710 715 720 Ile Ala Gly Ala Glu Lys Phe Val Gln Gln Ile Ala Ala Ala Phe Ala 725 730 735 Ala Arg Gly Ala Arg Thr Lys Pro Leu His Val Ser His Ala Phe His 740 745 750Ser Pro Leu Met Asp Pro Met Leu Glu Ala Phe Arg Arg Val Thr Glu 755 760 765 Ser Val Thr Tyr Arg Arg Pro Ser Ile Ala Leu Val Ser Asn Leu Ser Gly Lys Pro Cys Thr Asp Glu Val Ser Ala Pro Gly Tyr Trp Val Arg 785 790 795 800 His Ala Arg Glu Ala Val Arg Phe Ala Asp Gly Val Lys Ala Leu His 805 810 815 Ala Ala Gly Ala Gly Leu Phe Val Glu Val Gly Pro Lys Pro Thr Leu Leu Gly Leu Val Pro Ala Cys Leu Pro Asp Ala Arg Pro Val Leu Leu Pro Ala Ser Arg Ala Gly Arg Asp Glu Ala Ala Ser Ala Leu Glu Ala 850 860 Leu Gly Gly Phe Trp Val Val Gly Gly Ser Val Thr Trp Ser Gly Val 865 870 875 880 Phe Pro Ser Gly Gly Arg Arg Val Pro Leu Pro Thr Tyr Pro Trp Gln 885 890 895 Arg Glu Arg Tyr Trp Ile Glu Ala Pro Val Asp Arg Glu Ala Asp Gly 900 905 910 Thr Gly Arg Ala Arg Ala Gly Gly His Pro Leu Leu Gly Glu Val Phe 915 920 925 Ser Val Ser Thr His Ala Gly Leu Arg Leu Trp Glu Thr Thr Leu Asp Arg Lys Arg Leu Pro Trp Leu Gly Glu His Arg Ala Gln Gly Glu Val 945 950 955 960 Val Phe Pro Gly Ala Gly Tyr Leu Glu Met Ala Leu Ser Ser Gly Ala Glu Ile Leu Gly Asp Gly Pro Ile Gln Val Thr Asp Val Val Leu Ile Glu Thr Leu Thr Phe Ala Gly Asp Thr Ala Val Pro Val Gln Val Val Thr Thr Glu Glu Arg Pro Gly Arg Leu Arg Phe Gln Val Ala Ser Arg 1015

WO 99/66028 PCT/EP99/04171

Glu Pro Gly Glu Arg Arg Ala Pro Phe Arg Ile His Ala Arg Gly Val 1025 1030 1035 1040

Leu Arg Arg Ile Gly Arg Val Glu Thr Pro Ala Arg Ser Asn Leu Ala 1045 1050 1055

Ala Leu Arg Ala Arg Leu His Ala Ala Val Pro Ala Ala Ala Ile Tyr 1060 1065 1070

Gly Ala Leu Ala Glu Met Gly Leu Gln Tyr Gly Pro Ala Leu Arg Gly 1075 1080 1085

Leu Ala Glu Leu Trp Arg Gly Glu Gly Glu Ala Leu Gly Arg Val Arg 1090 1095 1100

Leu Pro Glu Ala Ala Gly Ser Ala Thr Ala Tyr Gln Leu His Pro Val 1105 1110 1115 1120

Leu Leu Asp Ala Cys Val Gln Met Ile Val Gly Ala Phe Ala Asp Arg 1125 1130 1135

Asp Glu Ala Thr Pro Trp Ala Pro Val Glu Val Gly Ser Val Arg Leu 1140 1145 1150

Phe Gln Arg Ser Pro Gly Glu Leu Trp Cys His Ala Arg Val Val Ser 1155 1160 1165

Asp Gly Gln Gln Ala Ser Ser Arg Trp Ser Ala Asp Phe Glu Leu Met 1170 1180

Asp Gly Thr Gly Ala Val Val Ala Glu Ile Ser Arg Leu Val Val Glu 1185 1190 1195 1200

Arg Leu Ala Ser Gly Val Arg Arg Arg Asp Ala Asp Asp Trp Phe Leu 1205 1210 1215

Glu Leu Asp Trp Glu Pro Ala Ala Leu Gly Gly Pro Lys Ile Thr Ala 1220 1225 1230

Gly Arg Trp Leu Leu Gly Glu Gly Gly Gly Leu Gly Arg Ser Leu 1235 1240 1245

Cys Ser Ala Leu Lys Ala Ala Gly His Val Val His Ala Ala Gly 1250 1255 1260

Asp Asp Thr Ser Thr Ala Gly Met Arg Ala Leu Leu Ala Asn Ala Phe 1265 1270 1275 1280

Asp Gly Gln Ala Pro Thr Ala Val Val His Leu Ser Ser Leu Asp Gly 1285 1290 1295

Gly Gly Gln Leu Gly Pro Gly Leu Gly Ala Gln Gly Ala Leu Asp Ala 1300 1305 1310

Pro Arg Ser Pro Asp Val Asp Ala Asp Ala Leu Glu Ser Ala Leu Met 1315 1320 1325

Arg Gly Cys Asp Ser Val Leu Ser Leu Val Gln Ala Leu Val Gly Met 1330 1340

Asp Leu Arg Asn Ala Pro Arg Leu Trp Leu Leu Thr Arg Gly Ala Gln 1345 1350 1355 1360

Ala Ala Ala Gly Asp Val Ser Val Val Gln Ala Pro Leu Leu Gly

1365 1370 1375

Leu Gly Arg Thr Ile Ala Leu Glu His Ala Glu Leu Arg Cys Ile Ser 1380 1385 1390

Val Asp Leu Asp Pro Ala Glu Pro Glu Gly Glu Ala Asp Ala Leu Leu 1395 1400 1405

Ala Glu Leu Leu Ala Asp Asp Ala Glu Glu Val Ala Leu Arg Gly 1410 1415 1420

Gly Asp Arg Leu Val Ala Arg Leu Val His Arg Leu Pro Asp Ala Gln 1425 1430 1435 1440

Arg Arg Glu Lys Val Glu Pro Ala Gly Asp Arg Pro Phe Arg Leu Glu 1445 1450 1455

Ile Asp Glu Pro Gly Ala Leu Asp Gln Leu Val Leu Arg Ala Thr Gly 1460 1465 1470

Arg Arg Ala Pro Gly Pro Gly Glu Val Glu Ile Ser Val Glu Ala Ala 1475 1480 1485

Gly Leu Asp Ser Ile Asp Ile Gln Leu Ala Leu Gly Val Ala Pro Asn 1490 1495 1500

Asp Leu Pro Gly Glu Glu Ile Glu Pro Leu Val Leu Gly Ser Glu Cys 1505 1510 1515 1520

Ala Gly Arg Ile Val Ala Val Gly Glu Gly Val Asn Gly Leu Val Val 1525 1530 1535

Gly Gln Pro Val Ile Ala Leu Ala Ala Gly Val Phe Ala Thr His Val 1540 1545 1550

Thr Thr Ser Ala Thr Leu Val Leu Pro Arg Pro Leu Gly Leu Ser Ala 1555 1560 1565

Thr Glu Ala Ala Ala Met Pro Leu Ala Tyr Leu Thr Ala Trp Tyr Ala 1570 1580

Leu Asp Lys Val Ala His Leu Gln Ala Gly Glu Arg Val Leu Ile His 1585 1590 1595 1600

Ala Glu Ala Gly Gly Val Gly Leu Cys Ala Val Arg Trp Ala Gln Arg 1605 1610 1615

Val Gly Ala Glu Val Tyr Ala Thr Ala Asp Thr Pro Glu Asn Arg Ala 1620 1625 1630

Tyr Leu Glu Ser Leu Gly Val Arg Tyr Val Ser Asp Ser Arg Ser Gly 1635 1640 1645

Arg Phe Val Thr Asp Val His Ala Trp Thr Asp Gly Glu Gly Val Asp 1650 1655 1660

Val Val Leu Asp Ser Leu Ser Gly Glu Arg Ile Asp Lys Ser Leu Met 1665 1670 1675 1680

Val Leu Arg Ala Cys Gly Arg Leu Val Lys Leu Gly Arg Arg Asp Asp 1685 1690 1695

Cys Ala Asp Thr Gln Pro Gly Leu Pro Pro Leu Leu Arg Asn Phe Ser 1700 1705 1710

- Phe Ser Gln Val Asp Leu Arg Gly Met Met Leu Asp Gln Pro Ala Arg 1715 1720 1725
- Ile Arg Ala Leu Leu Asp Glu Leu Phe Gly Leu Val Ala Ala Gly Ala 1730 1740
- Ile Ser Pro Leu Gly Ser Gly Leu Arg Val Gly Gly Ser Leu Thr Pro 1745 1750 1755 1760
- Pro Pro Val Glu Thr Phe Pro Ile Ser Arg Ala Ala Glu Ala Phe Arg 1765 1770 1775
- Arg Met Ala Gln Gly Gln His Leu Gly Lys Leu Val Leu Thr Leu Asp 1780 1785 1790
- Asp Pro Glu Val Arg Ile Arg Ala Pro Ala Glu Ser Ser Val Ala Val 1795 1800 1805
- Arg Ala Asp Gly Thr Tyr Leu Val Thr Gly Gly Leu Gly Gly Leu Gly 1810 1815 1820
- Leu Arg Val Ala Gly Trp Leu Ala Glu Arg Gly Ala Gly Gln Leu Val 1825 1830 1835 1840
- Leu Val Gly Arg Ser Gly Ala Ala Ser Ala Glu Gln Arg Ala Ala Val 1845 1850 1855
- Ala Ala Leu Glu Ala His Gly Ala Arg Val Thr Val Ala Lys Ala Asp 1860 1865 1870
- Val Ala Asp Arg Ser Gln Ile Glu Arg Val Leu Arg Glu Val Thr Ala 1875 1880 1885
- Ser Gly Met Pro Leu Arg Gly Val Val His Ala Ala Gly Leu Val Asp 1890 1895 1900
- Asp Gly Leu Leu Met Gln Gln Thr Pro Ala Arg Phe Arg Thr Val Met 1905 1910 1915 1920
- Gly Pro Lys Val Gln Gly Ala Leu His Leu His Thr Leu Thr Arg Glu 1925 1930 1935
- Ala Pro Leu Ser Phe Phe Val Leu Tyr Ala Ser Ala Ala Gly Leu Phe 1940 1945 1950
- Gly Ser Pro Gly Gln Gly Asn Tyr Ala Ala Ala Asn Ala Phe Leu Asp 1955 1960 1965
- Ala Leu Ser His His Arg Arg Ala Gln Gly Leu Pro Ala Leu Ser Ile 1970 1975 1980
- Asp Trp Gly Met Phe Thr Glu Val Gly Met Ala Val Ala Gln Glu Asn 1985 1990 1995 2000
- Arg Gly Ala Arg Gln Ile Ser Arg Gly Met Arg Gly Ile Thr Pro Asp 2005 2010 2015
- Glu Gly Leu Ser Ala Leu Ala Arg Leu Leu Glu Gly Asp Arg Val Gln 2020 2025 2030
- Thr Gly Val Ile Pro Ile Thr Pro Arg Gln Trp Val Glu Phe Tyr Pro
- Ala Thr Ala Ala Ser Arg Arg Leu Ser Arg Leu Val Thr Thr Gln Arg 2050 2055 2060

- Ala Val Ala Asp Arg Thr Ala Gly Asp Arg Asp Leu Leu Glu Gln Leu 2065 2070 2075 2080
- Ala Ser Ala Glu Pro Ser Ala Arg Ala Gly Leu Leu Gln Asp Val Val 2085 2090 2095
- Arg Val Gln Val Ser His Val Leu Arg Leu Pro Glu Asp Lys Ile Glu 2100 2105 2110
- Val Asp Ala Pro Leu Ser Ser Met Gly Met Asp Ser Leu Met Ser Leu 2115 2120 2125
- Glu Leu Arg Asn Arg Ile Glu Ala Ala Leu Gly Val Ala Ala Pro Ala 2130 2135 2140
- Ala Leu Gly Trp Thr Tyr Pro Thr Val Ala Ala Ile Thr Arg Trp Leu 2145 2150 2155 2160
- Leu Asp Asp Ala Leu Val Val Arg Leu Gly Gly Gly Ser Asp Thr Asp 2165 2170 2175
- Glu Ser Thr Ala Ser Ala Gly Ser Phe Val His Val Leu Arg Phe Arg 2180 2185 2190
- Pro Val Val Lys Pro Arg Ala Arg Leu Phe Cys Phe His Gly Ser Gly 2195 2200 2205
- Gly Ser Pro Glu Gly Phe Arg Ser Trp Ser Glu Lys Ser Glu Trp Ser 2210 2215 2220
- Asp Leu Glu Ile Val Ala Met Trp His Asp Arg Ser Leu Ala Ser Glu 2225 2230 2235 2240
- Asp Ala Pro Gly Lys Lys Tyr Val Gln Glu Ala Ala Ser Leu Ile Gln 2245 2250 2255
- His Tyr Ala Asp Ala Pro Phe Ala Leu Val Gly Phe Ser Leu Gly Val 2260 2265 2270
- Arg Phe Val Met Gly Thr Ala Val Glu Leu Ala Ser Arg Ser Gly Ala 2275 2280 2285
- Pro Ala Pro Leu Ala Val Phe Thr Leu Gly Gly Ser Leu Ile Ser Ser
- Ser Glu Ile Thr Pro Glu Met Glu Thr Asp Ile Ile Ala Lys Leu Phe 2305 2310 2315 2320
- Phe Arg Asn Ala Ala Gly Phe Val Arg Ser Thr Gln Gln Val Gln Ala 2325 2330 2335
- Asp Ala Arg Ala Asp Lys Val Ile Thr Asp Thr Met Val Ala Pro Ala 2340 2345 2350
- Pro Gly Asp Ser Lys Glu Pro Pro Val Lys Ile Ala Val Pro Ile Val 2355 2360 2365
- Ala Ile Ala Gly Ser Asp Asp Val Ile Val Pro Pro Ser Asp Val Gln 2370 2375 2380
- Asp Leu Gln Ser Arg Thr Thr Glu Arg Phe Tyr Met His Leu Leu Pro 2385 2390 2395 2400
- Gly Asp His Glu Phe Leu Val Asp Arg Gly Arg Glu Ile Met His Ile

- 72 -

2405 2410 2415

Val Asp Ser His Leu Asn Pro Leu Leu Ala Ala Arg Thr Thr Ser Ser 2420 2425 2430

Gly Pro Ala Phe Glu Ala Lys 2435

<210> 8

<211> 419

<212> PRT

<213> Sorangium cellulosum

<400> 8

Met Thr Gln Glu Gln Ala Asn Gln Ser Glu Thr Lys Pro Ala Phe Asp 1 5 10 15

Phe Lys Pro Phe Ala Pro Gly Tyr Ala Glu Asp Pro Phe Pro Ala Ile $20 \hspace{1cm} 25 \hspace{1cm} 30$

Glu Arg Leu Arg Glu Ala Thr Pro Ile Phe Tyr Trp Asp Glu Gly Arg 35 40 45

Ser Trp Val Leu Thr Arg Tyr His Asp Val Ser Ala Val Phe Arg Asp 50 60

Glu Arg Phe Ala Val Ser Arg Glu Glu Trp Glu Ser Ser Ala Glu Tyr 65 75 80

Ser Ser Ala Ile Pro Glu Leu Ser Asp Met Lys Lys Tyr Gly Leu Phe 85 90 95

Gly Leu Pro Pro Glu Asp His Ala Arg Val Arg Lys Leu Val Asn Pro 100 105 110

Ser Phe Thr Ser Arg Ala Ile Asp Leu Leu Arg Ala Glu Ile Gln Arg

Thr Val Asp Gln Leu Leu Asp Ala Arg Ser Gly Gln Glu Glu Phe Asp 130 135 140

Val Val Arg Asp Tyr Ala Glu Gly Ile Pro Met Arg Ala Ile Ser Ala 145 150 155 160

Leu Leu Lys Val Pro Ala Glu Cys Asp Glu Lys Phe Arg Arg Phe Gly

Ser Ala Thr Ala Arg Ala Leu Gly Val Gly Leu Val Pro Gln Val Asp

Glu Glu Thr Lys Thr Leu Val Ala Ser Val Thr Glu Gly Leu Ala Leu 195 200 205

Leu His Asp Val Leu Asp Glu Arg Arg Arg Asn Pro Leu Glu Asn Asp 210 215

Val Leu Thr Met Leu Leu Gln Ala Glu Ala Asp Gly Ser Arg Leu Ser 225 230 235 240

Thr Lys Glu Leu Val Ala Leu Val Gly Ala Ile Ile Ala Ala Gly Thr 245 250 255

Asp Thr Thr Ile Tyr Leu Ile Ala Phe Ala Val Leu Asn Leu Leu Arg

<210> 9 <211> 607 <212> PRT <213> Sorangium cellulosum

Lys Ala Gly

| | Leu | Pro | Arg | Phe | Glu | Asp | Asp | Ala | Asn | | Leu | Pro | Leu | Gly | |
|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|
| 145 | | | | | 150 | | | | | 155 | | | | | 160 |
| Met | Ser | Pro | Glu | Val 165 | Ala | Glu | Ala. | .Glu | Arg 170 | Arg | Leu | Arg | Ala | Ser 175 | Тут |
| Ala | Thr | Pro | Glu 180 | Leu | Ala | Cys | Ala | Ala 185 | Leu | Leu | Ala | Trp | Leu 190 | Gly | Thr |
| Gly | Ala | Gly 195 | Pro | Trp | Ser | Gly | Туг 200 | Pro | Ala | Tyr | Glu | Met 205 | Leu | Pro | Glu |
| Asn | Leu 210 | Leu | Leu | Gly | Phe | Gly 215 | Leu | Pro | Thr | Ala | 11e 220 | Ala | Ala | Ala | Ser |
| Ala 225 | Pro | Gly | Thr | Ser | Glu 230 | Ala | Ala | Leu | Arg | Gly 235 | Ala | Ala | Arg | Leu | Phe 240 |
| Ala | Ser | Trp | Glu | Val 245 | Val | Ser | Ser | Lys | Lys 250 | Ser | Gln | Leu | Gly | Asn 255 | Ile |
| Pro | Glu | Ala | Leu 260 | Trp | Glu | Arg | Leu | Arg 265 | Thr | Ile | Val | Arg | Ala 270 | Met | Gly |
| Asn | Ala | Asp 275 | Asn | Leu | Ser | Arg | Phe 280 | Glu | Arg | Ala | Glu | Ala 285 | Ile | Ala | Ala |
| Glu | Va1 290 | Arg | Arg | Leu | Arg | Ala 295 | Gln | Pro | Ala | Pro | Phe 300 | Ala | Ala | Gly | Ala |
| Gly 305 | Leu | Ala | Val | Ala | Gly 310 | Val | Ser | Ser | Ser | Gly 315 | Arg | Leu | Ser | Gly | Leu 320 |
| Val | Thr | Asp | Gly | Asp 325 | Ala | Leu | Tyr | Ser | Gly 330 | Asp | Gly | Asn | Asp | 11e 335 | Val |
| Met | Phe | Gln | Pro 340 | Gly | Arg | Ile | Ser | Pro 345 | Val | Val | Leu | Leu | Ala 350 | Gly | Thr |
| Asp | Pro | Phe 355 | Phe | Glu | Leu | Ala | Pro 360 | Pro | Leu | Ser | Gln | Met 365 | Leu | Phe | Val |
| Ala | His 370 | Ala | Asn | Ala | Gly | Thr 375 | Ile | Ser | Lys | Val | Leu 380 | Thr | Glu | Gly | Ser |
| Pro 385 | Leu | Ile | Val | Met | Ala 390 | Arg | Asn | Gln | Ala | Arg 395 | | Met | Ser | Leu | Val 400 |
| His | Ala | Arg | Gly | Phe 405 | Met | Ala | Trp | Val | Asn 410 | | Ala | Met | Val | Pro 415 | |
| Pro | Glu | Arg | Gly 420 | Ala | Pro | Phe | · Val | Val 425 | | Arg | Ser | Thr | 11e | | Glu |
| Phe | Glu | His 435 | Pro | Thr | Pro | Arg | Cys 440 | | His | s Glu | Pro | Ala 445 | | Ser | Ala |
| Phe | Ser 450 | | Ala | Cys | Asp | Glu 455 | | His | : Let | і Туі | Trp 460 | - | s Glu | Leu | Ser |
| Ala 465 | | Arg | Leu | Glu | Leu 470 | | Arg | , His | s Pro | His 475 | | Arg | y Pro | Gly | Ala 480 |
| Pro | Ser | Arg | , Phe | Ala 485 | | Let | ı Gly | / Glu | 1 His | | ıl. | e Ala | a Ala | Thr 495 | |

Tyr Pro Ser Leu Thr Leu Asn Ala Thr His Val Leu Trp Ala Asp Pro 505

Asp Arg Ala Ile Leu Gly Val Asp Lys Arg Thr Gly Val Glu Pro 515 520 525

Ile Val Leu Ala Glu Thr Arg His Pro Pro Ala His Val Val Ser Glu

Asp Arg Asp Ile Phe Ala Leu Thr Gly Gln Pro Asp Ser Arg Asp Trp 545 550 555 560

His Val Glu His Ile Arg Ser Gly Ala Ser Thr Val Val Ala Asp Tyr 565 570 575

Gln Arg Gln Leu Trp Asp Arg Pro Asp Met Val Leu Asn Arg Arg Gly

Leu Phe Phe Thr Thr Asn Asp Arg Ile Leu Thr Leu Ala Arg Ser 595 600 605

<210> 10

<211> 423 <212> PRT

<213> Sorangium cellulosum

Met Gly Ala Leu Ile Ser Val Ala Ala Pro Gly Cys Ala Leu Gly Gly
1 5 10 15

Ala Glu Glu Gly Gln Pro Gly Gln Asp Ala Gly Ala Gly Ala Leu 20 25 30

Ala Pro Ala Arg Glu Val Met Ala Ala Glu Val Ala Ala Gly Gln Met 35 40 45

Pro Gly Ala Val Trp Leu Val Ala Arg Gly Asp Asp Val His Val Asp 50 60

Ala Val Gly Val Thr Glu Leu Gly Gly Ser Ala Pro Met Arg Arg Asp 65 70 75 80

Thr Ile Phe Arg Ile Ala Ser Met Thr Lys Ala Val Thr Ala Thr Ala 85 90 95

Val Met Met Leu Val Glu Glu Gly Lys Leu Asp Leu Asp Ser Pro Val 105

Asp Arg Trp Leu Pro Glu Leu Ala Asn Arg Lys Val Leu Ala Arg Ile 115 120 125

Asp Gly Pro Ile Asp Glu Thr Val Pro Ala Glu Arg Pro Ile Thr Val 130 135 140

Arg Asp Leu Met Thr Phe Thr Met Gly Phe Gly Ile Ser Phe Asp Ala 150

Ser Ser Pro Ile Gln Arg Ala Ile Asp Glu Leu Gly Leu Val Asn Ala

Gln Pro Val Pro Met Thr Pro His Gly Pro Asp Glu Trp Ile Arg Arg

Leu Gly Thr Leu Pro Leu Met His Gln Pro Gly Ala Gln Trp Met Tyr 200 Asn Thr Gly Ser Leu Val Gln Gly Val Leu Val Gly Arg Ala Ala Asp Gln Gly Phe Asp Ala Phe Val Arg Glu Arg Ile Leu Ala Pro Leu Gly Met Arg Asp Thr Asp Phe His Val Pro Ala Asp Lys Leu Ala Arg Phe Ala Gly Cys Gly Tyr Phe Thr Asp Glu Gln Thr Gly Glu Lys Thr Arg 260 265 270Met Asp Arg Asp Gly Ala Glu Ser Ala Tyr Ala Ser Pro Pro Ala Phe Pro Ser Gly Ala Ala Gly Leu Val Ser Thr Val Asp Asp Tyr Leu Leu 290 295 300 Phe Ala Arg Met Leu Met Asn Gly Gly Val His Glu Gly Arg Arg Leu Leu Ser Ala Ala Ser Val Arg Glu Met Thr Ala Asp His Leu Thr Pro 330 Ala Gln Lys Ala Ala Ser Ser Phe Phe Pro Gly Phe Phe Glu Thr His Gly Trp Gly Tyr Gly Met Ala Val Val Thr Ala Pro Asp Ala Val Ser Glu Val Pro Gly Arg Tyr Gly Trp Asp Gly Gly Phe Gly Thr Ser Trp 370 380 Ile Asn Asp Pro Gly Arg Glu Leu Ile Gly Ile Val Met Thr Gln Ser 385 390 395 400Ala Gly Phe Leu Phe Ser Gly Ala Leu Glu Arg Phe Trp Arg Ser Val Tyr Val Ala Thr Glu Ser Ala

<210> 11 <211> 713

<212> PRT

<213> Sorangium cellulosum

<400> 11

Met His Gly Leu Thr Glu Arg Gln Val Leu Leu Ser Leu Val Thr Leu

Ala Leu Ile Leu Val Thr Ala Arg Ala Ser Gly Glu Leu Ala Arg Arg

Leu Arg Gln Pro Glu Val Leu Gly Glu Leu Phe Gly Gly Val Val Leu 35 40 45

Gly Pro Ser Val Val Gly Ala Leu Ala Pro Gly Phe His Arg Ala Leu

Phe Gln Glu Pro Ala Val Gly Val Val Leu Ser Gly Ile Ser Trp Ile

| | 65 | | | | | 70 | | | | | /5 | | | | | 80 |
|---|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|
| (| Gly | Ala | Leu | Leu | Leu 85 | Leu | Leu | Met | Ala | Gly 90 | Ile | Glu | Val | Asp | Val 95 | Gly |
| | Ile | Leu | Arg | Lys 100 | Glu | Ala | Arg | Pro | Gly 105 | Ala | Leu | Ser | Ala | Leu 110 | Gly | Ala |
| | Ile | Ala | Pro 115 | Pro | Leu | Ala | Ala | Gly 120 | Ala | Ala | Phe | Ser | Ala 125 | Leu | Val | Leu |
| 2 | Asp | Arg 130 | Pro | Leu | Pro | Ser | Gly 135 | Leu | Phe | Leu | Gly | 11e 140 | Val | Leu | Ser | Val |
| | Thr 145 | Ala | Val | Ser | Val | Ile 150 | Ala | Lys | Val | Leu | 11e 155 | Glu | Arg | Glu | Ser | Met 160 |
| 2 | Arg | Arg | Ser | Tyr | Ala 165 | Gln | Val | Thr | Leu | Ala 170 | Ala | Gly | Val | Val | Ser 175 | Glu |
| • | Val | Ala | Ala | Trp 180 | Val | Leu | Val | Ala | Met 185 | Thr | Ser | Ser | Ser | Туг 190 | Gly | Ala |
| | Ser | Pro | Ala 195 | Leu | Ala | Val | Ala | Arg 200 | Ser | Ala | Leu | Leu | Ala 205 | Ser | Gly | Phe |
| | Leu | Leu 210 | Phe | Met | Val | Leu | Val 215 | Gly | Arg | Arg | Leu | Thr 220 | His | Leu | Ala | Met |
| | Arg 225 | Trp | Val | Ala | Asp | Ala 230 | Thr | Arg | Val | Ser | Lys 235 | Gly | Gln | Val | Ser | Leu 240 |
| | Val | Leu | Val | Leu | Thr 245 | Phe | Leu | Ala | Ala | Ala 250 | Leu | Thr | Gln | Arg | Leu 255 | Gly |
| | Leu | His | Pro | Leu 260 | Leu | Gly | Ala | Phe | Ala 265 | Leu | Gly | Val | Leu | Leu 270 | Asn | Ser |
| | Ala | Pro | Arg 275 | Thr | Asn | Arg | Pro | Leu 280 | Leu | Asp | Gly | Val | Gln 285 | Thr | Leu | Val |
| | Ala | Gly 290 | Leu | Phe | Ala | Pro | Val 295 | Phe | Phe | Val | Leu | Ala 300 | Gly | Met | Arg | Val |
| | Asp 305 | Val | Ser | Gln | Leu | Arg 310 | Thr | Pro | Ala | Ala | Trp 315 | | Thr | Val | Ala | Leu 320 |
| | Leu | Leu | Ala | Thr | Ala 325 | Thr | Ala | Ala | Lys , | Val 330 | | Pro | Ala | Ala | Leu 335 | |
| | Ala | Arg | Leu | Gly 340 | Gly | Leu | Arg | Gly | Ser 345 | | Ala | Ala | Leu | Val 350 | | Val |
| | Gly | Leu | Asn 355 | | Lys | Gly | Gly | Thr 360 | | Leu | Ile | · Val | Ala 365 | | Val | Gly |
| | Val | Glu 370 | | Gly | Leu | Leu | Ser 375 | | Glu | Ala | туг | Thr 380 | | Туг | · Ala | Val |
| | Val 385 | Ala | Leu | Val | Thr | Val 390 | | Ala | Ser | Pro | 395 | | ı Let | ı Ile | Trp | Let 400 |
| | Glu | Lys | Arg | Ala | 405 | | Thi | Glr | Glu | Glu 410 | | Ala | a Arç | j Let | 415 | |

Glu Glu Ala Ala Arg Arg Ala Tyr Ile Pro Gly Val Glu Arg Ile Leu 420 425 430 Val Pro Ile Val Ala His Ala Leu Pro Gly Phe Ala Thr Asp Ile Val 440 Glu Ser Ile Val Ala Ser Lys Arg Lys Leu Gly Glu Thr Val Asp Ile 455 Thr Glu Leu Ser Val Glu Gln Gln Ala Pro Gly Pro Ser Arg Ala Ala Gly Glu Ala Ser Arg Gly Leu Ala Arg Leu Gly Ala Arg Leu Arg Val 485 490 495 Gly Ile Trp Arg Gln Arg Arg Glu Leu Arg Gly Ser Ile Gln Ala Ile Leu Arg Ala Ser Arg Asp His Asp Leu Leu Val Ile Gly Ala Arg Ser 515 520 525 Pro Ala Arg Ala Arg Gly Met Ser Phe Gly Arg Leu Gln Asp Ala Ile 535 Val Gln Arg Ala Glu Ser Asn Val Leu Val Val Val Gly Asp Pro Pro 550 555 Ala Ala Glu Arg Ala Ser Ala Arg Arg Ile Leu Val Pro Ile Ile Gly Leu Glu Tyr Ser Phe Ala Ala Ala Asp Leu Ala Ala His Val Ala Leu Ala Trp Asp Ala Glu Leu Val Leu Leu Ser Ser Ala Gln Thr Asp Pro Gly Ala Val Val Trp Arg Asp Arg Glu Pro Ser Arg Val Arg Ala Val Ala Arg Ser Val Val Asp Glu Ala Val Phe Arg Gly Arg Arg Leu Gly 625 630 635 640 Val Arg Val Ser Ser Arg Val His Val Gly Ala His Pro Ser Asp Glu 645 650 655 Ile Thr Arg Glu Leu Ala Arg Ala Pro Tyr Asp Leu Leu Val Leu Gly Cys Tyr Asp His Gly Pro Leu Gly Arg Leu Tyr Leu Gly Ser Thr Val Glu Ser Val Val Val Arg Ser Arg Val Pro Val Ala Leu Leu Val Ala 695 His Gly Gly Thr Arg Glu Gln Val Arg

<210> 12

<211> 126

<212> PRT <213> Sorangium cellulosum

<400> 12
Met Asp Lys Pro Ile Gly Arg Thr Arg Cys Ala Ile Ala Glu Gly Tyr

10 15 Ile Pro Gly Gly Ser Asn Gly Pro Glu Pro Gln Met Thr Ser His Glu Thr Ala Cys Leu Leu Asn Ala Ser Asp Arg Asp Ala Gln Val Ala Ile 35 40 Thr Val Tyr Phe Ser Asp Arg Asp Pro Ala Gly Pro Tyr Arg Val Thr 50 60 Val Pro Ala Arg Arg Thr Arg His Val Arg Phe Asn Asp Leu Thr Glu Pro Glu Pro Ile Pro Arg Asp Thr Asp Tyr Ala Ser Val Ile Glu Ser 85 90 95 Asp Ala Pro Ile Val Val Gln His Thr Arg Leu Asp Ser Arg Gln Ala 100 105 110 Glu Asn Ala Leu Leu Ser Thr Ile Ala Tyr Thr Asp Arg Glu <210> 13 <211> 149 <212> PRT <213> Sorangium cellulosum <400> 13 Met Lys His Val Asp Thr Gly Arg Arg Phe Gly Arg Arg Ile Gly His Thr Leu Gly Leu Leu Ala Ser Met Ala Leu Ala Gly Cys Gly Pro Ser Glu Lys Thr Val Gln Gly Thr Arg Leu Ala Pro Gly Ala Asp Ala 35 45 Arg Val Thr Ala Asp Val Asp Pro Asp Ala Ala Thr Thr Arg Leu Ala

Glu Arg Phe Val Val Trp Gln Arg Pro Ser Pro Glu Ser Pro Trp Arg 85 90 95

Val Asp Val Val His Leu Ser Pro Pro Glu Arg Leu Glu Ala Gly Ser 65 70 75

Arg Val Gly Val Leu Asp Tyr Asn Ala Asp Ser Arg Arg Gly Lys Leu $100 \hspace{1cm} 105 \hspace{1cm} 110$

Ala Glu Thr Thr Val Pro Tyr Ala Asn Phe Glu Leu Leu Ile Thr Ala 115 120 125

Glu Lys Gln Ser Ser Pro Gln Ser Pro Ser Ser Ala Ala Val Ile Gly 130 140

Pro Thr Ser Val Gly 145

<210> 14

<211> 184

<212> PRT

<213> Sorangium cellulosum

 <400> 14
 Val Thr Ser Glu Glu Val Pro Gly Ala Ala Leu Gly Ala Gln Ser Ser 15

 Leu Val Arg Ala Gln His Ala Ala Arg His Val Arg Pro Cys Thr Arg 20

 Ala Glu Glu Pro Pro Ala Leu Met His Gly Leu Thr Glu Arg Gln Val 45

 Leu Leu Ser Leu Val Ala Leu Ala Leu Val Leu Leu Thr Ala Arg Ala 65

 Phe Gly Glu Leu Ala Arg 70
 Arg Leu Arg Gln Pro Glu Val Leu Gly Ro 80

 Leu Phe Gly Gly Val Val Leu Gly Pro Ser Val Val Gly Ala Leu Ala 95

 Pro Gly Phe His Arg Val Leu Phe Gln Asp Pro Ala Val Gly Val Val 110

 Leu Ser Gly Ile Ser Trp Ile Gly Ala Leu Val Leu Leu Leu Leu Met Ala 125

 Gly Ile Glu Val Asp Val Ser Ile Leu Arg Lys Glu Ala Arg Pro Gly 135

 Ala Leu Ser Ala Leu Gly Ala Ile Ala Pro Pro Leu Arg Thr Pro Gly 155

 Ser Pro Arg Arg Ser Ala Gln Ala

<210> 15

<211> 145

<212> PRT

<213> Sorangium cellulosum

<400> 15

Val Asn Ala Pro Cys Met Arg Cys Thr Ser Gly Pro Gly Val Arg Ser 1 5 10 15

Gly Gly Ala Ile Ala Pro Ser Ala Glu Ser Ala Pro Gly Arg Ala Ser 20 25

Leu Arg Arg Met Leu Thr Ser Thr Ser Ile Pro Ala Met Ser Ser Arg 35 40 45

Thr Ser Ala Pro Ile Gln Glu Met Pro Glu Ser Thr Thr Pro Thr Ala 50 55 60

Gly Ser Trp Lys Arg Thr Arg Trp Asn Pro Gly Ala Ser Ala Pro Thr 65 70 75 80

Thr Asp Gly Pro Ser Thr Thr Pro Pro Lys Ser Ser Pro Ser Thr Ser 85 90 95

Gly Trp Arg Ser Arg Arg Ala Ser Ser Pro Lys Ala Arg Ala Val Arg 100 105 110

Arg Thr Ser Ala Arg Ala Thr Ser Glu Ser Arg Thr Cys Arg Ser Val 115 120 125

Arg Pro Cys Ile Arg Ala Gly Gly Ser Ser Ala Arg Val Gln Gly Arg 130 135 140

Thr 145

<210> 16

<211> 185

<212> PRT

<213> Sorangium cellulosum

<400> 16

Val Leu Ala Pro Pro Ala Asp Ile Arg Pro Pro Ala Ala Ala Gln Leu 1 5 10

Glu Pro Asp Ser Pro Asp Asp Glu Ala Asp Glu Ala Asp Glu Ala Leu $20 \hspace{1cm} 25 \hspace{1cm} 30$

Arg Pro Phe Arg Asp Ala Ile Ala Ala Tyr Ser Glu Ala Val Arg Trp 35 40 45

Ala Glu Ala Ala Gln Arg Pro Arg Leu Glu Ser Leu Val Arg Leu Ala 50 55 60

Ile Val Arg Leu Gly Lys Ala Leu Asp Lys Val Pro Phe Ala His Thr 65 70 80

Thr Ala Gly Val Ser Gln Ile Ala Gly Arg Leu Gln Asn Asp Ala Val $85 \hspace{1.5cm} 90 \hspace{1.5cm} 95$

Trp Phe Asp Val Ala Ala Arg Tyr Ala Ser Phe Arg Ala Ala Thr Glu
100 105 110

His Ala Leu Arg Asp Ala Ala Ser Ala Met Glu Ala Leu Ala Ala Gly

Pro Tyr Arg Gly Ser Ser Arg Val Ser Ala Ala Val Gly Glu Phe Arg 130 135 140

Gly Glu Ala Ala Arg Leu His Pro Ala Asp Arg Val Pro Ala Ser Asp 145 150 155 160

Gln Gln Ile Leu Thr Ala Leu Arg Ala Ala Glu Arg Ala Leu Ile Ala 165 170 175

Leu Tyr Thr Ala Phe Ala Arg Glu Glu

<210> 17

<211> 146

<212> PRT

<213> Sorangium cellulosum

<400> 17

Met Ala Asp Ala Ala Ser Arg Ser Ala Cys Ser Val Ala Ala Arg Lys 1 5 10 15

Leu Ala Tyr Arg Ala Ala Thr Ser Asn Gln Thr Ala Ser Phe Trp Ser 20 25 30

Leu Pro Ala Ile Trp Glu Thr Pro Ala Val Val Cys Ala Lys Gly Thr 35 40 45

Leu Ser Ser Ala Leu Pro Ser Arg Thr Ile Ala Ser Arg Thr Arg Leu 50 55 60

Ser Ser Arg Gly Arg Cys Ala Ala Ser Ala His Arg Thr Ala Ser Glu 65 70 75 80

Tyr Ala Ala Ile Ala Ser Arg Asn Gly Arg Ser Ala Ser Ser Ala Ser 85 90 95

Ser Ala Ser Ser Ser Gly Glu Ser Gly Ser Ser Trp Ala Ala Gly 100 105 110

Gly Arg Met Ser Ala Gly Gly Ala Ser Thr Gly Glu Val Tyr Glu Gln 115 120 125

Ala Pro Arg Leu Arg Leu Ala Gln Ser Val Ala Ala Arg Arg Arg Asp 130 135 140

Pro Thr 145

<210> 18

<211> 288

<212> PRT

<213> Sorangium cellulosum

<400> 18

Val Thr Val Ser Ser Met Pro Arg Ser Trp Ser Ser Arg Val Arg Thr 1 5 10 15

Val Val Thr Ala Leu Gly Cys Ala Arg Arg Leu Ser Gly Ser Ile Ser 20 25 30

Arg Leu Arg Arg His Pro Glu Ala Gly Arg Ala Pro Arg Ser Arg Leu 35 40 45

Arg Ala Trp Arg Arg Leu Pro Gln His Ile Ser Ser Pro Trp Arg His 50 60

Leu Pro Pro Gly Ala Arg Val Gly Thr Ser Cys Pro Ala Asp Arg Arg 65 70 75 80

Ile Leu Pro Ser His Arg Thr Ala Asp Leu Gly Thr Ser Gly Gly Thr 85 90 95

Leu Val Ala Arg Met Ser Gly His Val Ala Arg Asn Pro His Ala Ala 100 105 110

Val Leu Val Gly Asp Gly Ser Ala Arg Gly Arg Arg Arg Leu Ser Asn 115 120 125

Arg Arg Ala Glu Arg Arg Val Ser Asp Val Thr Cys Arg Glu Gly Gly 130 135 140

Glu Ala Met Gln Lys Ile Ala Gly Lys Leu Val Val Gly Leu Ile Ser 145 150 155 160

Val Ser Gly Met Ser Leu Leu Ala Ala Cys Gly Gly Glu Lys Arg Ser

Gly Gly Glu Ala Gln Thr Pro Gly Gly Ala Gln Gly Glu Ala Pro Val 180 Pro Val 180 Pro Val 180 Pro Val 180 Pro Val 185 Ala Gln Gly Glu Ala Pro Val 190 Pro Val 195 Pro Val 195 Pro Ala Val Asp Ser Ile Val Ala Ala Ala Arg Cys Asp Arg Glu Ala Arg Cys Asn Asn Ile Gly Gln Asp Arg Glu Tyr Ser Ser Lys 215 Pro Ala Cys Ser Asn Lys Ile Arg Ser Glu Trp Arg Asp Glu Leu Thr 240 Pro Gly Glu Cys Pro Gly Gly Ile Asp Ala Lys Gln Leu Asn Glu Cys Leu Glu Gly Ile Asp Ala Lys Gln Leu Asn Glu Cys Gly Arg Arg Asp Val Ala Cys Arg Ser Ser Asp Leu Cys Arg Asp Ala Arg

<210> 19

<211> 288

<212> PRT

<213> Sorangium cellulosum

<400> 19

Val Thr Val Ser Ser Met Pro Arg Ser Trp Ser Ser Arg Val Arg Thr
1 5 10 15

Val Val Thr Ala Leu Gly Cys Ala Arg Arg Leu Ser Gly Ser Ile Ser 20 25 30

Arg Leu Arg Arg His Pro Glu Ala Gly Arg Ala Pro Arg Ser Arg Leu 35 40 45

Arg Ala Trp Arg Arg Leu Pro Gln His Ile Ser Ser Pro Trp Arg His 50 60

Leu Pro Pro Gly Ala Arg Val Gly Thr Ser Cys Pro Ala Asp Arg Arg 65 70 75 80

Ile Leu Pro Ser His Arg Thr Ala Asp Leu Gly Thr Ser Gly Gly Thr 85 90 95

Leu Val Ala Arg Met Ser Gly His Val Ala Arg Asn Pro His Ala Ala 100 105 110

Val Leu Val Gly Asp Gly Ser Ala Arg Gly Arg Arg Leu Ser Asn 115 120 125

Arg Arg Ala Glu Arg Arg Val Ser Asp Val Thr Cys Arg Glu Gly Gly 130 135 140

Glu Ala Met Gln Lys Ile Ala Gly Lys Leu Val Val Gly Leu Ile Ser 145 150 155 160

Val Ser Gly Met Ser Leu Leu Ala Ala Cys Gly Glu Lys Arg Ser 165 170 175

Gly Gly Glu Ala Gln Thr Pro Gly Gly Ala Gln Gly Glu Ala Pro Val

<210> 20

<211> 155

<212> PRT

<213> Sorangium cellulosum

<400> 20

Met Asp Pro Arg Ala Arg Arg Glu Lys Arg Pro Ser Leu Leu Asp Ser 1 5 10 15

Arg Gly Arg Gln Pro Lys Arg Ser Gln Gln Gly Gly His Met Glu Lys 20 25 30

Pro Ile Gly Arg Thr Arg Trp Ala Ile Ala Glu Gly Tyr Ile Pro Gly 35

Arg Ser Asn Gly Pro Glu Pro Gln Met Thr Ser His Glu Thr Ala Cys 50 60

Leu Leu Asn Ala Ser Asp Arg Asp Ala Gln Val Ala Ile Thr Val Tyr 65 70 75 80

Phe Ser Asp Arg Asp Pro Ala Gly Pro Tyr Arg Val Thr Val Pro Ala 85 90 95

Arg Arg Thr Arg His Val Arg Phe Asn Asp Leu Thr Glu Pro Glu Pro 100 100 110

Ile Val Val Gln His Thr Arg Leu Asp Ser Arg Gln Ala Glu Asn Ala 130 135

Leu Ile Ser Thr Ile Ala Tyr Thr Asp Arg Glu 145 150 155

<210> 21

<211> 156

<212> PRT

<213> Sorangium cellulosum

<213> Sorangium cellulosum

<400> 22

Met Glu Lys Glu Ser Arg Ile Ala Ile Tyr Gly Ala Ile Ala Ala Asn 1 5 10

Ser Ala Met Leu Ser Glu Gly Val His Ser Leu Val Asp Thr Ala Asp 35 40 45

Gly Leu Leu Leu Leu Gly Lys His Arg Ser Ala Arg Pro Pro Asp 50 60

Ala Glu His Pro Phe Gly His Gly Lys Glu Leu Tyr Phe Trp Thr Leu 65 70 75 80

Ile Val Ala Ile Met Ile Phe Ala Ala Gly Gly Val Ser Ile Tyr 85 90 95

Glu Gly Ile Leu His Leu His Pro Arg Gln Ile Glu Asp Pro Thr 100 105 110

Trp Asn Tyr Val Val Leu Gly Ala Ala Ala Val Phe Glu Gly Thr Ser 115 120 125

Leu Ile Ile Ser Ile His Glu Phe Lys Lys Lys Asp Gly Gln Gly Tyr 130 135 140 Leu Ala Ala Met Arg Ser Ser Lys Asp Pro Thr Thr Phe Thr Ile Val Leu Glu Asp Ser Ala Ala Leu Ala Gly Leu Thr Ile Ala Phe Leu Gly Val Trp Leu Gly His Arg Leu Gly Asn Pro Tyr Leu Asp Gly Ala Ala Ser Ile Gly Ile Gly Leu Val Leu Ala Ala Val Ala Val Phe Leu Ala Ser Gln Ser Arg Gly Leu Leu Val Gly Glu Ser Ala Asp Arg Glu Leu Leu Ala Ala Ile Arg Ala Leu Ala Ser Ala Asp Pro Gly Val Ser Ala Val Gly Arg Pro Leu Thr Met His Phe Gly Pro His Glu Val Leu Val 245 250 255 Val Leu Arg Ile Glu Phe Asp Ala Ala Leu Thr Ala Ser Gly Val Ala Glu Ala Ile Glu Arg Ile Glu Thr Arg Ile Arg Ser Glu Arg Pro Asp Val Lys His Ile Tyr Val Glu Ala Arg Ser Leu His Gln Arg Ala Arg Ala 305 <210> 23 <211> 135 <212> PRT <213> Sorangium cellulosum Val Gln Thr Ser Ser Phe Asp Ala Arg Tyr Ala Gly Cys Lys Ser Ser 1 10 15 Arg Arg Ile Ala Arg Ser Gly Ser Ala Gly Ala Arg Ala Gly Arg Ala 20 25 30His Glu Gly Ala Ala Ser Ala Gly Phe Glu Gly Gly Asp Val Met Arg 35 40Lys Ala Arg Ala His Gly Ala Met Leu Gly Gly Arg Asp Asp Gly Trp 50 60Arg Arg Gly Leu Pro Gly Ala Gly Ala Leu Arg Ala Ala Leu Gln Arg 65 70 75 80 Gly Arg Ser Arg Asp Leu Ala Arg Arg Arg Leu Ile Ala Ser Val Ser 85 90 95

Leu Ala Gly Gly Ala Ser Met Ala Val Val Ser Leu Phe Gln Leu Gly

Ile Ile Glu Arg Leu Pro Asp Pro Pro Leu Pro Gly Phe Asp Ser Ala

| Lys Val Thr Ser Ser Asp Ile 130 135 | |
|--|----|
| <210> 24 <211> 19 <212> DNA <213> Artificial Sequence | |
| <220> <223> Description of Artificial Sequence: universal reverse primer | |
| <400> 24 ggaaacagct atgaccatg | 19 |
| <210> 25 <211> 17 <212> DNA <213> Artificial Sequence | |
| <220> <223> Description of Artificial Sequence: universal forward primer | |
| <400> 25 gtaaaacgac ggccagt | 17 |
| <210> 26 <211> 28 <212> DNA <213> Artificial Sequence | |
| <220> <223> Description of Artificial Sequence: PCR primer NH24 end "B" | |
| <400> 26 gtgactggcg cctggaatct gcatgagc | 28 |
| <210> 27 <211> 28 <212> DNA <213> Artificial Sequence | |
| <220> <223> Description of Artificial Sequence: PCR primer NH2 end "A" | |
| <400> 27 agcgggagct tgctagacat tctgtttc | 28 |
| <210> 28 <211> 24 <212> DNA <213> Artificial Sequence | |
| <220> <223> Description of Artificial Sequence: PCR primer NH2 end "B" | |
| <400> 28 gacgcgcctc gggcagcgcc ccaa | 24 |
| <210× 29 | |

PCT/EP99/04171

WO 99/66028

- 88 -

| <211> <212> <213> | | |
|----------------------------------|---|----|
| <220> <223> | Description of Artificial Sequence: PCR primer pEPO15-NH6 end "B" | |
| <400> | | ٥. |
| caccga | aageg tegatetggt ceate | 25 |
| <210> <211> <212> <213> | 25 | |
| <220> <223> | Description of Artificial Sequence: PCR primer pEPO15H2.7 end "A" | |
| <400> cggtca | 30 agate gaegaeggge tttee | 25 |
| | | |